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ABSTRACT	Microbes	can	exert	both	positive	and	negative	effects	on	animal	health	and	longevity.	The	nematode	worm,	Caenorhabditis	elegans,	and	its	bacterial	diet,	Escherichia.	coli,	provide	 a	 simplified	model	 to	 study	 animal-microbe	 interactions.	 Inhibiting	E.	 coli	folate	synthesis	has	been	found	to	increase	C.	elegans	lifespan	without	any	negative	effects	on	either	organism.	Specifically	disrupting	worm	folate	uptake	or	metabolism	was	not	found	to	influence	lifespan	and	it	was	therefore	hypothesized	that	a	folate-dependent	 bacterial	 activity	modulates	 ageing.	 This	 thesis	 aims	 to	 understand	 the	factors	 that	 influence	 bacterial	 folate	 synthesis	 with	 the	 ultimate	 aim	 of	understanding	how	bacterial	folate	affects	C.	elegans	ageing.			Firstly,	 a	 folate-free	 defined	 media	 was	 developed	 in	 order	 to	 sensitively	 control	bacterial	folate	synthesis	and	accurately	measure	bacterial	and	animal	folate	levels.	E.	
coli	folate	was	found	to	modulate	C.	elegans	lifespan	above	the	threshold	for	growth.	Secondly,	 the	 impact	 of	 folic	 acid	 on	 bacterial	 folate	 synthesis	was	 examined;	 LC-MS/MS	detected	degradation	of	folic	acid	into	PABA-glu,	where	uptake	of	this	folate	precursor	 by	E.	 coli	AbgT	 boosted	 bacterial	 folate	 synthesis	 and	was	 found	 to	 be	responsible	 for	 decreasing	 C.	 elegans	 lifespan.	 This	 work	 highlighted	 a	 novel	 and	harmful	role	of	bacterial	folate	following	folic	acid	supplementation.		An	investigation	into	bacterial	toxicity	revealed	a	folate-dependent	toxicity	common	to	a	pathogenic	bacterium	and	 the	E.	 coli	used	here.	The	bacterial	 stress	 response	transcriptional	regulator,	rpoS,	was	identified	as	a	novel	regulator	of	folate	synthesis	and	a	candidate	mutant	gene	screen	of	the	RpoS	regulon	for	C.	elegans	longevity	and	low	bacterial	folate	identified	the	fic	gene	as	a	possible	mediator	of	folate-dependent	toxicity.	An	examination	into	the	timing	of	E.	coli	folate	synthesis	revealed	a	temporal	window	co-incident	with	exponential	phase	growth.	Together,	this	work	has	provided	several	 novel	 insights	 into	 the	 extrinsic	 and	 intrinsic	 factors	 that	 influence	E.	 coli	folate	synthesis	within	the	context	of	C.	elegans	ageing.	
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CHAPTER	1:	INTRODUCTION	
1.1	OVERVIEW		The	thesis	uses	the	well-established	model	organism,	Caenorhabditis	elegans,	which	is	 maintained	 in	 the	 laboratory	 in	 monoculture	 with	 a	 non-pathogenic	 strain	 of	
Escherichia	coli,	as	an	animal-microbe	model	to	examine	how	bacterial	folate	affects	animal	 ageing.	 Previous	 work	 discovered	 that	 inhibiting	 E.	 coli	 folate	 synthesis	increases	C.	elegans	lifespan	(Virk	et	al.,	2012),	in	a	mechanism	independent	of	worm	folate	 metabolism	 and	 bacterial	 growth.	 This	 thesis	 combines	 a	 variety	 of	microbiological,	 genetic	 and	 bioanalytical	 techniques	 in	 order	 to	 investigate	 the	factors	 that	 influence	 bacterial	 folate	 synthesis,	 with	 the	 ultimate	 aim	 of	understanding	how	bacterial	folate	affects	C.	elegans	ageing.			The	first	section	of	this	introductory	chapter	will	discuss	what	is	known	about	folates:	synthesis,	 structure	 and	 function;	 bacterial	 folate	 synthesis	 in	 the	 microbiome;	intestinal	uptake	and	transport;	health	issues	relating	to	folate	deficiency	and	folate	toxicity;	and	the	methods	used	to	quantify	folates.	The	second	section	will	discuss	the	composition	and	function	of	the	human	gut	microbiome	in	relation	to	health,	disease	and	ageing	and	the	use	of	model	organisms.	The	third	section	will	introduce	C.	elegans	as	a	model	organism	and	discuss	its	use	as	a	simplified	model	to	study	animal-microbe	interactions	 and	 ageing.	 The	 final	 two	 sections	will	 summarise	 the	 previous	work	carried	out	in	the	Weinkove	laboratory	and	will	discuss	the	key	aims	of	this	thesis.	
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1.2	FOLATE	The	term	‘folate’	refers	to	a	family	of	structurally	related	cofactors	that	donate	and	activate	one-carbon	units	in	a	network	of	fundamental	biosynthetic	reactions	known	as	one-carbon	metabolism (Fox	and	Stover,	2008).	Animals	are	unable	to	synthesize	folate	 but	 can	 absorb	 plant-based	 dietary	 folate	 and	 folate	 synthesized	 by	 their	intestinal	 microbiota	 (Visentin	 et	 al.,	 2014).	 Disruption	 to	 folate	 uptake,	 folate	metabolism	 or	 inadequate	 dietary	 intake	 can	 cause	 folate	 deficiency,	 which	 is	associated	with	 several	 disorders	 and	diseases	 (Lucock,	 2000).	 Conversely,	 excess	folate,	which	can	be	caused	by	folic	acid	supplementation,	has	also	been	associated	with	 adverse	 health	 (Butterworth	 and	 Tamura,	 1989;	 Kim,	 2004;	 Shane,	 2003).	Despite	 being	 discovered	 as	 a	 family	 of	 essential	 vitamins	 over	 70	 years	 ago,	 the	impact	of	both	dietary	and	microbial	folates	on	animal	folate	status	and	health	and	disease	are	not	completely	understood.		
1.2.1	Structure	and	function	
Folates	are	tripartite	compounds	(figure	1.1).	The	central	aromatic	compound,	para-aminobenzoic	acid	(PABA),	is	linked	by	a	methylene	bridge	to	a	pteridine	ring,	to	form	pteroic	acid.	The	carboxyl	group	of	PABA	is	conjugated	to	the	amino	group	of	an	L-glutamic	acid	residue	by	a	peptide	bond.	The	active	form	of	folate	is	reduced	on	its	pteridine	moiety	to	form	tetrahydropteroyl	glutamic	acid,	or	tetrahydrofolate	(THF) (Angier	et	al.,	1948).	THFs	vary	 in	one-carbon	substitution	at	N5	(R1)	and/or	N10	(R2)	nitrogen	atoms	of	the	pterin	moiety,	with	either	a	methyl	(-CH3),	formyl	(-CH=O)	methylene	(=CH2)	or	methenyl	(-CH4)	group	(figure	1.1) (Appling,	1991;	Strong	and	Schirch,	1989).	THFs	are	interconverted	by	the	transfer	and	acceptance	of	these	one-
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carbon	units	in	reactions	catalysed	by	folate-dependent	enzymes.	These	reactions	are	known	collectively	as	one-carbon	metabolism	and	facilitate	the	synthesis	of	purines,	thymidylate,	 formylated	 methionyl-tRNA,	 the	 remethylation	 of	 homocysteine	 to	methionine	and	the	interconversion	of	glycine	and	serine	(figure	1.2)	(Fox	and	Stover,	2008).		THFs	also	vary	in	the	length	of	their	glutamate	‘tail’	which	is	formed	enzymatically	by	gamma	glutamyl	bonds	between	the	amino	group	and	the	carboxyl	group	of	preceding	glutamates	(Qi	et	al.,	1999;	Turner	et	al.,	1999).	Polyglutamation	increases	the	affinity	of	 THFs	 as	 cofactors	 for	 folate-dependent	 enzymes	 and	 favours	 cellular	 retention	(Egan	et	al.,	1995;	Schirch	and	Strong,	1989;	Turner	et	al.,	1999),	whereas	mono-	and	diglutamated	 THFs	 are	 favoured	 by	 transporters	 which	 facilitate	 intestinal	 and	systemic	transport (Baugh	et	al.,	1971).		Folates	 are	 chemically	 unstable.	 Several	 studies	 have	 demonstrated	 that	 the	methylene	bridge	linking	PABA	and	pterin	is	prone	to	disassociation	(in	response	to	light,	low	pH,	oxidation)	to	generate	PABA-glu	and	pterin	(De	Brouwer	et	al.,	2007;	Gazzali	 et	 al.,	 2016;	 Gregory,	 1989;	 Hanson	 and	 Gregory,	 2011;	 Maruyama	 et	 al.,	1978).	PABA-glu	can	further	disassociate	to	PABA	and	glutamate (Der-Petrossian	et	al.,	2007;	Thiaville	et	al.,	2016).	One-carbon	substitution	is	thought	to	determine	the	stability	of	THFs;	DHF	and	THF	are	the	most	unstable,	followed	by	5-methyl	THF	and	5-formyl	THF	is	considered	the	most	stable	THF (Gregory,	1989;	Hawkes	and	Villota,	1989).	It	is	important	to	note	that	most	of	these	studies	have	been	carried	out	in	vitro	and	little	is	known	about	the	stability	of	THFs	within	cells.		
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	 Tetrahydrofolate	(THF)	 R1	 R2	5-methyl-THF	 CH3	 H	5-formyl-THF	 CHO	 H	10-formyl-THF	 H	 CHO	5,10-methenyl-THF	 								=CH-	5,10-methylene-THF	 								-CH2-	
	
Figure	1.1	Structure	of	tetrahydrofolate	(THF)	THFs	are	composed	of	pterin,	PABA	and	glutamate.	The	pterin	moiety	is	substituted	 at	N5	 (R1)	 and/or	N10	 (R2)	 nitrogen	 atoms	with	 either	 a	methyl	 (-CH3),	 formyl	 (-CH=O)	 methylene	 (=CH2)	 or	 methenyl	 (-CH4)	group.	THFs	also	vary	in	the	length	of	their	glutamate	‘tail’,	which	varies	in	length	depending	on	function.		
n 
pterin	 																							PABA																					glutamate(s) 
R1 R2 
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1.2.2	Bacterial	folate	synthesis		
1.2.2i	Pathway	of	tetrahydrofolate	synthesis	
De	novo	folate	synthesis	does	not	occur	in	the	animal	kingdom.	In	bacteria	such	as	E.	
coli	that	can	synthesis	folate,	THF	precursors	are	synthesized	de	novo	in	two	separate	branches:	the	PABA	branch	and	the	GTP/	pterin	branch (Green and Matthews, 2007).	The	GTP/pterin	branch	synthesizes	6-hydroxymethyl-7,8-dihydropterin	diphosphate	(DHNDP)	in	a	series	of	enzymatic	steps	using	GTP	as	a	precursor.	The	PABA	branch	synthesizes	PABA	in	a	two-step	reaction	from	chorismate	and	glutamine.	Chorismate	itself	 is	 synthesized	 by	 the	 Shikimic	 acid	 pathway,	 which	 is	 responsible	 for	 the	synthesis	 of	 aromatic	 amino	 acids	 and	 quinones,	 in	 addition	 to	 PABA (Green	 and	Matthews,	2007)	(figure	1.2).		The	first	reaction	in	the	PABA	branch	is	catalysed	by	the	heterodimeric	complex,	4-amino-4-deoxychorismate	 synthase,	 encoded	 by	 pabA	 and	 pabB,	 and	 forms	 the	intermediate,	 4-amino-4-deoxychorismate	 (ADC)	 (figure	 1.2).	 PabA,	 a	 glutamine	amidotransferase,	hydrolyzes	the	ammonia	group	from	glutamine,	which	is	used	by	PabB	along	with	chorismate,	to	form	ADC (Green	and	Nichols,	1991).	The	second	step	is	catalysed	by	aminodeoxychorismate	lyase	(PabC)	(Green	et	al.,	1992).		PABA	 and	 DHNDP	 are	 condensed	 enzymatically	 to	 generate	 dihydropteroate,	 by	dihydropteroate	synthase,	which	 is	then	glutamylated	to	form	dihydrofolate	(DHF)	and	 reduced	 to	 THF	 by	 dihdyrofolate	 reductase	 (DHFR)	 (figure	 1.2)	 (Hoffbrand,	1975).	Only	DHFR	is	present	in	the	animal	kingdom.		
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Figure	1.2	E.	coli	tetrahydrofolate	synthesis	and	the	one-carbon	metabolism	folate	cycle.	The		folate	 precursors,	 para-aminobenzoic	 acid	 (PABA)	 (synthesized	 from	 chorismate	 and	 glutamine)	and	 6-hydroxymethyl-7,8-dihydropterin	 diphosphate	 (DHNDP)	 (synthesized	 from	 GTP)	 are	conjugated	to	form	dihydropteroate,	which	is	glutamylated	and	reduced	to	form	tetrahydrofolate.	THF	species	are	formed	by	the	acceptance	and	transfer	of	one-carbon	units	in	reactions	that	facilitate	cellular	biosynthesis	and	methylation.	DHNP:	7,8-dihydroneopterin.	
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1.2.2	ii	Bacterial	folate	uptake	and	salvage		The	import	and	export	of	intact	monoglutamated	folates	by	bacteria	is	an	established	phenomenon	(Shane	and	Stokstad,	1975),	although	in	the	vast	majority	of	bacteria,	transporters	are	yet	to	be	identified.	E.	coli	is	unable	to	transport	intact	folate,	but	can	use	folate	degradation	and	catabolism	products,	PABA	or	PABA-glu,	as	precursors	for	folate	 synthesis	 (Carter	 et	 al.,	 2007).	 PABA	 freely	 diffuses	 across	 biological	membranes,	 but	 PABA-glu	 is	 transported	 via	 the	 specialized	 para-aminobenzoyl	glutamate	transporter,	AbgT	(Carter	et	al.,	2007;	Hussein	et	al.,	1998).	Once	inside	the	cell,	PABA-glu	is	cleaved	by	the	heterodimeric	glutamate	carboxypeptidase	protein,	AbgA/B	 to	 generate	 free	PABA	 that	 can	be	used	 for	 folate	 synthesis (Carter	 et	 al.,	2007)	(figure	1.3).		
	
Figure	 1.3	 Diagram	 of	 a	 generalized	 bacterium	 illustrating	 the	 mechanisms	 via	 which	
bacteria	can	synthesize,	import	or	salvage	folate	1.	de	novo	folate	synthesis	2.	Folate	salvage	of	folate	breakdown	products,	PABA	and/	or	PABA-glu	3.	Uptake	of	exogenous	THFs	from	dietary	or	microbial	sources	via	transporters	3.	Uptake	of	oxidized	folates	via	transporters.	E.	coli	is	capable	of	pathways	 1	 and	 2.	 PABA=	 para-aminobenzoic	 acid	 PABA-glu=	 PABA-glutamate;	 DHP=	dihydropteroate;	DHF=	dihdyrofolate;	THF=	tetrahydrofolate	
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1.2.2iii	Bacterial	folate	synthesis	in	the	human	intestine		In	1941,	Mitchell	and	colleagues	proposed	that	the	compound	they	had	isolated	and	concentrated	from	four	tonnes	of	spinach	leaves	should	be	called	‘folic	acid’	from	the	Latin,	folium,	meaning	leaf.	They	also	showed	that	this	compound	had	vitamin	activity	in	 rats	 and	 suggested	 that	 it	 was	 likely	 to	 be	 synthesized	 by	 intestinal	 bacteria	(Mitchell	et	al.,	1941).	In	vitro	studies	followed	which	reported	synthesis	of	‘folic	acid’	or	 folate	by	bacteria	which	normally	 inhabit	 the	human	 intestine	(Hutchings	et	al.,	1941;	Jukes	and	Stokstad,	1948;	Lascelles	and	Woods,	1952;	Miller	and	Rekate,	1944;	Niven	and	Sherman,	1944).	Subsequent	 in	vivo	animal	studies	 indicated	 that	 folate	synthesized	 by	 intestinal	 bacteria	 could	 compensate	 for	 induced	 dietary	 folate	deficiency,	 although	 the	 role	 that	 coprophagy	 (the	 ingestion	 of	 faeces)	 played	 in	rodent	models	here	was	unclear	(Daft	et	al.,	1963;	Miller	and	Luckey,	1963).		Early	 studies	 in	 humans	 reported	 that	 folate	 synthesized	 by	 the	 colonic	 bacteria,	where	bacterial	load	is	highest,	exceeds	dietary	intake	by	3-5	fold	(Denko	et	al.,	1946;	Klipstein,	1967).	More	recent	studies	have	verified	that	the	human	colon	provides	a	large	 depot	 of	 absorbable	 monoglutamated	 folate	 which	 is	 indeed	 in	 excess	 of	recommended	dietary	intakes	(Kim	et	al.,	2004;	O'Keefe	et	al.,	2009).	Animal	studies	have	demonstrated	that	folate	can	be	incorporated	into	host	tissues	following	infusion	of	[3H]	PABA,	the	bacterial	folate	precursor,	into	the	cecum	of	conventionally	raised	rats	(Rong	et	al.,	1991)	and	piglets	(Asrar	and	O'Connor,	2005).	A	similar	study	also	using	[3H]	PABA	reported	that	bacterially	synthesized	folate	in	the	small	intestine	also	increases	 host	 folate	 status,	 as	 a	 result	 of	 bacterial	 overgrowth	 associated	 with	
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gastritis	 (Camilo	 et	 al.,	 1996).	 Together,	 these	 studies	 provide	 evidence	 that	bacterially	synthesized	folate	can	be	absorbed	from	the	intestine	and	metabolized.		Recent	advances	in	metagenomic	technologies	have	enabled	the	folate	synthesizing	members	of	the	human	intestine	to	be	identified.	Magnusdottir	et	al.	probed	the	B-vitamin	 synthetic	 capacity	of	256	 common	human	gut	 associated	bacterial	 species	(Magnusdottir	 et	 al.,	 2015).	 The	 complete	 de	 novo	 folate	 synthesis	 pathway	 was	identified	in	43%	of	bacterial	genomes,	including	nearly	all	Bacteroidetes	and	most	Fusobacteria	 and	 Proteobacteria,	 whereas	 folate	 synthesis	 was	 uncommon	 in	Actinobacteria	 and	 Firmicutes	 genomes	 (Magnusdottir	 et	 al.,	 2015).	 Two	 similar	studies	focusing	on	intestinal-specific	Lactobacilli	and	Bifidobacteria	species	revealed	that	 most	 Bifidobacterium	 are	 able	 to	 synthesize	 folate	 de	 novo,	 whereas	 most	
Lactobacillum	species	only	possess	the	enzymes	involved	in	the	later	stages	of	folate	synthesis	and	some	only	have	DHFR	(LeBlanc	et	al.,	2013;	Rossi	et	al.,	2011).	As	all	bacteria	require	folate	to	survive,	this	functional	gap	in	the	folate	synthetic	ability	of	gut	microbes	indicates	a	folate-dependent	coevolution	in	the	microbiota,	suggesting	that	 folate	and	precursors	are	actively	exchanged	between	 folate-synthesizers	and	folate-autotrophs,	by	the	mechanisms	outlined	in	figure	1.3.		
1.2.3	Animal	folate	uptake	and	transport	
1.2.3i	Folate	absorption	in	the	intestine	There	are	two	main	folate	carriers	expressed	in	the	gastrointestinal	tract:	the	reduced	folate	 carrier	 (RFC),	 which	 is	 expressed	 ubiquitously	 in	 the	 body	 and	 functions	optimally	at	the	higher	pH	of	the	large	intestine	(pH	~	7.4)	(Dixon	et	al.,	1994;	Dudeja	
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et	 al.,	 1997;	 Kumar	 et	 al.,	 1997);	 and	 the	 intestine-specific	 proton-coupled	 folate	transporter	(PCFT),	which	functions	optimally	at	the	lower	pH	of	the	proximal	small	intestine	(pH	~	5.5)	(Qiu	et	al.,	2006).	At	their	optimal	pHs,	PCFT	has	a	high	affinity	for	both	THFs	(Km	~	4	μM)	and	oxidized	folates	such	as	folic	acid	(Km	~	1	μM),	while	RFC	has	a	high	affinity	for	THFs	(Kt	of	2–7	μM)	and	a	low	affinity	for	folic	acid	(Ki	~	150–200	μM)	 (Dudeja	 et	 al.,	 2001;	Matherly	 and	Goldman,	 2003;	Whetstine	 et	 al.,	2002;	 Zhao	 et	 al.,	 2009).	 It	 is	 generally	 accepted	 that	 dietary	 folates,	 like	 most	micronutrients,	 are	mainly	 absorbed	 in	 the	 small	 intestine	 by	 PCFT,	 where	 folate	transporter	expression	is	high	and	there	are	relatively	few	microbes	competing	with	the	 host	 for	 absorption,	 whereas	 the	 majority	 of	 bacterially	 synthesized	 folate	 is	absorbed	in	the	large	intestine	by	RFC	(Balamurugan	and	Said,	2006)	where	microbial	load	is	highest	(figure	1.4)	(Visentin	et	al.,	2014).		The	 relative	 contributions	 of	 the	 small	 and	 large	 intestine	 to	 host	 folate	 status	 is	unclear.	The	absorptive	capacity	of	the	 large	intestine	has	been	examined	by	using	infusion	 of	 a	 physiological	 dose	 of	 [13C5]	 5-formylTHF	 into	 the	 cecum	 of	 patients	undergoing	 colonoscopies	 (Aufreiter	 et	 al.,	 2009)	 and	 in	 a	 subsequent	 study	 by	ingestion	 of	 [13C5]	 5-formylTHF	 in	 a	 pH-sensitive	 enteric	 coated	 caplet	 by	 healthy	adults	 (Lakoff	 et	 al.,	 2014).	 These	 two	 studies,	 carried	 out	 by	 the	 same	 group,	monitored	the	appearance	of	plasma	[13C5]	5-methylTHF	formation	by	LC-MS/MS	and	concluded	 that	 the	 colon	 makes	 a	 significant	 contribution	 to	 host	 folate	 status	(Aufreiter	et	al.,	2009;	Lakoff	et	al.,	2014),	but	at	an	order	of	magnitude	lower	than	the	 absorption	 of	 [13C5]	 5-formylTHF	 across	 the	 small	 intestine	 as	 measured	 by	similar	studies	(Wright	et	al.,	2003;	Wright	et	al.,	2005).	
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Despite	 the	 large	difference	 in	 the	 rate	of	 absorption	between	 the	 small	 and	 large	intestine,	the	difference	in	net	absorption	is	approximated	to	be	much	smaller	due	to	the	 constant	 and	 excessive	 supply	 of	 bacterially	 synthesized	 folate	 in	 the	 large	intestine,	compared	to	the	fluctuating	supply	in	the	small	intestine.	Furthermore,	the	transit	time	of	material	is	estimated	to	be	20	times	longer	in	the	large	intestine	than	the	small	intestine	(Ghoshal	et	al.,	2012;	Kim,	1968).		
1.2.3ii	Folate	deconjugation	Both	PCFT	and	RFC	preferentially	import	mono-	and	diglutamated	folates	(Halsted	et	al.,	 1986).	As	dietary	 and	microbial	 folates	 are	mostly	 polyglutamated	derivatives,	they	must	be	deconjugated	before	they	can	be	absorbed.	In	mammals,	this	is	thought	to	be	carried	out	by	glutamate	carboxypeptidase	II	(GCPII),	which	is	expressed	in	the	apical	 brush-border	 of	 the	 small	 intestine	 (Halsted	 et	 al.,	 1998).	 Monoglutamated	folates	can	then	be	transported	into	enterocytes	and	exported	vectorially	across	the	enterocyte	basolateral	membrane	into	the	hepatic	portal	vein	(figure	1.4)	(Wright	et	al.,	2005).	Monoglutamated	5-methyl	THF	is	the	main	circulatory	folate	form	and	it	is	thought	 that	 dietary	 and	 microbial	 THFs	 are	 converted	 to	 5-methyl	 THF	 in	enterocytes	(Pietrzik	et	al.,	2010).	It	is	not	clear	whether	5-methyl	THF	is	exported	by	PCFTs	or	RFCs.	The	mechanism	of	uptake	of	the	oxidized,	synthetic	monoglutamated	folate	supplement,	folic	acid,	is	not	clear.	Some	studies	suggests	it	is	taken	up	in	the	small	intestine	by	PCFT,	but	others	indicate	RFCs	also	play	a	role.	It	is	not	clear	if	folic	acid	is	metabolized	in	enterocytes	or	in	liver	cells,	to	5-methyl	THF	(Milman,	2012).		
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Figure	 1.4	Model	 of	 intestinal	 uptake	 and	metabolism	 of	 dietary	 and	 bacterial	 sources	 of	
folate.	Animals	obtain	folate	from	their	diet,	intestinal	bacterial	and	folate	supplements,	such	as	folic	acid.	The	majority	of	dietary	folates	are	absorbed	in	the	small	intestine	by	RFCs	and	PCFTs	expressed	in	 the	 apical	membrane	 of	 the	 epithelium.	These	 THFs	 are	mostly	 polyglutamated	 and	must	 be	hydrolysed	by	GCPII	into	monoglutamated	THFs	before	transport.	Folic	acid	is	monoglutamated	and	can	be	absorbed	directly	by	PCFTs.	Bacterial	load	is	highest	in	the	large	intestine	and	bacterial	folates	synthesized	here	are	thought	to	be	transported	by	RFCs.	The	pH	of	the	intestine	increases	proximally	to	distally,	where	pH	 favours	PCFT	 function	 in	 the	 small	 intestine	 and	RFC	 function	 in	 the	 large	intestine.	THFs	are	thought	to	beconverted	into	5-methyl	THF-glu	in	intestinal	epithelial	cells,	before	being	exported	(by	either	RFC	or	PCFT)	into	the	hepatic	portal	vein.	It	is	not	clear	whether	folic	acid	
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is	metabolized	in	intestinal	epithelial	cells,	but	it	is	found	in	the	liver	after	supplementation,	where	it	is	thought	to	be	reduced	by	DHFR	into	THF	and	5-methyl	THF	which	can	be	exported	to	peripheral	cells.	 Monoglutamated	 5-methyl	 THF	 is	 transported	 into	 peripheral	 cells	 by	 RFCs,	 where	 it	 is	polyglutamated	by	FPGS	and	converted	into	other	THFs	by	enzymes	in	the	folate	cycle.	THFs-glun	are	hydrolysed	by	GGH	and	exported	by	RFCs	to	re-enter	circulation	and	be	transported	to	other	tissues.	Dotted	arrows	indicate	lower	affinity	of	transporter.	THF-glu,	generic	monoglutamted	THF;	THF-glun,	 generic	 polyglutamated	 THF;	 5-meTHF-glu,	 5-methylTHF;	 RFC,	 reduced	 folate	 carrier;	PCFT,	 proton-coupled	 folate	 transporter;	 FPGS,	 folyl	 polyglutamate	 synthase;	 GCPII,	 glutamate	carboxypeptidase	II;	GGH,	gamma-glutamyl	hydrolase.		
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1.2.3iii	Folate	polyglutmation		RFCs	mediate	 the	uptake	of	 circulatory	monoglutamated	 folate	 into	 systemic	 cells.	Similarly	to	in	enterocytes,	FPGS	activity	then	catalyzes	the	addition	of	subsequent	glutamic	 acid	 residues	 to	 generate	 polyglutamated	 THFs,	which	 are	 the	 preferred	substrates	 for	 the	 folate-dependent	 enzymes	 involved	 in	 one-carbon	 metabolism	(Allegra	 et	 al.,	 1987;	Allegra	 et	 al.,	 1985;	 Schirch	 and	 Strong,	 1989).	 Furthermore,	THFs	with	glutamate	chains	where	n>3,	are	no	longer	substrates	for	RFCs	(Matherly	and	Goldman,	2003);	FPGS	activity	therefore	also	aids	cellular	retention.	In	order	to	maintain	 a	 balance	 of	 THFs	 within	 the	 body, γ-glutamyl	 hydrolase	 (GGH)	 acts	synergistically	 with	 FPGS	 to	 generate	 monoglutamated	 derivatives	 that	 can	 be	exported	out	of	 cells	 to	 re-enter	 circulation (Egan	et	 al.,	 1995;	Garrow	and	Shane,	1993).	See	figure	1.4	for	a	model	of	folate	uptake	in	the	human	intestine.	
1.2.4	Folate	deficiency	and	supplementation	
1.2.4i	Causes	and	effects	Failure	to	supply	cells	with	sufficient	THF	cofactors	has	been	associated	with	several	health	 problems,	 including:	 anaemia,	 congenital	 birth	 defects	 such	 as	 neural	 tube	defects	(NTDs)	(Hibbard,	1964;	Hibbard	et	al.,	1965),	cardiovascular	abnormalities	and	cancer	(Bailey	et	al.,	2015;	Ebbing	et	al.,	2009).	As	has	been	discussed,	acquiring	sufficient	folate	for	one-carbon	metabolism	relies	on	a	multitude	of	factors,	including:	dietary	folate	intake,	intestinal	folate	biosynthesis,	folate	transporter	efficiency,	folate	deconjugase	and	glutamation	activity,	and	the	activity	of	enzymes	 involved	 in	one-carbon	 metabolism.	 Several	 of	 these	 processes	 can	 be	 disrupted	 by	 genetic	
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polymorphisms (Devlin	et	al.,	2006;	Fodinger	et	al.,	2001;	Winkelmayer	et	al.,	2003),	certain	drugs	(sulphonamides	and	anti-cancer	drugs) (Goldberg,	1983;	Halsted	et	al.,	1981) and	 alcoholism	 (Tamura	 et	 al.,	 1981).	 Increased	 demand	 for	 folate	 during	pregnancy	 can	 also	 exacerbate	 folate	 deficiency.	 Folate	 deficiency	 is	 therefore	 a	multifactorial	 disorder,	 the	 pathogenesis	 of	 which	 is	 not	 completely	 understood	(Boyles	et	al.,	2006).		
1.2.4ii	Folic	acid:	supplementation	and	toxicity	In	1931,	 a	 substance	 in	both	Marmite	and	yeast	that	would	later	be	identified	as	folic	acid (Mitchell	et	al.,	1941),	was	recognised	 by	 its	 ability	 to	 prevent	megaloblastic	 anemia	 in	 pregnancy (Wills,	 1931)	 (box	 1).	 Following	 its	synthesis	in	1945	(Angier	et	al.,	1945)	and	continued	work	by	Wills	during	the	Second	World	 War,	 folic	 acid	 began	 to	 be	 used	 as	 a	 supplement	 to	 treat	 megaloblastic	anaemia.	The	initial	discovery	of	folic	acid	sparked	the	body	of	research	concerning	folates	and	their	roles	as	cofactors	in	one-carbon	metabolism.			In	the	early	90s,	large-scale	randomized	trials	of	folic	acid	supplementation	were	carried	 out	 and	 together	 they	 concluded	 that	 folic	 acid	 supplementation	 before	conception	could	reduce	the	risk	of	NTDs	(1991;	Berry	et	al.,	1999;	Czeizel	et	al.,	1992)	This	 led	to	the	 introduction	of	widespread	folic	acid	 fortification	of	grains	
Box	1.	Who	was	Lucy	Wills?	
Lucy	 Wills	 “is	 remembered	 as	 aristocratic,	
independent	 and	 radical	 in	 outlook,	 critical	 of	
established	conservative	medical	and	scientific	
committees.	 She	 rode	 to	 work	 on	 a	 bicycle	
rather	 than	 in	 a	 large	car	 as	 did	many	of	her	
colleagues” (Hoffbrand	and	Weir,	2001)		
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and	cereals	in	1998	in	the	US.	Subsequent	similar	programmes	were	implemented	in	other	countries,	including	Canada,	Chile,	South	Africa	and	Jordan.	Declines	in	the	frequency	of	NTDs	in	these	countries	were	reported	(Imbard	et	al.,	2013).			However,	to	date,	no	EU	countries	have	adopted	folic	acid	fortification	programmes.	This	 is	 because	 of	 uncertainties	 over	 whether	 an	 optimal	 dosage	 for	 an	 entire	population	can	be	achieved	and	concerns	over	folic	acid	toxicity	(Butterworth	and	Tamura,	1989).	Indeed,	folic	acid	supplementation	has	been	linked	to	several	health	complications,	 including:	 zinc	 deficiency	 caused	 by	 impaired	 absorption	 in	 the	intestine (Milne	et	al.,	1984);	progression	of	neurological	damage	in	megaloblastic	anaemia	due	to	masking	of	the	signs	of	B12	deficiency (Selhub	et	al.,	2009);	and	an	increased	 risk	 of	 colon	 cancer	 (Cole	 et	 al.,	 2007;	 Kim,	 2004).	 Furthermore,	 two	mouse	studies	have	reported	that	excessive	folic	acid	supplementation	may	disrupt	embryonic	development (Marean	et	al.,	2011;	Pickell	et	al.,	2011).			The	 association	 of	 folic	 acid	 supplementation	 with	 colorectal	 cancer	 is	 unclear;	several	 independent	 meta-analyses	 have	 failed	 to	 reach	 a	 unanimous	 conclusion	(Carroll	et	al.,	2010),	(Fife	et	al.,	2011),	(Qin	et	al.,	2015).	One	epidemiological	study	has	 reported	 a	 temporal	 association	 between	 the	 introduction	 of	 folic	 acid	fortification	in	the	US	and	Canada	with	increased	incidences	of	colon	cancer	(Mason	et	 al.,	 2007);	 however,	 another	 study	 reported	 that	 incidences	 have	 continued	 to	decline	(Edwards	et	al.,	2010).		
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1.2.5	Quantification	of	folates	
Quantifying	folate	levels	is	important	for	clinicians	and	nutritionists;	however,	several	factors	make	this	intrinsically	difficult.	As	described,	folates	exist	as	interconvertible	THF	derivatives	and	are	unstable	and	sensitive	to	light,	pH	and	temperature.	In	the	1930s,	a	microbiological	assay	was	developed	 to	measure	 the	 level	of	active	 folate	within	 a	 given	 sample (Baker et al., 1959).	 The	 growth	 of	 the	 folate-auxotroph,	
Lactobacillus	casei,	is	used	as	a	readout,	however	the	sample	must	be	first	hydrolysed	by	 GGH	 in	 order	 to	 convert	 all	 polyglutamated	 folates	 into	 transportable	monoglutamated	 folates.	This	assay	therefore	does	not	provide	 information	on	the	polyglutamation	 profile	 and	 cannot	 differentiate	 between	 individual	 folate	derivatives	within	a	sample.			Protein	binding	assays	were	developed	 in	 the	1970s	and	1980s	as	a	more	 simple,	rapid	and	effective	means	to	measure	folate	levels	within	a	sample.	Later,	automated	assays	were	 developed	 for	 use	 clinically	 and	 are	 still	 used	 today	 (Gregory,	 1982).	Whilst	 these	 assays	 are	 not	 sensitive	 to	 antibiotics	 and	 anti-folate	 drugs,	 they	 are	subject	 to	 the	 same	 limitations	as	 the	microbiological	 assays	and	 therefore	 cannot	differentiate	between	specific	folate	derivatives (Shane	et	al.,	1980).	Nevertheless,	the	use	of	these	assays	has	guided	the	recommended	dietary	intakes	for	folate	and	the	concentrations	of	 folate	supplements.	 It	 is	 suggested	 that	 the	 insensitivity	of	 these	methods	has	led	to	over-estimations	of	recommended	intakes	(Ringling	and	Rychlik,	2017).			
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More	 recently,	 bioanalytical	 techniques	 using	 (ultra)	 high	 performance	 liquid	chromatography	 (HPLC)	coupled	 to	mass	 spectrometry	 (MS)	have	been	developed	and	made	it	possible	to	identify	individual	folate	species	within	a	sample (McDowell 
et al., 2008).	Several	LC-MS	methods	are	outlined	in	the	literature	and	differ	in	their	chromatography	mode	(reversed	phase	or	hydrophilic	interaction	chromatography),	ionization	mode	(positive	or	negative)	and	mass	spectrometry	detection	mode	(MS-only	or	tandem	MS)	(Meadows,	2017).	These	methods	are	becoming	more	common,	but	 require	 high	 initial	 set-up	 costs,	 expensive	 reagents	 and	 procedures	 are	 time-consuming.	In	light	of	this,	the	microbiological	assay	remains	the	method	by	which	recommended	dietary	folate	intakes	are	set.	In	this	thesis,	a	LC-MS	method	coupled	to	a	multiple	 reaction	monitoring	 (MRM)	 technique	 has	 been	 used	 to	 achieve	 highly	specific	and	sensitive	folate	detection	in	E.	coli	and	C.	elegans	extracts.	This	will	be	described	in	more	detail	in	Chapter	3.			
1.3	THE	HUMAN	GUT	MICROBIOME		Microbes	have	evolved	 to	occupy	nearly	every	ecological	niche	on	Earth,	 including	multicellular	 organisms	 (Lozupone	 and	 Knight,	 2007).(Ebbing	 et	 al.)	 In	 humans,	microbes	 inhabit	 the	skin,	 the	oral	cavity	and	airways,	 the	urogenital	area	and	 the	gastrointestinal	 (GI)	 tract	 (Human	 Microbiome	 Project,	 2012).	 These	 diverse	 and	distinct	communities	consist	of	bacteria,	archaea,	fungi,	viruses	and	protists,	and	are	referred	 to	 as	 ‘microbiotas’,	 whilst	 their	 collective	 genomes	 within	 a	 defined	ecosystem	 are	 termed	 ‘microbiomes’	 (Lederberg	 and	McCray,	 2001;	Marchesi	 and	Ravel,	2015).	Animals	represent	a	nutrient	rich	and	stable	ecosystem	for	microbes	to	
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thrive,	 and	microbes	benefit	 the	host	 by	digesting	 complex	dietary	 carbohydrates,	providing	essential	micronutrients,	and	supporting	the	development	and	function	of	the	immune	system	(Marchesi	et	al.,	2016).		The	human	gut	microbiota	(HGM)	is	one	of	 the	 most	 densely	 populated	 ecosystems	 on	 the	 planet,	 where	 the	 number	 of	bacterial	cells	reaches	up	to	100	trillion	cells	in	the	colon	and	its	genetic	capacity	is	estimated	to	outnumber	that	of	the	human	genome	by	2	orders	of	magnitude	(Qin	et	al.,	2010).		
1.3.1	Composition,	structure	and	function	
Recent	 advances	 in	 culture-independent	 sequencing	 technologies	 have	 enabled	identification	of	 the	bacterial	 taxa	which	make	up	 the	HGM (Ebbing	 et	 al.;	Human	Microbiome	Project,	2012).	Studies	agree	 that	Firmicutes	and	Bateriodetes	are	 the	dominant	phyla,	followed	by	Proteobacteria	and	Actinobacteria	(Human	Microbiome	Project,	2012;	Ley	et	al.,	2006;	Yatsunenko	et	al.,	2012).	Over	1000	bacterial	species	have	 been	 associated	with	 the	HGM	 across	 different	 studies,	 with	 each	 individual	predicted	 to	 host	 around	 160	 (Qin	 et	 al.,	 2010).	 Efforts	 to	 characterize	 the	 core	bacterial	 constituents	 of	 a	 ‘healthy’	 gut	 microbiota	 have	 been	 complicated	 by	extensive	 interpersonal	 variation	 at	 species	 and	 strain	 level	 identified	 in	 these	studies,	however,	metagenomic	studies	have	suggested	that	the	HGM	is	conserved	at	the	functional	level	(Shafquat	et	al.,	2014;	Turnbaugh	et	al.,	2009).		It	 has	 been	 proposed	 that	 the	 colonization	 of	 bacteria	with	 specific	 functions	 into	distinct	spatial	niches	along	the	GI	tract	is	driven	by	proximal-	distal	gradients	of	pH,	oxygen,	nutrient	availability	and	the	host	secretion	of	antimicrobial	peptides	and	bile	
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acids	(Tropini	et	al.,	2017).	The	small	 intestine	is	mainly	inhabited	by	fast-growing	facultative	 anaerobes	 that	 compete	 with	 host	 epithelial	 transporters	 for	 dietary	nutrients (Donaldson	et	al.,	2016).	In	contrast,	the	large	intestine	has	a	higher	species	diversity,	 is	 more	 densely	 populated	 (Booijink	 et	 al.,	 2010)	 and	 is	 inhabited	 by	anaerobic	species	which	metabolize	the	indigestible	components	of	our	diet,	such	as	complex	 carbohydrates	 and	 oligosaccharides	 and	 generate	 easily	 absorbable,	 high	energy	 short-chain	 fatty	 acids	 (Macfarlane	 and	 Macfarlane,	 2003).	 As	 has	 been	discussed,	 inhabitants	 of	 the	 colon	 synthesize	 essential	 amino	 acids	 and	 vitamins,	including	 folate	(Flint,	2012).	Latitudinal	microhabitats	created	by	 the	secretion	of	mucin	by	the	host	epithelia	play	an	important	role	in	immune	function	(Pereira	and	Berry,	2017).		A	healthy	gut	microbiota	is	also	inhabited	by	a	low	abundance	of	enteric	pathogens,	or	‘pathobionts’.	Studies	suggests	that	pathobionts	are	tolerated	as	they	are	directly	suppressed	by	other	beneficial	or	 ‘commensal’	bacteria,	and	 indirectly	 through	the	bacterial	 induction	 of	 host	 immune	 regulatory	 action	 	 (Kamada	 et	 al.,	 2013).	 The	majority	of	pathobionts	belong	to	families	of	the	Proteobacteria	phylum,	particularly	Enterobactericaeae	 (E.	 coli,	 Yersinia	 spp.,	 Salmonella	 spp.,	 Shigella	 spp.),	 and	 also	Vibrionaceae	(Vibrio	cholerae)	and	Campylobacteriaceae	(Campylobacter	spp.)	(Shin	et	al.,	2015).	
1.3.2	Dysbiosis	and	disease	
Disruption	 to	 the	 spatial	 structure	 and	 composition	 of	 the	 healthy	microbiota	 has	been	termed	‘dysbiosis’	(Tamboli	et	al.,	2004).	Dysbiosis	can	be	caused	by	intrinsic	
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factors	 (genetics,	 disease,	 ageing)	 and	extrinsic	 factors	 (dietary	 changes,	 antibiotic	treatment,	 stress,	 smoking)	 and	 is	 associated	 with	 decreased	 bacterial	 diversity,	where	commensal	bacteria	decrease	in	abundance	and	the	abundance	of	pathobionts	increases	 (figure	 1.5)	 (Mukhopadhya	 et	 al.,	 2012;	 Nagao-Kitamoto	 et	 al.,	 2016).	Indeed,	Proteobacteria	have	been	coined	the	‘microbial	signature	of	dysbiosis’	in	the	microbiota	(Shin	et	al.,	2015)		Dysbiosis	 is	 associated	 with	 distinct	 changes	 in	 gut	 morphology,	 such	 as	 the	breakdown	 of	 barrier	 function	 and	 the	 activation	 of	 host	 inflammatory	 immune	signalling	 pathways (Vindigni	 et	 al.,	 2016).	 This	 is	 thought	 to	 create	 a	 favourable	environment	for	the	further	colonization	of	enteric	pathogens	and	the	propagation	and	 progression	 of	 pathogenesis	 (figure	 1.5).	 Dysbiosis	 has	 been	 associated	 with	several	intestinal	diseases,	such	as	inflammatory	bowel	disease,	colon	and	stomach	cancer (Carding	 et	 al.,	 2015).	 There	 is	 increasing	 evidence	 that	 dysbiosis	 is	 also	associated	with	extra-intestinal	disorders,	such	as:	obesity	(Backhed	et	al.,	2004;	Ley	et	al.,	2005),	type	II	diabetes (Navab-Moghadam	et	al.,	2017),	cardiovascular	disease (Fava	et	al.,	2006)	and	even	autism (Williams	et	al.,	2011)	and	anorexia	(Kleiman	et	al.,	 2015).	 There	 has	 been	 extensive	 work	 carried	 out	 to	 characterize	 the	compositional	 changes	 in	 disease-associated	 microbiomes,	 however,	 descriptive	studies	have	been	unable	to	demonstrate	a	causal	link	between	these	changes	and	the	progression	of	disease.						
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Figure	 1.5	 A	 schematic	 illustrating	 the	model	 of	 how	 dysbiosis	 can	 cause	 disease.	 Several	environmental	 and	 genetic	 factors	 can	 influence	 the	 composition	 of	 the	 gut	 microbiota	 either	directly	or	 indirectly	by	 inducing	host	 immune	response	pathways.	This	 creates	an	environment	where	pathobionts	bloom	and	become	more	abundant	and	symbionts	become	less	abundant.	These	changes	impair	epithelial	and	mucosal	integrity	and	activate	an	abnormal	host	immune	response.	This	further	propagates	the	changes	in	the	microbiota	and	continued	immune	activation	results	in	the	pathogenesis	of	several	diseases	and	disorders.	Adapted	from	Nagao-Kitamoto	et	al.	2016. 					
Abnormal	immune	response 
GI	and	metabolic	
diseases 
Environmental	and	genetic	factors	
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1.3.2i	Model	organism	case-study:	mice,	obesity	and	lipopolysaccharide	(LPS)	Studies	in	mice	have	sought	to	investigate	the	host-microbe	interactions	that	underpin	disease	progression	in	obesity.	In	2004,	it	was	found	that	the	transfer	of		cecal	microbiota	from	a	healthy	adult	mouse	into	that	of	a	germ	free	(GF)	adult	mouse	caused	a	60%	increase	 in	body	fat	content	 in	the	GF	mouse	(Backhed	et	al.,	2004).	Subsequent	studies	demonstrated	that	GF	mice	did	not	become	obese	on	a	high	fat	diet,	whereas	the	control	group	with	a	conventional	microbiota	did (Backhed	et	al.,	2007;	Rabot	et	al.,	2010).	Obese	mice	on	a	HF	diet	and	the	obese	mouse	model	(ob/ob)	both	show	phylum-level	microbiota	changes	associated	with	human	obesity,	namely:	a	 reduction	 in	 Bacteroidetes	 and	 an	 increase	 in	 Firmicutes	 and	 Proteobacteria (Hildebrandt	et	al.,	2009;	Ley	et	al.,	2005;	Murphy	et	al.,	2010;	Turnbaugh	et	al.,	2008).		One	 of	 the	 possible	mechanisms	by	which	 this	 shift	 in	 gut	 bacteria	may	modulate	obesity	 is	by	elevated	 levels	of	 the	bacterial	gram-negative	toll-like	receptor	(TLR)	ligand,	 lipopolysaccharide	 A	 (LPS);	 activation	 of	 the	 TLR,	 TNF-α,	 by	 LPS	mediates	insulin	 resistance	 and	 is	 associated	 with	 obesity	 in	 mice	 and	 humans	 (Borst	 and	Conover,	2005;	Bouter	et	al.,	2010).	Cani	et	al.	demonstrated	that	obese	mice	on	a	HF	diet	had	increased	levels	of	plasma	LPS	and	that	direct	infusion	of	LPS	into	mice	on	a	normal	diet	caused	obesity	(Cani	et	al.,	2007).	Furthermore,	plasma	LPS	levels	were	reduced	following	antibiotic-treatment	(Cani	et	al.,	2008).	Subsequent	studies	have	indicated	 that	 this	mechanism	may	 be	 conserved	 in	 humans	 (Fei	 and	 Zhao,	 2013;	Lassenius	et	al.,	2011).	Here,	a	model	organism	approach	has	elucidated	a	microbial	
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molecular	mechanism	that	assigns	causality	to	the	bacterial	changes	associated	with	obesity.		
1.3.3	Dysbiosis	and	ageing	
Ageing	 is	 associated	with	 decreased	 intestinal	motility	 (Madsen	 and	 Graff,	 2004),	increased	 intestinal	permeability	(Hollander	and	Tarnawski,	1985;	Ma	et	al.,	1992;	Tran	and	Greenwood-Van	Meerveld,	2013),	chronic	low-level	 inflammation,	known	as	‘inflamm-ageing’	(Franceschi,	2007;	Guigoz	et	al.,	2008),	dietary	changes	(Flint	et	al.,	2008)	and	increased	antibiotic	use	(Augustine	and	Bonomo,	2011).	Studies	have	found	 that	 the	 composition	 of	 the	 microbiota	 also	 changes	 with	 age,	 where	 the	relatively	stable	adult	microbiota	begins	to	lose	both	stability	and	diversity	with	old	age	(Yatsunenko	et	al.,	2012).		Metagenomic	 cohort	 studies	 have	 aimed	 to	 identify	 characteristic	 changes	 in	 the	elderly	microbiome.	A	 study	of	 a	 cohort	of	Northern	 Italian	 centenarians	 reported	increased	 abundance	 of	 Proteobacteria	 and	 other	 changes	 in	 dominant	 phyla	compared	 to	a	 control	 group	of	 younger	adults (Biagi	 et	 al.,	 2010).	These	 changes	were	 also	 associated	 with	 increases	 in	 circulating	 pro-inflammatory	markers	 and	were	only	reported	in	centenarians	and	not	in	a	group	of	older	adults	with	an	average	age	of	70	(Biagi	et	al.,	2010).	A	more	recent	study	by	the	same	group	found	that	an	increase	 in	 ‘health-associated’	 taxa,	 such	 as	Bifidobacteria	 in	 extremely	 long-living	people	(Biagi	et	al.,	2016).	In	contrast	to	the	earlier	Biagi	et	al.	study,	an	Irish	study	reported	increased	abundance	of	Bacteroides	and	distinct	changes	in	other	dominant	phyla	in	adults	over	65	years	of	age (Claesson	et	al.,	2011)	and	found	that	both	diet	
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and	 antibiotic	 use	 were	 key	 predictors	 of	 shifts	 in	microbiome	 composition.	 This	study	 also	 positively	 correlated	 increased	 levels	 of	 pro-inflammatory	 circulatory	markers	 with	 measures	 of	 frailty	 and	 comorbidity	 (Claesson	 et	 al.,	 2012).	 These	studies	consistently	report	that	ageing	is	associated	with	both	reduced	diversity	and	increased	 interpersonal	 variability	 in	 microbiota	 composition	 (Yatsunenko	 et	 al.,	2012).		Together,	these	studies	indicate	that	age-related	changes	in	the	composition	of	the	gut	microbiota	are	 inextricably	 linked	 to	 the	 increased	 inflammatory	status	associated	with	age	(Buford,	2017).	It	is	therefore	unsurprising	that	microbiota	composition	in	the	elderly	shares	a	similar	profile	to	patients	with	diseases	and	disorders	associated	with	inflammation,	such	as	IBD	and	obesity	(Franceschi	and	Campisi,	2014).	However,	it	is	unclear	from	these	metagenomic	descriptive	studies	whether	the	compositional	changes	described	are	a	cause	or	consequence	of	ageing.			
1.3.3i	Model	organism	case	study:	fruit	flies,	intestinal	barrier	dysfunction	and	ageing	The	fruit	fly,	Drosophila	melanogaster,	has	proved	to	be	a	useful	model	to	study	host-microbe	interactions	in	ageing,	as	the	fly	hosts	up	to	approximately	just	30	bacterial	taxa	 (Broderick	 and	 Lemaitre,	 2012)	 and	 it	 has	 a	 shorter	 lifespan	 and	 cheaper	husbandry	 costs	 compared	 to	 mice.	 Moreover,	 studies	 have	 characterized	 age-associated	intestinal	cellular	alterations	in	ageing	flies,	which	are	associated	with	an	increased	load	of	intestinal	microbes (Broderick	et	al.,	2014;	Buchon	et	al.,	2009;	Rera	et	al.,	2011).	In	2015,	Clark	et	al.	demonstrated	that	specific	age-related	changes	in	
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microbiota	 composition,	 namely	 an	 increase	 in	 the	 abundance	 of	
Gammaproteobacteria	and	a	decrease	in	the	proportion	of	Firmicutes,	activates	host	pro-inflammatory	immune	signalling	pathways	which	leads	to	cellular	changes	and	compromised	 intestinal	 barrier	 integrity	 (Clark	 et	 al.,	 2015).	 These	 changes	were	found	to	prompt	further	dysbiosis,	namely	expansion	of	Alphaproteobacteria,	which	caused	further	immune	activation.	These	changes	were	found	to	be	primary	cause	of	ageing.	This	study	 therefore	provides	evidence	 that	microbiota	alterations	actively	promote	age-related	intestinal	dysfunction	by	prompting	immune	activation,	which	then	further	propagates	pathogenesis	(Clark	et	al.,	2015).	In	mice,	increased	intestinal	membrane	permeability,	 or	 ‘leaky	 gut’	 has	been	 cited	 as	 a	possible	mechanism	by	which	LPS	may	translocate	from	the	intestine	into	the	plasma	(Cani	et	al.,	2008).			
1.4	CAENORHABDITIS	ELEGANS	AS	A	MODEL	ORGANISM	In	this	thesis,	the	nematode	worm,	C.	elegans,	which	is	maintained	in	the	laboratory	on	a	monoculture	of	E.	coli	as	a	 ‘food	source’,	 is	used	as	a	read-out	to	investigate	a	specific	 aspect	 of	 bacterial	 metabolism,	 namely	 folate	 synthesis.	 This	 section	 will	introduce	C.	elegans	as	a	model	organism	and	outline	the	research	related	to	using	C.	
elegans	as	a	model	to	study	ageing.	This	will	be	followed	by	a	review	of	more	recent	work	which	discusses	the	nature	of	the	relationship	between	C.	elegans	and	E.	coli,	with	the	aim	of	persuading	the	reader	that	C.	elegans-E.	coli	is	a	useful	model	system	to	study	animal-microbe	interactions.		
1.4.1	Why	C.	elegans?		
C.	 elegans	 was	 introduced	 as	 a	model	 organism	 in	 1963	 by	 Sydney	 Brenner,	 who	
27 
 
recognized	 the	 need	 to	 simplify	 biological	 systems	 in	 order	 to	make	 fundamental	discoveries	about	cell	biology	(Brenner,	1974).	C.	elegans	are	small	(about	1mm	in	length)	 transparent	 organisms	 that	 can	 be	 maintained	 in	 large	 numbers	 in	 the	laboratory	using	simple	techniques	and	inexpensive	equipment.	C.	elegans	are	mostly	self-fertilizing	 hermaphrodites	 and	 can	 lay	 between	 300-350	 eggs	 within	 a	 short	reproductive	window:	males	will	make	up	only	a	small	proportion	of	the	progeny,	but	if	 a	male	mates	with	a	hermaphrodite,	 the	progeny	will	be	50:50 	 .	 The	C.	 elegans	lifespan	is	short	and	temperature	dependent,	developing	from	an	egg	through	4	larval	stages	(L1-L4)	within	just	3	days	at	25	°C	(figure	1.6).	The	average	adult	lifespan	is	only	around	12-15	days	at	25	°C,	thus	lending	itself	to	ageing	studies.	Worms	can	be	frozen	 at	 -80	 °C	 and	 revived	 after	 several	 years,	 thus	 facilitating	 the	 storage	 of	transgenic	strains	(Brenner,	1974).		Indeed,	 C.	 elegans	 are	 extremely	 tractable	 genetically	 and	 biochemically.	 It	 is	relatively	simple	to	knockdown	a	gene	by	RNAi	(microinjection	of	feeding) (Fire	et	al.,	1991)	and	knockout	strains	can	be	obtained	from	the	gene	knockout	consortium	at	the	CGC	(C.	elegans	Genetics	Center).	More	recently,	CRISPR/	Cas	9	genome	editing	has	been	established	in	C.	elegans	and	provides	a	simple	way	to	specifically	knockout	genes	 of	 interest	 (Frokjaer-Jensen,	 2013	 #960).	 The	 C.	 elegans	 genome	 is	 fully	sequenced	and	annotated,	with	studies	showing	that	60-	80%	of	human	genes	have	orthologs	in	C.	elegans	(Kaletta	and	Hengartner,	2006).	Indeed,	out	of	the	17	known	signal	 transduction	pathways	 in	humans,	12	are	conserved	 in	C.	elegans	 (Lai	et	al.,	2000).	 Together,	 these	 characteristics	make	 the	worm	 an	 extremely	 useful	model	organism	to	investigate	diverse	aspects	of	biology.		
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Figure	 1.6.	 Life	 cycle	 of	 C.	 elegans.	 C.	 elegans	 develop	 from	 a	 fertilized	 egg,	 through	 four	developmental	larval	stages	(L1-L4)	before	becoming	a	young	adult	and	then	a	gravid	(egg-laying)	adult	(hermaphrodites	only).	At	25	°C	when	maintained	on	E.	coli,	this	entire	life	cycle	takes	just	3	days.	C.	elegans	can	enter	a	state	known	as	dauer	formation	at	L2	stage,	in	response	to	crowding,	starvation	or	high	temperatures.	C.	elegans	can	remain	in	dauer	stage	for	up	to	four	months	and	can	re-enter	L4	stage	when	adverse	conditions	are	cleared.	Worms	can	also	arrest	at	the	L1	larval	stage.	Image	taken	from	(Clark	and	Hodgkin,	2014).	
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1.4.3	C.	elegans	as	a	model	to	study	ageing	
Ageing	is	the	accumulation	of	cellular	defects	over	time	which	cause	tissue	damage	and	deterioration	and	increase	the	likelihood	of	mortality.	Ageing	within	populations	is	characterized	by	a	high	degree	of	heterogeneity	(Kirkwood	et	al.,	2005).	Likewise,	in	 isogenic	 C.	 elegans	 populations,	 despite	 highly	 controlled	 dietary	 and	environmental	 conditions,	 heterogeneity	 in	 ageing	 is	 a	defining	 feature	 (Kirkwood	and	Finch,	2002).	C.	elegans	show	several	physiological	and	physical	changes	which	positively	 correlate	 with	 physiological	 age,	 including:	 reduced	motility,	 decreased	rate	 of	 pharyngeal	 pumping	 (feeding	 mechanism),	 accumulation	 of	 lipofuscin,	appearance	of	vacuole-like	structures	and	intestinal	tissue	disruption	(Klass,	1977).	With	their	short	lifespan,	low	husbandry	costs	and	the	ability	to	maintain	over	one	hundred	animals	on	a	single	petri	dish,	C.	elegans	is	a	fantastic	model	to	study	ageing.			In	 1983,	 a	 method	 to	 screen	 for	 long-lived	 C.	 elegans	mutants	 was	 reported	 and	isolated	eight	mutants	that	likely	extended	lifespan	by	restricting	the	calorie	intake	of	the	worm	(Klass,	1983).	A	few	years	later,	Friedman	and	Johnson	identified	the	age-1	long-lived	mutant	((Friedman	and	Johnson,	1988a,	b).	In	1993,	the	Kenyon	laboratory	discovered	the	daf-2	mutant	and	its	dependence	on	daf-16,	thus	identified	the	role	of	the	 insulin/insulin-like	 growth	 factor-1	 signaling	 (IIS)	 pathway	 in	 lifespan	modulation	(Kenyon	et	al.,	1993).	This	pathway	has	since	been	found	to	be	involved	in	 ageing	 in	 conserved	 mechanisms	 in	 Drosophila	 (Clancy	 et	 al.,	 2001)	 and	mice	(Bluher	et	al.,	2003;	Holzenberger	et	al.,	2003).	Polymorphisms	in	these	genes	have	also	been	associated	with	longevity	in	humans	(Suh	et	al.,	2008).	Subsequent	research	
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using	C.	elegans	has	uncovered	other	conserved	pathways	which	can	be	targeted	to	modulate	 ageing,	 including:	 the	 target	 of	 rapamycin	 (mTOR),	 sirtuin	 and	 AMPK	signalling	pathways	(Uno	and	Nishida,	2016).	Thus,	many	fundamental	insights	into	the	mechanisms	underpinning	mammalian	ageing	have	been	gleaned	 from	studies	using	C.	elegans	(Kenyon,	2010).	
1.4.4	Living	in	a	bacterial	world	
1.4.4i	E.	coli	as	C.	elegans	diet	In	 the	 laboratory,	 C.	 elegans	 are	 conventionally	 maintained	 on	 a	 peptone-based	growth	medium	(NGM),	which	supports	the	growth	and	proliferation	of	a	‘lawn’	of	the	
E.	coli	B-strain,	OP50	(Brenner,	1974).	Other	E.	coli	strains	are	also	commonly	used	as	a	C.	elegans	food	source,	such	as	the	K12	strain,	MG1655.	C.	elegans	is	solely	dependent	on	E.	coli	for	all	the	macro-	and	micronutrients	required	for	growth,	development	and	reproduction.	C.	 elegans	 feed	by	 sucking	 in	bacterial	 cells	with	a	 specialized	organ	called	the	pharynx,	which	then	grinds	up	cells	and	pumps	them	into	the	intestine.	The	pumping	 and	 peristaltic	 mechanisms	 ensure	 that	 cell	 debris	 passes	 through	 the	intestine	efficiently,	nutrients	are	absorbed,	and	the	remainder	is	swiftly	defecated	(Kim	and	Mylonakis,	2012),	with	an	estimated	transit	time	of	3-10	minutes	in	young	worms	(Avery	and	Shtonda,	2003).	
1.4.4ii	E.	coli	as	C.	elegans	microbiota	OP50	and	the	other	E.	coli	strains	used	 in	C.	elegans	studies	are	 lab-adapted	E.	coli	strains	 which	 are	 unable	 to	 colonize	 the	 C.	 elegans	 intestine	 or	 establish	 a	 stable	association	(Browning	et	al.,	2013).	Only	in	older	worms,	when	the	pharynx	and	the	
31 
 
peristaltic	 muscles	 deteriorate,	 and	 defences	 breakdown,	 do	 bacterial	 cells	accumulate	in	the	intestine	(Garigan	et	al.,	2002).	Thus,	C.	elegans	does	not	constitute	a	‘host’	in	the	conventional	sense,	nor	E.	coli	a	‘microbiota’.	Nevertheless,	C.	elegans	swim	in	a	sea	of	bacterial	cells	and	secreted	bacterial	metabolites	for	the	duration	of	their	lifetime	and	are	therefore	in	constant	intimate	contact	with	their	bacterial	‘diet’.		In	the	wild,	however,	three	recent	independent	studies	have	suggested	that	C.	elegans	have	a	stable	associated	microbiota	in	their	natural	habitat	(Berg	et	al.,	2016;	Dirksen	et	 al.,	 2016;	 Samuel	 et	 al.,	 2016),	where	 they	 are	 found	 on	 rotting	 fruit	 and	 plant	material	(Barriere	and	Felix,	2005;	Felix	and	Braendle,	2010).	These	studies	reported	similarities,	 despite	 different	 geographical	 collection	 sites:	 all	 studies	 identified	Proteobacteria,	particularly	gram-negative	Enterobactericeae	as	the	most	abundant	taxa	 and	 two	 identified	 significant	 abundances	 of	 Bacteriodetes	 and	 Firmicutes	(Dirksen	 et	 al.,	 2016;	 Samuel	 et	 al.,	 2016).	 However,	 others	 in	 the	 field	 remain	sceptical	about	whether	these	 identified	taxa	constitute	a	microbiota	or	are	simply	the	bacteria	that	predominate	in	the	C.	elegans	natural	habitat,	and	were	associated	with	the	worm	at	the	time	of	collection (Zhang	et	al.,	2017).		
1.4.4iii	E.	coli	as	a	C.	elegans	pathogen	Maintenance	of	C.	elegans	on	axenic	media	compromises	fitness,	as	discussed,	but	also	results	 in	a	significant	 increase	 in	 lifespan	(Croll	et	al.,	1977).	This	may	reflect	 the	impact	of	sub-optimal	nutrition,	and	thus	dietary	restriction,	or	it	may	be	due	to	the	removal	of	toxic	bacterial	factors	that	are	detrimental	to	C.	elegans	longevity.	Indeed,	
C.	elegans	are	long-lived	on	heat-killed	or	antibiotic-treated	E.	coli	(in	which	cells	are	
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alive	but	not	proliferating) (Garigan	et	al.,	2002;	Gems	and	Riddle,	2000)	and	Leanerts	et	 al.	 demonstrated	 that	 the	 developmental	 phenotypes	 could	 not	 be	 rescued,	 nor	lifespan	reversed,	by	supplementation	of	the	required	dietary	components	into	the	axenic	 medium	 (Leanerts	 et	 al.	 2008).	 Together,	 these	 studies	 indicated	 that	 the	nutritional	content	of	E.	coli	is	uncoupled	from	its	impact	on	lifespan.		In	line	with	this	hypothesis	was	the	observation	that	C.	elegans	were	longer-lived	on	the	gram-positive	soil	bacterium,	Bacillus	subtilis,	compared	to	on	E.	coli	OP50,	but	no	differences	in	developmental	rate	or	reproduction	were	found	(Garsin	et	al.,	2003).	This	suggested	that	the	two	bacterial	species	have	similar	macronutrient	content	and	lifespan	is	modulated	by	an	E.	coli-	specific	component.	A	subsequent	study	found	that	
C.	 elegans	 on	 OP50	 show	 higher	 expression	 of	 the	 stress-response	 gene,	 sod-3,	compared	 to	 on	B.	 subtilis	 (Sanchez-Blanco	 and	 Kim,	 2011).	 The	 same	 group	 also	showed	that	worms	express	the	antimicrobial	gene,	lys-8,	5-fold	higher	when	fed	live	OP50	compared	to	UV-	killed	OP50	(Hahm	et	al.,	2011).	Another	study	investigated	the	 impact	 of	 the	 growth	 medium	 on	 E.	 coli,	 and	 found	 that	 C.	 elegans	 lived	significantly	 shorter	 when	 OP50	 was	 cultured	 on	 a	 rich	 agar	 growth	 medium	compared	 to	NGM.	The	 authors	 cited	 an	unknown	 change	 in	bacterial	metabolism	and/or	increase	in	pathogenic	behaviour	(Garsin	et	al.,	2001).			The	notion	that	E.	coli	has	a	mild	pathogenic	effect	on	C.	elegans	was	supported	by	the	discovery	of	an	OP50	mutant,	ubiG,	which	increased	C.	elegans	lifespan	(Larsen	and	Clarke,	 2002).	 This	 mutant	 disrupted	 bacterial	 respiration	 and	 caused	 delayed	intestinal	bacterial	accumulation,	without	affecting	nutritional	 content	 (Saiki	et	al.,	
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2008).	Together	with	the	observation	that	accumulation	of	E.	coli	in	the	intestine	is	a	biomarker	of	C.	 elegans	ageing	 (Garigan	et	 al.,	 2002),	 it	was	hypothesized	 that	 the	proliferative	capacity	of	live	E.	coli	in	the	C.	elegans	intestine	is	mildly	pathogenic	to	C.	
elegans	(Portal-Celhay	et	al.,	2012).		Several	recent	studies	have	challenged	this	hypothesis	by	tracking	individual	worms,	rather	than	heterogeneous	populations,	and	finding	no	correlation	between	bacterial	intestinal	 accumulation	 and	 mortality	 (Han	 et	 al.,	 2017;	 Virk	 et	 al.,	 2016).	 As	previously	discussed,	the	Henderson	lab	found	that	neither	OP50	nor	the	K12	strain	were	 able	 to	 colonize	 the	C.	 elegans	 intestine,	 and	only	upon	 restoration	of	 the	O-antigen	component	of	K12	LPS,	were	E.	coli	cells	able	to	colonize	the	intestine	and	kill	
C.	elegans	at	rates	similar	to	pathogenic	bacteria	(Browning	et	al.,	2013).		
1.4.5	C.	elegans-	E.	coli	as	a	simplified	animal-microbe	model	
Together,	 these	 studies	 support	 the	model	 that	E.	 coli	 is	 both	 the	 diet	 and	 a	mild	pathogen	of	C.	elegans,	but	not	a	microbiota	in	the	conventional	sense.	Manipulations	to	E.	coli	metabolism	and	physiology	in	this	simplified	animal-microbe	model	system	therefore	 provide	 a	 means	 to	 explore	 how	 specific	 bacterial	 genes,	 pathways	 or	metabolites	 affect	 animal	 health,	 fitness	 and	 longevity	 (figure	 1.7)	 (Cabreiro	 and	Gems,	2013;	Kim,	2013).					
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Figure	1.7	 Schematic	model	of	 the	C.	 elegans-	 E.	 coli	 animal-microbe	 system.	C.	 elegans	are	maintained	on	a	monoculture	of	E.	coli,	upon	which	they	are	almost	solely	dependent	on	for		micro-	and	macronutrients.	C.	elegans	can	also	take	up	some	dietary	components	from	the	growth	media	directly.	E.	coli	growth,	proliferation	and	metabolism	are	dependent	on	the	growth	media	and	thus	the	growth	media	both	directly	and	indirectly	affects	C.	elegans.	Constituents	of	the	growth	media	can	be	 chemically	defined	and	altered.	E.	 coli	and	C.	 elegans	can	be	genetically	manipulated	 (red	crosses)	and	xenobiotics	can	be	added	to	the	growth	media.	The	impact	of	these	manipulations	can	be	quantified	by	monitoring	several	C.	elegans	phenotypes.		
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1.5	BACKGROUND	WORK	The	following	sections	detail	the	work	carried	out	in	the	Weinkove	laboratory	that	identified	E.	coli	folate	synthesis	as	a	determinant	of	C.	elegans	longevity	(Virk	et	al.,	2012).	 This	 work	 will	 be	 described	 in	 considerable	 detail	 as	 it	 provides	 the	background	for	the	aims	of	this	thesis.				
1.5.1	A	serendipitous	aroD	mutant	extends	C.	elegans	lifespan	
A	spontaneous	mutation	in	the	E.	coli	RNAi	strain,	HT115	(DE3)	was	found	to	extend	lifespan	of	the	long-lived	C.	elegans	mutant,	daf-2.	This	mutant	strain	had	a	growth	defect	on	minimal	media.	A	screen	for	growth	complementation	was	conducted	and	sequence	 analysis	 identified	 a	 mutation	 in	 the	 aroD	 gene.	 aroD	 gene	 encodes	 3-dehydroquinate	dehydratase,	an	essential	enzyme	in	the	shikimic	acid	pathway.	The	shikimic	acid	pathway	is	involved	in	the	biosynthesis	of	several	aromatic	compounds,	including	PABA	(figure	1.8a).	Lifespan	was	extended	on	an	aroD	deletion	strain	from	the	Keio	collection,	BW25113	(K12)	and	reversed	with	supplementation	of	shikimic	acid	and	PABA	 into	NGM	(figure	1.8b).	Plasmid	complementation	of	 the	aroD	gene	restored	normal	wild-type	lifespan.	The	aroD	mutant	did	not	show	any	growth	defects	compared	to	WT	E.	coli.	Together,	this	provided	strong	evidence	that	the	aroD	gene	and	disruption	to	the	shikimic	acid	pathway	was	mediating	C.	elegans	longevity	(Virk	et	al.,	2012).	
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1.5.2	Inhibiting	folate	synthesis	with	a	sulfonamide	extends	C.	elegans	lifespan	without	
inhibiting	bacterial	growth	
The	 sulfonamide	 drug,	 sulfamethoxazole	(SMX),	is	a	structural	mimic	and	competitive	inhibitor	 of	 PABA	 (box	 2)	 (Seydel,	 1968).	Virk	 et	 al.	 found	 that	 SMX	 increased	 C.	
elegans	 longevity	 in	 a	 dose-dependent	manner,	 between	 1	 µg/ml	 to	 256	 µg/ml	(figure	 1.8c).	 Bacterial	 growth	 was	monitored	 and	 surprisingly,	 no	 significant	bacteriostatic	 effect	 was	 observed	 (figure	1.8e).	 SMX	 did	 not	 have	 any	 effect	 on	 C.	
elegans	development	or	 fecundity	(data	not	shown	here)	and	therefore	lifespan	extension	was	not	found	to	have	a	negative	trade-off	(Virk	et	al.	2012).			In	order	to	determine	whether	this	effect	was	folate-specific,	250	µM	PABA	was	added	into	 the	 growth	media	 and	 longevity	 on	 SMX	 was	 completely	 reversed.	 SMX	 was	unable	to	extend	the	lifespan	of	C.	elegans	maintained	on	OP50	transformed	with	the	sulfonamide-resistant	plasmid,	R26	(figure	1.8d).	Together,	this	indicated	that	E.	coli	folate	synthesis	is	responsible	for	modulating	lifespan	(Virk	et	al.	2012).			
Box	2.	What	are	sulfonamides?	
 
- The	first	systematically	used	
antibiotics	
	
- Structural	analogs	of	PABA	and	
therefore	competitive	inhibitors	
of	dihydropteroate	synthase	
(DHPS)	
 
- Bacteriostatic:	inhibit	growth	
and	proliferation	of	bacteria		
	
	
	
 
Sulfonanilimide	 	 PABA	
 
	
	
	
R	group	of	sulfamethoxazole	(SMX)	
	
 
2 
2		
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Figure	1.8	Summary	of	background	work	demonstrating	that	inhibiting	E.	coli	folate	synthesis	
extends	C.	elegans	 lifespan	without	negatively	affecting	bacterial	growth	a)	schematic	of	the	shikimic	 acid	 pathway	 b)	 lifespan	 of	 C.	 elegans	on	aroD	mutant	 is	 reversed	with	 PABA	 and	 not	shikimic	acid	c)	C.	elegans	mean	lifespan	increases	with	increasing	[SMX]	d)	C.	elegans	lifespan	is	not	increased	on	sulfonamide	resistant	OP50	in	the	presence	of	SMX	e)	E.	coli	growth	is	not	affect	by	concentrations	of	SMX	that	extend	lifespan.	Taken	from	Virk	et	al.	2012. 
 
 
A.	
B.	 C.	
D.	 E.	
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1.5.3	Inhibiting	folate	synthesis	lowers	folates	in	both	E.	coli	and	C.	elegans		
As	SMX	did	not	cause	a	growth	defect	in	either	bacteria	or	the	worm,	it	was	verified	that	 SMX	 did	 indeed	 decrease	 folate	 levels	 in	 both	 E.	 coli	 and	 C.	 elegans.	 Folate	extraction	methods	were	optimised	from	published	 literature	protocols	(Garratt	et	al.,	2005;	Lu	et	al.,	2007)	and	samples	were	analysed	by	LC-MS.	The	equipment	used	in	this	study	was	not	as	sensitive	as	that	which	can	be	achieved	today,	and	only	the	most	abundant	folate	derivatives	could	only	just	be	detected:	5/10-formyl	THF-glu3	(in	E.	coli	)	and	5-methyl	THF-glu5	(in	C.	elegans)	(figure	1.9)		In	E.	coli treated with	128	µg/ml	SMX-treated,	5/10-formyl	THF-glu3	folate	could	not	be	detected;	the	threshold	for	detection	was	2	µg/ml	(figure	1.9a).	 In	C.	elegans	on	SMX-treated	E.	 coli,	 levels	 of	 5-methyl	 THF-glu5	were	 significantly	 lower	 at	 just	 1	µg/ml	 SMX,	 compared	 to	 non-supplemented	 conditions;	 levels	 were	 further	decreased	 at	 4	 µg/ml	 SMX,	 after	 which	 further	 decreases	 were	 indistinguishable	(figure	1.9b)	(Virk	et	al.	2012).	Together,	these	data	indicate	that	despite	not	affecting	
E.	coli	or	C.	elegans	growth	or	development,	SMX-treatment	significantly	decreased	folate	levels	in	both	organisms.	However,	the	LC/MS	data	collected	here	was	limited	and	signals	obtained	were	noisy	and	close	to	the	limit	of	detection.	A	more	accurate	detection	method	is	required	to	provide	a	more	complete	picture	of	the	folate	profile	of	both	E.	coli	and	C.	elegans.				
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A.	
B.		
	
Figure	1.9	LC-MS	detection	of	E.	coli	and	C.	elegans	folate	in	response	to	SMX	a)	5/10-formyl	THF-glu3	was	detected	in	E.	coli	at	0.1	and	1	µg/ml	SMX,	and	levels	were	below	the	level	of	detection	above	this	concentration	b)	5-methyl	THF-glu3	was	detected	in	C.	elegans	up	to	128	µg/ml.	Levels	were	normalized	to	levels	of	co-enzyme	A	as	an	internal	standard.	Taken	from	Virk	et	al.	2012.						
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1.5.4	Folate-dependent	lifespan	extension:	animal	or	microbe?	
As	folates	seemed	to	be	lowered	in	both	E.	coli	and	C.	elegans	on	conditions	that	extend	lifespan,	 it	 was	 unclear	 whether	 the	 mechanism	 underpinning	 longevity	 was	dependent	on	animal	or	microbe	folates,	or	both.	It	was	important	to	distinguish	this	as	 any	 intervention	which	 targets	 folate	 synthesis	must	 ensure	 that	 animal	 folate	levels	 are	 sufficient.	 Caloric	 restriction	 was	 ruled	 out	 as	 neither	 aroD,	 nor	 SMX,	affected	bacterial	growth.	Furthermore,	the	initial	aroD	mutation	extended	C.	elegans	lifespan	in	a	daf-2	mutant	background.	However,	the	lack	of	dietary	folate,	a	specific	folate	or	a	folate-dependent	micronutrient,	could	induce	a	specific	dietary-restriction	which	increases	lifespan.	Alternatively,	inhibition	of	folate	synthesis	may	prevent	E.	
coli	accumulation	in	the	C.	elegans	intestine	with	age,	a	phenomenon	which	is	widely	thought	 to	accelerate	ageing.	More	subtly,	 folate-dependent	alterations	 in	bacterial	metabolism	may	either	promote	a	beneficial	activity,	or	attenuate	a	toxic	one,	which	increases	C.	elegans	lifespan.	The	experiments	carried	out	to	test	these	possibilities	are	detailed	below.			
1.5.4i	C.	elegans	folates	do	not	impact	lifespan		Folate	supplementation	into	NGM	in	a	form	which	was	presumed	to	be	directly	absorbed	by	C.	elegans	(folinic	acid/	5-formyl	THF-glu1)	did	not	decrease	lifespan	in	an	SMX	background.	Also,	the	lifespan	of	a	C.	elegans	folate-uptake	mutant,	gcp-2.1	
(ok1004),	which	does	not	show	any	abnormal	developmental	phenotypes,	was	not	long-lived.	Disruption	of	the	C.	elegans	folate	cycle	by	methotrexate	(MTX),	which	targets	the	DHFR	enzyme,	also	did	not	impact	lifespan.	Together,	these	results	
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suggested	that	neither	folate	supplementation	nor	folate	deficiency	impact	C.	elegans	lifespan,	and	thus	the	possibility	that	lack	of	dietary	folate	extends	lifespan,	was	ruled	out	(Virk	et	al.,	2016).	However,	C.	elegans	folate	measurements	were	not	carried	out	to	substantiate	these	claims	as	the	LC-MS	facility	was	not	accessible	at	this	time;	this	will	be	addressed	in	this	thesis	in	Chapter	5,	using	a	more	sensitive	detection	method.		
1.5.4ii	Reduced	intestinal	accumulation	does	not	underpin	lifespan	extension	The	possibility	that	the	inhibition	of	folate	synthesis	increases	lifespan	by	decreasing	intestinal	bacterial	load	was	addressed	by	quantifying	the	fluorescence	of	GFP-tagged	OP50	 in	 the	 C.	 elegans	 lumen	 after	 day	 5	 of	 adulthood.	 Individual	 animals	 were	separated	into	‘high’	and	‘low’	accumulation	cohorts	and	lifespans	carried	out	on	SMX	and	 control	 conditions.	 Lifespan	 was	 dictated	 solely	 by	 SMX	 treatment,	 with	 no	significant	impact	of	‘high’	or	‘low’	accumulation.	In	the	untreated	control	condition,	approximately	50%	of	 recently	dead	worms	showed	no	visible	 accumulation.	 SMX	was	found	to	delay	accumulation,	but	did	not	prevent	it.	Overall,	it	was	concluded	that	intestinal	accumulation	cannot	be	attributed	to	the	lifespan	extension	on	SMX.	This	has	 since	 been	 endorsed	 by	 a	 similar	 study	 which	 found	 no	 correlation	 between	intestinal	 colonization	 of	E.	 coli	mutants	 and	 their	 lifespan-extending	 effects	 on	C.	
elegans	(Han	et	al.,	2017).			
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1.5.4iii	A	screen	of	1000+	E.	coli	mutants	 for	C.	elegans	 longevity	 revealed	novel	genes	
which	influence	lifespan	and	are	involved	in	virulence	in	pathogenic	microbes	
In	order	to	further	understand	how	E.	coli	influences	C.	elegans	lifespan,	the	Weinkove	laboratory	conducted	a	screen	of	over	1,000	E.	coli	K12	deletion	mutants	 from	the	Keio	collection.	These	mutants	are	constructed	by	replacing	the	open-reading	frame	of	individual	genes	with	a	kanamycin	resistance	gene,	flanked	by	FLP	recognition	sites	(Baba	et	al.,	2006).	On	these	mutants,	bacterial	C.	elegans	longevity	was	not	found	to	correlate	to	bacterial	growth.	Following	several	rounds	of	screening,	only	9	mutants	were	identified	to	robustly	increase	lifespan	(figure	1.10).	Encouragingly,	two	of	the	genes	 identified	 were	 pabA	 and	 pabB	 which	 encode	 the	 heterodimeric	 enzymatic	complex,	 4-amino-4-deoxychorismate	 synthase,	 responsible	 for	 PABA	 synthesis	(figure	1.2).	Three	of	the	mutants,	metL,	ihfA,	and	ihfB,	caused	a	distinct	change	in	the	biophysical	properties	of	the	bacterial	‘lawn’	and	altered	the	feeding	and	movement	of	C.	elegans.	The	other	mutants	identified,	ompA	,	znuB,	tatC	and	rpoS	did	not	change	the	appearance	of	the	bacteria	on	the	agar	plates	and	were	therefore	focused	on.			Briefly,	ompA	is	an	abundant	outer	membrane	transporter(Smith	et	al.,	2007);	znuB	encodes	 part	 of	 the	 ZnuABC	 zinc	 transporter,	 which	 facilitates	 uptake	 of	 low	concentrations	of	zinc	(Patzer	and	Hantke,	1998);	tatC	encodes	a	component	of	the	twin	 arginine	 translocation	 pathway,	 which	 transports	 folded	 proteins	 to	 the	periplasm	(Sargent	et	al.,	2001);	and	rpoS	encodes	the	global	stress	response	sigma	factor,	 responsible	 for	 the	 transcription	 of	 several	 hundred	 genes	 involved	 in	responses	to	abiotic	stress	(Dong	et	al.,	2008).	
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	Interestingly,	a	common	factor	of	the	genes	isolated	in	the	screen,	including	pabA	and	
pabB,	is	that	they	reduce	virulence	when	mutated	in	pathogenic	bacteria	(Brown	and	Stocker,	1987;	Chimalapati	et	al.,	2011;	Dong	and	Schellhorn,	2010;	Gabbianelli	et	al.,	2011;	Ochsner	 et	 al.,	 2002).	E.	 coli	 strains	 used	 for	C.	 elegans	 culture	 do	 not	 have	known	virulence	factors,	however,	it	was	hypothesized	that	the	genes	isolated	in	the	screen	might	 regulate	 other,	 as	 yet	 unidentified,	 factors	with	 a	milder	but	 chronic	effect	on	their	hosts.	The	role	of	the	rpoS	gene	in	E.	coli	folate	synthesis,	toxicity	and	
C.	elegans	lifespan	will	be	explored	in	Chapter	7.			
	
Figure	1.10	Screen	for	E.	coli	mutants	that	robustly	extend	C.	elegans	lifespan	revealed	9	genes	
where	 longevity	 did	 not	 depend	on	 reduced	bacterial	 growth.	Of	 the	 1000+	E.	 coli	mutants	tested,	overall	there	was	not	correlation	between	the	growth	the	mutant	strains	in	LB	and	C.	elegans	survival	at	day	11	or	12.	The	mutants	that	increased	lifespan	after	the	fourth	round	of	the	screen	are	indicated.	Taken	from	Virk	et	al.	2016.		
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1.5.4	iv	Mutations	in	(most)	E.	coli	folate	cycle	genes	did	not	extend	lifespan		In	order	to	determine	whether	a	specific	folate	or	by-product	of	the	folate	cycle	was	responsible	 for	C.	 elegans	 lifespan,	 lifespan	assays	were	 carried	out	on	mutants	of	genes	involved	in	the	folate	cycle.	Of	the	23	non-essential	genes	involved	in	the	folate	cycle	or	related	reactions,	only	a	small	significant	effect	on	lifespan	on	the	glyA	mutant	was	observed.	glyA	encodes	 serine	hydroxymethyltransferase	 (SHMT) (Shen	et	 al.,	1997)	and	uses	5,10-methylene	THF	as	a	methyl	donor	to	convert	glycine	to	serine	and	also	catalyzes	the	reverse	reaction,	using	THF.	SHMT	also	converts	5-methenyl	THF	to	5-formyl	THF.	metL,	which	was	identified	in	the	screen,	is	involved	in	two	steps	in	the	methionine	biosynthesis	pathway	(Zakin	et	al.,	1983).	No	other	genes	involved	in	 methionine	 biosynthesis	 had	 any	 impact	 on	 lifespan.	 Due	 to	 the	 ‘watery’	consistency	of	the	metL	lawn	cited,	metL	was	disregarded	as	having	any	biochemical	impact	on	longevity.	Virk	et	al	therefore	hypothesized	that	folate	synthesis,	not	the	folate	cycle,	is	responsible	for	C.	elegans	lifespan	(Virk	et	al.	2012).		
1.5.5	Summary	of	background	work	and	limitations	to	the	study	
Virk	et	al.	 identified	E.	coli	folate	synthesis	as	a	target	to	extend	C.	elegans	lifespan.	This	 was	 achieved	 genetically	 (aroD,	 pabA,	 pabB	mutants)	 and	 pharmacologically	(SMX)	 without	 affecting	 bacterial	 growth	 or	 C.	 elegans	 health.	 LC-MS	 detection	identified	 one	 folate	 species	 in	 both	 E.	 coli	 and	 C.	 elegans	 that	 was	 significantly	decreased	 in	response	 to	SMX,	however	LC-MS	measurements	were	 limited	due	 to	lack	of	sensitivity.	No	impact	of	limiting	or	supplementing	C.	elegans	folate	on	lifespan	was	 found,	 indicating	 that	a	bacterial	 folate-dependent	process	underpins	 lifespan,	however,	LC-MS	measurements	were	not	carried	out	under	these	conditions.	Efforts	
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to	 identify	 an	 E.	 coli	 folate-dependent	 process	 responsible	 for	 lifespan	 increase	eliminated	 several	 hypotheses	but	 did	not	 illuminate	 a	mechanism.	An	E.	 coli	K12	mutant	gene	screen	 for	C.	elegans	 longevity	 isolated	genes	 involved	 in	virulence	 in	pathogenic	microbes	(including	pabA	and	pabB),	but	it	was	not	clear	whether	folate	synthesis	was	acting	via	this	mechansism	in	E.	coli	to	shorten	C.	elegans	lifespan.			
1.6	AIMS	OF	THESIS	The	initial	aims	of	 this	PhD	are	to	address	the	 limitations	of	 the	previous	study	by	developing	 a	more	 controlled	 and	 sensitive	model	 system	 in	 order	 to	 control	 and	accurately	detect	folate	levels	in	the	media,	the	microbe	and	the	worm.	This	optimised	system	 will	 then	 be	 used	 to	 understand	 the	 factors	 that	 influence	 E.	 coli	 folate	synthesis,	both	extrinsically	and	genetically,	with	the	ultimate	aim	of	understanding	how	bacterial	folate	synthesis	and	one-carbon	metabolism	affect	C.	elegans	health	and	longevity.	This	thesis	therefore	takes	an	E.	coli–centric	view,	where	C.	elegans	lifespan	(and	development,	reproduction	and	behaviour)	will	be	used	as	a	phenotypic	read-out	in	response	to	perturbations	that	influence	bacterial	folate	synthesis.	
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CHAPTER	2:	MATERIALS	AND	GENERAL	METHODS	
2.1	STRAINS	
2.1.1	C.	elegans	strains		
Strain	 Genotype	 Source/Origin	N2		 																																							wild	type		 (Brenner,	1974)	SS104		 																																						glp-4(bn2)		 (Beanan	and	Strome,	1992)	UF208		 																																							wild	type		 (Virk	et	al.,	2016)		 UF209			 	 gcp-2.1(ok1004)			 (Virk	et	al.,	2016)		
2.1.2	E.	coli	strains		
Strain	 Genotype	 Plasmid	 Characteristics	 Source	OP50	 wild-type	 n/a	 ura-	 (Brenner,	1974)	BW25113	 wild-type	 pGreen	0029	 kanr	 (Baba	et	al.,	2006)	JW3323-1	 ΔpabA	 n/a	 kanr	 "	JW5437-1	 ΔrpoS		 n/a	 kanr	 "	JW1253-1	 ΔtrpB	 n/a	 kanr	 "	JW3686-7	 ΔtnaA	 n/a	 kanr	 "	JW0912-1	 ΔompF	 n/a	 kanr	 "	JW3325-1	 ΔyhfG	 n/a	 kanr	 "	JW0554-1	 ΔompT	 n/a	 kanr	 "	JW1023-1	 ΔcsgD	 n/a	 kanr	 "	JW0230-1	 Δcrl	 n/a	 kanr	 "	JW0940-6	 ΔompA	 n/a	 kanr	 "	JW5181-1	 ΔhlyE	 n/a	 kanr	 "	JW2203-1	 ΔompC	 n/a	 kanr	 "	JW1736-1	 ΔastA	 n/a	 kanr	 "	JW5571-1	 ΔbipA	 n/a	 kanr	 "	JW2284-6	 ΔlrhA	 n/a	 kanr	 "	JW5702-4	 Δcrp	 n/a	 kanr	 "	
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JW1653-1	 Δcfa	 n/a	 kanr	 "	JW3484-1	 ΔgadX	 n/a	 kanr	 "	JW5571-1	 ΔbipA	 n/a	 kanr	 "		JW2449-4	 ΔtktB	 n/a	 kanr	 "	JW4338-1	 ΔosmY	 n/a	 kanr	 "	JW1488-7	 ΔgadB	 n/a	 kanr	 "	JW3474-5	 Δslp	 n/a	 kanr	 "	JW1912-1	 ΔmysB	 n/a	 kanr	 "	JW3480-2	 ΔgadE	 n/a	 kanr	 "	JW1653-1	 Δcfa	 n/a	 kanr	 "	JW1477-1	 ΔosmC	 n/a	 kanr	 "	JW3221-5	 ΔcsrA	 n/a	 kanr	 "	JW3485-1	 ΔgadA	 n/a	 kanr	 "	JW2448-4	 ΔtalA	 n/a	 kanr	 "	JW2755-3	 ΔrelA	 n/a	 kanr	 "	JW3879-1	 ΔsodA	 n/a	 kanr	 "	JW1886-1	 ΔotsB	 n/a	 kanr	 "	JW3323-1	 Δfic	 n/a	 kanr	 "	JW1736-1	 ΔastA	 n/a	 kanr	 "	JW5702-4	 Δcrp	 n/a	 kanr	 "		JW5437-1	 ΔrpoS	 n/a	 kanr	 "	JW2284-6	 ΔlrhA	 n/a	 kanr	 "	JW5822-1	 ΔabgT	 n/a	 kanr	 "	CMabgTpabA	 ΔabgT	ΔpabA	 n/a	 n/a	 This	study	CM1/puc19*	 WT	 pUC19‡,	pGreen	0029	 kanr,	amp	r	 This	study	CM2/puc19*	 ΔpabA	 pUC19	 kanr,	amp	r	 This	study	CM3/puc19*†	 ΔabgTΔpabA	 pUC19	 kanr,	amp	r	 This	study	CM1/pJ128*	 WT	(abgT	OE)	 pJ128‡,	pGreen	0029	 kanr,	amp	r	 This	study	CM2/pJ128*	 ΔpabA	(abgT	OE)	 pJ128	 kanr,	amp	r	 This	study	CM3/pJ128*†	 ΔabgTΔpabA	
(abgT	OE)	 pJ128	 kanr,	amp	r	 This	study	
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*Derived	from	BW25113	or	relevant	mutant	strain	†	ΔabgTΔpabA	double	mutant	strain	made	by	P1	transduction	(section	2.X)	‡	 pUC19	 and	 pJ128	 plasmids	 were	 obtained	 with	 thanks	 from	 Jacalyn	 Green’s	laboratory,	Northwestern	University,	Chicago.		
2.2	GENERAL	SOLUTIONS			LB	(Luria	Bertolani	broth)	(10.0g/l	Tryptone	(95039,	Sigma-Aldrich),	5.0g/l	Yeast	Extract	 (Y1625,	 Sigma-Aldrich),	 10.0g/l	 NaCl,	 to	 distilled	 water	 and	 mixed	thoroughly.			M9	 buffer	 (7.37g/l	 Na2HPO4.2H2O	 (≥99.0%,	 Sigma-Aldrich),	 3.00g/l	 KH2PO4	(≥99.0%,	 Sigma-Aldrich),	 and	 5.00g/l	NaCl	 (≥99.0%,	 Sigma-Aldrich),	 to	 distilled	water,	 stirred	 until	 dissolved.	 Solutions	 were	 divided	 into	 250ml	 aliquots	 and	autoclaved	at	121°C	for	20	minutes	sterilise.		
2.3	PLATE	PREPARATION		
2.3.1	Nematode	Growth	Media	(NGM)	plate	preparation		
NGM	 was	 prepared	 by	 adding	 3.00g/l	 NaCl,	 2.50g/l	 Peptone	 (70171,	 Sigma-Aldrich)	and	20.0g/l	Agar	(05038,	Sigma	Aldrich)	to	distilled	water.	The	media	was	then	autoclaved	at	121°C	for	20	minutes	to	sterilise.	Once	the	autoclave	cycle	had	completed,	 the	 media	 was	 cooled	 to	 55°C	 at	 which	 point,	 1ml/l	 of	 Cholesterol	(≥99.0%,	SigmaAldrich)	(from	5mg/ml	cholesterol	solution	dissolved	in	ethanol),	1ml/l	of	1M	CaCl2	(≥96.0%,	Sigma-Aldrich),	1ml/l	of	1M	MgSO4	(≥99.5%,	Sigma-
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Aldrich)	and	25ml/l	of	1M	KH2PO4	(pH	6.0)	were	added	aseptically	in	a	flow	cabinet.	15	ml	NGM	was	aliquoted	into	60	mm	plates	and	left	to	dry.	Plates	were	stored	at	4-5	°C	for	up	to	three	weeks	and	used	for	C.	elegans	maintenance.		
2.3.2	Defined	Media	(DM)	plate	preparation		
Defined	media	was	prepared	by	adding	3.00g/l	NaCl,	and	18.0g/l	high-purity	agar	(56763,	Sigma	Aldrich) to distilled water. The	media	was	autoclaved	at	121°C	for	20	minutes	and	cooled	to	55°C.	The	following	constituents	were	added	aseptically	in	a	flow	 cabinet:	 1ml/l	 of	 Cholesterol	 (≥99.0%,	 Sigma-Aldrich)	 (from	 5mg/ml	cholesterol	 solution	 dissolved	 in	 ethanol),	 1ml/l	 of	 1M	MgSO4	 (≥99.5%,	 Sigma-Aldrich)	and	25ml/l	of	1M	KH2PO4	(pH	6.0).	20.3	ml/l	of	an	amino	acid	solution	(see	below),	0.2ml/l	of	a	trace	metal	solution†	and	10	nM	B12	were	also	added	in	the	flow	 cabinet.	 Antibiotics	 and	 additional	 components	were	 added	 at	 this	 stage	 if	required‡.		15	ml	DM	was	aliquot	into	60	mm	plates	and	left	to	solidify.	Plates	were	stored	 at	 4-5	 °C	 and	 used	 within	 2-3	 days.	 DM	 was	 used	 for	 all	 experimental	procedures	in	this	thesis	unless	otherwise	stated.		
2.3.2i	Amino	acid	solution	for	defined	media	
Amino	acid	 g/	750ml	
Alanine	 1.0643	
Arginine	 0.9698	
Aspartic	acid	 1.3365	
Cysteine	 0.0765	
Glutamic	acid	 2.2455	
Glycine	 2.5605	
Histidine	 0.2115	
Isoleucine	 0.3510	
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Leucine	 0.6345	
Lysine	 0.6930	
Methionine	 0.1643	
Phenylalanine	 0.4118	
Proline	 1.5480	
Serine	 0.6323	
Threonine	 0.4005	
Tryptophan	 0.0428	
Tyrosine	 0.2385	
Valine	 0.47025		
2.3.2ii	Trace	metal	solution	for	defined	media†	2000	x	trace	metals	solution	was	made	up	using	the	stock	solutions	of	individual	metals	as	detailed	below.	Except	for	FeCl3,	stock	solutions	of	were	autoclaved	and	stored	at	room	temperature.	Used	at	0.2x.	
 2000	x	trace	metals	 MW	 1	x	conc.	36	ml	distilled,	sterilized	water	
50	ml	 0.1	M	 FeCl3	in	~0.12	M	HCl		 270.3	 50	μM	Fe	
2	ml	 1	M	 CaCl2	 110.99	 20	μM	Ca	
1	ml	 1	M	 MnCl2-4H2O	 197.91	 10	μM	Mn	
1	ml	 1	M	 ZnSO4-7H2O	 287.56	 10	μM	Zn	
1	ml	 0.2	M	 CoCl2-6H2O	 237.95	 2	μM	Co	
2	ml	 0.1	M	 CuCl2-2H2O	 170.486	 2	μM	Cu	
1	ml	 0.2	M	 NiCl2-6H2O	 237.72	 2	μM	Ni	
2	ml	 0.1	M	 Na2MoO4-2H2O	 241.98	 2	μM	Mo	
2	ml	 0.1	M	 Na2SeO3-5H2O	 263.03	 2	μM	Se	
	2	ml	 0.1	M	 H3BO3	 61.83	 2	μM	B	
 	
2.3.2iii	Antibiotic	and	folate	solutions	added	to	defined	media‡	100	x	stock	solutions	of	antibiotics	(kanamycin,	25	mg/ml;	carbenicillin,	50	mg/	ml)	and	folates	were	made	before	adding	the	appropriate	volume	into	DM	after	all	other	
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constituents	had	been	added.	Antibiotic	solutions	were	dissolved	in	distilled	water	and	aliquot	into	1.5	ml	Eppendorf	tubes	and	stored	at	-20	ᵒC	for	several	weeks.	Folic	acid	(16.203,	Schircks),	folinic	acid	(96.220,	Schircks),	PABA-glu	(16.701,	Schircks),	PABA	(≥99.0%,	Sigma-Aldrich),	and	SMX (S7507,	Sigma-Aldrich)	solutions		were	dissolved	in	minimum	concentrations	of	NaOH	(1	mM-	100	mM)	and	were	not	stored	after	use.	All	stock	solutions	were	filter	sterilised	using	a	0.2μm	filter.	
	
2.4	PREPARATION	OF	LB	BACTERIAL	CULTURES		5	ml	of	sterile	LB	was	pipetted	aseptically	into	a	sterile	10	ml	falcon	tube.	A	sterile	pipette	tip	was	used	to	inoculate	the	LB	with	E.	coli	from	a	stock	culture	stored	at	-80ᵒC.	Tubes	were	 then	 incubated	overnight	 at	37°C	 in	 an	orbital	 shaker	 (Stuart	SSL1	Lab-scale	orbital	shaker)	at	220rpm.	LB	bacterial	cultures	used	to	seed	NGM	plates	for	worm	maintenance	were	stored	at	4	ᵒC	for	a	maximum	of	one	week.		LB	cultures	were	also	used	to	inoculate	DM	cultures	for	experimental	procedures	(see	below),	and	were	used	the	following	day	and	not	stored	for	further	use.			
2.5	PREPARATION	OF	DM	BACTERIAL	CULTURES		DM	cultures	were	used	for	all	experimental	procedures	carried	out	on	DM	plates.	3	ml	of	sterile	DM	was	pipetted	aseptically	into	a	sterile	10	ml	falcon	tube.	A	sterile	pipette	 tip	was	used	 to	 inoculate	 the	DM	with	30	µl	 of	 an	LB	overnight	 culture.	Tubes	were	 incubated	 as	described	 above,	 but	 for	 a	 set	 time	of	 18	hours.	 Strict	stipulations	with	protocol	here	have	been	optimised	in	order	to	ensure	minimum	and	controlled	carryover	of	nutrients	from	LB.			
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2.6	SEEDING	NGM	AND	DM	PLATES	WITH	E.	COLI		Agar	media	 in	 plates	was	 seeded	with	 100μl	 of	 bacterial	 culture	 using	 a	 repeat	pipette	dispenser	under	sterile	conditions.	The	plates	were	incubated	at	25ᵒC	for	2	days	before	use	C.	elegans	were	transferred.	DM	plates	were	always	seeded	with	DM	cultures.	NGM	plates	were	always	seeded	with	LB	cultures.			
2.7	MEASURING	BACTERIAL	GROWTH	
2.7.1	Agar	media	
E.	 coli	 seeded	 onto	 agar	 DM	 (C.	 elegans	 experimental	 conditions)	 was	 removed	 by	pipetting	1ml	M9	onto	the	plate	and	a	glass	spreader	was	used	to	scrape	of	the	bacterial	lawn.	The	bacterial	suspension	was	pipetted	into	a	1.5	ml	Eppendorf	and	the	volume	was	 recorded.	 Tubes	 were	 vortex	 vigourously	 in	 order	 to	 obtain	 a	 homogenised	solution.	100	µl	was	taken	and	diluted	with	900	µl	M9	in	a	cuvette.	A	spectrophotometer	was	 used	 to	 read	 bacterial	 growth	 at	 600	 nm.	 Bacterial	 growth	 was	 calculated	 by	multiplying	OD	600	by	the	volume	of	the	sample.		
2.7.2	Liquid	96-well	microtiter	plates	
In	 order	 to	 measure	 bacterial	 growth	 over	 time	 and	 test	 a	 range	 of	 experimental	conditions	simultaneously,	a	liquid	growth	assay	was	developed.	96-well	round-bottom	microtiter	plates	(Greiner)	were	used.	Wells	were	filled	to	200	µl	with	DM	containing	appropriate	 supplement	 and	 were	 inoculated	 to	 a	 starting	 OD600	 of	 0.001	 of	 an	overnight	DM	culture.	The	plate	was	incubated	at	37ᵒC	with	continuous	shaking	in	a	Synergy	 H4	 Hybrid	 Multi-Mode	 Microplate	 Reader.	 Readings	 were	 taken	 every	 5	
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minutes	for	~18-22h	to	give	kinetic	growth	curves.	Mean	growth	curves	were	created	using	readings	from	at	least	3	replica	wells	in	each	case.		
 
2.8	C.	ELEGANS	STRAIN	MAINTENANCE		
C.	elegans	populations	were	maintained	on	NGM	plates	seeded	with	OP50	E.	coli.	When	the	E.	coli	had	been	used	up	and	animals	had	starved,	~	1	cm3	sections	of	agar	with	starved	worms	were	cut	using	a	sterile	scalpel	blade	and	placed	onto	NGM	agar	plates	with	‘fresh’	OP50	(seeded	two	days	previously).	This	enables	starved	worms	to	re-enter	development.		
2.9	OBTAINING	SYNCHRONISED	POPULATIONS	OF	C.	ELEGANS		
2.9.1	Bleaching	(carried	out	on	NGM)	
Gravid	 unstarved	 worms	 were	 subjected	 to	 bleaching	 as	 a	 method	 to	 obtain	 a	synchronized	 and	 sterile	 population	 of	 eggs.	 Four	 plates	 were	 used	 per	 worm	strain.	 1ml	M9	was	used	 to	wash	worms	off	 each	plate	 and	washings	 from	 two	plates	were	pooled	into	a	1.5	ml	Eppendorf	tubes.	Gravid	worms	were	left	to	settle	and	 excess	 M9	 was	 carefully	 removed,	 leaving	 approximately	 200μl.	 125μl	 of	bleach	solution	(7:8	sodium	hypochlorite	(425044,	Sigma-Aldrich)	and	4M	NaOH	respectively)	was	added	to	each	tube	and	the	tubes	were	shaken	continuously	by	hand	for	approximately	3	minutes,	until	the	solutions	became	uniformly	cloudy	and	worm	 definition	 was	 lost.	 At	 this	 point,	 1	 ml	 M9	 was	 added	 to	 each	 tube	 and	centrifuged	for	1.5	mins	at	3000	rpm	in	a	Spectrafuge	24D	bench	top	centrifuge	(Jencons-PLS).	The	 supernatant	was	 removed,	 leaving	 approximately	20-40μl	 in	
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the	tube	and	1	ml	fresh	M9	was	added	to	wash	the	eggs	and	remove	traces	of	bleach.	The	 pellet	was	 dissasociated	 by	 shaking	 and	 c	 centrifuged	 again	 as	 before.	 The	supernatant	 was	 again	 removed	 and	 1	 ml	 M9	 added	 again.	 Tube	 were	 again	centrifuged	and	 the	supernatant	was	removed	as	before	–	 leaving	20-40	μl.	The	pellet	was	resuspended	by	shaking	and	5	μl	pipetted	onto	a	seeded	agar	plate	in	order	 to	 rougly	 quantify	 the	 number	 of	 eggs	 within	 each	 tube	 and	 normalize	volumes	 pipetted	 onto	 plates	 between	 tubes.	 Approximately	 50-200	 eggs	 were	pipetted	onto	each	plate.	NGM	plates	were	used	for	bleaching.				
2.9.2	Egg-lay	(carried	out	on	DM)	
Populations	of	worms	obtained	by	bleaching	are	not	used	directly	for	experimental	analysis	due	to	potentially	adverse	effects	of	bleaching	on	fitness.	Eggs	obtained	from	bleaching	are	raised	until	gravid	and	an	egg-lay	is	performed	in	order	to	again	gain	 synchronized	populations	 for	 experiments.	 Egg-lays	 are	 carried	out	 on	DM	plates.	3-5	gravid	worms	are	transferred	onto	seeded	DM	plates,	where	the	number	of	 replicates	 per	 condition	 depends	 on	 the	 experiment	 being	 carried	 out:	 for	lifespan	assays,	4-5	plates	are	used	for	each	condition	to	obtain	sufficient	numbers	of	 worms.	 Plates	 are	 incubated	 overnight	 at	 20	 °C	 (15	 °C	 if	 using	 temperature	sensitive	 SS104	 for	 lifespan	 analysis)	 and	 gravid	worms	 are	 removed	 from	 the	plates	after	ensuring	that	sufficient	eggs	have	been	laid.	Egg-lays	were	set	up	either	in	the	late	afternoon	and	worms	removed	early	the	next	morning	(overnight	egg-lay)	or	set-up	early	in	the	morning	and	removed	in	the	later	afternoon	(day	time	egg-lay).	Worms	were	then	incubated	at	the	temperature	appropriate	for	further	analysis.		
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2.10	DEVELOPMENTAL	ASSAY:	BODY	LENGTH	QUANTIFICATION	
C.	elegans	body	length	at	L4	stage	was	used	to	measure	development.	Following	egg-prep,	an	egg-lay	onto	the	appropriate	experimental	condition	was	carried	out.	Gravid	adults	were	removed	and	plates	were	incubated	at	25	°C	for	2.5	days	until	L4	stage.	Plates	were	imaged	using	a	1.0x	PLANAPO	lens	and	4.0x	magnification	and	captured	using	a	digital	microscope	camera	with	a	CCD	(charge-coupled	device)	sensor.	ImageJ	was	used	to	measure	C.	elegans	body	length.	A	randomly-offset	10x	8	grid	overlay	was	applied	to	each	image	and	each	square	assigned	a	grid	reference.	A	random	number	generator	was	 used	 to	 arbitrarily	 select	 squares	 and	 any	worms	 falling	within	 this	square	 were	 measured.	 Those	 worms	 that	 occupied	 two	 squares	 or	 more	 were	discounted.	 A	 total	 of	 40	worms	were	measured	 for	 condition.	Measurements	were	made	using	the	freehand	line	tool	by	tracing	a	 line	along	the	extent	of	the	C.	elegans	body	axis	(figure	2.1).	Measurements	were	converted	from	pixels	to	mm,	where	at	this	magnification,	1	pixel=	0.011mm.	Measurements	were	carried	out	blinded.	
2.11	DEVELOPMENTAL	ASSAY:	FECUNDITY	ASSAY	Following	bleaching,	an	egg-lay	onto	the	appropriate	experimental	condition	was	carried	out.	Plates	were	incubated	at	25°C	for	3	days	until	worms	developed	into	young	adults.	10	individual	worms	were	transferred	onto	10	separate	plates	per	condition*.	Once	worms	began	laying	eggs	they	were	transferred	to	freshly	
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Figure	2.1	Representative	images	obtained	for	body	length	measurement	
	ImageJ	was	used	to	measure	C.	elegans	body	length	a)	to	reduce	bias	in	measuring,	a	randomly-offset	10x	8	grid	overlay	was	applied	to	each	image	and	each	square	assigned	a	grid	reference.	A	random	number	generator	was	used	to	arbitrarily	select	squares	and	any	worms	falling	within	this	square	were	measured	b)	measurements	were	made	using	the	freehand	line	tool	by	tracing	a	line	along	the	C.	elegans	body	axis.	
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seeded	plates	each	day.	Plates	with	eggs	were	maintained	at	25°C	for	24	hours	to	allow	 the	 larvae	 to	 develop	 and	 the	 number	 of	 viable	 progeny	was	 counted*.	plates	per	condition.	Unhatched	eggs	were	also	counted	and	recorded	separately.			*fecundity	assay	carried	out	at	SJTU	(Chapter	7)	used	3	worms	per	plate	and	5	replicates		
2.12	C.	ELEGANS	LIFESPAN	ANALYSIS	Lifespan	 experiments	 were	 performed	 using	 the	 glp-4(bn2)	 SS104	 C.	 elegans	strain.	 This	 strain	was	 used	 as	 it	 sterile	 at	 25°C	 and	 therefore	 eliminates	 the	complication	of	progeny	production	during	lifespan	analysis.	The	full	procedure	for	a	 lifespan	analysis	 is	detailed	 in	 figure	2.2,	using	the	techniques	previously	outlined	in	this	chapter.	Egg-prep	and	egg-lay	procedures	are	carried	out	at	15°C,	where	the	latter	is	on	DM.	OP50	carryover	from	NGM	at	this	stage	is	minimized	as	OP50	cannot	survive	on	DM	as	it	does	not	contain	uracil,	and	the	majority	of	DM	plates	contained	25	µg/	ml	kanamycin	due	to	the	requirements	of	the	E.	coli	strains	used.			Plates	are	shifted	to	25	°C	following	the	egg-lay	when	worms	reach	L3/	early	L4	stage.	The	following	day,	L4	worms	(as	distinguished	here	by	appearance	of	the	lumen	of	the	uterus	as	a	clear	crescent),	25	animals	are	transferred	onto	seeded	DM	 plates,	 with	 5	 plates	 per	 condition,	 so	 n~	 125	 worms	 for	 each	 lifespan	condition.	Plates	are	maintained	at	25	°C	for	the	duration	of	the	lifespan.	Worms	are	counted	after	7	days	incubation,	where	this	is	recorded	as	day	7	of	adulthood,		
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Figure	2.2.	Diagrammatic	representation	of	the	lifespan	protocol.	Lines	represent	C.	elegans,	black	dots	represent	C.	elegans	eggs,	blue	dot	containing	black	dots	represents	C.	elegans	eggs	from	bleaching	 protocol.	 Adapted	 from	 Marjanne	 Bourgeois,	 a	 Master’s	 student	 in	 the	 Weinkove	laboratory.	
						NGM	+	OP50	
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and	then	counted	every	other	day	for	remainder	of	the	lifespan.	Worms	are	scored	as	alive,	dead	or	censored.	At	days	7	and	14,	worms	are	transferred	onto	freshly	seeded	plates	in	order	to	ensure	sufficient	‘food.’	If	plates	developed	contamination,	all	the	animals	on	the	plate	were	censored,	although	this	was	rare	due	to	the	presence	of	kanamycin.	 See	 supplementary	 table	 1	 for	 full	 details	 of	 all	 lifespan	 experiments	carried	out	in	this	thesis,	including	statistical	analyses.		
2.13	FOLATE	EXTRACTION	AND	LC-MS/MS		
2.13.1	Folate	extraction	for	E.	coli		
100	µl	E.	coli	DM	culture	were	seeded	onto	DM	plates	of	the	experimental	condition.	Two	plates	per	replicate	were	required	and	4-5	replicates	per	condition	were	carried	out.	Plates	were	incubated	for	four	days	(unless	otherwise	stated)	at	25	ᵒC	before	the	folate	extraction	procedure	was	carried	out.	E.	coli	was	removed	from	the	two	plates	within	a	 replicate	using	a	 sterile	glass	 spreader	and	2	ml	 sterile	M9,	 and	bacterial	solution	was	pipetted	 into	a	1.5	ml	Eppendorf	 tube;	 sample	volume	was	recorded.	Tubes	were	vortexed	vigorously	in	order	to	obtain	a	homogenised	solution.	100	µl	of	sample	was	 removed	and	diluted	1:10	with	M9	 in	a	plastic	 cuvette	 and	OD600	was	measured	and	recorded.	Eppendorf	tubes	were	kept	on	ice.		
Eppendorfs	 were	 centrifuged	 for	 8	 minutes	 at	 4000	 rpm	 in	 a	 chilled	 centrifuge.	Supernatant	was	discarded	and	excess	was	removed	by	dabbing	inverted	tubes	on	a	paper	towel.	Tubes	were	snap	frozen	in	liquid	nitrogen.	Samples	can	be	stored	at	-80	ᵒC	at	this	stage	if	necessary.	A	specific	amount	(see	below)	of	90:10	ice	cold	methanol:	
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folate	extraction	buffer	(50mM	HEPES,	50mM	CHES,	0.5%	w/v	ascorbic	acid,	0.2M	DTT,	pH	7.85	with	NaOH),	spiked	with	MTX-glu6	as	an	internal	standard,	was	added	to	each	tube	and	vortexed	vigorously	until	the	pellet	was	dissolved.	Samples	were	left	on	ice	for	15	minutes	and	then	centrifuged	for	15	minutes	at	full	speed	in	a	chilled	centrifuge.	Supernatant	was	decanted	and	transferred	to	a	fresh	Eppendorf	tube.	20	µl	supernatant	was	aliquot	into	vials	for	LC-MS/MS	analysis,	or	stored	at	-80°C.	
Volume of folate extraction buffer was calculated by:  !"#. %&'()*'+",	./00%(	 1# = 3)45#%	6"#. 4# 	×89:;;×37.5 
 
2.13.2	Folate	extraction	for	C.	elegans		
An	overnight	egg-lay	at	20ᵒC	was	carried	out	onto	DM	seeded	9cm	plates	(of	the	experimental	 condition)	 in	 order	 to	 gain	 a	 large	 synchronized	 population	 of	worms	 (~200)	 (four	 plates	 per	 replicate,	 with	 four	 replicates	 per	 condition).	Plates	were	stored	at	25°C	for	2	days	to	allow	worm	development	to	L4/	young	adulthood.	Worms	were	washed	off	the	agar	with	3ml	sterile	M9,	pooled	into	50	ml	falcon	tubes,	and	allowed	to	settle	before	removing	the	supernatant	to	5	ml.	To	remove	remaining	bacteria,	worms	were	again	washed	with	M9,	allowed	to	re-settle,	and	the	supernatant	removed	to	1	ml.	Worms	were	transferred	to	1.5	ml	Eppendorf	 tubes,	 gently	 centrifuged	 (2000rpm)	 for	 10	 seconds	 and	 pellet	volumes	estimated	and	recorded.			The	 supernatant	 was	 removed	 before	 adding	 1ml	 of	 folate	 extraction	 buffer	(50mM	HEPES,	50mM	CHES,	0.5%	w/v	ascorbic	 acid,	0.2M	DTT,	pH	7.85	with	
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NaOH)	spiked	with	MTX-glu6	as	an	internal	standard,	and	the	samples	vortexed	and	 gently	 centrifuged	 (2000rpm)	 for	 10	 seconds.	 Supernatant	 removal	 and	addition	 of	 folate	 extraction	 buffer	 was	 repeated,	 and	 worms	 left	 in	 an	 FEB	volume	of	twice	the	pellet	volume.	Procedures	described	thus	far	were	carried	out	on	ice	and	in	chilled	centrifuges.			Proteinase	K	was	added	to	a	final	concentration	of	500	μg/ml,	samples	vortexed,	and	shaken	vigorously	at	37°C	for	60-90	minutes	to	lyse	worm	cells.	Tubes	were	covered	with	aluminium	foil	due	to	light	sensitivity	of	folates.	A	volume	of	ice-cold	methanol	equal	to	that	in	the	Eppendorf	tube	was	added	to	lyse	remaining	cells,	samples	 vortexed,	 and	 centrifuged	 (13000rpm)	 at	 4°C	 for	 10	 minutes.	 20	 µl	supernatant	was	aliquot	into	vials	for	LC-MS/MS	analysis,	or	stored	at	-80°C.		
2.13.3	Tandem	liquid	chromatography-mass	spectrometry	(LC-MS/MS)	analysis	
The	methodology	was	based	on	published	literature (Lu	et	al.,	2007)	and	parameters	were	optimised	by	Ian	Cummins	in	the	Durham	University	Biosciences	Department,.	Folates	were	detected	by	multiple	reaction	monitoring	(MRM)	analysis	using	a	SCIEX	QTRAP	6500	instrument.	MRM	conditions	for	5-methylTHF-glu3	and	formyTHF-glu3	were	optimised	by	first	infusing	these	standards	(Schircks)	into	the	instrument,	and	were	applied	to	other	folates	using	MRM	transitions	previously	described	(Lu	et	al.,	2007).	Folate	identity	was	confirmed	by	performing	enhanced	product	ion	scans	of	relevant	folates	and	comparing	fragment	spectra	with	known	standards.		
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In	ESI+	mode	the	QTRAP	6500	was	interfaced	with	a	Shimadzu	Nexera	UHPLC	system.	Samples	were	separated	using	a	Thermo	PA2	C18	column	(2.2μm,	2.1x100mm)	with	a	gradient	of	0.1%	 formic	acid	 in	water	 (mobile	phase	A)	and	acetonitrile	 (mobile	phase	B).	Samples	were	maintained	at	4⁰C	and	2μl	aliquots	injected.	The	column	was	maintained	at	40⁰C	with	a	flow	rate	of	200μl/min,	starting	at	2%	B,	held	for	2	minutes,	with	a	linear	gradient	to	100%	B	at	7	minutes,	held	for	1	minute,	before	a	7	minute	re-equilibration	 step	 at	 2%	 B,	 necessary	 for	 consistent	 retention	 times.	 The	 QTRAP	switching	valve	controlled	eluate	 flow	to	 the	mass	spectrometer,	allowing	analysis	between	4-8	minutes	to	minimise	instrument	contamination.	Folates	were	quantified	from	the	mass	spectrometry	traces	using	Analyst	software.	See	figure	2.3	for	elution	profiles	of	C.	elegans	5-methyl-THF-glu1-6	detected	by	LC-MS/MS.	
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Figure	2.3	Separation	of	polyglutamated	folates	by	LC-MS/MS	with	detection	by	multiple	
reaction	monitoring	(MRM)	–glu1-5	derivatives	of	5-methylTHF	in	a	C.	elegans	extract	as	an	example	of	the	specificity	and	sensitivity	of	the	detection	method.	
5-methyl	THF-glu5	
5-methyl	THF-glu4	
5-methyl	THF-glu3	
5-methyl	THF-glu2	
5-methyl	THF-glu	
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2.14	PROCEDURE	FOR	QUANTITATIVE	REAL	TIME	PCR	
2.14.1	Extraction	of	bacterial	RNA	
DM	plates	were	seeded	with	a	DM	culture	and	incubated	for	the	required	period	at	25	ᵒC.	Two	plates	were	required	per	extraction,	with	four	replicates	per	condition.	2ml	of	2:1	stabilization	mixture	(2	volumes	Qiagen	RNAprotect	bacteria	reagent:	1	volume	M9)	was	pipetted	onto	 the	 two	plates	and	bacteria	was	 removed	carefully	using	a	glass	 spreader	 and	 pipetted	 into	 a	 1.5	 ml	 Eppendorf	 tube.	 Tubes	 were	 mixed	 by	vortexing	 for	30	 secs	and	 incubated	at	 room	 temperature	 for	5	mins.	Volume	was	recorded.	100	µl	of	sample	was	taken	and	diluted	1:10	(with	M9)	in	a	plastic	cuvette.	OD600	was	measured	and	the	required	sample	volume	was	calculated	to	obtain	7.5	x	108	cells	was	calculated	as	below:	
?%@/+(%A	3)45#%	6"#/4% = 7.580	×89:;;	The	 appropriate	 amount	 of	material	was	 pipetted	 into	 a	 new	Eppendorf	 tube	 and	samples	were	centrifuged	 for	10	mins	at	3000	x	g.	 Supernatant	was	decanted	and	residual	supernatant	was	carefully	removed	by	dabbing	inverted	tube	onto	a	paper	towel.	The	enzymatic	lysis	of	the	bacteria	was	carried	by	incubation	with	200	µl	of	TE	buffer	(30	mM	Tris.	Cl,	1	MM	EDTA,	pH	8.0)	containing	1	mg/	ml	lysozyme.	Samples	were	vortexed	for	30	secs	before	incubation	for	5	mins,	with	vortexing	every	minute	for	10	secs.	β-mercaptoethanol	was	added	to	a	lysate	buffer	to	inactivate	RNases	in	the	lysate	and	samples	were	precipitated	using	96-100%	ethanol.	RNA	was	purified	from	 the	bacterial	 lysate	using	Qiagen	RNeasy	mini	 spin	 columns	according	 to	 the	manufacturer’s	 directions.	 RNA	was	 eluted	 using	 RNase-free	water.	 Samples	were	
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subjected	to	off-column	DNase	treatment	using	Turbo	DNA-free	kit	(Invitrogen).	RNA	purity	 and	 concentration	 was	 quantified	 using	 the	 NanoDrop™	 8000	Spectrophotometer.	
2.14.2	Reverse	transcription	of	RNA	to	cDNA	
Taqman	reverse	transcriptase	reagents	(Applied	Biosystems/	Life	Technologies)	were	used	to	generate	cDNA.	A	master	mix	was	prepared	as	below,	mixed	and	briefly	centrifuged	before	adding	aliquoting	and	adding	random	hexamers	and	template	RNA	into	separate	PCR	tubes.		Component	 20	ul-rxn	 Final	concentration	DEPC-treated	water	 to	20	µl	 -	10X	RT	Buffer	 2.0	µl	 1X	25	mM	MGCl2	 1.4	µl	 1.75	mM	10	mM	dNTP	mix	(2.5	mM	each)	 4.0	µl	 0.5	mM	each	100	mM	DTT	 1.0	µl	 5.0	mM	Rnase	inhibitor	(20	U/	uL)	 1.0	µl	 1.0	U/	µl	Multiscribe	RT	(50	U/	uL)	 1.0	µl	 2.5	U/	µl		Mixed	and	briefly	centrifuged:	 	 	50	µM	random	hexamers	 1.0	µl	 2.5	µM	Template	RNA	 varies	 1	µg		PCR	tubes	were	capped	tightly,	mixed	and	briefly	centrifuged	before	using	a	bench	top	thermocycler	to	complete	the	following	incubation	programme:		Temperature	 Time		25°C		 10	minutes	37°C		 30	minutes	95°C		 5	minutes	4°C		 indefinitely		Samples	were	stored	at	-	20ᵒC	until	use	for	qPCR.	
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2.14.3	Quantitative	real-time	PCR	(RT-qPCR)	
Products	were	detected	using	SYBR	green	fluorescence	using	SensiFast	SYBR	Lo-Rox	kit	(Bioline)	in	reactions	set-up	as	below:	Component	 20	ul-rxn	 Final	concentration	DEPC-treated	water		 3.4	µl	 -	SYBR	 10	µl	 1x	Fwd	primer	 0.8	µl	 400	nM	Rev	primer	 0.8	µl	 400	nM	cDNA	(1:50)	 5	µl	 20	ng		qPCR	reactions	were	carried	out	using	the	Bioline	micPCR	v2.2	thermocycler.	Using	the	parameters	outlined	below:	Step	 Temperature	 Time	Initial	hold	 95°C	 2 mins 
Cycle	x	40 Denaturation	 95°C		 5	secs	Annealing	 60°C		 10	secs	Extension	 72°C		 10	secs		Primers	for	qPCR	were	designed	to	have	similar	annealing	temperatures.		1:50	was	 chosen	as	optimal	 cDNA	concentration	after	 running	 several	dilutions	of	pooled	WT	cDNA	(1:5,	1:10,	1:50,	1:100,	1:500)	against	the	primer	pairs	for	the	two	reference	genes,	rrsA	and	mdoG,	and	all	the	primer	pairs	for	all	the	genes	of	interest	(pabA,	rpoS,	fic,	abgT).	A	no	template	control	was	included	here,	as	standard	with	all	reactions.	The	standard	curves	are	shown	in	figure	2.4,	where	primer	efficiencies	have	been	calculated	and	fall	within	90-110%.		
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Gene	 R2	 Gradient	 Primer	efficiency	(%)	
rrsA	 0.9926	 -3.153	 107.57	
mdoG	 0.9879	 -3.257	 102.78	
pabA	 0.9978	 -3.428	 95.76	
rpoS	 0.998	 -3.54	 91.64	
fic	 0.9934	 -3.091	 110.63	
abgT	 0.9978	 -3.347	 98.964	
	
Figure	2.4	Standard	curves	demonstrating	primer	efficiency	in	pooled	WT	cDNA	
 	Gene	expression	was	normalized	to	the	expression	of	the	rrsA	transcript	and	used	to	calculate	log2	fold-change	using	the	ΔΔct	method	(Nolan	et	al.	2006).	Values	given	are	the	averages	of	three	replicate	RNA	extractions.			
	
2.14.4	Primers	for	qPCR	
Primers	were	designed	using	ApE	-	A	Plasmid	Editor	Version	1.17.	Primers	were	designed	to	give	products	~200	bp.		
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Primer	 Sequence	(5'	>	3')	 Tm	[ᵒC]	
rrsA	fwd	 GAATGCCACGGTGAATACGTT	 57.9	
rrsA	rev	 ACCCACTCCCATGGTGTGA	 58.8	
mdoG	fwd	 GCAATTGATACCGCCTTGC	 56.7	
mdoG	rev	 TTCGACTGCACATCCACAAC	 57.3	
pabA	fwd	 ACTTTACCGCCAAATGCCTG	 57.3	
pabA	rev	 TGGTTAAGCGCAACGATGC	 56.7	
rpoS	fwd	 TGGACCATGAACCAAGTGC	 56.7	
rpoS	rev	 TCGTCATCTTGCGTGGTATC	 57.3	
fic	fwd	 TCCAGGCCTTGATATCATGC	 57.3	
fic	rev	 AGCGCCGTCATTTCGTAAG	 56.7	
abgT	fwd	 AGCCACATTTCTTCCGATGC	 57.3	
abgT	rev	 CATTTGCGGATTGAACGCAG	 57.3	
 
2.15	ASSEMBLING	NEW	E.	COLI	K12	STRAINS	BY	P1	PHAGE	TRANSDUCTION	The	abgTpabA	double	mutant	was	created	using	the	single	mutants	from	the	KEIO	collection,	abgT	(JW5822-1)	and	pabA	(JW3323-1).	Several	other	mutants	were	also	made	for	the	Weinkove	laboratory	but	have	not	been	cited	in	this	thesis.	The	method	here	consists	of	three	steps:	1.	Removal	of	the	kanamycin	marker	from	the	‘recipient’	strain	2.	Preparation	of	phage	lysate	of	‘donor’	strain	3.	P1	Phage	transduction.		
2.15.1	Removal	of	the	kanamycin	marker	from	KEIO	strains	
In	 KEIO	 strains,	 the	 kanamycin	 resistance	 gene	 alleles	 are	 flanked	 by	 FRT	 (FLP	recognition	target)	sites.	If	FLP	recombinase	is	expressed,	the	kanamycin	resistance	gene	is	eliminated	through	the	deletion	by	homologous	recombination	at	FRT	sites.	This	was	 achieved	 using	 the	 pCP20	 plasmid:	 an	 AmpicillinR	 and	 ChloamphenicolR	plasmid	with	 temperature-sensitive	 replication	and	 constitutive	 expression	of	FLP	recombinase.	 	pCP20	was	transformed	into	competent	cells	(see	section	2.3)	of	the	
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strain	 containing	 the	kanamycin	gene	 to	be	 removed	 (recipient	 strain).	Cells	were	plated	onto	LB/amp	plates	and	incubated	overnight	at	30	ᵒC.	5	colonies	were	picked	and	streaked	onto	on	an	LB	plate	without	selection	and	incubated	for	18	hours	at	43	ᵒC	in	order	to	eliminate	the	plasmid.	20	single	colonies	were	picked	from	each	of	the	5	colonies	streaked	and	were	patched	(twizzle	pipette	tip	with	colony	in	LB)	onto	3	separate	plates	(LB,	LB/kan,	LB/amp)	and	incubated	over	night	at	37	ᵒ C.	Select	clones	which	grow	on	LB	only,	and	thus	have	lost	both	pCP20	and	the	kanamycin	resistance	gene.		
2.15.2	Preparation	of	phage	lysate	
An	 overnight	 culture	 of	 donor	 strain	 (grown	 with	 selection	 for	 the	 marker	 to	 be	transduced	(25	µg/ml	kanamycin))	was	diluted	1:100	in	fresh	LB	supplemented	with	10-25	mM	MgCl2,	5	mM	CaCl2,	and	0.1-0.2%	glucose	(1	mL	per	lysate).	Cultures	were	incubated	37	 ˚C	 for	1-2	hr.	When	cells	 reached	early	 log-phase,	40	µL	of	P1	phage	lysate	 was	 added	 to	 the	 culture	 and	 continue	 growing	 at	 37	 ˚C.	 Cultures	 were	monitored	for	1–3	hr	until	cellular	debris	was	visible	in	the	tube,	indicating	that	cells	had	 lysed.	 Several	 drop	 of	 chloroform	 (50-100	 µL)	 were	 added	 to	 the	 lysate	 and	vortexed.	Lysates	were	centrifuged	(15	minutes,	3000	x	g)	to	remove	debris	and	the	supernatant	was	transferred	to	a	fresh	tube.	A	few	drops	of	chloroform	were	added	and	lysates	were	stored	at	4	˚C.	
2.15.3	P1	phage	transduction		
An	overnight	LB	culture	of	recipient	strain	(with	kan	marker	removed)	was	pelleted	by	centrifugation	(2	min,	6000	rpm)	and	resuspended	in	1/5-	1/3	of	the	harvested	
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culture	volume	in	fresh	LB	+	100	mM	MgSO4	+	5	mM	CaCl2.	100	uL	(for	each	reaction)	of	transducing	P1	lysate	was	incubated	(caps	open)	for	37	˚ C	for	~30	minutes	to	allow	excess	chloroform	to	evaporate	from	the	phage	stock.	During	this	time,	resuspended	recipient	strain	cells	were	incubated	at	37	ᵒC.	Four	conditions	were	set	up	(A-D)	by	adding	the	recipient	cells	to	the	tubes	with	phage.	Contents	were	mixed	rapidly	after	addition.	A.	100	µL	undiluted	P1	lysate	+	100	µL	recipient	cells	B.	100	µL	1:10	diluted	P1	 lysate	+	100	µL	 recipient	 cells	C.	100	µL	LB	+	100	µL	 recipient	 cells	D.	100	µL	undiluted	P1	lysate	+	100	µL	LB.	LB	used	here	was	LB	+	100	mM	MgSO4	+	5	mM	CaCl2.		Tubes	were	incubated	at	37	˚C	for	30	min.	200	µL	1	M	Na-Citrate	(pH	5.5)	was	added	and	then	1	mL	LB	(normal	LB)	and	incubated	at	37	˚C	for	1	hr	to	allow	expression	of	the	antibiotic	resistance	marker.	Cells	were	centrifuged	for	5	min	at	6000	rpm	and	resuspended	in	100	µL	LB	supplemented	with	100	mM	Na-Citrate	(pH	5.5).	Cells	were	vortexed	 before	 plating	 onto	 LB/	 kan	 plates	 and	 incubated	 at	 37	 ᵒC	 overnight.	Colonies	were	picked	and	restreaked	on	LB/kan	plates	spread	with	100	µL	of	1	M	citrate	 (pH	5.5)	 in	order	 to	obtain	 isolate	 colonies	 free	 from	phage.	Colonies	were	tested	for	the	absence	of	the	recipient	mutant	gene	by	diagnostic	PCR	(section	2.16)	
2.15.4	Preparation	of	competent	cells	and	transformation		
An	overnight	culture	of	the	appropriate	strain	was	diluted	1:100	in	fresh	LB.	OD600	was	monitored	until	~0.5-0.7.	Cultures	were	places	in	ice	water	for	15	minutes	and	then	pelleted	by	centrifugation	in	a	chilled	centrifuge	for	5	minutes,	5000	rpm.	The	supernatant	was	removed	and	cells	were	resuspended	in	1/	10	of	the	original	volume	in	TSS	solution	(10%	(w/v)	PEG	8000,	5%	(v/v)	DMSO,	30	mM	MgCl2,	pH	6.5).		
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50	µL	cells	per	transformation	were	aliquot	into	separate	tubes	and	incubated	on	ice	for	 10	minutes,	 followed	 by	 room	 temperature	 incubation	 for	 10	minutes	 and	 ice	again	for	10	minutes.	Plasmid	DNA	was	added	(<1	µl)	and	heat	shocked	for	60	seconds	at	42	ᵒC.	Cells	were	places	on	ice	for	10	minutes.	900	µl	LB	was	added	and	cells	were	incubated	with	shaking	at	37	ᵒC	for	1	hours.	100	µl	cells	were	plated	onto	LB	plate	containing	appropriate	marker.	50	µg/ml	ampicillin	and	25	µg/ml	kanamycin	was	required	for	pUC19	and	pJ128	transformations.	
	
2.16	COLONY	DIAGNOSTIC	PCR	This	 technique	was	 carried	out	 in	order	 to	ensure	 that	 the	mutants	 created	by	P1	transduction	 contained	 the	 desired	 mutations.	 Individual	 colonies	 were	 picked	carefully	with	a	pipette	tip	from	an	LB	plate	and	twizzled	in	5	µl	of	distilled	H2O	in	the	bottom	of	a	PCR	tube.	The	tip	was	them	dropped	into	a	15ml	Falcon	tube	for	overnight	culture.	20	µl	reactions	were	set	up	as	followed:		Component	 Volume		 Final	concentration	dH2O	 3.8	µl	 -	Master	Mix	Promega	 10	µl	 2x	Gene	primer(s)	 0.4	µl	 400	nM	Kanamycin	(K2)	primer	 0.4	µl	 400	nM	Colony	in	dH2O	 5	µl	 -			The	K2	primer	is	specific	to	the	kanamycin	resistance	gene	and	will	give	a	product	of	~891-1025	bp	with	a	gene	specific	external	primer	if	the	gene	is	knocked	out.			PCR	reactions	were	carried	out	as	outlined	below:		
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Step		 Temperature		 Time		Denaturation		 94	°C		 25	secs		Annealing		 51	°C		 30	secs		Elongation		 72	°C		 30	secs		Extension	 72	°C	 10	minutes		Hold	 4	°C	 indefinitely		
2.17	AGAROSE	GEL	ELECTROPHORESIS		10	µl	of	each	sample	was	loaded	into	wells	of	a	1%	agarose	(MB1200,	Melford)	gel.	Gels	were	run	for	approximately	20	minutes	at	110V	and	PCR	products	were	visualised	with	ethidium	bromide.			
2.18	STATISTICAL	ANALYSIS		Statistical	analysis	of	C.	elegans	 lifespan	assays	was	carried	out	using	the	statistical	software	JMP	Pro	12.2	8.0.2.	Survival	function	was	estimated	using	the	Kaplan-Meier	estimator.	 	 This	 accounts	 for	 right-censoring	 (when	 worms	 are	 censored	 and	withdrawn	 from	 the	 assay).	 Statistical	 significance	 was	 determined	 by	 the	 non-parametric	statistical	tests:	Log-Rank	and	Wilcoxon.	 In	the	text,	 test	statistics	 from	Log-Rank	tests	have	been	cited.		Full	statistical	analysis	of	lifespan	data	can	be	seen	in	supplementary	table	1.			Student’s	t	tests	have	been	used	to	compare	means	between	two	different	samples.	Test	statistics	have	been	quoted	in	the	text	where	appropriate.		
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CHAPTER	3:	DEVELOPING	METHODS	TO	CONTROL	AND	MEASURE	E.	COLI	FOLATE	IN	
THE	C.	ELEGANS-	E.	COLI	MODEL	SYSTEM		
3.1	INTRODUCTION	In	 our	model	 system,	 C.	 elegans	 is	 almost	 entirely	 dependent	 on	E.	 coli	 for	 all	macro-	and	micronutrients,	 including	folate.	Bacterial	synthesis	of	these	dietary	components	 is	 itself	 dependent	 on	 the	 constituents	 of	 the	 growth	 media.	 The	growth	media	 therefore	 indirectly	 impacts	 C.	 elegans	 health	 by	 altering	E.	 coli	metabolism.	The	growth	media	conventionally	used	for	C.	elegans	assays,	NGM,	is	a	 soy	 peptone-based	 media	 consisting	 of	 a	 homogenised	 mixture	 of	 peptides,	amino	acids,	vitamins,	trace	metals	and	fatty	acids.	It	is	likely	to	contain	sources	of	folate	and/	or	folate	precursors.		In	order	to	understand	how	bacterial	folate	synthesis	is	modulating	lifespan,	we	must	 be	 able	 to	 sensitively	 control	 and	 accurately	 measure	 the	 process.	 The	constituents	of	the	growth	media	must	therefore	be	defined.	This	chapter	outlines	the	 development	 of	 a	 chemically	 defined	 media	 for	 use	 in	 E.	 coli-	 C.	 elegans	research	 and	 the	 characterisation	 of	 bacterial	 and	 animal	 phenotypes	 on	 said	media.	 This	 media	 will	 also	 facilitate	 sensitive	 bioanalytical	 techniques,	 thus	enabling	accurate	quantification	of	both	E.	coli	and	C.	elegans	folate	levels	by	LC-MS/MS.	 An	 alternative	 in	 vivo	method	 to	 analyse	 E.	 coli	 folate	 status	 is	 also	developed	and	characterized	here.	Using	these	methods,	the	aim	is	to	determine	and	distinguish	between	the	folate	levels	which	support	E.	coli	growth,	and	that	which	is	‘excessive’	and	has	a	negative	impact	on	C.	elegans	lifespan.		
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3.1.1	Development	of	a	chemically	defined	media	A	 Master’s	 student	 working	 in	 the	 Weinkove	 laboratory,	 Noel	 Helliwell	 (NH),	began	creating	a	folate-free	chemically	defined	media.	NH	replaced	the	peptone	constituent	of	NGM	with	individually	defined	amino	acids	and	trace	metals,	and	replaced	the	normal	agar	with	‘high-purity’	agar	(see	Chapter	2).	NH	reported	that	the	media	 supported	normal	E.	 coli	growth,	 but	 did	not	 characterize	C.	 elegans	phenotypes.	The	first	section	of	this	chapter	outlines	further	optimisation	of	this	media,	 which	 will	 be	 referred	 to	 as	 defined	 media	 (DM),	 hereafter,	 and	characterizes	E.	coli	and	C.	elegans	phenotypes	on	DM	in	order	to	establish	it	as	a	chemically	controllable	alternative	to	NGM.	
3.1.2	LC-MS/MS:	a	highly	sensitive	method	to	detect	specific	folate	species	A	 high	 performance	 liquid	 chromatography	 QTRAP	mass	 spectrometry	 facility	(referred	 to	 as	 LC-MS/MS	 hereafter)	 was	 installed	 in	 the	 Durham	 University	Biosciences	Department	towards	the	end	of	this	PhD	research	period.	QTRAPs	use	multiple	 reaction	 monitoring	 (MRM)	 to	 obtain	 a	 high	 level	 of	 selectivity	 and	sensitivity	 and	 can	detect	 specific	 compounds	 in	 a	 sample	within	 the	picomole	range	(figure	3.1).	
	
Figure	 3.1.	 Diagrammatic	 representation	 of	 the	 LC-MS/MS	 QTRAP.	QTRAPS	 have	 three	separation	modules	or	quadropoles,	Q1-Q3:	Q1	is	set	to	select	a	specific	‘precursor	ion’	of	known	mass,	where	it	is	then	fragmented	in	Q2;	the	‘product	ion’	is	selected	in	Q3	and	detected.	This	is	known	as	multiple	reaction	monitoring	and	is	capable	of	highly	specific	and	sensitive	detection.		
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LC-MS/MS	 settings	were	 optimized	 for	 folate	 detection	 by	 Ian	 Cummins	 in	 the	Durham	 Biosciences	 Bioanalytics	 facility	 based	 on	 parameters	 set	 out	 in	 the	literature	(Lu	et	al.,	2007)	(see	Chapter	2,	section	2.13.3).	This	method	differs	from	the	previous	detection	method	(LC-MS)	used	by	the	Weinkove	laboratory,	where	the	former	method	scanned	all	peaks	within	a	sample	and	selected	only	the	most	abundant	for	fragmentation	and	quantification.	
3.1.3	C.	elegans	gcp-2.1	mutant:	a	phenotypic	bioassay	to	detect	E.	coli	folate	status	Due	to	the	insensitivity	of	the	LC-MS	technique	used	in	the	previous	study	(Virk	et	al.	2012)	and	the	lack	of	a	replacement	facility	for	the	first	half	of	this	PhD	research	period,	there	was	a	need	to	develop	an	alternative	method	to	measure	bacterial	folate.	It	was	hypothesized	that	in	a	genetically	susceptible	background,	C.	elegans	life-traits	 which	 have	 a	 high	 demand	 for	 folate,	 such	 as	 development	 and	reproduction,	 could	 be	 sensitized	 to	 low	 levels	 of	 dietary/	 E.	 coli	 folate.	Quantification	of	these	phenotypes	would	act	as	a	readout	of	the	bacterial	folate	status.	Furthermore,	as	this	is	an	in	vivo	quantification	method,	it	acts	as	a	readout	of	functional	folate	levels.			Work	 carried	 out	 by	 Bhupinder	 Virk	 (BV),	 a	 PhD	 student	 in	 the	 Weinkove	laboratory,	 sought	 to	 restrict	C.	 elegans	 folate	uptake	by	knocking	out	 the	gene	thought	to	be	responsible	for	the	deconjugation	of	polyglutamated	folates	in	the	intestine,	 thus	 generating	 monoglutamated	 folates	 for	 absorption.	 A	 BLASTp	search	 revealed	a	C.	 elegans	protein,	 encoded	 for	by	 the	R57.1	 gene,	with	35%	sequence	identity	to	the	mammalian	glutamate	carboxypeptidase	protein,	GCPII	(see	 Chapter	 1	 for	 more	 information	 on	 GCPII).	 Two	 other	 glutamate	carboxypeptidase	genes,	C35C5.2	and	C35C5.11	were	also	identified,	but	as	R57.1	
76 
 
had	been	identified	 in	a	study	using	an	 intestine	specific	promoter	to	probe	for	intestinally-expressed	genes	(Pauli	et	al.,	2006),	it	was	carried	forward	for	further	research.	R57.1,	C35C5.2	and	C35C5.11	were	named	gcp-2.1,	gcp-2.2	and	gcp-2.3,	respectively,	by	the	Weinkove	group.			BV	out-crossed	 the	gcp-2.1	mutant	strain	obtained	 from	the	C.	elegans	Genetics	Gentre	(CGC)	to	wild-type	to	create	the	gcp-2.1(ok1004)	strain.	This	strain	contains	a	 <TCTCTTCTTTTCCGAAAGTGGTGACGTCATTTATC>	 insertion	 and	 a	 functional	1523bp	deletion	in	the	gcp-2.1	gene	(gcp-2.1	(ok1004)),	which	is	located	on	the	X	chromosome.	Phenotypic	analysis	revealed	that	this	strain	had	no	development	defects	or	survival	differences	compared	to	the	wild-type	parent	strain,	however,	on	SMX-treated	E.	coli,	gcp-2.1	mutants	had	stunted	developmental	growth	at	L4	stage	and	were	sterile.	The	phenotype	was	rescued	with	a	transgene	containing	a	genomic	 fragment	 including	 the	 gcp-2.1	 gene.	 This	 chapter	 details	 the	 further	characterization	of	the	gcp-2.1	strain	as	a	bioassay	to	detect	low	E.	coli	folate	levels.	
3.2	CHAPTER	AIMS	
• Aim	1:	Optimize	the	defined	media	and	establish	it	as	an	alternative	to	NGM	
• Aim	2:	 Use	 defined	media	 to	 sensitively	 detect	 the	 folate	 thresholds	 for	bacterial	growth	and	lifespan	modulation		
• Aim	 3:	 Characterize	 the	 gcp-2.1	 (ok1004)	 strain	 and	 develop	 it	 as	 a	phenotypic	assay	of	bacterial	folate	status		
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3.3	RESULTS	
3.3.1	Establishing	defined	media	as	a	suitable	alternative	to	NGM	
	DM	was	optimised	by	NH	for	E.	coli	growth,	however,	when	the	media	began	to	be	used	for	C.	elegans	assays,	several	issues	became	apparent.	Namely,	plate	drying	and	 ‘cracking’,	 the	 presence	 of	 crystalline	 deposits,	 and	 a	 lack	 of	 vitamin	 B12.	These	 issues	were	resolved	relatively	simply	and	are	detailed	here.	Lower	agar	percentages	(from	2%)	were	trialed	and	1.7%	agar	was	found	to	mitigate	the	issue	with	plate	cracking,	which	was	proving	a	particular	problem	during	incubation	at	25°C	over	the	course	of	lifespan	assays.	Omitting	the	addition	of	1	mM	CaCl2	post-autoclaving	(as	standard	with	NGM)	was	found	to	solve	the	issue	of	the	crystalline	deposits	in	the	media,	which	was	likely	due	to	excessive	calcium	in	the	media:	this	was	an	oversight	as	CaCl2	is	also	included	in	the	trace	metal	solution.	10	nM	B12	was	added	to	 the	media	as	 it	 is	an	essential	 requirement	 for	both	E.	coli	and	C.	
elegans.	Following	this	optimization,	E.	coli	growth	and	several	C.	elegans	life-traits	were	monitored	on	DM.		
3.3.1i	Defined	media	supports	wild-type	E.	coli	growth		The	 wild-type	 E.	 coli	 K12	 parental	 strain,	 BW25113,	 transformed	 with	 a	kanamycin	 resistance	plasmid,	 pGreen,	 is	 used	here	 for	 all	 experiments,	 unless	otherwise	stated,	and	referred	to	hereafter	as	WT	E.	coli.	Growth	of	WT	E.	coli	on	NGM	and	DM	solid	agar	(with	and	without	10	nM	B12)	was	measured	by	OD	600	after	24,	48	and	72	hours	of	growth	(see	Chapter	2,	section	2.7.1).	Bacterial	growth	on	DM,	regardless	of	B12,	was	not	significantly	different	to	growth	on	NGM	(figure	2.2).	This	is	consistent	with	the	preliminary	work	carried	out	by	NH	and	indicates	
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that	 the	manipulations	made	 to	optimize	DM	do	not	 alter	 its	 ability	 to	 support	bacterial	growth.		
3.3.1ii	Defined	media	supports	C.	elegans	development,	fecundity	and	lifespan		Previous	work	did	not	carry	out	a	phenotypic	analysis	of	C.	elegans	life-traits	on	DM.	Here,	body	length	at	L4	stage,	fecundity	and	lifespan	on	DM	are	compared	to		
	
Figure	3.2	Defined	media	supports	wild-type	E.	coli	growth	similarly	to	on	NGM	WT	 E.	 coli	 was	 seeded	 onto	 DM	 agar	 plates	 and	 incubated	 at	 25	 ˚C.	 Bacterial	 growth	 was	measured	at	24,	48	and	72	hours	after	seeding	(see	Chapter	2,	section	2.9).	Error	bars	represent	standard	deviation	over	10	replicate	plates	per	condition.		
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on	NGM.	The	wild	type	C.	elegans	Bristol	N2	strain	was	used	to	conduct	fecundity	analysis	and	the	temperature-sensitive	sterile	glp-4	(SS104)	strain	was	used	for	the	development	assay	and	all	 lifespan	assays	 in	 this	 thesis	 (Chapter	2,	 section	2.12).	Development	was	quantified	by	raising	synchronized	populations	of	worms	from	egg	on	stated	growth	media	and	measuring	body	length	at	L4	stage	(2.5	days	at	25°C)	(see	Chapter	2,	section	2.9)	(figure	3.3a).	No	significant	difference	in	body	length	was	observed	in	worms	raised	on	DM,	with	or	without	B12,	compared	to	NGM.	These	worms	were	transferred	at	day	1	of	adulthood	onto	freshly	seeded	E.	
coli	plates	of	the	same	condition	they	were	raised	on	and	the	other	two	conditions	(figure	3.3b),	and	lifespan	assays	were	carried	out	(figure	3.3c).			As	for	all	lifespans	presented	in	this	thesis,	please	see	Supplementary	table	1	for	a	full	outline	of	experimental	conditions,	strains	used,	number	of	animals	included	in	each	condition,	mean	lifespans	and	statistical	analysis	(indexed	by	Chapter	no.,	fig	no.).	Kaplan	Meier	survival	curves	are	plotted	using	the	statistical	software	JMP.	The	non-parametric	statistical	tests	of	survival,	Log-rank	and	Wilcoxon,	were	used	to	test	significance	between	two	lifespan	conditions.	The	result	of	Log-rank	tests	will	be	quoted	in	the	text	where	appropriate.		It	was	 found	 that	 if	worms	were	 raised	on	NGM	and	 shifted	 to	DM	at	day	1	of	adulthood,	mean	lifespan	was	increased	by	8.80%	(P=0.0254)	and	if	shifted	to	DM	+	10	nM	B12,	mean	lifespan	was	increased	by	16.33%,	(P<0.0001)	compared	to	worms	that	remained	on	NGM	(figure	3.3).	If	raised	on	DM	and	shifted	to	NGM	for	lifespan,	 survival	 was	 not	 statistically	 significant	 from	 that	 of	 worms	 on	 NGM	throughout	their	lifespan,	however,	if	maintained	on	DM	for	lifespan	or	shifted	to	
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DM	 +	 B12,	 mean	 lifespan	 was	 increased	 by	 8.57%	 (P=0.0351)	 and	 12.46%	(P=0.0067),	respectively.	Likewise,	if	raised	on	DM	+	B12	and	shifted	to	NGM	for	lifespan,	survival	was	not	affected,	however,	a	large	increase	in	mean	lifespan	was	measured	when	worms	were	maintained	on	DM	+	B12	(28.795)	or	shifted	to	DM	(17.19%),	where	Log-rank	P<0.0001,	 in	both	cases.	Together	this	 indicates	that	that	 DM	 in	 adulthood	 extends	 lifespan	 and	 that	 worms	 require	 B12	 in	 both	development	and	adulthood	for	optimal	lifespan.				Fecundity	 analysis	 was	 carried	 out	 using	 the	 N2	 WT	 strain.	 Synchronized	populations	of	worms	were	raised	from	egg	on	stated	condition	until	adulthood	and	 individual	 gravid	 (egg-laying)	 hermaphrodites	 were	 transferred	 onto	individual	plates	(n=10)	where	they	were	then	transferred	again	onto	a	fresh	plate	each	 day	 for	 4	 days.	 Plates	 were	 incubated	 at	 25	 ˚C	 and	 viable	 progeny	 were	counted	 24	 hours	 after	 the	worm	was	 removed	 (see	 Chapter	 2,	 section	 2.9.2).	Interestingly,	there	was	a	significant	reduction	in	the	number	of	progeny	produced	on	NGM	compared	to	DM	(±	B12)	on	day	1	of	egg-laying	(figure	3.4).	Overall,	there	was	no	significant	difference	 in	 the	 total	progeny	produced	over	 the	egg-laying	period	in	animals	raised	on	NGM	or	DM,	with	or	without	supplemental	B12.			Together,	 these	 data	 demonstrate	 that	 DM	 sufficiently	 supports	 C.	 elegans	development,	 fecundity	 and	 lifespan	 in	 line	with	 that	observed	on	NGM.	DM	 in	adulthood	 and	B12	during	both	development	 and	 adulthood	 increases	 survival	compared	to	NGM.	10	nM	B12	was	added	to	DM	for	all	subsequent	experiments.			
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Figure	3.3	Development	and	lifespan	analysis	of	C.	elegans	on	NGM	and	DM±	B12.	C.	elegans	were	raised	on	either	NGM,	DM	or	DM	+	B12	until	L4	stage	(at	15	˚C)	and	a)	body	length	was	measured.	Error	bars	represent	standard	deviation	b)	worms	were	then	shifted	to	25	˚C	for	24	hrs	and	transferred	onto	fresh	plates	of	each	of	the	three	conditions	for	lifespan	anlysis	c)	Kaplan	Meier	suvirval	curves	of	worms	raised	on	i.	NGM	ii.	DM	iii.	DM	+	B12.	See	supplementary	table	1	for	full	details	of	lifspan	analysis.	
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Figure	3.4	Fecundity	analysis	of	C.	elegans	on	NGM	and	DM±	B12.	C.	elegans	were	raised	on	either	NGM,	DM	or	DM	+	B12	until	L4	stage	and	individual	worms	were	transferred	onto	plates	for	fecunity	analysis	a)	number	of	viable	progeny	produced	over	four	day	reproductive	window	was	monitored	(n=10	worms	per	condition)	b)	total	number	of	progeny	produced	by	10	worms	over	4	days.		Error	bars	represent	standard	deviation.							
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3.3.2	Using	DM	to	examine	E.	coli	folate	threshold	for	growth	and	C.	elegans	lifespan	
modulation		
In	 order	 to	 monitor	 how	 DM	 affects	 the	 growth	 of	 the	 E.	 coli	 folate-synthesis	mutant,	 pabA,	 a	 96-well	 microtiter	 plate	 assay	 was	 developed.	 Plates	 were	incubated	at	37	°C	and	OD	600	monitored	by	a	plate	reader	every	5	minutes	(after	shaking)	for	20	hours	(See	chapter	2,	section	2.7.2).	Optimization	of	this	assay	was	required	 as	 pabA	 growth	was	 initially	 similar	 to	WT	 (data	 not	 shown);	 it	 was	hypothesized	that	E.	coli	cells	carry	over	PABA	from	the	initial	culture	in	LB	into	the	DM.	An	intermediate	‘subculture’	step	from	LB	into	an	overnight	DM	culture	was	introduced	in	order	to	‘wash’	the	cells	of	PABA.	This	subculture	was	then	used	to	inoculate	the	wells	at	OD600	=0.001	(figure	3.5b).	This	produced	a	robust	and	repeatable	 sensitized	 pabA	 baseline	 growth	 ‘curve’.	 The	 need	 for	 these	 steps	emphasizes	 the	 sensitivity	 of	 E.	 coli	 to	 small	 quantities	 of	 exogenous	 folate	precursors.			The	 growth	of	WT	E.	 coli	and	 all	pab	mutants	were	 assayed	 (figure	3.5a).	 This	would	ensure	that	limited	pabA	growth	on	DM	was	folate	specific	and	not	due	to	a	folate-independent	defect	 in	 this	 strain.	Both	pabA	and	pabB	showed	negligible	growth	in	DM,	whereas,	despite	an	extended	lag	phase,	the	pabC	mutant	reached	end-point	growth	in	line	with	WT	E.	coli	(figure	3.5a).	This	is	consistent	with	the	lifespan	screen	data	from	the	Weinkove	lab,	where	pabA	and	pabB	mutants	were	found	to	significantly	extend	lifespan,	but	the	pabC	mutant	did	not.		
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3.3.2ii	pabA	mutant	growth	is	sensitive	to	defined	media	and	is	rescued	with	PABA		The	pabA	mutant	was	focused	on	for	all	following	experiments.	The	impact	of	the	folate	 precursor,	 PABA,	 on	pabA	growth	 in	DM	was	 assayed	 by	 supplementing	wells	with	varying	concentrations	of	PABA.	A	dose-dependent	growth	response	of	
pabA	to	PABA	supplementation	was	observed	(figure	3.5bi),	where	50	nM	PABA	completely	rescued	pabA	growth	and	a	partial	rescue	in	growth	was	observed	with	just	1	nM.	Growth	curves	represent	an	average	of	4	technical	replicate	wells.	This	assay	was	repeated	several	times	with	similar	results.			In	order	to	assess	the	impact	of	PABA	on	pabA	growth	under	conditions	used	for	
C.	elegans	experiments,	the	assay	was	also	carried	out	on	agar	DM	(figure	3.5bii).	Plates	were	incubated	at	25	°C	and	OD600	was	measured	at	24,	48	and	72	hrs	after	‘seeding’	 the	 E.	 coli	 liquid	 DM	 sub-culture	 onto	 the	 agar	 DM.	 Again,	 a	 dose-dependent	response	 to	PABA	was	observed,	but	a	10-fold	higher	concentration	was	required	here	to	rescue	growth:	100	nM	PABA	completely	restored	growth,	whereas1	nM	PABA	had	a	negligible	effect	(figure	3.5bii).	Together	these	assays	identify	that	the	pabA	mutant	requires	nanomolar	quantities	of	PABA	for	growth.		
3.3.2iii	1µM	PABA	reverses	C.	elegans	longevity	on	pabA	mutant	on	defined	media	Having	identified	the	lower	folate	threshold	required	to	support	pabA	growth	on	DM,	lifespan	assays	were	carried	out	on	the	pabA	mutant	in	order	to	determine	the	folate	threshold	which	dictates	C	elegans	 lifespan.	C.	elegans	were	raised	on	DM	plates	 seeded	 with	 DM	 subcultures	 of	 WT	 E.	 coli	 until	 adulthood	 and	 then	transferred	onto	either	pabA	or	WT	seeded	DM	plates	supplemented	with	a	range	of	PABA	concentrations.	The	lowest	PABA	concentration	used	was	100	nM	so	as	to	ensure	pabA	growth	and	eliminate	a	confounding	effect	of	dietary	restriction	on		
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Figure	3.5	Growth	of	pabA	 strains	on	solid	and	 liquid	DM	supplemented	with	PABA	ai)	growth	 of	pabA,	 pabB	and	pabC	 in	 liquid	 conducted	 at	 37	 °C	 in	microtiter	 plates	 and	OD	 600	measured	after	shaking,	every	5	mins	for	19	hrs.	each	curve	is	the	mean	reading	from	4	biological	replicates	 aii)	 depicts	 experimental	 set-up.	 Growth	 of	 pabA	 supplemented	 with	 PABA	 was	assessed	in	bi)	liquid	DM	(37	°C	)	and	bii)	solid	agar	DM	(25	°C).	For	solid	agar	assay,	E.	coli	was	washed	off	after	4	days	growth,	using	sterile	media	at	24,	48	and	72	hrs.	Error	bars	represent	standard	deviation	over	5	biological	replicates.	
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Figure	 3.6.	 PABA	 reverses	 lifespan	 of	 C.	 elegans	 on	 pabA	mutant	 E.	 coli.	 Temperature-sensitive	 C.	 elegans	 (glp-4)	 at	 L4	 stage	 (n=150)	were	 transferred	 onto	 DM	 solid	 agar	 plates	supplemented	with	PABA	and	seeded	with		a)	WT	or	b)	pabA	E.	coli	and	incubated	at	25	°C	for	the	duration	of	their	lifespan.	Animals	were	transferred	onto	plates	with	‘fresh’	E.	coli	at	days	7	and	14	of	adulthood.	All	plates	contained	0.1	µM	PABA	to	ensure	sufficient	bacterial	growth	c)	Mean	 lifespan	on	each	 condition.	Error	bars	 represent	 standard	error.	Asterisks	 indicate	 the	result	of	non-parametric	Log-rank	statistical	analyses	comparing	 indicated	pabA	condition	 to	WT	control	(WT		+	0.1	µM	PABA),	where	**P<0.005,	***P<0.0001	
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lifespan.	As	nano/	micromolar	concentrations	of	PABA	are	used	here,	any	impact	of	PABA	on	C.	elegans	lifespan	can	be	attributed	to	changes	in	E.	coli	metabolism	as	C.	elegans,	like	all	animals,	lack	the	enzymatic	machinery	to	metabolize	PABA.			Figure	3.6	displays	both	the	Kaplan-Meier	survival	curves	and	mean	lifespans	on	each	condition.	PABA	supplementation	was	not	found	to	impact	the	lifespan	of	C.	
elegans	fed	WT	E.	coli.	Mean	lifespan	of	C.	elegans	on	the	pabA	E.	coli	mutant	on	DM	supplemented	with	100	nM	PABA	was	33.36%	higher	compared	to	on	WT	E.	
coli	on	the	same	condition	(P<0.0001).	A	dose-dependent	reduction	in	C.	elegans	lifespan	on	the	pabA	E.	coli	mutant	was	observed	between	0.2	µM-1	µM	PABA,	where	lifespan	was	reverted	to	WT	at	1	µM	PABA.	Higher	concentrations	of	PABA	did	 not	 further	 decrease	 lifespan.	 This	 lifespan	 assay	 demonstrates	 that	supplementation	of	PABA	into	DM,	above	the	threshold	required	to	support	pabA	
E.	coli	growth,	acts	to	decrease	C.	elegans	lifespan.	Thus,	the	folate	thresholds	for	bacterial	growth	(0.1	µM	PABA)	and	that	which	reverses	C.	elegans	 lifespan	(1	µM)	on	the	pabA	E.	coli	mutant	are	determined	and	distinguished	between.		
3.3.2iv	PABA	increases	pabA	folate	levels	in	correlation	with	its	impact	on	lifespan	Given	 the	 central	 hypothesis	 that	 E.	 coli	 folate	 synthesis	 shortens	 C.	 elegans	lifespan,	it	was	assumed	from	the	previous	data	that	PABA	supplementation	at	1	µM	would	increase	folate	synthesis	and	thus	folate	increase	levels	in	the	pabA	E.	
coli	mutant	in	line	with	the	WT	E.	coli	strain.	In	order	to	test	this,	the	LC-MS/MS	facility	 was	 used	 to	 detect	 levels	 of	 individual	 folates	 in	 the	 pabA	mutant	 in	response	to	PABA.	Optimization	of	the	extraction	technique	was	carried	out	in	order	to	prevent	folate	degradation,	promiscuous	interconversions	and	to	obtain	
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maximum	yield.	Please	see	Chapter	2,	section	2.13	for	a	full	outline	of	the	folate	extraction	protocol	and	LC-MS/MS	detection.		The	pabA	mutant	and	WT	E.	coli	were	seeded	onto	DM	agar	plates	supplemented	with	PABA	at	0.1	µM,	1	µM,	10	µM	and	100	µM.	Folate	extractions	were	carried	out	after	4	days	growth	at	25	°C.	This	was	deemed	an	appropriate	 time	point	relevant	to	C.	elegans	experiments.	Samples	were	normalized	for	growth	prior	to	extraction.	Signals	were	normalized	 to	 that	of	 an	 internalized	standard	 (MTX-glu6)	 added	 to	 the	 extraction	 buffer	 in	 order	 to	 control	 for	 variability	 in	 MS	sensitivity	over	the	large	number	of	samples	analyzed.	Tri-glutamated	folates	are	presented	here	(figure	3.7)		In	pabA	mutant	extracts	with	0.1	µM	PABA,	levels	of	5-methyl	THF	(P=0.002),	5-formyl	THF	(P<0.001),	THF	(P=0.002)	and	5,10-methenyl	THF	(P<0.001)	were	detected	at	significantly	lower	levels	compared	to	WT	extracts	with	0.1	µM	PABA,	as	determined	by	Student’s	t-tests.	However,	1	µM	PABA	significantly	increased	levels	of	all	folates	in	pabA	mutants	extracts	compared	to	pabA	mutants	with	0.1	
µM	 PABA.	 Folate	 levels	 in	 pabA	mutant	 extracts	 with	 1	 µM	 PABA	 were	 not	significantly	different	compared	to	in	WT	extracts	with	0.1	µM	PABA	(figure	3.7),	however,	as	1	µM	PABA	also	markedly	increased	WT	folate	levels,	folate	levels	in	
pabA	mutant	extracts	with	1	µM	PABA	were	significantly	different	compared	to	in	WT	extracts	with	1	µM	PABA.	At	10µM	PABA,	all	folate	levels	in	pabA	mutant	extracts	were	detected	at	levels	similar	to	WT.	100	µM	PABA	did	not	increase	the	folate	levels	further	in	either	WT	or	pabA	extracts.		
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Figure	3.7.	LC-MS/MS	detection	of	folate	species	in	WT	and	pabA	supplemented	with	PABA.	WT	and	pabA	E.	coli	were	seeded	onto	DM	and	incubated	at	25	°C	for	4	days.	Samples	were	normalized	for	growth	before	extraction.	Folate	levels	are	expressed	as	a	ratio	of	an	internal	MTX-glu6	spike.	Error	bars	represent	standard	deviation	(4	biological	replicates).	Asterisks	denote	the	result	of	Student’s	t-Tests,	of	pabA	condition	compared	to	relevant	WT	condition	(same	[PABA]),	where	*	P<0.05	**P<0.005,	***P<0.001. 
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Together,	this	demonstrates	that	the	impact	of	PABA	on	C.	elegans	lifespan	on	the	
pabA	mutant	is	correlated	to	bacterial	folate	status,	as	a	wild-type	folate	profile	is	restored	in	the	pabA	mutant	at	1	µM	PABA.	The	increase	in	folate	levels	above	1	
µM	PABA,	in	both	WT	and	pabA,	despite	no	further	impact	on	lifespan,	indicates	that	 a	 folate-dependent	 activity	 within	 the	 0.1	 µM	 to	 1	 µM	 PABA	 window	 is	responsible	for	lifespan	modulation.	
3.3.3	Characterizing	the	C.	elegans	gcp-2.1	folate-uptake	mutant	strain	as	a	biological	
read-out	of	E.	coli	folate	status	
The	 LC-MS/MS	 facility	 became	 available	 only	 towards	 the	 end	 of	 the	 research	period.	There	was	therefore	a	need	to	develop	a	method	to	assess	bacterial	folate	status.	As	discussed,	previous	work	carried	out	by	BV	in	the	Weinkove	laboratory	created	the	gcp-2.1(ok1004)	and	hypothesized	that	folate	uptake	in	the	intestine	is	disrupted	due	 to	knockout	of	 the	gene	required	 for	 folate	deconjugation.	These	claims	 were	 based	 on	 the	 observation	 that	 the	 gcp-2.1	mutants	 strain	 has	 no	abnormal	phenotypes	on	NGM	on	WT	E.	coli,	but	 it	exhibits	developmental	and	reproductive	sensitivity	to	SMX-treated	E.	coli.		
3.3.3i	gcp-2.1	mutants	show	normal	developmental	phenotypes	on	NGM	and	DM	As	this	thesis	uses	DM,	and	the	preliminary	work	was	carried	out	on	NGM,	it	was	first	 tested	whether	 the	 folate-free	DM	caused	 further	gcp-2.1	 sensitivity.	Body	length	 and	 fecundity	 of	 gcp-2.1	mutants	 and	 the	 wild-type	 parent	 strain	 were	monitored,	as	previously	described,	on	both	DM	and	NGM	seeded	with	WT	E.	coli		No	significant	difference	in	body	length	at	L4	stage	of	gcp-2.1	mutants	on	DM	or	NGM	was	found	compared	to	the	wild-type	strain	on	either	condition	(figure	3.8a).	Fecundity	 analysis	 revealed	 a	 slight	 delay	 in	 the	 reproductive	 period	 of	 both	
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mutant	and	wild-type	strains	on	NGM	compared	to	DM	(figure	3.8bi,ii).	This	was	also	observed	in	N2	worms	on	NGM	compared	to	DM	(figure.	3.4a).	The	mean	total	number	 of	 eggs	 laid	 per	worm	was	 not	 statistically	 different	 across	 any	 of	 the	conditions	 (figure.	 8biii).	 This	 demonstrates	 that	 DM	 is	 capable	 of	 supporting	normal	development	and	reproduction	of	the	gcp-2.1	strain	on	WT	E.	coli,	and	is	consistent	with	the	ability	of	DM	to	support	WT	E.	coli	growth	in	line	with	that	on	NGM.		
3.3.3ii	gcp-2.1	mutants	show	stunted	growth	and	sterility	on	pabA	and	SMX-treated	E.	
coli	The	previous	work	had	not	quantified	the	phenotypes	of	the	gcp-2.1	mutant	strain	on	 SMX-treated	E.	 coli.	 In	 order	 to	 establish	 this	 strain	 as	 a	 reliable	 sensor	 of	bacterial	folate	levels,	quantification	on	both	SMX	and	the	pabA	mutant	needed	to	be	carried	out.	WT	and	pabA	mutant	E.	coli	was	seeded	onto	DM	agar	plates	and	WT	was	also	seeded	onto	plates	supplemented	with	128	µg/ml	SMX.	100	nM	PABA	was	 supplemented	 into	 the	 media	 in	 order	 to	 ensure	 bacterial	 growth.	Synchronized	 populations	 of	 worms	were	 obtained	 by	 egg-lay	 onto	 the	 stated	condition,	with	4	replicates	per	condition.			As	shown	in	figure	3.9	the	body	length	of	the	gcp-2.1	mutant	strain	at	L4	stage	was	reduced	by	over	50%	on	both	the	pabA	mutant	and	on	SMX	compared	to	on	control	
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Figure	3.8	The	C.	elegans	gcp-2.1	mutant	has	normal	developmental	and	reproduction	on	
WT	E.	coli	on	NGM	and	DM.	gcp-2.1	mutants	were	raised	from	egg	on	NGM	and	DM	seeded	with	WT	E.	 coli	and	 incubated	at	 25	 °C	until	 L4	 stage	when	a)	body	 length	was	measured	and	b)	progeny	 produced	 of	 i)	WT	 and	 ii)	gcp-2.1	mutants	 over	 a	 4	 day	 reproductive	window	was	monitored	 iii)	 Total	 number	 of	 progeny	 produced	 by	 WT	 and	 gcp-2.1	mutants.	 Error	 bars	represent	standard	deviation	of	10	worms	per	experimental	condition.		
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WT	E.	coli.	The	wild-type	C.	elegans	strain	did	not	show	a	growth	defect	on	these	conditions	(figure	3.9a).	A	fecundity	analysis	was	not	carried	out	as	the	number	of	eggs	laid	by	the	gcp-2.1	strain	on	the	sensitive	conditions	was	negligible.	
3.3.3ii	PABA	rescues	the	gcp-2.1	phenotype	on	pabA	mutant	E.	coli		In	order	to	verify	that	these	phenotypes	are	folate-dependent,	PABA	was	added	into	the	media	in	order	to	rescue	bacterial	folate	synthesis	in	the	pabA	mutant,	and	thus	 increase	 the	 amount	of	 folate	 available	 to	 the	gcp-2.1	mutant.	The	gcp-2.1	strain	was	raised	on	pabA	mutant	E.	coli	on	DM	agar	plates	supplemented	with	0.1	
µM,	0.2	µM,	0.5	µM	and	1	µM	PABA.	A	concentration-dependent	increase	in	gcp-
2.1	 body	 length	 with	 PABA	 was	 observed,	 where	 wild-type	 body	 length	 was	restored	at	1	µM	PABA	(figure	3.9b).	This	is	consistent	with	the	restoration	of	wild-type	folate	levels	in	the	pabA	mutant	at	this	concentration	(figure	3.7).	Together,	these	data	verify	that	the	developmental	phenotype	of	the	gcp-2.1	strain	can	be	used	as	a	readout	of	E.	coli	folate	levels.	Following	this	characterization,	the	gcp-
2.1	strain	has	been	used	throughout	this	thesis	to	test	for	genetic	manipulations	and	extrinsic	factors	that	modulate	bacterial	folate	synthesis.
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Figure	3.9.	C.	elegans	gcp-2.1	mutant	has	abnormal	development	on	SMX	and	pabA	E.	coli	
but	is	rescued	by	PABA.	WT	and	gcp-2.1	mutants	were	synchronized	by	overnight	egg-lay	(20	°C)	onto	DM	plates	and	incubated	at	25	°C	until	L4	stage	when	body	length	was	measured.	C.	elegans	were	maintained	 from	egg	on	plates	 seeded	with	a)	WT	or	pabA	mutant	E.	 coli,	or	onto	plates	seeded	with	WT	E.	 coli	 containing	 128	µg/ml	 SMX	 and	 on	b)	 plates	 seeded	with	pabA	mutant	supplemented	with	PABA.	All	plates	in	(a)	contained	0.1	µM	PABA	to	ensure	sufficient	bacterial	growth.	Error	bars	represent	standard	deviation.	Asterisks	denote	the	result	of	Student’s	t-	tests	of	denoted	condition	compared	to	a)	WT	C.	elegans	on	same	bacterial	condition	and	b)	WT	worms	on	DM	+	0.1	µM	PABA,	where	***P<0.005,	**P<0.01	*<0.05.	
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3.4	DISCUSSION	
3.4.1	 Defined	 media	 is	 a	 chemically	 definable,	 highly	 controllable	 and	 effective	
replacement	for	NGM		Given	that	bacterial	metabolism	can	be	altered	by	its	external	environment,	which	in	our	controlled	system	is	the	NGM,	and	that	here	we	are	investigating	a	specific	aspect	of	bacterial	metabolism,	it	was	essential	to	control	the	components	of	NGM	that	may	be	modulating	bacterial	folate	synthesis.	The	first	section	of	this	chapter	outlined	the	development	of	a	 folate-free,	chemically	defined	media	(DM)	and	demonstrated	 its	capability	to	support	normal	E.	coli	growth	and	C.	elegans,	development,	reproduction	and	lifespan.	DM	provides	control	over	all	components	of	the	E.	coli	‘diet’	by	precisely	defining	concentrations	of	all	amino	acids	and	trace	metals	(see	Chapter	2,	section	2.3.2).	This	media	may	therefore	be	useful	to	other	C.	elegans	laboratories,	or	indeed	microbiology	groups,	interested	in	controlling	bacterial	metabolism	and/	or	altering	specific	aspects	of	the	bacterial	diet.	LC-MS/MS	detection	of	E.	coli	folates	on	DM	was	more	sensitive	and	reliable	compared	to	on	NGM;	DM	therefore	also	provides	a	‘clean’	platform	for	bioanalytical	analyses.		
3.4.2	Folates	for	one-carbon	metabolism	and	beyond	Due	 to	 the	 confounding	 impact	 of	 bacterial	 folate	 precursors	 in	 the	 media,	 the	previous	study	was	unable	to	differentiate	between	the	folate	threshold	required	to	support	bacterial	growth	and	that	which	shortens	C.	elegans	lifespan.	Here,	the	use	of	DM	 in	 combination	with	E.	 coli	genetic	manipulation	has	enabled	control	of	E.	 coli	folate	levels	in	order	to	define	these	thresholds.	The	sensitized	growth	of	the	pabA	
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mutant	on	DM	facilitated	assays	in	which	the	effect	of	the	folate	precursor,	PABA,	on	
E.	 coli	growth	and	C.	 elegans	 lifespan	were	distinguished:	0.1	µM	PABA	 supported	
pabA	growth	(figure	3.5),	whereas	1	µM	PABA	shortened	C.	elegans	lifespan	on	pabA	(figure	3.6).	LC-MS/MS	enabled	highly	sensitive	detection	of	E.	coli	folates	under	these	conditions,	revealing	that	at	1	µM	PABA,	folate	levels	in	pabA	mutants	were	increased	to	wild-type	levels	(figure	3.7)		In	previous	work,	only	one	folate	species	(5/10-formyl	THF-glu3)	could	be	detected	in	E.	coli	under	conditions	that	extend	lifespan	and	signals	were	noisy	and	close	to	the	threshold	 of	 detection.	 Here,	 low	 levels	 of	 bacterial	 folates	 have	 been	 sensitively	detected	by	LC-MS/MS	and	it	has	been	shown	that	the	pabA	mutant	extends	lifespan	above	 the	 threshold	 for	bacterial	 growth	and	 that	 lifespan	 is	 reversed	when	 these	levels	 are	 restored	 to	 wild-type	 levels.	 The	 finding	 that	 folate	 levels	 continue	 to	increase	beyond	this	window,	despite	no	effect	on	lifespan,	provides	a	small	target	window	 for	 further	 investigation.	 This	 also	makes	 it	 unlikely	 that	 PABA	or	 folates	themselves	are	directly	toxic	to	C.	elegans,	as	we	would	expect	to	see	lifespan	decline	in	 response	 to	 increasing	 PABA/	 folate	 levels.	 The	 data	 is	more	 consistent	with	 a	threshold	model	whereby	either	a	folate-dependent	beneficial	activity	is	promoted,	or	a	harmful/	toxic	activity	is	attenuated	when	folate	levels	are	low	(figure	3.10).	This	discrepancy	will	be	addressed	further	in	Chapter	8.			
3.4.3	The	gcp-2.1	mutant	strain	provides	a	phenotypic	readout	of	low	E.	coli	folate	levels	The	characterization	of	a	C.	elegans	folate	uptake	mutant	strain,	gcp-2.1	(ok1004)	was	described	in	this	chapter	with	the	aim	of	developing	a	novel	method	to	assay	E.	coli	
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folate	levels.	The	data	is	consistent	with	a	model	whereby	gcp-2.1	mutants	are	able	to	obtain	 sufficient	 monoglutamated	 folates	 from	 their	 bacterial	 diet	 on	 WT	 E.	 coli,	however,	when	this	level	is	decreased	by	inhibiting	bacterial	folates	synthesis	(pabA	mutant,	 SMX-treatment),	 the	 monoglutamated	 portion	 of	 the	 diet	 is	 no	 longer	sufficient	to	support	a	functional	folate	cycle,	and	a	developmental	folate	deficiency	is	manifest	(figure	3.11).	Supplementation	with	the	bacterial	folate	synthesis	precursor,	PABA,	 rescues	 this	 deficiency	on	 the	pabA	mutant,	 likely	due	 to	 the	 restoration	of	bacterial	folate.	This	data	is	consistent	with	a	role	of	GCP-2.1	in	the	C.	elegans	intestine,	where	it	cleaves	glutamates	off	polyglutamated	E.	coli	folates	to	facilitate	absorption.	The	folate	profile	of	the	gcp-2.1	mutant	strain	will	be	analysed	in	further	detail	by	LC-MS/MS	 in	 Chapter	 5,	 alongside	 other	 C.	 elegans	 folate	 measurements	 which	 are	relevant	to	the	following	chapters.	Together,	this	data	establishes	the	gcp-2.1	strain	as	a	phenotypic	readout	of	E.	coli	folate.			
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Figure	 3.10	 Model	 of	 the	 bacterial	 thresholds	 of	 folate	 which	 support	 growth	 and	
modulate	C.	elegans	lifespan.	When	[PABA]	<	0.1	µM,	folate	levels	are	insufficient	to	support	bacterial	growth.	Above	this	threshold,	bacterial	growth	is	supported	and	C.	elegans	are	long-lived	when	[PABA]	<1	µM.	Above	this	threshold,	folate	levels	are	excessive	and	C.	elegans	are	short-lived.	 It	 is	 not	 clear	whether	 folate	 has	 a	 beneficial	 effect	 on	C.	 elegans	 lifespan	 at	 the	‘sufficient’	level,	or	a	toxic	effect	when	levels	are	excessive.		
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Figure	3.11	Model	of	the	gcp-2.1	mutant	bioassay	with	representative	images.	Top	left	panel:	wild-type	worms	obtain	both	THF-glun	and	THF-glu	from	WT	E.	coli.	THF-glun	are	hydrolysed	to	
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generate	 THF-glu	 which	 can	 be	 absorbed	 by	 C.	 elegans	 reduced	 folate	 carrier,	 FOLT-1.	Monoglutamated	THFs	are	transported	to	peripheral	tissues	to	supply	cells	with	cofactors	for	one-carbon	metabolism.	Top	right	panel:	wild-type	worms	on	folate-deficient	bacteria	have	a	limited	supply	of	THF-glun	and	THF-glu	but	this	 is	sufficient	to	support	develoment.	Bottom	left	panel:	
gcp-2.1	mutant	worms	on	WT	E.	coli	receive	sufficient	THF-glu	to	support	development.	Bottom	right	panel:	gcp-2.1	mutant	worms	on	folate-deficient	E.	coli	do	not	receive	sufficient	THF-glu	to	support	 development.	 Representative	 images	 taken	 on	 plates	 ±	 128	 µg/ml	 SMX.	 THF-glun	represents	a	general	tetrahydrofolate	with	more	than	one	glutamate	residue.	THF-glu	represents	a	monoglutamated	general	tetrahydrofolate		
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CHAPTER	4.	EXAMINING	C.	ELEGANS	FOLATE	STATUS	UNDER	CONDITIONS	THAT	
INFLUENCE	LIFESPAN	
 
 
4.1	INTRODUCTION	Previous	 work	 in	 the	 Weinkove	 laboratory	 revealed	 that	 inhibiting	 E.	 coli	 folate	synthesis	with	SMX	decreased	folate	levels	in	C.	elegans	(Virk	et	al.	2012).	In	order	to	distinguish	 between	 the	 impact	 of	 bacterial	 and	 host	 folate	 status	 on	 lifespan,	 the	Weinkove	 group	 carried	 out	 lifespan	 analyses	 under	 conditions	 where	 C.	 elegans’	folate	was	specifically	limited	(gcp-2.1	mutant)	or	supplemented	(SMX	+	folinic	acid).	Neither	intervention	was	found	to	alter	lifespan,	thus,	it	was	hypothesized	that	worm	folate	status	was	not	a	determinant	of	lifespan.	However,	the	folate	status	of	C.	elegans	was	not	tested	under	these	interventions.	In	this	chapter,	LC-MS/MS	detection	of	C.	
elegans	 folate	 under	 these	 conditions	 is	 carried	 out	 in	 an	 attempt	 to	 verify	 this	hypothesis.	DM	is	used	in	order	to	eliminate	any	background	sources	of	folate	which	may	otherwise	confound	results.			
4.2	CHAPTER	AIMS	Using	LC-MS/MS	detection	of	C.	elegans	folates,	this	chapter	aims	to:	
• Aim	1:	Examine	the	folate	status	of	the	C.	elegans	gcp-2.1	mutant		
• Aim	2:	Examine	the	impact	of	folinic	acid	on	C.	elegans	folate	levels	
4.3	RESULTS	Considerable	 preliminary	 work	 was	 carried	 out	 to	 optimize	 the	 folate	 extraction	protocol	for	C.	elegans	(data	not	shown).	Previously,	only	5-methylTHF-glu5	could	be	
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detected	 in	C.	 elegans	(Virk	et	al.	2012).	Here,	using	 the	more	sensitive	LC-MS/MS	technique,	-glu1-5	derivatives	of	5-methyl	THF,	5/10-formyl	THF	and	THF	have	been	detected	at	reliable	levels.	Student’s	t-tests	have	been	carried	out	here	to	determine	significance	between	two	folate	species	under	different	experimental	conditions,	and	P	 values	 will	 be	 quoted	 in	 the	 text	 where	 appropriate.	 As	 with	 all	 LC-MS/MS	measurements,	levels	of	two	different	folate	species	cannot	be	directly	compared,	as	the	level	here	is	an	arbitrary	unit	and	dependent	on	the	ability	of	the	compound	to	travel	in	the	MS	reaction	chamber,	which	varies	depending	on	compound.	Absolute	values	can	only	be	obtained	when	known	concentrations	of	standards	are	infused	into	the	LC-MS/MS.		
4.3.1	Examining	the	folate	profile	of	the	C.	elegans	gcp-2.1	mutant	strain	
In	order	to	understand	how	the	gcp-2.1	mutation	affects	C.	elegans	folate	levels,	folate	extractions	on	synchronized	populations	of	L4/	young	adult	wild-type	and	gcp-2.1	populations	maintained	on	WT	E.	coli	were	performed	in	quadruplicate	and	samples	were	 analyzed	 by	 LC-MS/MS	 (Figure	 4.1).	 Despite	 normalizing	 for	 worm	 pellet	volume	between	each	condition,	extractions	on	gcp-2.1	worms	on	low	folate	E.	coli	were	not	 included	in	the	analysis	due	to	 lack	of	material.	As	standard,	 folate	 levels	were	normalized	to	that	of	an	internal	MTX-glu6	spike	added	to	the	extraction	buffer.	As	 the	 gcp-2.1	 gene	 is	 predicted	 to	 be	 involved	 in	 polyglutamated	 folate	deconjugation,	LC-MS/MS	parameters	were	optimized	 to	detect	–glu1-5	of	all	 folate	species.			
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4.3.1i	gcp-2.1	mutation	shifts	folates	towards	polyglutamated	derivatives	In	gcp-2.1	mutant	extracts,	levels	of	all	mono-	and	diglutamated	folates	were	detected	at	significantly	lower	levels	than	in	WT	extracts	(with	the	exception	of	5/10-formyl	THF-glu1):	methyl	THF	–glu1	(P=0.002)	and	–glu2	 (P=0.023),	5/10-formyl	THF-glu2	(P=0.047),	 THF-glu1	 (P=0.012)	 and	 THF-glu2	 (P=0.049)	 (figure	 4.1).	 Unexpectedly,	levels	of	-glu3	and	–glu4	derivatives	were	significantly	higher	in	the	gcp-2.1	extracts	than	in	the	WT	extracts	(with	the	exception	of	THF-glu4):	methyl	THF	–glu3	(P=0.005)	and	–glu4	(P=0.004),	5/10-formyl	THF-glu3	(P=0.041)	and	–glu4	(P=0.023)	and	THF-glu3	(P=0.028).	Interestingly,	the	most	significantly	decreased	folate	in	gcp-2.1	mutant	extracts	 was	 5-methyl	 THF-glu1	 (P<0.001),	 the	 main	 circulatory	 folate	 form	 in	mammals.			The	overall	pattern	in	figure	4.1	illustrates	a	shift	towards	polyglutmated	THFs	and	a	restricted	 supply	 of	 mono-	 and	 diglutamated	 folates	 in	 gcp-2.1	 mutants.	 As	polyglutamted	THFs	are	the	required	substrate	for	the	enzymes	that	carry	out	one-carbon	metabolism	reactions,	this	may	account	for	the	lack	of	folate-deficiency	in	the	
gcp-2.1	 strain.	 This	 data	 provides	 an	 insight	 into	 the	 functional	 role	 of	polyglutamation	 in	C.	elegans.	Having	gained	a	more	complete	picture	of	 the	 folate	status	of	the	gcp-2.1	mutant	strain,	the	results	are	not	consistent	with	the	hypothesis	that	the	gcp-2.1	mutation	lowers	the	levels	status	of	the	worm;	its	use	as	a	mutant	to	demonstrate	 that	worm	 folate	 status	 is	 not	 a	 determinant	 of	 lifespan	 is	 therefore	questioned.	This	will	be	discussed	in	more	detail.			
104 
 
	
	
	
Figure	4.1.	LC-MS/MS	detects	altered	polyglutamtion	profile	in	gcp-2.1	mutant	C.	elegans.	Synchronized	populations	of	wild-type	and	gcp-2.1	mutant	C.	elegans	were	raised	on	WT	E.	coli	incubated	at	25	°C	until	L4/	young	adult	stage.	Folate	extractions	were	normalized	for	volume	and	 analyzed	 by	 LC-MS/MS.	 5-methyl	 THF,	 5/10-formyl	 THF	 and	 THF-glu1-5	were	 detected.	Folate	levels	are	expressed	as	a	ratio	of	an	internal	MTX-glu6	spike	added	to	the	extraction	buffer.	All	 plates	 contained	0.1	µM	PABA.	Error	bars	 represent	 standard	deviation	over	4	biological	replicates.	 Asterisks	 denote	 significance	 of	 Student’s	 t-Test	 of	 folate	 level	 in	 gcp-2.1	mutant	compared	to	in	WT	worms,	where	*P<0.05,	**P<0.01,	***P<0.005	
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4.3.2	Examining	the	impact	of	folinic	acid	on	C.	elegans	folate		
In	order	to	test	the	hypothesis	that	folinic	acid	increases	C.	elegans	folate	status,	folate	extractions	were	carried	out	as	previously	described,	on	synchronized	populations	of	L4/	young	adult	wild-type	C.	elegans	on	DM	agar	plates	supplemented	with	10	µM	folinic	acid	on	both	WT	E.	coli	and	the	pabA	mutant.	Non-supplemented	conditions	were	 included	 as	 controls.	 10	 µM	 folinic	 acid	was	 chosen	 as	 it	 rescues	 the	 folate-deficiency	of	the	gcp-2.1	strain	on	pabA	(Chapter	7,	figure	7.12),	but	does	not	impact	the	lifespan	of	wild-type	C.	elegans	on	pabA	(Chapter	7,	figure	7.10)	or	on	SMX-treated	WT	E.	 coli	 (Virk	et	 al.	 2016);	 it	 is	 therefore	hypothesized	 that	 folinic	 acid	must	be	supplementing	C.	elegans	directly.	Folate	extractions	were	also	carried	out	in	parallel	on	 folic	 acid	 supplemented	 conditions,	 with	 separate	 non-supplemented	 controls.	Folinic	 acid	 extractions	 were	 carried	 out	 by	 Emma	 Williams,	 an	 undergraduate	student	working	in	the	Weinkove	laboratory	under	my	supervision.			
4.3.2i	Folinic	acid	does	not	increase	the	folate	status	of	wild-type	C.	elegans	on	either	WT	
or	pabA	mutant	E.	coli		As	shown	in	figure	4.2,	in	response	to	folinic	acid,	there	was	a	significant	increase	in	5/10-formyl	 THF-glu1	 in	 C.	 elegans	 raised	 on	 both	 WT	 and	 pabA	mutant	 E.	 coli	(P<0.001,	in	both	cases),	most	likely	corresponding	to	uptake	and	accumulation	of	5-formyl	 THF-glu1	 (folinic	 acid).	 Despite	 this,	 levels	 of	 all	 other	 folate	 derivatives	remained	unchanged	in	WT	E.	coli	extracts.	On	the	pabA	mutant	on	non-supplemented	conditions,	5-methyl	THF-glu1	(P=0.005),	–glu2	and	–glu3	(P=0.002,	in	both	cases)	and		
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Figure	4.2.	LC-MS/MS	detects	no	impact	of	folinic	acid	on	C.	elegans	folate	levels	Wild-type	
C.	elegans	were	raised	on	WT	or	pabA	mutant	E.	coli	±	10	µM	folinic	acid	supplemented	into	the	DM	and	folate	extractions	performed	at	L4/	young	adult	stage.	All	plates	contained	0.1	µM	PABA.	Error	 bars	 represent	 standard	 deviation	 over	 4	 biological	 replicates.	 Asterisks	 denote	significance	of	Student’s	t-Test	of	non-supplemented	or	folinic	acid	supplemented	condition	on	
pabA	E.	coli	compared	to	on	WT	E.	coli.	For	5.10-formyl	THF,	asterisks	denote	significance	of	folinic	 acid	 supplemented	 conditions	 compared	 to	 non-supplemented	 conditions,	 where	*P<0.05,	**P<0.01,	***P<0.005.		
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THF-glu3	(P=0.039)	were	significantly	decreased	compared	to	on	WT	E.	coli,	as	was	expected,	 however	 levels	 of	 all	 5-formyl	 THF	 derivatives	 remained	 unchanged.	Again,	despite	an	 increase	 in	5/10-formyl	THF-glu1	 in	response	to	 folinic	acid,	C.	
elegans	folate	levels	were	not	increased	on	the	pabA	mutant.	5-methyl	THF-glu2-4	showed	 detectable	 decreases	 in	 the	 pabA	 mutant	 in	 response	 to	 folinic	 acid	supplementation	 compared	 to	 on	 WT	 E.	 coli	 (P=0.006,	 0.035,	 0.040,	 <0.001,	respectively),	as	did	THF-glu2	and	-glu3	(P=0.049,	P=0.010,	P=0.037,	respectively).	
5-methyl	THF-glu5	was	not	affected	(figure	4.2).	As	folinic	acid	did	not	increase	C.	
elegans	 folate	 status,	 these	 data	 also	 question	 the	 use	 of	 folinic	 acid	supplementation	 as	 a	 means	 to	 demonstrate	 that	 worm	 folate	 status	 is	 not	 a	determinant	 of	 lifespan.	 However,	 the	 increase	 in	 5-formyl	 THF-glu1	 provides	relatively	clear	evidence	that	folinic	acid	is	indeed	taken	up	by	the	worm,	so	the	data	may	perhaps	be	limitations	of	only	looking	at	folate	levels	at	a	single	time	point.			In	 the	 folic	 acid	 non-supplemented	 control	 (figure	 4.3),	 only	 5-methyl-glu1	(P=0.024)	was	significantly	decreased	on	pabA	compared	to	on	WT	E.	coli.	Similarly	to	folinic	acid,	levels	of	5-methyl	THF-glu1-4	(P<0.001,	in	all	cases)	and	THF-glu1-3	(P=0.024,	P=0.012,	P=0.001,	respectively)	were	significantly	decreased	in	response	to	folic	acid	on	pabA.	Again,	5-methyl	THF-glu5	was	not	affected.	Notably,	levels	of	5/10-formyl	 THF	 were	 not	 affected	 under	 any	 condition	 (figure	 4.3).	 The	unexpected	decrease	in	C.	elegans	folate	levels	in	response	to	both	folinic	and	folic	acid	on	pabA	mutant	E.	coli	will	be	discussed.		
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Figure	4.3:	LC-MS/MS	detects	no	impact	of	10	µM	folic	acid	on	folate	levels	or	glutamation	in	
wild-type	C.	elegans.	Wild-type	C.	elegans	were	raised	on	WT	or	pabA	mutant	E.	coli	±	10	µM	folic	acid	supplemented	 into	the	DM	and	folate	extractions	performed	at	L4/	young	adult	stage.	Error	bars	represent	standard	deviation	over	4	biological	replicates.	All	plates	contained	0.1	µM	PABA.	Asterisks	denote	significance	of	Student’s	t-Test	of	non-supplemented	or	 folic	acid	supplemented	condition	on	pabA	E.	coli	compared	to	on	WT	E.	coli.,	where	*P<0.05,	**P<0.01,	***P<0.005.		
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4.3.2ii	Folinic	acid	increases	the	folate	status	of	gcp-2.1	mutants		As	discussed,	the	data	that	suggested	folinic	acid	supplements	C.	elegans	was	based	on	the	rescue	of	the	gcp-2.1	mutant	strain	on	the	pabA	mutant	(Chapter	7,	7.12).	Folate	extractions	of	gcp-2.1	mutants	supplemented	with	10	µM	folinic	acid	were	therefore	carried	out	as	a	positive	control,	alongside	the	extractions	on	wild-type	C.	elegans,	as	presented	above.	To	clarify,	the	wild-type	extractions	presented	in	figure	4.4	here	are	the	same	as	those	in	figure	4.2.	Folate	extractions	of	gcp-2.1	mutants	supplemented	with	10	µM	folic	acid	were	also	carried	out	as	a	negative	control	(figure	4.5),	as	this	concentration	did	not	have	an	appreciable	impact	on	gcp-2.1	body	length	(Chapter	7,	figure	 7.12)	 The	wild-type	 extractions	 in	 figure	 4.5	 are	 the	 same	 as	 in	 figure	 4.3.	Separate	 wild-type	 control	 C.	 elegans	 extractions	 were	 carried	 out	 for	 the	 folic	extractions,	 but	 were	 performed	 within	 the	 same	 experiment	 as	 the	 folinic	 acid	extractions.			In	 gcp-2.1	 extracts,	 significant	 increases	 were	 detected	 in	 5-methyl	 THF-glu3	(P=0.050)	 and	 –glu4	 (P=0.002),	 5/10-formyl	 THF-glu4	 (P=0.038)	 and	 THF-glu3	(P=0.007)	and	–glu4	(P=0.049)	in	response	to	folinic	acid.	This	suggests	that	it	is	taken	up	more	effectively	in	this	strain	compared	to	in	wild-type	worms	(figure	4.3).	Indeed,	the	accumulation	of	5/10-formylTHF-glu1	following	folinic	acid	supplementation	was	lower	 in	 gcp-2.1	 extracts	 compared	 to	 WT	 extracts	 (although	 difference	 was	 not	significant,	P=0.060),	suggesting	that	more	of	this	mono-glutamate	folate	source	may	be	used	up	in	gcp-2.1	mutants	than	in	wild-type	worms.	As	expected,	folic	acid	did	not	increase	levels	of	any	folates	in	the	wild-type	strain	or	the	gcp-2.1	mutant	(figure	4.4).	
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Figure	4.4:	LC-MS/MS	detects	10	µM	folinic	acid	increases	glutamation	of	gcp-2.1	mutant	C.	
elegans.	Wild-type	and	gcp-2.1	mutant	C.	elegans	were	raised	on	WT	E.	coli	±	10	µM	folinic	acid	supplemented	into	the	DM	and	folate	extractions	performed	at	L4/	young	adult	stage.	Error	bars	represent	 standard	 deviation	 over	 4	 biological	 replicates.	 All	 plates	 contained	 0.1	 µM	 PABA.	Asterisks	denote	significance	of	Student’s	t-Test	of	either	gcp-2.1	mutants	compared	to	WT	worms	or	gcp-2.1	mutants	+	folinic	acid	compared	to	non-supplemented	gcp-2.1	mutants,	where	*P<0.05,	**P<0.01,	***P<0.005	
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Figure	4.5:	LC-MS/MS	detects	no	impact	of	10	µM	folic	acid	on	folate	levels	in	gcp-2.1	mutant	
C.	elegans.	Wild-type	and	gcp-2.1	mutant	C.	elegans	were	raised	on	WT	E.	coli	±	10	µM	folic	acid	supplemented	into	the	DM	and	folate	extractions	performed	at	L4/	young	adult	stage.	Error	bars	represent	 standard	 deviation	 over	 4	 biological	 replicates.	 Asterisks	 denote	 significance	 of	Student’s	t-Test	of	either	gcp-2.1	mutants	compared	to	WT	worms	or	gcp-2.1	mutants	+	folic	acid	compared	to	non-supplemented	gcp-2.1	mutants,	where	*P<0.05,	**P<0.01,	***P<0.005	
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This	experiment	also	provided	further	clarification	of	the	folate	status	of	the	gcp-2.1	strain:	5-methyl-glu1	and	–glu2	(P<0.001,	in	both	cases)	and	THF-glu1	(P=0.007)	were	significantly	 lower	 and	 5-methylTHF-glu3	 (P=0.010)	 and	 –glu4	 (P=0.008);	 5/10-formyl	 THF-glu3	 (P=0.015)	 and	 –glu4	 (P=0.019)	 and	 THF-glu3	 (P=0.003)	 and	 –glu4	(P=0.011)	were	 significantly	 higher	 in	 gcp-2.1	 extracts	 in	 the	 folinic	 acid	 controls	compared	to	WT	(figure	4.4).	Likewise,	in	the	folic	acid	controls,	a	similar	pattern	in	
gcp-2.1	polyglutmation	was	observed	(figure	4.5).			
4.4	DISCUSSION	
C.	 elegans	 folate	 extractions	 had	 been	 performed	 previously	 in	 the	Weinkove	 lab,	however,	 only	5-methyl	THF-glu5	could	be	detected	 close	 to	 the	 level	 of	detection.	Here,	following	optimisation	of	the	extraction	protocol,	this	chapter	presents	the	first	LC-MS/MS	 analysis	 of	 the	 polyglutamated	 derivatives	 of	 C.	 elegans	 5-methyl	 THF,	5/10-formylTHF	and	THF.	This	was	carried	out	to	test	the	hypotheses	that	specifically	supplementing	or	limiting	C.	elegans	folate	does	not	affect	lifespan.	As	discussed,	this	was	based	on	two	observations,	namely:	that	although	folinic	acid	supplements	the	C.	
elegans	gcp-2.1	mutant,	it	does	not	decrease	(wild-type)	C.	elegans	lifespan	on	either	SMX-treated	WT	E.	 coli	or	 the	pabA	mutant;	 and	 that	 although	 the	gcp-2.1	mutant	shows	a	folate	deficiency	on	both	SMX-treated	WT	E.	coli	and	the	pabA	mutant,	it	does	not	have	an	increased	lifespan	on	wild-type	E.	coli.		
	The	 hypothesis	 that	C.	 elegans	 folate	 status	 does	 not	 affect	 lifespan	was	 therefore	based	on	the	two	assumptions	that:	1.	folinic	acid	supplements	gcp-2.1	mutants	and	
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wild-type	worms	similarly	and	2.	the	gcp-2.1	mutant	strain	has	low	folate	levels	on	wild-type	E.	coli.	The	data	collected	here	does	not	support	 these	 two	assumptions.	Firstly,	we	find	evidence	that	folinic	acid	increases	folate	levels	in	gcp-2.1	mutants,	but	not	in	wild-type	worms	on	WT	E.	coli,	and	that	on	pabA	E.	coli,	folinic	acid	decreases	levels	of	the	detectable	folates	in	wild-type	worms.	In	the	gcp-2.1	mutant	strain,	folate	levels	were	not	uniformly	lowered	as	was	expected;	only	–glu1	and	–glu2	derivatives	were	 lowered,	whereas	–glu3	and	–glu4	derivatives	were	markedly	 increased.	Thus,	the	use	of	these	two	lifespan	conditions	as	examples	of	where	C.	elegans	folate	status	is	specifically	supplemented	or	restricted,	is	not	substantiated	here.		It	 is	 possible,	 however,	 that	 results	may	 be	 confounded	 by	 technicalities	with	 the	experimental	procedure.	 In	both	cases,	 folate	extractions	were	only	carried	at	only	one	time-point	(L4/	young	adult	stage)	on	populations	synchronized	by	egg-lay	onto	the	stated	condition.	This	was	done	to	ensure	that	 large	populations	and	sufficient	extraction	material	 was	 obtained.	 However,	 when	 carrying	 out	 lifespan	 assays,	 C.	
elegans	are	transferred	onto	the	stated	conditions	only	at	L4/	young	adult	stage.	It	is	likely	 that	 the	 folate	 profile	 will	 fluctuate	 with	 developmental	 stage	 and	 into	adulthood.	Extractions	should	be	repeated	with	time-points	during	development	and	into	adulthood	and	on	conditions	where	worms	are	only	 transferred	at	L4/	young	adult	 stage.	 This	 may	 reveal	 folate-flux	 through	 the	 system	 which	 could	 not	 be	detected	at	a	single	time-point.		
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4.4.1	C.	elegans	folate	status	does	not	correlate	with	lifespan	
Despite	these	limitations,	the	data	presented	in	this	chapter	are	consistent	with	the	hypothesis	 that	C.	 elegans	 folate	 status	does	not	 correlate	with	 lifespan.	C.	 elegans	folate	levels	are	decreased	on	the	pabA	mutant	when	supplemented	with	10	µM	folic	acid,	 however	 lifespan	 is	 partially	 shortened	 on	 this	 condition.	 Moreover,	 10	 µM	folinic	acid	has	a	similar	effect	on	C.	elegans	folate	levels	on	pabA	as	folic	acid,	however	lifespan	is	not	affected	on	this	condition.	The	decrease	in	worm	folate	levels	on	the	
pabA	mutant	 in	 response	 to	 folic	 and	 folinic	 acid	 is	 puzzling	 and	 requires	 further	investigation.	The	phenomena	may	perhaps	be	explained	by	sequestration	of	folate	in	forms	which	 are	 less	 available	 to	 C.	 elegans	 in	 the	 pabA	mutant	 (protein	 bound).	Indeed,	the	effect	is	more	pronounced	in	response	to	folic	acid,	suggesting	that	uptake	by	E.	coli	may	be	confounding	the	results	here.	Although	this	was	not	the	focus	of	this	chapter,	C.	elegans	 folate	extractions	on	the	abgTpabA	mutant	may	provide	further	insight	into	this	conundrum.		
4.4.2	gcp-2.1	folate	profile:	insights	into	the	role	of	folate	polyglutamation	in	folate	
deficiency	
It	was	previously	hypothesized	 that	gcp-2.1	was	expressed	 solely	 in	 the	C.	 elegans	intestine,	 similarly	 to	 the	 mammalian	 glutamate	 carboxypeptidase	 gene,	 folate	hydrolase	(FH),	acting	to	deconjugate	E.	coli	polyglutamated	THFs	to	generate	mono-glutamated	THFs	 for	 uptake	 and	 transport	 (see	 Chapter	 1).	 Thus,	gcp-2.1	deletion	would	 act	 to	 create	 a	 functional	 folate	 deficiency	 on	 conditions	 where	 the	monoglutamated	folate	pool	provided	by	E.	coli	was	decreased	(SMX	treatment	and	
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pabA	deletion).	If	this	was	the	case,	we	would	expect	to	see	a	decrease	in	all	folates	in	the	 gcp-2.1	 strain.	 However,	 the	 shift	 towards	 polyglutamated	 folates,	 which	 are	generally	considered	to	be	intracellular	derivatives	of	the	vitamin,	indicates	that	gcp-
2.1	may	also	have	a	role	in	cellular	export	of	folates,	in	a	similar	role	to	mammalian	GGH	(see	Chapter	1).	 Indeed,	this	 is	consistent	with	the	finding	by	E.	Williams	that	mutants	of	 the	other	C.	 elegans	genes	 encoding	glutamate	 carboxypeptidase	 genes	(gcp-2.2	and	gcp-2.3),	do	not	exhibit	folate	deficiency	on	SMX-treated	or	pabA	mutant	
E.	coli	(data	not	shown).	In	order	to	verify	localisation	of	GCP-2.1	GFP	transcriptional	and	translational	gcp-2.1/	GCP-2.1	fusions	were	attempted	but	were	not	successful.	Expression	of	gcp-2.2	was	detected	in	two	tail	neurons	and	gcp-2.3	in	the	secretory	system	 following	 the	 creation	 of	 fusion	 constructs	 and	 transgenic	 lines	 by	 an	undergraduate	project	student,	Alex	Crisp.			In	 humans,	 GGH	 acts	 in	 opposition	 with	 the	 FPGS	 enzyme,	 where	 the	 latter	polyglutamylates	 folates	 that	 have	 been	 transported	 into	 cells	 by	 RFC	 in	 order	 to	increase	 their	 affinity	 for	 folate	dependent	 enzymes	and	prevent	 their	 export	 (see	Chapter	 1,	 section	 1.2.3).	 A	 BLASTn	 search	 search	 revealed	 a	 C.	 elegans	 gene	(F25B5.6)	 with	 similar	 nucleotide	 scaffolds	 to	 human	 FPGS.	 Expression	 of	 a	 GFP	translational	F25B5.6	fusion	construct	has	been	detected	in	the	pharynx,	intestine	and	hypodermis	in	C.	elegans	(Dupuy	et	al.,	2007).	Thus,	if	GCP-2.1	is	involved	in	cellular	export,	knockout	would	be	expected	to	‘trap’	THFs	as	polyglutamates	(figure	4.6).	It	would	be	interesting	to	examine	the	C.	elegans	folate	profile	in	F25B5.6	knock-out	or	knock-down	mutants	in	order	to	characterize	the	opposing	functions	of	GCP-2.1	and	FPGS.	 	 It	would	 be	 expected	 that	 inhibition	 of	 FPGS	 activity	would	 shift	 the	 folate	
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profile	 toward	 mono-	 and	 glutamated	 derivatives,	 and	 perhaps	 cause	 a	 folate-deficiency	due	to	a	 lack	of	suitable	derivatives	for	enzymes	involved	in	one-carbon	metabolism.		
4.4.3	E.	coli	provides	folates	in	excess	of	that	required	by	C.	elegans	for	one	carbon	
metabolism	
The	data	collected	here	is	consistent	with	the	hypothesis	made	by	Virk	et	al.	in	2012	that	 E.	 coli	 provides	 folates	 in	 excess	 of	 that	 required	 by	 C.	 elegans	 to	 support	 a	functional	folate	cycle	(Virk	et	al.	2012).	For	example,	in	the	pabA	mutant,	bacterial	folate	 levels	are	very	 low	(Chapter	3),	however,	 the	C.	elegans	 folate	status	on	 this	strain	is	only	mildly	affected,	and	worms	show	no	phenotypic	abnormalities.			It	 would	 be	 interesting	 to	 examine	 whether	 adaptive	 mechanisms	 in	 worms	 are	compensating	for	the	decreased	dietary	supply	of	folate.	Indeed,	animal	studies	have	reported	 that	 an	 increase	 in	FPGS	activity	 in	 response	 to	dietary	 folate	deficiency,	which	acts	to	shift	the	folate	glutamation	equilibrium	towards	polyglutamation	and	increase	cofactors	available	for	one-carbon	metabolism	(Ifergan	and	Assaraf,	2008;	Mendelsohn	 et	 al.,	 1996).	 Increased	 expression	 of	 cellular	 and	 intestinal	 folate	transporters	 (RFCs	 and	 PCFTs)	 is	 also	 a	 well	 reported	 and	 recognized	 adaptive	response	 to	 folate	 deficiency	 (Ifergan	 and	 Assaraf,	 2008)	 and	 has	 also	 been	demonstrated	in	C.	elegans	(Ortbauer	et	al.,	2016).		
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Figure	 4.	 6	 A	 model	 representing	 the	 predicted	 roles	 of	 C.	 elegans	 GCP-2.1	 in	 folate	
transport	and	metabolism.	E.	coli	cells	in	the	C.	elegans	intestine	will	be	disintegrated	by	the	grinding	of	 the	pharynx.	E.	coli	provide	both	monoglutamated	(THF-glu)	and	polyglutamated	(THF-glun)	 THFs.	 THF-glun	 are	 hydrolysed	 by	 GCP-2.1	 expressed	 in	 the	 membrane	 of	 the	intestinal	epithelial	cells	for	absorption	as	THF-glu	by	the	reduced	folate	carrier,	FOLT-1.	THF-glu	 from	E.	 coli	 can	 be	 absorbed	 directly,	 but	 these	 represent	 a	 low	 percentage	 of	 the	 total	bacterial	 folate	 pool.	 Monoglutamated	 THFs	 are	 transported	 out	 of	 epithelial	 cells	 and	 to	peripheral	 cells,	 where	 they	 are	 imported	 by	 the	 ubiquitously	 expressed	 FOLT-1.	Polyglutamation	of	THFs	 is	 carried	out	by	 folyl-polyglutamate	synthase	 (FPGS).	THF-glun	are	used	by	folate-dependent	enzymes	for	one-carbon	metabolism.	In	order	to	be	exported,	THF-	glun	must	be	hydrolysed	by	GCP-2.1	to	THF-glu1.	Loss	of	gcp-2.1	is	predicted	to	shift	the		glutamtion	equilibrium	towards	polyglutamation,	and	thus	‘trap’	THF-glun	intracellularly.	
THF-glun THF-glu	n+1 
GCP-2.1 
FPGS 
• Export/	import	
• Transport	
• Cellular	retention	
• Increased	affinity	for	
folate-dependent	
enzymes	
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Furthermore,	the	inability	of	folinic	acid	to	increase	C.	elegans	folate	levels	on	wild-type	 E.	 coli,	 despite	 an	 accumulation	 of	 5/10-formyl	 THF-glu1,	 may	 be	 due	 to	 a	saturation	of	FPGS	and/	or	of	the	enzymes	involved	in	one-carbon	metabolism	and	THF	interconversions.	Indeed,	the	only	effect	of	folate	supplementation	observed	here	is	with	10	µM	 folinic	 acid	 in	gcp-2.1	mutants,	where	 enzymes	 are	 likely	 to	be	 less	saturated.	This	 is	 consistent	with	 the	ability	of	 this	 concentration	of	 folinic	acid	 to	rescue	the	gcp-2.1	folate-deficient	phenotype	on	pabA	mutant	E.	coli	(Chapter	7,	figure	7.12).	As	a	positive	control,	it	would	be	interesting	to	test	whether	over-expression	of	
C.	elegans	genes	 involved	 in	 folate	metabolism	can	 increase	the	 folate	status	of	 the	worm	on	wild-type	E.	coli	in	response	to	folinic	acid.		
Together,	the	data	presented	in	this	chapter	provide	several	novel	insights	into	the	C.	
elegans	 folate	 uptake	 and	 metabolism	 and	 highlights	 several	 areas	 for	 further	investigation.	Although	the	LC-MS/MS	measurements	do	not	support	the	use	of	either	the	gcp-2.1	mutant	as	a	condition	which	specifically	restricts	worm	folates,	nor	the	supplementation	of	wild-type	worms	on	pabA	with	folinic	acid	as	a	condition	which	specifically	increases	worm	folates,	overall	the	data	indicates	that	the	folate	status	of	the	worm	is	not	a	determinant	of	lifespan.	Furthermore,	the	data	also	demonstrate	that	E.	coli	synthesizes	folate	 in	excess	of	that	required	by	C.	elegans	and	therefore	prompts	 further	 investigation	 into	 the	 underlying	 mechanism	 responsible	 for	apparent	over	production	of	folate.	Finally,	an	insight	is	provided	into	the	interplay	between	E.	 coli	 and	C.	 elegans	 genotype	 in	 determining	 the	 response	 to	 folic	 acid	supplementation.	
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CHAPTER	5:	INVESTIGATING	THE	GROWTH	PHASE	DEPENDENCE	OF	E.	COLI	FOLATE	
SYNTHESIS	
 
5.1	INTRODUCTION		It	has	been	established	that	E.	coli	provides	a	source	of	THFs	above	the	threshold	required	for	sufficient	one-carbon	metabolism	in	both	E.	coli	and	C.	elegans.	It	is	clear	that	this	activity	negatively	impacts	C.	elegans	lifespan,	however,	it	is	unclear	why	E.	
coli	appears	to	waste	biosynthetic	energy	in	this	manner.	Little	is	known	about	the	regulation	of	bacterial	folate	synthesis;	no	transcription	factors	have	been	identified	and	it	is	not	clear	whether	folates	are	synthesized	constitutively	or	within	a	specific	growth	phase.	This	chapter	aims	to	provide	insight	into	this	matter	by	investigating	the	growth	phase	dependence	of	E.	coli	folate	synthesis	at	25	°C	on	DM	agar.	Here,	LC-MS/MS	will	be	used	to	examine	how	THF	levels	fluctuate	over	time	and	this	will	be	combined	with	an	examination	of	longitudinal	pabA	gene	expression	under	the	same	 conditions,	 using	 qPCR.	 Lifespan	 analyses	 where	 E.	 coli	 folate	 synthesis	 is	inhibited	at	different	temporal	stages	will	be	carried	out	with	the	aim	of	identifying	a	target	window	for	lifespan	extension.			
5.2	CHAPTER	AIMS	
• Aim	1:	Examine	E.	coli	growth	and	folate	levels	over	time	using	LC-MS/MS	
• Aim	2:	Investigate	the	temporal	expression	of	pabA	using	qPCR	
• Aim	3:	 Investigate	how	 inhibiting	E.	 coli	 folate	synthesis	at	different	 time-points	impacts	lifespan	
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5.3	RESULTS	
5.3.1i	Longitudinal	LC-MS/MS	detection	of	E.	coli	folate	levels	reveals	a	folate	peak	in	
exponential	growth	phase	
E.	 coli	 growth	 and	 folate	 levels	 were	 monitored	 over	 a	 six	 day	 time	 course	 on	conditions	used	for	C.	elegans	experiments.	WT	and	pabA	mutant	E.	coli	were	seeded	onto	 DM	 agar	 plates	 and	 incubated	 at	 25	 °C.	 WT	 was	 also	 seeded	 onto	 plates	supplemented	 with	 128	 µg/ml	 SMX,	 as	 a	 negative	 control.	 All	 plates	 were	supplemented	with	0.1	µM	PABA	to	ensure	comparable	growth	between	WT	and	
pabA	mutant	E.	coli.	Optical	density	at	600	nM	was	used	to	measure	bacterial	growth	and	this	was	used	to	normalize	the	extraction	volume.	Extractions	were	performed	in	quadruplicate	on	consecutive	days	over	six	days.	Extracts	were	subjected	to	LC-MS/MS	and	the	levels	of	THF,	5/10-formyl	TH,	5-methyl	THF,	5,10-methenyl	THF	and	5,10-methylene	THF	–glu3	derivatives	were	normalized	to	an	internal	MTX-glu6	spike.	WT	E.	 coli	and	 the	pabA	mutant	 showed	 similar	 growth	 kinetics	 and	both	reached	stationary	phase	at	day	5.	The	growth	conditions	of	SMX-treated	E.	coli	have	not	been	optimized	for	growth	on	DM	and	it	is	clear	from	the	growth	curves	in	figure	5.1	 (first	 panel)	 that	 0.1	 µM	 PABA	 is	 not	 sufficient	 to	 support	 normal	wild-type	growth.	Nevertheless,	extracts	were	normalized	for	growth	and	the	SMX	condition	provides	a	negative	control.		LC-MS/MS	detection	revealed	that	THF	levels	in	WT	E.	coli	extracts	were	higher	than	in	pabA	extracts,	both	of	which	were	significantly	higher	 than	 folates	detected	 in	SMX	extracts	(figure	5.1).	In	WT	extracts,	folate	levels	peaked	at	day	3	in	THF,	5/10-formyl	 THF,	 5,10-methylene	 THF	 (P<0.001,	 in	 all	 3	 cases)	 and	 day	 2/3	 in	 5,10-
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methenyl	THF	(P=0.023),	where	P	values	here	 indicate	 the	result	of	a	 two-tailed,	paired	 Student’s	 t-test,	 comparing	 the	 stated	 day	 from	 day	 1.	 The	 peak	 in	 5-methylTHF	at	day	3	was	not	significant	(P=0.065).	After	this	peak,	levels	of	THF	and	5,10-methenyl	THF	exhibited	a	gradual	decline,	whereas	levels	of	5/10-formyl	THF,	5,10-methylene	 THF	 and	 5-methyl	 THF	 fluctuated,	 but	 remained	 constant.	 The	decrease	 in	 5-methyl	 THF	 at	 day	 4	 was	 significant	 (P<0.001),	 but	 remains	unresolved.	The	difference	in	the	consumption	of	these	THFs	may	represent	their	different	roles	in	one-carbon	metabolism.			Folate	levels	in	pabA	extracts	showed	a	gradual	decline	over	the	six	day	time	course	(figure	5.1).	The	lack	of	an	early	peak	suggests	that	pabA	activity	is	responsible	for	the	 high	 levels	 observed	 in	WT	 extracts	 at	 days	 2/3.	 This	 indicates	 that	 pabA	 is	expressed	and	active	during	 the	 first	48-72	hours	of	bacterial	growth,	 coinciding	with	early	exponential	phase.	The	decline	in	folate	levels	after	this	period,	despite	continued	 bacterial	 growth	 in	 line	 with	 WT,	 suggests	 that	 pabA	 activity	 either	declines	after	this	initial	period,	as	sufficient	folate	has	been	synthesized,	or	activity	is	maintained,	but	folate	is	used	up	for	cellular	biosynthetic	reactions	more	rapidly	than	it	is	being	synthesized.	This	discrepancy	will	be	addressed	by	examining	pabA	expression	under	these	conditions.			The	folate	levels	at	day	1	in	pabA	extracts	were	similar	to	those	in	WT	extracts.	This	might	be	due	to	carryover	of	folate	synthesized	in	pabA	cells	from	exogenous	PABA	in	the	LB	overnight	culture.	Despite	‘washing’	cells	using	a	DM	subculture	as			
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Figure	5.1	LC-MS/MS	detects	fluctuations	in	folate	level	in	WT	E.	coli	±	SMX	and	pabA	mutant	E.	coli	over	six	days	of	bacterial	growth.	Levels	of	THFs	detected	in	extracts	of	WT,	pabA	mutant	and	WT	+	SMX	E.	coli	over	a	six	day	time	course	were	measured	by	LC-MS/MS.	Folate	level	is	displayed	as	a	ratio	of	an	internal	MTX-glu6	spike	for	normalization	between	samples.	Top	left	panel	shows	bacterial	growth	over	the	six	day	time	course.	Error	bars	represent	standard	deviation.	Asterisks	denote	the	result	of	Student’s	t-	tests	of	folate	level	on	denoted	condition	compared	to	folate	level	on	day	1,	where	***P<0.001,	**P<0.01	*<0.05.	
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outlined	 in	 Chapter	 3,	 E.	 coli	 only	 requires	 nanomolar	 quantities	 of	 PABA	 to	support	 folate	 synthesis	 (Chapter	3,	 figure	3.6).	 0.1	µM	PABA	added	 to	 the	DM	plates	is	not	sufficient	to	allow	continued	synthesis	in	pabA	mutants,	thus	we	see	a	decline	in	folate	levels	over	the	six	day	time	course.	In	contrast,	SMX	blocks	the	ability	of	cells	to	use	exogenous	PABA,	therefore,	detectable	levels	of	folate	were	low	from	day	1	in	SMX-treated	WT	E.	coli	extracts	(figure	5.1).	As	extracts	were	normalized	for	growth,	the	lower	levels	of	folate	in	SMX-treated	conditions	cannot	be	attributed	 to	 the	sub-optimal	growth.	Slight	 increases	 in	all	 folate	species	 in	SMX-treated	WT	extracts	were	detected	towards	the	end	of	the	time	course.	This	may	be	due	to	the	degradation	of	SMX	over	time	in	the	plates,	or	the	accumulation	of	PABA	over	time,	causing	competition	between	PABA	and	SMX.			
5.3.1	ii	THF	peak	in	exponential	phase	is	accentuated	with	glucose		
The	impact	of	glucose	on	E.	coli	growth	kinetics	was	first	described	by	Monod	in	1949	 (Monod,	 1949).	 The	 ability	 of	 E.	 coli	 (and	 many	 other	 bacteria)	 to	preferentially	 use	 glucose	 as	 a	 carbon	 source	 is	 now	 referred	 to	 as	 carbon	catabolite	 repression	 (Stulke	 and	 Hillen,	 1999)	where	 the	 use	 of	 other	 carbon	sources	is	suppressed	in	favour	of	glucose	metabolism.	0.1%	glucose	was	added	to	the	amino	acid	media	here,	post-autoclaving,	in	order	to	alter	the	growth	kinetics	of	E.	coli.	Monitoring	the	temporal	pattern	of	folate	levels	in	response	to	glucose	would	 therefore	 act	 as	 a	 positive	 control	 to	 determine	 whether	 folate	 is	synthesized	in	association	with	a	specific	growth	phase.	Folate	extractions	of	WT	and	pabA	E.	coli	on	glucose	DM	over	a	six-day	time	course	were	carried	out	and	subjected	to	LC-MS/MS	in	parallel	with	the	control	non-supplemented	extractions	
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already	discussed.	WT	E.	coli	on	SMX	and	glucose	DM	was	included	as	a	negative	control	condition	(figure	5.2).			Consistent	with	glucose	being	a	more	readily	utilizable	carbon	source	than	amino	acids,	 0.1%	 glucose	 increased	 exponential	 phase	 growth	 in	 all	 conditions	 as	bacterial	 growth	 reached	 stationary	 phase	 at	 the	 same	 time-point	 as	 control	conditions,	but	the	final	OD600	was	significantly	higher	in	all	cases	(figure	5.2,	first	panel).	It	was	hypothesized	that	glucose	would	shift	the	peak	in	folate	levels	to	the	left	of	 the	graphs,	but	would	not	 increase	overall	 folate	 levels	as	 the	extraction	volumes	would	be	normalized	for	growth	before	LC-MS/MS	detection.	Indeed,	in	WT	extracts	on	0.1%	glucose	DM,	the	peak	in	all	folate	species	was	shifted	to	day	2,	but	unexpectedly,	the	level	of	this	peak	was	significantly	increased	in	all	cases	compared	 to	 the	 non-supplemented	 controls	 (P<0.001)	 (figure	 5.2).	 After	 this	peak,	levels	returned	to	those	in	line	with	the	control	extracts,	with	the	exception	of	 5-methylTHF.	 It	 was	 ensured	 that	 glucose	 did	 not	 interfere	 with	 the	 MTX	internal	standard	and	that	there	were	no	peculiarities	with	day	2	extractions.			In	pabA	extracts	on	0.1%	glucose	DM,	a	peak	at	day	2	was	not	observed.	In	a	similar	manner	 to	 the	 non-supplemented	 pabA	 extracts,	 folate	 levels	 declined	 for	 the	remainder	of	the	time	course,	again	with	the	exception	of	5-methyl	THF,	which	was	detected	at	increasingly	higher	levels	from	days	2-5,	followed	by	a	decrease	on	day	5.	 Similarly	 to	 the	 non-supplemented	 control	 extracts,	 folate	 levels	 in	 pabA	extracts	on	0.1%	glucose	DM	were	again	detected	at	similar	levels	to	those	in	WT	extracts	on	day	1,	likely	owing	to	initial	synthesis	supported	by	trace	PABA	from	
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Figure	5.2	LC-MS/MS	detects	an	increase	in	folate	level	in	WT	E.	coli	in	response	to	0.1%	glucose.	Levels	of	THFs	detected	in	E.	coli	extracts	of	WT	±	0.1%	glucose,	pabA	mutant	+	0.1%	glucose,	and	WT	+	SMX	+	0.1%	glucose	measured	by	LC-MS/MS.	Folate	level	is	displayed	as	a	ratio	of	an	internal	MTX-glu6	spike	for	normalization	between	samples.	0.1%	here	represents	0.1%	glucose	added	to	the	DM	agar	media	post-autoclaving.	Top	left	panel	shows	bacterial	growth	over	the	six	day	time	course.	Error	bars	represent	standard	deviation.	Asterisks	denote	the	result	of	Student’s	t-	tests	of	folate	level	on	denoted	condition	compared	to	on	day	1	of	the	same	condition,	where	***P<0.001,	**P<0.01	*<0.05.	
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LB.	Overall,	these	data	suggest	that	E.	coli	folate	synthesis	is	temporally	regulated,	not	constitutive,	in	our	model	system.	Folates	seem	to	be	synthesized	in	excess	in	early	 exponential	 phase,	 and	 after	 this	 point	 in	 general,	 folate	 levels	 begin	 to	gradually	 decline.	 Furthermore,	 the	 data	 here	 has	 revealed	 a	 novel	 association	between	 glucose	 and	 folate	 synthesis,	 indicating	 that	 cells	 using	 glucose	 as	 a	carbon	source	generate	more	folate.	This	will	be	discussed	in	more	detail.	
5.3.2	pabA	expression	peaks	in	exponential	phase	and	decreases	in	stationary	phase	
In	order	to	verify	that	folate	synthesis	is	active	in	exponential	phase,	pabA	gene	expression	 in	 WT	 E.	 coli	 under	 the	 same	 conditions	 used	 for	 LC-MS/MS	 was	examined	 using	 qPCR.	 WT	 E.	 coli	 was	 seeded	 onto	 DM	 agar	 plates	 (again	supplemented	 with	 0.1	 µM	 PABA)	 and	 RNA	 extractions	 were	 carried	 out	 in	quadruplicate	after	6,	24,	48,	72	and	96	hours.	Note	the	earlier	time	point	in	order	to	capture	lag	phase,	which	was	missing	from	the	previous	folate	extraction	data.	RNA	extractions	of	4	independent	overnight	DM	liquid	cultures	were	carried	out	before	they	were	pooled	and	used	to	seed	the	plates.	RNA	was	converted	to	cDNA	and	 qPCR	 carried	 out	 as	 previously	 described	 (see	 methods).	 Normalized	expression	levels	were	obtained	using	the	delta	delta	ct	method,	using	rrsA	as	an	internal	reference	gene	and	normalizing	to	expression	in	the	overnight	cultures.	
As	 depicted	 in	 figure	 5.3,	 pabA	 expression	 was	 increased	 during	 exponential	growth,	with	a	6-fold	increase	after	24	hours	and	reaching	a	peak	in	expression	after	 48	 hours	 growth,	 with	 a	 22-fold	 increase	 compared	 to	 expression	 in	 the	overnight	 culture.	 After	 this	 point,	when	 cells	 began	 to	 enter	 stationary	 phase,	
pabA	expression	was	reduced,	however	it	was	maintained	8-10-fold	higher	than	in	the	overnight	culture	at	72	and	96	hours.	As	the	time	course	did	not	continue	past	
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4	days	of	bacterial	growth,	it	is	not	clear	how	long	pabA	expression	is	maintained	at	this	level.	Overall,	the	temporal	expression	pattern	of	pabA	is	consistent	with	the	temporal	pattern	of	folate	levels	detected	by	LC-MS/MS.	
5.3.3	Inhibiting	folate	synthesis	has	a	partial	protective	effect	on	glucose-induced	
lifespan	reduction	
The	Kenyon	lab	has	demonstrated	that	0.1%	glucose	negatively	effects	C.	elegans	lifespan	 by	 stimulating	 the	 insulin/	 IGF-1	 signalling	 pathway	 and	 thereby	inhibiting	the	transcription	of	DAF-16/	FOXO	downstream	genes	(Lee	and	Kenyon,	2009).	As	the	data	here	suggests	that	glucose	has	a	marked	effect	on	E.	coli	folate	levels,	it	was	examined	whether	glucose	may	have	an	as	of	yet	undetermined	and	indirect	impact	on	C.	elegans	lifespan.	
Lifespan	assays	were	carried	out	on	the	same	conditions	used	for	the	glucose	LC-MS/MS	extractions	(figure	5.4).	These	lifespans	were	conducted	by	Lucy	Lancaster	(LL),	 a	 Masters	 student	 in	 the	 Weinkove	 laboratory	 working	 under	 my	supervision.	Figures	5.4	depicts	 the	Kaplan	Meier	survival	 curves.	The	P	values	here	 are	 the	 test-statistic	 of	 Log-rank	 tests.	 Consistent	with	 the	 peer-reviewed	findings,	 0.1	 %	 glucose	 significantly	 reduced	 lifespan	 by	 24%	 on	 WT	 E.	 coli	(P<0.0001).	In	line	with	work	presented	in	this	thesis	and	that	previously	carried	out	in	the	lab,	lifespans	carried	out	by	LL	on	pabA	mutant	and	SMX-treated	WT	E.	
coli	were	significantly	increased,	by	45%	and	47%	respectively	(P<0.0001,	in	both	cases).	In	both	these	cases,	glucose	was	found	to	decrease	lifespan	significantly,	but	to	a	lesser	extent	than	on	WT	E.	coli.	Lifespan	on	the	pabA	mutant	with	glucose	was	40%	higher	and	on	SMX-treated	E.	coli	with	glucose,	13%	higher	than	lifespan	on	WT	E.	coli	with	glucose	(figure	5.4).	This	suggests	that	there	is	a	partially		
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Figure	5.3	Normalized	mRNA	expression	level	of	pabA	in	WT	E.	coli	over	a	96	hour	time	
course.	RNA	extractions	were	performed	on	agar	DM	seeded	with	WT	E.	coli.	Expression	here	represents	the	fold	change	normalized	to	expression	measured	the	DM	overnight	culture	used	to	seed	the	plates,	and	to	the	internal	reference	gene,	rrsA,	as	determined	by	qPCR.	Error	bars	represent	standard	deviation	over	4	biological	replicates.	Bacterial	growth	is	plotted	on	the	y	axis.	
	
Figure	5.4	SMX	and	 the	pabA	mutant	are	partially	protective	of	 the	negative	 impact	of	
0.1%	glucose	on	C.	elegans	lifespan.	Kaplan-Meier	survival	curves	of	C.	elegans	on	WT,	WT	+	SMX,	pabA	mutant	±	0.1%	glucose	(added	into	DM	post-autoclaving).	Worms	were	added	onto	the	experimental	condition	at	day	1	of	adulthood.	[SMX]	=	128	µg/ml.	
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protective	 effect	 of	 inhibiting	 folate	 synthesis	 on	 glucose-induced	 lifespan	reduction.	This	is	in	line	with	the	observation	that	glucose	increases	E.	coli	folate	synthesis,	and	demonstrates	that	this	has	an	indirect	and	previously	unaccounted	for	impact	on	lifespan.			
5.3.4	SMX	extends	lifespan	most	effectively	when	the	first	2	days	of	bacterial	growth	
are	targeted	
In	order	to	confirm	that	the	folate	synthesized	during	early	exponential	phase	is	responsible	for	folate-induced	lifespan	modulation,	folate	synthesis	was	inhibited	with	SMX	at	different	time	points	within	the	first	4	days	of	bacterial	growth	and	lifespans	were	carried	out.	Conventionally,	128	µg/ml	SMX	is	added	to	the	agar	media	 post-autoclaving	 (after	 cooling	 to	 50	 °C)	 before	 pouring	 the	 plates	 (see	methods).	 E.	 coli	 is	 cultured	 in	 LB	 overnight	 and	 then	 sub-cultured	 into	 DM	overnight	before	‘seeding’	onto	DM	agar	plates	and	incubated	at	25°C	for	48	hours.	L4/	young	adult	C.	elegans	are	then	transferred	onto	the	plates	for	aversion	and	lifespan	assays,	where	this	represents	day	1	of	adulthood	(figure	5.5).	As	bacteria	are	subjected	to	SMX	for	the	entirety	of	their	growth	on	the	agar	plates,	it	is	not	clear	at	what	stage	SMX	is	acting.	It	was	hypothesized	that	SMX	may	have	less	of	an	effect	on	C.	elegans	lifespan	if	it	is	added	after	exponential	growth	phase.		
Lifespans	 in	 the	Weinkove	 laboratory	 are	 conducted	 by	 transferring	worms	 at	days	 7	 and	 14	 of	 adulthood	 onto	 ‘freshly’	 seeded	 (48	 hours	 previously)	E.	 coli	plates.	This	 is	done	to	prevent	worms	from	starving	and	to	reduce	plate-drying	and	cracking	which	can	lead	to	C.	elegans	desiccation	and	censorship.	However,	this	procedure	will	 triple	the	exposure	of	C.	elegans	to	exponential	phase	E.	coli	during	 the	 course	 of	 their	 lifespan.	 It	 was	 hypothesized	 that	 lifespan	 may	 be	
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increased	if	worms	are	not	transferred	to	fresh	E.	coli	during	their	lifespan.	These	two	hypotheses	were	tested	using	the	experimental	set-up	as	depicted	in	figure	5.5.	Eight	lifespan	conditions	were	set	up,	where	half	would	be	the	‘transfer’	cohort	and	transferred	to	freshly	seeded	E.	coli	plates	on	day	7	and	day	14	of	their	adult	lifespan	 (as	 standard	procedure)	and	 the	other	half	would	 remain	on	 the	 same	plate	from	day	1	of	adulthood,	the	‘non-transfer’	cohort.	Within	each	cohort,	there	were	4	conditions:	control,	non-supplemented;	SMX	control,	added	directly	after	autoclaving;	SMX	added	after	2	days	of	bacterial	growth;	SMX	added	after	4	days	of	bacterial	growth.	No	additional	SMX	would	be	added	to	the	non-transfer	cohort,	but	SMX	would	be	added	to	the	transfer	cohort	after	transfer	on	days	2	and	4	of	bacterial	growth,	respectively	(see	Figure	5.5	for	experimental	set-up).	
Figure	 5.6	 depicts	 the	 Kaplan	Meier	 survival	 curves	 (5.6a,	 5.6b)	 and	 the	mean	lifespans	(5.6c)	on	each	condition.	P	values	here	 indicate	the	result	of	Log-rank	statistical	analysis.	On	control	SMX	plates,	 lifespan	was	extended	by	54%	in	the	transfer	 cohort	 and	 43%	 in	 the	 non-transfer	 cohort	 (P<0.0001,	 in	 both	 cases)	compared	 to	 their	 respective	 non-supplemented	 controls,	where	 the	 difference	between	these	two	lifespans	was	not	significant.	Likewise,	there	was	no	significant	difference	in	lifespan	between	the	two	non-supplemented	conditions.		
In	the	transfer	cohort	(figure	5.6a),	when	SMX	was	added	after	2	days	of	bacterial	growth,	lifespan	extension	increased	by	only	15.24%.	When	added	after	4	days	of	bacterial	growth,	SMX	failed	to	have	any	effect	on	lifespan.	In	contrast,	in	the	non-	transfer	cohort	(figure	5.6b),	lifespans	were	significantly	higher	compared	to	their	relative	 transfer	cohort	 lifespans	(P<0.0001,	 in	both	cases),	where	 lifespan	was	increased	by	33%	when	SMX	was	added	after	2	days	of	bacterial	growth	and	11%		
131 
 
	
Figure	5.5	Experimental	schematic	for	examining	the	impact	of	SMX	at	different	stages	of	bacterial	growth	on	C.	elegans	lifespan.	Plates	were	seeded,	as	standard,	2	days	before	C.	elegans	are	added.	Conditions	(1,	2)	are	control	plates;	(2,	6)	SMX	control	(128	µg/ml	SMX	added	after	autoclaving);	(3,	7)	SMX	added	at	day	2;	and	(4,	8)	SMX	added	at	day	4	of	bacterial	growth.	Worms	are	added	onto	plates	at	day	2	of	bacterial	growth	(at	day	1	of	adulthood).	At	day	7	and	14	of	adulthood,	worms	on	conditions	1-4	are	transferred	onto	fresh	plates	(and	receive	SMX	again	at	days	2	or	4	of	bacterial	growth).	Worms	on	conditions	5-8	remain	on	same	plates	and	do	not	receive	additional	SMX.	
132 
 
when	added	after	4	days.	This	may	seem	initially	counter	intuitive	as	the	worms	which	 lived	 the	 longest	 were	 on	 E.	 coli	 conditions	 which	 received	 less	 SMX	throughout	their	lifespan,	however	these	worms	were	only	exposed	to	exponential	phase	E.	 coli	once.	Additionally,	 in	 both	 cohorts,	worms	 lived	 longest	 on	plates	supplemented	with	SMX	after	2	days	of	bacterial	growth	than	4,	and	longest	on	control	SMX	plates.	Thus,	the	number	and	length	of	exposure	to	exponential	phase	non-SMX	treated	E.	coli	determines	lifespan.		
Together,	 this	 supports	 the	 hypothesis	 that	 folate	 synthesis	within	 the	 first	 48	hours	 of	 bacterial	 growth	 is	 responsible	 for	 C.	 elegans	 lifespan	 decrease.	 That	lifespan	is	not	further	decreased	in	the	transfer	cohort	on	the	non-supplemented	control	plates	compared	to	the	non-transfer	conditions	may	represent	a	limit	for	lifespan	decrease	via	this	means.	
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Figure	5.6.	Addition	of	SMX	within	the	first	two	days	of	bacterial	growth	is	most	effective	
at	extending	C.	elegans	lifespan	a-b)	Kaplan-Meier	survival	curves	of	C.	elegans	on	WT	E.	coli	supplemented	with	 SMX	either	post-autoclaving	or	 after	2	days	or	4	days	of	 bacterial	 growth	where	a)	worms	were	transferred	onto	fresh	E.	coli	at	days	7	and	14	of	adulthood	and	b)	worms	were	not	transferred	c)	mean	lifespan	on	all	conditions	(error	bars	represent	standard	error).		
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5.4	DISCUSSION	
5.4.1	Excess	folate	responsible	for	lifespan	decrease	is	generated	in	early	exponential	
phase		
This	chapter	aimed	to	determine	when	E.	coli	synthesizes	folate	and	how	folate	levels	fluctuate	over	 time,	under	conditions	used	 for	C.	elegans	experiments.	Rather	 than	continuous	constitutive	synthesis,	both	LC-MS/MS	detection	of	 folate	 levels	 (figure	5.1,	5.2)	and	qPCR	analysis	of	pabA	gene	expression	(figure	5.3)	were	consistent	with	a	model	whereby	 the	majority	 of	 folate	 synthesis	 occurs	 during	 early	 exponential	growth	phase,	after	which	point	activity	is	decreased,	but	a	basal	level	is	maintained	into	stationary	phase.	In	our	model	system,	early	exponential	phase	here	coincides	with	2/3	days	after	seeding	 the	bacteria	onto	 the	DM	agar	plates,	when	plates	are	incubated	at	25	°C.	It	is	also	shown	here	that	inhibiting	E.	coli	folate	synthesis	with	SMX	increases	C.	elegans	lifespan	most	effectively	when	this	early	window	is	targeted	(figure	 5.6).	 Together,	 this	 work	 provides	 a	 novel	 insight	 into	 the	 temporality	 of	bacterial	 folate	 synthesis	 and	 demonstrates	 that	 excessive	 folate	 synthesis	 occurs	during	early	exponential	phase	growth.		
5.4.2	A	novel	association	between	glucose	and	E.	coli	folate	synthesis	
Glucose	is	a	readily	utilizable	carbon	source	and	is	well	known	to	increase	bacterial	growth.	0.1%	glucose	was	included	here	in	order	to	shift	the	growth	kinetics	of	E.	coli	compared	to	growth	on	amino	acids,	and	therefore	act	as	a	positive	control	for	the	temporality	of	folate	synthesis.	Indeed,	glucose	did	increase	bacterial	growth	and	this	correlated	 to	 a	 left	 shift	 in	 the	 peak	 of	 folate	 levels	 (from	day	 3	 to	 day	 2).	 As	 the	
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extracts	were	normalized	for	growth,	the	effect	of	glucose	on	detectable	folate	levels	was	 separated	 from	 increased	 cell	 number,	 but	 unexpectedly	 glucose	 markedly	increased	the	levels	of	all	folate	species	at	day	2.	Glucose	is	not	a	recognised	extrinsic	factor	known	to	increase	bacterial	folate	synthesis,	and	it	has	only	previously	been	described	anecdotally	 (Sybesma	et	al.,	2003).	The	effect	was	not	observed	 in	pabA	mutant	 or	 SMX-treated	 extracts,	 indicating	 that	 glucose	 increases	 folate	 levels	 by	boosting	 bacterial	 folate	 synthesis.	 Unfortunately,	 pabA	 expression	 was	 not	monitored	in	WT	E.	coli	on	0.1%	glucose	media,	but	it	 is	hypothesized	that	glucose	would	increase	pabA	expression	and	perhaps	other	genes	involved	in	folate	synthesis			The	 impact	 of	 glucose	 on	bacterial	 folate	 synthesis	was	here	 found	 to	 be	partially	responsible	 for	 the	 negative	 impact	 of	 glucose	 on	 C.	 elegans	 longevity,	 which	 is	regarded	in	the	field	to	be	mediated	directly	through	C.	elegans.	Together	this	work	reveals	a	novel	role	of	glucose	in	boosting	E.	coli	folate	synthesis	and	thus	indirectly	modulating	C.	elegans	lifespan.	The	mechanism	underlying	this	phenomena	was	not	further	explored	within	the	scope	of	this	thesis,	however,	areas	for	further	study	and	the	translational	implications	of	this	work	will	be	discussed	in	Chapter	8.		
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CHAPTER	6.	BACTERIAL	FOLATE	SYNTHESIS	AND	THE	TOXICITY	HYPOTHESIS		
 
6.1	INTRODUCTION		As	discussed	in	Chapter	1,	studies	have	indicated	that	E.	coli	K12	and	OP50	impact	
C.	 elegans	 lifespan	 in	 mechanisms	 independent	 of	 nutritional	 content,	 and	consistent	with	a	mild	pathogenicity	or	toxicity	(Kim,	2013).	The	data	presented	in	this	thesis	have	demonstrated	that	E.	coli	synthesizes	folate	above	the	threshold	required	 for	growth	and	biosynthesis	and	 that	 this	negatively	affects	C.	elegans	lifespan.	This	chapter	investigates	whether	excessive	bacterial	folate	synthesis	is	associated	with	a	toxicity	and	explores	a	potential	genetic	mechanism	via	which	this	toxicity	may	occur.		
6.1.1	C.	elegans	as	sensors	of	toxicity	
C.	elegans	encounter	diverse	microbes	in	the	wild	and	must	be	able	to	differentiate	between	those	that	are	beneficial	and	those	that	are	harmful.	As	such,	C.	elegans	have	evolved	mechanisms	to	escape	and	defend	against	pathogenic	bacteria	and	toxic	metabolites	(Pujol	et	al.,	2008;	Schulenburg	et	al.,	2008;	Shtonda	and	Avery,	2006;	 Stupp	 et	 al.,	 2013;	 Zhang,	 2008).	 C.	 elegans	 can	 be	 maintained	 in	monoculture	on	a	wide	range	of	 commensal	and	pathogenic	bacteria	and	 these	mechanisms	have	been	characterized	in	the	laboratory	(Clark	and	Hodgkin,	2014;	Couillault	 and	 Ewbank,	 2002).	 One	 of	 the	most	well	 established	 phenotypes	 is	sensing	and	avoidance,	termed	aversion	behaviour	(Bargmann	et	al.,	1993;	Melo	and	Ruvkun,	2012).	 Furthermore,	the	sensitivity	of	C.	elegans	developmental	and	reproductive	phenotypes	to	toxicity	is	also	being	used	as	a	platform	to	screen	for	toxic	chemicals	(Hunt,	2017;	Xiong	et	al.,	2017).	The	first	section	of	this	chapter	
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will	 harness	 these	 phenotypes	 in	 order	 to	 assess	 folate-dependent	 bacterial	toxicity.		
6.1.2	The	global	stress	response	sigma	factor,	RpoS	
Sigma	 factors	 are	 conserved	 bacterial	 proteins	 which	 associate	 with	 RNA	polymerase	 and	 provide	 promoter	 specific	 recognition.	 They	 facilitate	transcription	by	contributing	to	DNA	strand	separation	and	disassociate	following	transcription	initiation.	Prokaryotes	have	several	sigma	factors,	each	of	which	has	a	specific	regulon,	and	therefore	provide	a	means	to	simultaneously	regulate	the	expression	of	a	large	subset	of	genes	(Davis	et	al.,	2017).	
	RpoS,	 or	 σS,	 is	 the	 global	 stress	 response	 sigma	 factor	 responsible	 for	 the	transcription	 of	 genes	 involved	 in	 the	 response	 to	 external	 stimuli,	 such	 as:	nutrient	 starvation,	 hyperosmolarity,	 low	 pH,	 low	 temperature	 and	 oxidative	stress	(Hengge-Aronis,	2002).	In	E.	coli,	the	RpoS-regulon	is	predicted	to	positively	regulate	over	400	genes	 (Patten	et	 al.,	 2004).	RpoS	was	 initially	 identified	as	 a	component	 necessary	 for	 survival	 in	 stationary	 phase	 (Tanaka	 et	 al.,	 1993),	however,	 subsequent	 studies	 have	 found	 that	 RpoS	 function	 is	 not	 confined	 to	stationary	 phase	 (Hengge-Aronis,	 1996),	 with	 significant	 regulatory	 activity	reported	 during	 exponential	 growth	 (Dong	 et	 al.,	 2008;	 Hengge-Aronis,	 1996;	Seputiene	et	al.,	2006;	Vijayakumar	et	al.,	2004)		
As	discussed	in	Chapter	1,	the	rpoS	gene	is	of	interest	as	it	was	identified	in	the	Weinkove	 laboratory	during	a	screen	of	E.	coli	mutants	 for	C.	elegans	 longevity.		
rpoS	has	also	been	extensively	 linked	to	the	expression	of	virulence	factors	and	toxins	 in	pathogenic	bacteria	 (Bachman	and	Swanson,	 2001;	Dong	 et	 al.,	 2008;	
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Iriarte	et	al.,	1995;	Suh	et	al.,	1999;	Yildiz	and	Schoolnik,	1998).	In	C.	elegans,	rpoS	deletion	 in	 Serratia	 sp.	 ATCC	 39006	 (Wilf	 and	 Salmond,	 2012)	 and	 Salmonella	
typhimurium	(Labrousse	et	al.,	2000)	have	been	reported	to	reduce	virulence	and	extend	lifespan.	rpoS	expression	has	also	been	identified	as	a	necessary	factor	for	infection	in	mouse	models	(Allen-Vercoe	et	al.,	1998;	Banik	et	al.,	2011;	Lee	et	al.,	2007)	and	human	infections (Preziosi	et	al.,	2012).		Furthermore,	although	rpoS	has	not	explicitly	been	 linked	 to	 folate	 synthesis,	 a	literature	search	revealed	two	E.	coli	microarray	data	sets	that	pulled	out	pabA	as	significantly	downregulated	in	an	rpoS	mutant	(Ito	et	al.,	2008;	Weber	et	al.,	2005).	Combined	with	the	finding	in	the	Weinkove	laboratory	that	the	E.	coli	K12	rpoS	mutant	extends	C.	elegans	lifespan	(Virk	et	al.	2016),	the	hypothesis	was	made	that	excessive	folate	synthesis	in	E.	coli	K12	may	be	regulated	by	rpoS	in	a	mechanism	either	directly	or	indirectly	related	to	virulence	and/	or	toxicity.	In	this	chapter,	this	hypothesis	will	be	tested	by	examining	whether	C.	elegans	lifespan	extension	on	 the	 rpoS	 mutant	 is	 folate-dependent	 and	 screening	 for	 rpoS	 and	 folate-dependent	mechanisms	of	toxicity.	
6.2	CHAPTER	AIMS	
• Aim	1:	Investigate	the	coincidence	of	bacterial	folate	synthesis	and	toxicity	-using	C.	elegans	aversion	to	the	bacterial	lawn	-investigating	the	Enterobacter	cloacae	B29	strain		
• Aim	2:	Investigate	the	role	of	rpoS	in	folate-dependent	bacterial	toxicity		
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6.3	RESULTS	
6.3.1	C.	elegans	aversion	as	a	phenotypic	readout	of	folate-dependent	bacterial	
toxicity	
Here,	C.	elegans	aversion	to	E.	coli	is	used	as	a	proxy	for	bacterial	toxicity	and	will	be	measured	by	calculating	percentage	aversion	to	the	bacterial	lawn,	where:		
%	aversion = 	 N	(off	lawn)N	(total) 	x	100	
6.3.1i.	SMX	decreases	C.	elegans	aversive	behaviour	and	increases	lifespan	on	two	E.	
coli	strains	The	impact	of	SMX	on	the	aversive	behaviour	of	two	wild-type	C.	elegans	strains	(N2	and	SS104)	on	agar	seeded	with	either	OP50	or	K12	E.	coli	was	measured.	128	µg/	ml	SMX	was	used	in	all	cases.	Aversion	was	calculated	24	hours	after	transfer	of	 50	 L4/	 young	 adult	worms	 onto	 each	 plate,	with	 5	 replicates	 per	 condition.	When	SMX	was	present	in	the	media,	the	percentage	aversion	of	both	SS104s	and	N2s	was	significantly	lower	compared	to	the	non-supplemented	control	on	both	wild-type	strains	of	E.	coli	(P<0.001	in	all	cases)	(figure	1a).	In	the	absence	of	SMX,	the	mean	percentage	aversion	was	significantly	higher	on	K12	WT	compared	to	OP50,	in	both	SS104s	(P=0.017)	and	N2s	(P=0.020).	Whilst	this	does	not	provide	direct	 evidence	 of	 toxicity,	 the	 data	 is	 consistent	 with	 the	 hypothesis	 that	inhibiting	 folate	 synthesis	 attenuates	 a	 folate-dependent	 activity	 that	 normally	deters	C.	elegans	from	the	bacterial	lawn.			Using	just	the	temperature	sensitive	sterile	C.	elegans	strain,	SS104	(glp-4(bn2)),	lifespan	assays	were	carried	out	on	K12	and	OP50	treated	with	SMX	(figure	6.1b).	In	line	with	a	higher	percentage	of	aversion	on	K12	compared	to	OP50,	C.	elegans	
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Figure	6.1	SMX	decreases	C.	elegans	aversion	and	increases	lifespan	on	OP50	and	K12	E.	
coli	a)	50	worms	were	transferred	onto	each	plate,	with	5	replicates	per	condition,	after	2	days	of	bacterial	growth.	Aversion	of	two	wild-type	C.	elegans	strains,	N2	and	SS104,	was	measured	after	 3	 days	 of	 bacterial	 growth.	 Error	 bars	 represent	 standard	 deviation	 b)	 Kaplan-Meier	survival	curves	of	the	SS104	strain	on	OP50	and	K12	with	and	without	SMX.	Assays	were	carried	out	on	NGM.	Assays	performed	at	25°C.	[SMX]	=	128	µg/ml.		
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were	also	shorter	lived	on	K12	(P<0.0001).	Likewise,	SMX	increased	survival	of	C.	
elegans	on	both	E.	coli	strains	compared	to	their	untreated	conditions	(P<0.0001	in	both	cases),	however	survival	of	worms	on	K12	remained	significantly	shorter	than	worms	on	OP50.		
	
6.3.2ii	pabA	and	rpoS	mutant	E.	coli	decrease	C.	elegans	aversion	In	order	to	verify	that	the	impact	of	SMX	on	C.	elegans	aversion	is	folate-dependent	and	not	an	artefact	of	a	xenobiotic,	aversion	assays	were	carried	out	DM	plates	seeded	with	pabA	mutant	E.	coli,	with	SMX	included	as	a	positive	control	(figure	6.2).	Aversion	was	also	measured	on	 the	rpoS	mutant.	Consistent	with	a	 folate-dependent	activity	mediating	C.	elegans	aversion,	the	pabA	mutation	significantly	decreased	 aversive	 behaviour	 of	 both	 N2	 (P=0.004)	 and	 SS104s	 (P=0.001)	compared	to	the	WT	E.	coli	control,	verifying	that	aversion	is	folate-dependent.	On	
rpoS	 mutant	 E.	 coli,	 both	 N2	 (P<0.001)	 and	 SS104	 (P=0.001)	 also	 showed	significantly	decreased	aversive	behaviour.	The	difference	in	aversion	of	N2	and	SS104	worms	on	rpoS	was	not	significant	(P=0.092).		
	
6.3.1iii	SMX	impacts	C.	elegans	aversion	most	effectively	in	E.	coli	exponential	phase	In	order	to	investigate	whether	aversion	and	lifespan	are	affected	by	the	same	folate-dependent	activity,	aversion	was	measured	on	the	conditions	used	for	the	lifespans	in	Chapter	6	(figure	6.6):	SMX	was	either	added	into	the	media	after	autoclaving,	 or	 pipetted	 on	 top	 of	 the	 agar	 media	 at	 the	 appropriate	concentration,	after	2	or	4	days	of	bacterial	growth.	25	L4/	young	adult	worms	were	transferred	onto	10	plates	per	each	condition,	after	the	bacteria	had	been		
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Figure	6.2	C.	elegans	aversion	is	decreased	on	pabA	and	rpoS	mutants.	E.	coli	strains	were	seeded	onto	DM	plates.	N2	and	SS104	C.	elegans	strains	were	transferred	onto	each	plate	(n=50),	with	5	replicates	per	condition,	after	2	days	of	bacterial	growth.	Aversion	was	measured	after	3	days	of	bacterial	growth.	[SMX]	=	128	µg/ml.	Error	bars	represent	standard	deviation.	Asterisks	denote	the	result	of	two-tailed	Student’s	t-test’s	of	denoted	condition	compared	to	on	WT	E.	coli	of	the	same	C.	elegans	strain,	where	*P<0.05,	**P<0.005,	***P<0.001	
	
Figure	 6.3	 SMX	 is	 most	 effective	 at	 decreasing	 C.	 elegans	 aversion	 during	 early	
exponential	phase	growth.	128	µg/ml	SMX	was	added	to	DM	plates	either	post-autoclaving	into	cooled,	liquid	media,	or	pipetted	on	top	of	seeded	plates	in	evenly	distributed	aliquots	after	either	 2	 or	 4	 days	 of	 bacterial	 growth.	 50	worms	were	 transferred	 onto	 each	 plate,	 with	 5	replicates	per	condition,	after	2	days	of	bacterial	growth.	Aversion	was	measured	after	6	days	of	bacterial	growth.	Error	bars	represent	standard	deviation.	Asterisks	denote	the	result	of	two-tailed	 Student’s	 t-test’s	 of	 SMX	 condition	 compared	 to	 control	 condition,	 where	 *P<0.05,	**P<0.005,	***P<0.001	
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seeded	 and	 incubated	 at	 25	 ˚C	 for	 48	 hours.	 On	 all	 conditions,	 aversion	 to	 the	bacterial	lawn	was	measured	on	the	6th	day	of	bacterial	growth	(worms	on	plates	for	4	days).	
Consistent	with	 the	previous	data,	adding	SMX	to	 the	 liquid	agar	growth	media	post-autoclaving	 resulted	 in	 very	 low	 aversion	 (6%),	markedly	 lower	 than	 the	non-supplemented	 control	 (85%)	 (figure	 6.3).	 Percentage	 aversion	 was	significantly	higher	on	plates	supplemented	after	2	days	(18%)	and	higher	again	on	plates	supplemented	at	4	days	(56%)	(figure	6.3).	This	data	is	consistent	with	the	decreased	efficacy	of	SMX	as	a	means	to	extend	lifespan,	the	later	the	phase	of	bacterial	 growth	 it	 is	 added.	 It	 also	 suggests	 that	 the	 same	 folate-dependent	activity	 during	 exponential	 phase	 of	 bacterial	 growth	 is	 modulating	 C.	 elegans	aversion	and	lifespan.		
6.3.2	Folate-dependent	toxicity	in	the	Enterobacter	cloacae	strain,	B29	
The	 LPS	 endotoxin	 producing	 Enterobacter	 cloacae	 strain,	 B29	 (Fei	 and	 Zhao,	2013),	was	used	 to	 investigate	 folate-dependent	 toxicity	 in	a	different	bacterial	species.	Previous	work	carried	out	by	B.	Virk	in	collaboration	with	the	Zhao	lab	at	Shanghai	Jiao	Tong	University	(SJTU)	found	that	C.	elegans	can	be	maintained	on	B29,	but	that	worms	display	strong	aversive	behaviour,	a	reduced	brood	size	and	shortened	 lifespan.	These	phenotypes	could	not	be	rescued	by	knockout	of	 two	genes	required	for	LPS	biosynthesis,	waaG	and	wbbL	(Virk	et	al.,	unpublished).	In	this	chapter,	work	carried	out	during	a	six-week	visit	to	SJTU	investigated	whether	this	toxicity	is	folate-dependent.	Due	to	time	constraints,	C.	elegans	aversion	and	reproductive	fitness	were	focused	on	in	preference	to	lifespan.	Experiments	were	carried	out	on	NGM	due	to	the	lack	of	amino	acids	and	trace	metals	available	at	
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SJTU.		
6.3.2i	SMX	decreases	C.	elegans	aversive	behaviour	on	B29	Aversion	of	N2	worms	on	the	B29	strain	seeded	onto	plates	supplemented	with	128	µg/ml	SMX	was	measured.	SMX	was	not	 found	to	affect	B29	growth	at	this	concentration	(data	not	shown).	Percentage	aversion	was	found	to	be	significantly	higher	on	B29	compared	to	OP50	(P=0.011)	(figure	6.4a)	When	SMX	was	present	in	 the	 media,	 aversion	 was	 significantly	 decreased	 on	 both	 OP50	 and	 B29	(P<0.001)	and	nearly	all	worms	were	found	on	the	bacterial	lawn	on	both	bacterial	species	(figure	6.4a).			
6.3.1	ii	SMX	rescues	defective	reproductive	phenotype	on	B29	Preliminary	work	indicated	that	C.	elegans	have	a	significantly	reduced	brood	size	on	B29	compared	to	on	OP50	or	K12	E.	coli	(Virk	et	al.,	unpublished).	Here,	the	folate-dependence	 of	 this	 phenotype	 was	 investigated	 further.	 Progeny	production	was	monitored	over	a	4-day	egg-laying	period,	where	N2	C.	elegans	were	 transferred	 to	 fresh	 plates	 each	 day	 (see	 methods).	 Each	 experimental	condition	 consisted	 of	 5	 biological	 replicates	 of	 3	 egg-laying	 gravid	 adults	 per	plate.	 In	 the	 same	 procedure	 as	 described	 in	 Chapter	 3,	 gravid	 adults	 were	transferred	onto	fresh	plates	each	day	for	4	consecutive	days.	Hatched	larvae	and	unhatched	eggs	were	counted	after	 the	worms	had	been	transferred	onto	 fresh	plates	and	the	progeny	plate	had	been	incubated	at	25°C	for	at	least	24	hours	(see	methods).	The	phenomena	of	matricidal	hatching	or	‘bagging’	was	observed	in	C.	
elegans	on	B29;	although	this	is	interesting	as	it	is	indicator	of	bacterial	toxicity,	(Mosser	et	al.	2011)	these	worms	were	censored	and	removed	from	the	assay.	
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Figure	6.4	 SMX	 rescues	C.	 elegans	 aversion	 and	 reproductive	phenotypes	 on	B29	a)	C.	
elegans	aversion	on	OP50	and	B29	±	SMX	was	carried	out	as	previously	described	bi)	number	of	viable	progeny	produced	by	C.	elegans	on	OP50	and	B29	±	SMX	during	a	4	day	window	bii)	total	number	of	viable	progeny	produced	c)	unhatched	eggs	produced	by	C.	elegans	on	OP50	and	B29	±	 SMX	within	 4	 day	 window.	 [SMX]	 =	 128	 µg/ml.	 Error	 bars	 represent	 standard	 deviation.	Asterisks	denote	the	result	of	two-tailed	Student’s	t-test’s	of	SMX	condition	compared	to	control	condition,	where	*P<0.05,	**P<0.005,	***P<0.001		
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The	reproductive	schedule	of	C.	elegans	on	B29	was	consistent	with	that	observed	on	OP50,	however	the	total	number	of	viable	progeny	was	significantly	less	on	B29	compared	to	OP50	(P=0.0131)	(figure	6.4b).	When	SMX	was	present	in	the	plates,	progeny	production	on	B29	was	restored	to	OP50	levels	(P=	0.1236),	suggesting	that	 the	 impaired	 reproductive	 phenotype	 of	 C.	 elegans	 on	 B29	 is	 folate-dependent.	On	both	OP50	and	B29,	 the	number	of	unhatched	eggs	was	seen	 to	increase	over	the	4	day	period	(figure	6.4c).	On	days	2	and	3,	this	percentage	was	markedly	higher	on	B29	than	on	OP50.	The	number	of	unhatched	eggs	was	not	affected	by	SMX	and	therefore	cannot	account	for	the	decreased	brood	size	on	B29.	This	indicates	a	separate	folate-independent	bacterial	effect	on	C.	elegans.			Together,	 this	 work	 has	 found	 that	 the	 inhibition	 of	 folate	 synthesis	 in	
Enterobacter	cloacae	B29	with	SMX	decreases	C.	elegans	aversive	behaviour	and	restores	 reproductive	 fitness.	 Previous	 work	 also	 found	 that	 SMX	 increases	lifespan	on	B29	(Virk	et	al.,	unpublished).	Aversion	and	lifespan	have	also	been	identified	here	as	conserved	folate-dependent	C.	elegans	phenotypes	in	E.	coli	K12	and	 OP50.	 The	 data	 is	 consistent	 with	 a	 model	 whereby	 a	 broad-scale	 folate-dependent	 toxicity	 in	E.	 coli	K12	 and	OP50	 affects	 several	 C.	 elegans	 life-traits,	where	this	toxicity	is	amplified	in	Enterobacter	cloacae,	B29.		
6.3.3	Candidate	mutant	gene	screen	of	the	RpoS	regulon	for	genes	which	modulate	
lifespan	and	decrease	folate	levels	
As	discussed,	the	sigma	factor	encoded	for	by	rpoS	transcribes	hundreds	of	genes	in	 response	 to	 stress,	 many	 of	 which	 are	 involved	 in	 toxicity	 and	 virulence	 in	pathogenic	 bacteria.	 Deletion	 of	 rpoS	 has	 previously	 been	 found	 to	 extend	 C.	
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elegans	lifespan	(Virk	et	al.	2016)	and	here,	decrease	aversive	behaviour	(figure	6.2).	In	order	to	investigate	whether	rpoS	is	involved	in	folate-dependent	toxicity,	a	candidate	screen	of	rpoS	downstream	genes	cited	to	be	involved	in	toxicity	and/	or	virulence	was	 set	up,	where	mutants	would	be	 tested	 for	 their	 impact	on	C.	
elegans	lifespan,	and	if	positive,	carried	forward	and	tested	for	their	folate	status	using	the	gcp-2.1	assay.				There	is	significant	variation	in	the	number	of	genes	cited	in	the	literature	to	be	under	 rpoS	 regulatory	 control,	 likely	 due	 to	 differences	 between	 studies	 in	 the	growth	media	used	and	the	stage	of	bacterial	growth	at	which	RNA	extracts	were	made.	As	not	all	of	the	RpoS	regulon	could	be	screened	within	the	scope	of	this	PhD,	 interesting	 candidate	 genes	 involved	 in	 toxicity	 or	 virulence	mechanisms	were	chosen	from	the	studies	where	pabA	had	been	identified	as	a	downstream	target	(Weber	et	al.	2005;	Ito	et	al.	2008).	In	addition,	three	global	transcriptional	regulators,	crp,	 lrhA	and	relA	were	also	 included	for	their	reported	associations	and	transcriptional	cross-over	with	rpoS.	rpoS	was	included	as	a	positive	control	and	all	experiments	were	carried	out	on	DM	unless	otherwise	stated.			
6.3.3ii	Candidate	mutant	screen	for	downstream	RpoS	genes	that	modulate	lifespan	15	 E.	 coli	 deletion	 mutant	 strains	 were	 tested	 in	 the	 first	 screen	 and	 five	significantly	increased	C.	elegans	survival,	namely:	astA,	bipA,	,	crp	and	lrhA	(figure	6.5a).	 These	 genes	 were	 carried	 forward	 into	 a	 second	 lifespan	 screen	 (figure	6.5b).	Four	more	genes	were	 identified	 to	significantly	extend	 lifespan,	namely,	
relA,	sodA,	otsB	and	fic	(P<0.005).	cfa	did	not	have	as	much	of	a	significant	effect	on	lifespan	(P<0.05),		
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Figure	6.5	Candidate	gene	screen	for	mutants	in	the	RpoS	regulon	that	increase	C.	elegans	
lifespan.	 Lifespans	were	 conducted	 in	 two	 separate	 rounds.	 Positive	mutants	 from	 the	 first	round	(a)	were	tested	again	in	the	second	round	(b)	along	with	additional	candidates.	Error	bars	represent	standard	error.	Dark	blue	bars	indicate	mutants	carried	forward	to	the	next	round	of	the	screen.	Light	blue	bars	indicate	significance	compared	to	WT	but	were	not	carried	forward.	Asterisks	denote	result	of	Log-rank	statistical	analyses	of	Kaplan-Meier	survival	curves,	where	***P<0.001,	 **P<0.01,	 *P<0.05.	 See	 supplementary	 table	 1	 for	 full	 outline	 of	 conditions,	statistical	analysis	and	n	numbers.				
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and	bipA	did	 not	 significantly	 extend	 lifespan	 here.	 Genes	 involved	 in	 classical	virulence	mechanisms,	such	as	hlyE	(Kerenyi	et	al.,	2005),	crl	(Dudin	et	al.,	2013)	and	csgD	(Uhlich	et	al.,	2002)		(figure	6.5a)	were	not	found	to	increase	lifespan,	thus	eliminating	several	hypotheses.		
	
6.3.3ii	 gcp-2.1	bioassay	 to	examine	 the	 folate	 status	of	 rpoS	and	downstream	 rpoS	
positive	lifespan	mutants	The	folate	status	of	these	positive	lifespan	mutants	was	examined	using	the	gcp-
2.1	mutant	bioassay,	as	previously	described.	pabA	mutant	and	SMX-treated	WT	E.	
coli	were	included	as	positive	controls	and	the	wild-type	C.	elegans	strain	was	used	to	control	for	folate-independent	effects	on	worm	development.	On	both	rpoS	and	
fic	mutants,	gcp-2.1	body	length	was	significantly	shortened	at	L4	stage	compared	to	on	WT	E.	coli	(P<0.001,	in	both	cases),	where	neither	mutant	exerted	any	effect	on	 the	 wild-type	 C.	 elegans	 strain	 (figure	 6.6a).	 The	 lrhA	mutant	 significantly	reduced	body	length	of	both	gcp-2.1	mutants	and	the	wild-type	strain.	No	effect	on	
gcp-2.1	body	length	was	measured	for	any	of	the	other	mutants.		This	assay	was	repeated	with	just	the	gcp-2.1	mutants	on	WT	E.	coli,	pabA,	rpoS,	fic	and	 a	 negative	 control	 mutant,	 ygfA.	 All	 mutants	 were	 also	 tested	 on	 SMX	supplemented	plates.	Consistent	with	previous	findings,	gcp-2.1	mutant	growth	at	L4	 stage	 was	 significantly	 stunted	 on	 pabA,	 rpoS	 and	 fic	mutants	 and	 on	 all	conditions	with	SMX	(P<0.001,	 in	all	cases)	(figure	6.6b).	 Interestingly,	SMX	did	not	significantly	further	decrease	body	length	on	pabA,	rpoS	or	fic,	suggesting	that	these	 two	 interventions	 may	 be	 working	 in	 the	 same	 pathway	 (figure	 6.6b).	Together,	this	points	to	a	novel	role	of	both	rpoS	and	fic	in	bacterial	folate	synthesis			
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Figure	 6.6	 gcp-2.1	 mutants	 exhibit	 developmental	 folate	 deficiency	 on	 rpoS	 and	 fic	
mutants.	a)	gcp-2.1	mutant	body	length	at	L4	stage	on	all	positive	E.	coli	mutants	identified	in	the	candidate	gene	screen,	ordered	by	decreasing	mean	body	length,	left	to	right	b)	gcp-2.1	body	length	on	just	positive	mutants	from	(a)	including	a	negative	control	(ygfA)	±	128	µg/ml	SMX.	Error	bars	represent	standard	deviation,	where	n≥	40	in	all	cases.	Asterisks	denote	the	results	of	Student’s	t-tests,	where	*P<0.05	**P<0.01	***P<0.001	of	denoted	condition	compared	to	WT	
E.	coli.					
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and/	or	metabolism.	This	is	interesting	considering	the	recently	elucidated	role	of	Fic	proteins	in	bacterial	toxicity,	which	will	be	discussed	in	more	detail	in	Chapter	8.	
6.3.4	Examining	the	folate	status	of	rpoS	and	fic	mutants	
The	data	above	indicates	that	rpoS	and	fic	mutants	have	a	lowered	levels	of	folate,	however,	it	is	not	clear	whether	these	genes	are	mediating	this	via	altered	folate	synthesis	 and/	 or	 one-carbon	metabolism.	 In	 order	 to	 clarify	 how	 rpoS	and	 fic	interact	with	E.	coli	folate,	and	thus	C.	elegans	lifespan,	the	folate	status	of	these	mutants	 was	 examined	 more	 sensitively	 and	 specifically	 using	 LC-MS/MS	detection.			
6.3.4i	LC-MS/MS	verifies	the	low	folate	status	of	rpoS	and	fic	mutants	Folate	extractions	were	carried	out	on	WT,	rpoS,	fic,	pabA	and	lrhA	mutant	E.	coli	which	had	been	seeded	onto	DM	agar	plates	and	for	4	days	at	25°C,	as	is	standard	procedure.	 lrhA	was	 included	for	 interest	due	to	 its	reported	regulation	of	rpoS	expression.	 As	 the	 focus	 of	 the	 experiment	 was	 not	 pabA,	 and	 the	 folate	requirements	 of	 the	 strains	 in	 question	 were	 unclear,	 0.1	 µM	 PABA	 was	 not	supplemented	 into	 the	DM	 so	 as	 not	 to	 confound	 results.	 Only	 the	pabA	 strain	showed	 a	 growth	 defect	 on	 DM	 without	 PABA	 (figure	 6.7b).	 Nevertheless,	 as	standard	 with	 all	 folate	 extraction	 procedures,	 samples	 were	 normalized	 for	bacterial	growth	and	folate	levels	are	displayed	as	a	ratio	of	an	internal	MTX-glu6	spike.		
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Figure	6.7	LC-MS/MS	reveals	low	folate	levels	in	E.	coli	pabA,	rpoS	and	fic	mutants	a)	levels	of	THFs	detected	in	extracts	of	WT	E.	coli	and	pabA,	fic,	rpoS,	lrhA	mutants	displayed	as	a	ratio	of	an	internal	MTX-glu6	spike	for	normalization	between	samples.	Extracts	were	made	after	4	days	of	bacterial	growth	at	25°C	b)	growth	of	strains	used	for	this	assay	as	measured	by	OD600	before	extractions	were	made.	Extractions	were	normalized	for	growth.		Error	bars	represent	standard	deviation.	Asterisks	denote	the	test	statistic	from	Student’s	t	test	comparison	of	means,	where	*P<0.05;	**P<0.01.				
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All	detectable	folate	species	were	significantly	lower	in	rpoS,	fic	and	pabA	extracts		compared	to	WT	(P<0.01)	and	only	5-methyl	THF-glu3	was	significantly	lower	in	
lrhA	 (P<0.05)	 (figure	 6.7).	 Thus,	 LC-MS/MS	 analysis	 of	 rpoS	 and	 fic	mutants	 is	consistent	with	 the	results	of	 the	gcp-2.1	bioassay	and	supports	 the	hypothesis	that	these	genes	are	involved	in	folate	synthesis	and/	or	one-carbon	metabolism.		
	
6.3.4ii	PABA	supplementation	reveals	altered	one-carbon	metabolism	in	rpoS	mutant	
as	detected	by	LC-MS/MS	In	 order	 to	 understand	 if	 rpoS	 and	 fic	 regulate	 folate	 synthesis	 or	 one-carbon	metabolism,	the	impact	of	the	folate	precursor,	PABA,	on	the	folate	profile	of	these	strains	was	examined.	Folate	extractions	were	carried	out	as	above	and	on	plates	supplemented	with	0.1	µM	and	1	µM	PABA.	Consistent	with	figure	6.7,	levels	of	all	folate	 species	 were	 significantly	 lower	 than	 WT	 in	 rpoS,	 pabA	 and	 fic	 mutant	extracts	on	non-supplemented	control	plates,	with	the	exception	of	DHF	in	pabA	and	fic	and	5/10-formyl	THF	in rpoS	(figure	6.8).	PABA	increased	folate	levels	in	the	WT	and	pabA	extracts,	where	folates	in	pabA	extracts	were	detected	at	lower	levels	than	in	the	relative	WT	condition	(with	the	exception	of	DHF	and	THF	at	0.1	µM	PABA).	At	1	µM	PABA,	folate	levels	in	pabA	extracts	were	detected	at	similar	levels	to	those	in	WT	extracts	at	0.1	µM	PABA	(with	the	exception	of	THF	at	1	µM	PABA).	Folate	levels	in	fic	mutant	extracts	showed	a	similar	profile	and	response	to	PABA	as	seen	in	pabA	extracts,	consistent	with	a	role	of	fic	in	folate	synthesis,	acting	upstream	of	pabA.			Folate	levels	in	rpoS	mutant	extracts	showed	a	more	complex	response	to	PABA:	levels	of	5-methyl	THF	and	5,10-methenyl	THF	increased	in	response	to	PABA	in	
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Figure	6.8	LC/MS-MS	reveals	differential	impact	of	PABA	on	folate	levels	in	E.	coli	WT,	pabA,	rpoS	and	fic	mutants.	Folate	levels	in	extracts	of	WT,	pabA,	rpoS	and	fic	mutant	E.	coli	were	analysed	by	LC-MS/MS.	Extracts	were	made	after	4	days	of	bacterial	growth	on	DM	at	25°C.	Samples	were	normalized	for	growth	before	extractions.	Levels	of	tri-glutamated	THFs	detected	in	extracts	are	displayed	as	a	ratio	of	an	internal	MTX-glu6	spike	for	normalization	between	samples.	Error	bars	represent	standard	deviation.	Asterisks	denote	the	test	statistic	from	Student’s	t	test	of	folate	level	in	denoted	condition	compared	to	the	WT	E.	coli		extract	of	the	same	condition,	where	*	=	P<0.05;	**=	P<0.01.		
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line	with	 the	 comparative	WT	 condition	 and	5/10-formyl	THF	was	detected	 at	significantly	higher	levels	at	both	0.1	and	1	µM	PABA	compared	to	the	relative	WT		Conditions	(figure	6.8).	In	contrast,	levels	of	5,10-methylene	and	DHF	in	rpoS	were	significantly	 lower	 than	 WT	 on	 all	 conditions.	 5,10-methylene	 levels	 in	 rpoS		extracts	were	significantly	lower	than	in	pabA	extracts	at	1	µM	PABA.	DHF	levels	were	significantly	lower	in	rpoS	than	pabA	at	both	0.1	µM	and	1	µM	PABA.		Folate	extractions	of	rpoS	mutants	were	repeated	on	non-supplemented	and	1	µM	PABA	supplemented	conditions	(figure	6.9).	The	impact	of	the	rpoS	mutation	and	its	response	to	PABA	was	consistent	between	these	two	experiments:	all	folates	were	 at	 lower	 levels	 in	 rpoS	 mutant	 extracts	 than	 WT	 extracts	 on	 non-supplemented	conditions,	again	with	the	exception	of	5-formyl	THF.	In	response	to	PABA,	5/10-formyl	THF	and	5-methyl	THF	was	significantly	higher	than	in	WT	extracts	and	5-10-methylene	THF	and	DHF	were	significantly	lower.	Toegther	this	indicates	 that	 rpoS	may	 have	 a	 role	 in	 both	 folate	 synthesis	 and	 one-carbon	metabolism.		
6.3.4iii	 E.	 coli	 rpoS	mutants	 have	 low	 levels	 of	 the	pterin	branch	 intermediate,	 7,8-
Dihydro-D-neopterin,	and	accumulate	PABA	The	low	level	of	most	folate	species	in	non-supplemented	control	extracts	of	rpoS	and	 fic	mutants	was	consistent	with	a	role	of	 these	genes	 in	 folate	synthesis.	 In	order	 to	 examine	 this	 further,	 the	 pterin	 branch	 intermediate,	 7,8-Dihydro-D-neopterin	(DHNP)	(Chapter	1,	figure	1.2)	and	PABA	were	obtained	from	Schircks	laboratories	and	standard	solutions	were	injected	into	the	LC-MS/MS	to	
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Figure	6.9	LC-MS/MS	confirms	altered	folate	profile	of	the	E.	coli	rpoS	mutant.	Folate	levels	in	extracts	of	WT,	pabA,	rpoS	and	fic	mutant	E.	coli	was	analysed	by	LC-MS/MS.	Extracts	were	made	after	4	days	of	bacterial	growth	on	DM	at	25°C.	Samples	were	normalized	for	growth	before	extractions.	Levels	of	tri-glutamated	THFs	detected	in	extracts	are	displayed	as	a	ratio	of	an	internal	MTX-glu6	spike	for	normalization	between	samples.	Asterisks	denote	the	test	statistic	from	Student’s	t	test	of	folate	level	in	rpoS	mutant	extract	compared	to	in	to	the	WT	extract	of	the	same	condition,	where	*	=	P<0.05;	**=	P<0.01.	Error	bars	represent	standard	deviation.	
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determine	retention	times.	Other	pterin	intermediates	were	not	tested	due	to	their	inhibitory	costs.	Levels	of	both	of	these	compounds	were	detected	by	LC-MS/MS	in	 the	 first	 folate	 extraction	 experiment	 (figure	 6.8),	 but	 have	 been	 presented	subsequently	for	data	clarity.			In	WT,	pabA	and	fic	E.	coli	extracts,	DHNP	was	detected	at	similar	levels,	where	a	significant	 decrease	was	 observed	 in	 all	 extracts	 at	 1	µM	PABA	 (P<0.05,	 in	 all	cases).	 This	may	 indicate	 an	 increased	 consumption	 of	 DHNP	when	 cells	 have	excess	PABA.	However,	in	rpoS	extracts,	DHNP	levels	were	significantly	lower	on	control	 (P<0.001),	 0.1	 µM	 PABA	 (P=0.005)	 and	 1	 µM	 PABA	 (P=0.029)	supplemented	 conditions	 compared	 to	 relative	WT	 extracts.	 This	 suggests	 that	either	rpoS	mutant	cells	are	less	able	to	synthesize	or	stabilize	DHNP,	or	it	is	being	used	up	more	efficiently.			PABA	levels	in	all	E.	coli	mutants	on	non-supplemented	conditions	were	markedly	lower	 than	 in	WT	 E.	 coli	 extracts;	 pabA	 (P=0.005),	 fic	 (P=0.002)	 rpoS	 extracts	(P=0.018),	consistent	with	a	role	of	these	genes	in	PABA	synthesis.	In	response	to	0.1	µM	PABA,	 levels	of	 intracellular	PABA	were	 significantly	higher	 in	 the	rpoS	mutant	(P=0.005)	compared	to	WT	at	 this	concentration;	 levels	 in	pabA	and	 fic	were	similar	to	WT.	At	1	µM	PABA,	PABA	levels	were	consistent	across	strains	and	were	detected	at	 least	50-fold	higher	 in	pabA,	 fic	and	WT	extracts	 (and	10-fold	higher	 in	rpoS)	compared	to	at	0.1	µM	PABA,	despite	only	a	10-fold	 increase	 in	PABA	concentration.	This	is	suggestive	of	PABA	accumulation,	which	occurs	at	a	lower	concentration	 in	rpoS	mutants.	Combined	with	the	 low	levels	of	DHNP	in	
rpoS	mutants,	this	data	indicates	that	folate	synthesis	is	inhibited	in	rpoS	mutants	
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Figure	6.10	LC-MS/MS	reveals	low	levels	of	a	pterin	intermediate	and	accumulation	of	PABA	in	the	rpos	mutant.	Levels	of	PABA	and	7,8-dihydro-D-neopterin	(DHNP)	in	extracts	of	WT,	pabA,	rpoS	and	fic	mutant	E.	coli	were	analysed	by	LC-MS/MS.	Extracts	were	made	after	4	days	of	bacterial	growth	on	DM	at	25°C.	Samples	were	normalized	for	growth	before	extractions.	Levels	are	displayed	as	a	ratio	of	an	internal	MTX-glu6	spike	for	normalization	between	samples.	Error	bars	represent	standard	deviation.	Asterisks	denote	the	significance	of	Student’s	t	test	of	folate	level	in	denoted	condition	compared	to	the	WT	extract,	where	*	=	P<0.05;	**=	P<0.01.		
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due	 to	 lack	of	 7,8-dihydropterin	 to	 conjugate	with	PABA	 to	 form	dihydropteroate.	These	data	reveal	that	rpoS	has	a	complex	regulatory	role	over	both	the	PABA	and	GTP/	 pterin	 branches	 of	 folate	 synthesis	 and	 on	 enzymes	 involved	 in	 one-carbon	metabolism;	this	will	be	discussed	in	more	detail	in	section	6.4.	On	the	other	hand,	folate	levels	in	fic	mutants	are	similar	to	those	detected	in	pabA	mutants,	suggesting	that	fic	is	involved	only	in	the	PABA	branch	of	folate	synthesis.			
6.3.3i	rpoS	expression	correlates	with	pabA	expression	in	exponential	phase	The	data	in	Chapter	6	indicates	that	pabA	is	expressed	most	highly	during	exponential	phase	of	bacterial	growth	(day	2)	and	that	this	corresponds	to	the	window	of	toxicity	which	is	responsible	for	lifespan	decrease.	In	order	to	examine	the	interaction	of	rpoS	and	pabA,	here,	the	same	cDNA	used	to	monitor	longitudinal	pabA	expression	in	WT	
E.	coli	(Chapter	6,	figure	6.3)	was	used	to	probe	for	rpoS	expression.	
Expression	of	rpoS	was	found	to	mirror	pabA:	expression	peaked	at	48	hours	by	12.5-fold	compared	to	expression	in	the	overnight	culture,	and	decreased	after	this	peak,	with	a	4-fold	increase	after	72	and	96	hours.	In	order	to	eliminate	the	speculation	that	the	 similar	 pattern	may	 arise	 from	differential	 RNA	 integrity	 at	 the	 different	 time	points,	attention	should	be	drawn	to	figure	7.9,	Chapter	7,	in	which	the	same	cDNA	was	used	to	probe	abgT	expression:	high	abgT	expression	was	detected	after	6	hours,	with	maximal	expression	at	24	hours.	This	data	indicates	that	rpoS	and	pabA	are	at	least	co-expressed.		
6.3.4	iv	pabA	expression	is	downregulated	in	rpoS	and	fic	mutants	
pabA,	fic	and	rpoS	gene	expression	was	examined	in	WT	E.	coli	and	in	mutants	of	pabA,		
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Figure	 6.11	 Normalized	 mRNA	 expression	 level	 of	 E.	 coli	 pabA,	 rpoS	 and	 fic	 genes	 as	
determined	 by	 qPCR.	Expression	 in	mutants	 here	 represents	 the	 fold	 change	 compared	 to	expression	in	WT	and	normalized	to	the	internal	reference	gene,	rrsA	a)	rpoS	expression	in	WT	
E.	coli	mRNA	over	a	96	hour	time	course.	Expression	of	bi)	pabA	,	bii)	fic	and	biii)	rpoS	in	pabA,	
fic	and	rpoS	mutants	c)	the	impact	of	PABA	on	rpoS	expression	in	pabA	mutant	mRNA. 	
0
2
4
6
8
10
12
0
5
10
15
O/N log 24	hrs 48	hrs 72	hrs 96	hrs
Ba
ct
er
ia
l	g
ro
w
th
	(O
D 6
00
)
No
ra
m
liz
ed
	ex
pr
es
sio
n	
le
ve
l
6	hrs
bacterial	growth
0
0.4
0.8
1.2
WT rpoS fic pabA
No
rm
al
ize
d	
ex
pr
es
sio
n
pabA expression
0
4
8
12
16
20
WT rpoS fic pabA
fic expression
0
10
20
30
40
50
WT rpoS fic pabA
No
am
liz
ed
	e
xp
re
ss
io
n
rpoS expression
0
10
20
30
40
50
0 0.1 1
[PABA]	(µM)
rpoS	expression
pabA
WT
biii. 
a. 
bi. 
c. 
bii. 
161 
 
rpoS	and	fic.	RNA	extractions	were	carried	out	on	non-supplemented	DM	agar	plates	after	4	days	of	bacterial	growth	at	25	°C.	This	was	followed	by	DNase	treatment	and	cDNA	 synthesis	 (see	methods).	 Gene	 specific	 internal	 primers	were	 designed	 and	used	 to	probe	 gene	 expression	via	quantitative	PCR.	Normalized	 expression	 levels	were	calculated	using	the	delta	delta	ct	method,	using	rrsA	as	an	internal	reference	gene	and	normalizing	to	expression	in	WT	extracts.		
Consistent	with	the	predicted	gene	interactions,	pabA	expression	was	downregulated	in	both	rpoS	and	fic	mutants	(figure	6.11ai)	and	fic	expression	was	downregulated	in	the	rpoS	mutant	(figure	6.11aii).	Unexpectedly,	fic	expression	was	16-fold	higher	in	the	pabA	mutant,	indicating	that	fic	may	be	negatively	regulated	when	pabA	is	active.	
rpoS	expression	was	significantly	higher	in	both	pabA	and	fic	mutants	(figure	6.11aiii),	suggestive	of	the	activation	of	an	RpoS	stress	response,	likely	due	to	low	folate	levels.	In	response	to	PABA	supplementation,	rpoS	expression	in	the	pabA	mutant	did	not	change	(figure	6.11b).	
6.3.4	vi	Lifespan	on	rpoS	is	not	shortened	by	PABA	supplementation	The	data	in	this	section	has	painted	a	complex	picture	of	the	interaction	of	rpoS	with	folate	synthesis,	one-carbon	metabolism	and	folate-dependent	toxicity.	RpoS	seems	to	have	regulatory	control	over	both	fic	and	pabA,	and	thus	the	PABA	branch	of	folate	synthesis.	Moreover,	 the	 data	 suggests	 that	RpoS	 also	 regulates	 the	 activity	 of	 the	pterin	branch	and	the	altered	folate	profile	of	the	rpoS	mutant	in	response	to	PABA	suggests	 RpoS	may	 also	 regulate	 folate-dependent	 enzymes	 involved	 in	 the	 folate	cycle.	 However,	 the	 finding	 that	 rpoS	 expression	 does	 not	 respond	 to	 PABA	 was	surprising.	It	is	not	clear	whether	these	predicted	RpoS-gene	interactions	are	direct		
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Figure	 6.12	 C.	 elegans	 lifespan	 on	 E.	 coli	 rpoS	 mutant	 is	 not	 affected	 by	 PABA	
supplementation	a)	C.	elegans	lifespans	carried	out	from	day	1	of	adulthoof	on	DM	plates	seeded	with	 the	 rpoS	mutant	 and	 supplemented	 with	 varying	 concentrations	 of	 PABA	 b)	 lifespans	carried	out	on	DM	plates	seeded	with	the	rpoS	mutant	and	supplemented	with	folic	and	folinic	acid,	with	PABA	as	a	control.	See	supplementary	table	1	for	full	outline	of	conditions,	statistical	analysis	and	n	numbers.					
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or	indirect.	In	order	to	clarify	whether	these	interactions	are	associated	with	the	toxic	activity	 that	 shortens	C.	 elegans	 lifespan,	 lifespan	 assays	were	 carried	out	 on	 rpoS	mutants	on	DM	supplemented	with	 	PABA,	folic	acid	and	folinic	acid.	Unlike	on	the	
pabA	mutant	 (Chapter	 3,	 figure	 3.7),	 PABA	was	 not	 found	 to	 have	 an	 effect	 on	C.	
elegans	lifespan	on	the	rpoS	mutant	at	a	range	of	concentrations	(figure	6.12a).	This	experiment	was	carried	out	in	conjunction	with	the	pabA	lifespan	(Chapter	3,	figure	3.7),	which	acted	as	a	positive	control,	ruling	out	the	possibility	that	the	PABA	stock	was	 degraded/	 inactive.	 In	 contrast,	 similarly	 to	 the	 pabA	 mutant,	 folic	 acid	significantly	 reduced	 lifespan	on	 rpoS	by	12%	 (P=0.0041),	 and	 folinic	 acid	had	no	effect	 (figure	 6.12b).	 Together,	 this	 suggests	 that	 the	 mechanism	 by	 which	 RpoS	modulates	 lifespan	 is	 not	 dependent	 on	 its	 regulation	 of	 fic	 or	 pabA,	 but	 on	 its	regulation	 of	 one-carbon	 metabolism.	 This	 is	 consistent	 with	 the	 sustained	 high	expression	of	rpoS	in	the	pabA	mutant	despite	PABA	supplementation	(figure	6.11b)		
6.3.4vii	gcp-2.1	phenotype	on	rpoS	is	not	rescued	by	PABA	supplementation		The	impact	of	PABA	supplementation	on	the	sensitivity	of	the	gcp-2.1	mutant	strain	to	rpoS	was	examined.	DM	agar	plates	supplemented	with	varying	concentrations	of	PABA	and	were	seeded	with	the	rpoS	mutant.	WT	and	pabA	mutant	conditions	were	included	as	controls	and	plates	supplemented	with	varying	concentrations	of	folinic	acid	were	also	included	as	controls,	as	folinic	acid	supplementation	rescues	gcp-2.1	folate	deficiency	directly	(Chapter	7,	figure	7.12).			Consistent	with	Chapter	3,	figure	9,	a	dose-dependent	rescue	of	gcp-2.1	body	length	 
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Figure	6.13	C.	elegans	gcp-2.1	mutant	developmental	folate	deficiency	on	the	E.	coli	rpoS	
mutant	is	not	rescued	by	PABA.	gcp-2.1	mutants	were	raised	from	egg	on	WT,	rpoS	or	pabA	mutant	on	DM	plates	supplemented	with	varying	concentrations	of	a)	PABA	or	b)	folinic	acid.	Plates	 were	 incubated	 at	 25	 °C	 and	 body	 length	 measured	 at	 L4	 stage	 (n>40).	 Error	 bars	represent	standard	deviation.		
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	 With	PABA	was	observed	on	the	pabA	mutant,	with	complete	restoration of 
body length at 1µM PABA (figure 6.13a). On	the	rpoS	mutant,	gcp-2.1	body	length	was	significantly	 increased	 at	 0.2	µM	 (P=0.0085),	 0.5	µM	 (P=0.031)	 and	 1.0	µM	PABA	(P<0.001),	however,	compared	to	on	WT	E.	coli,	body	length	remained	significantly	lower	on	all	conditions	(P<0.001,	in	all	cases).	Similar	responses	to	folinic	acid	in	gcp-
2.1	mutants	on	pabA	and	rpoS	were	observed;	wild-type	body	length	was	reached	at	10	µM	folinic	acid	in	both	cases	(figure	6.13b).	The	inability	of	PABA	to	effect	the	gcp-
2.1	 phenotype	 and	 lifespan,	 despite	 this	 strain	 being	 able	 to	 use	 PABA	 for	 folate	synthesis,	suggests	that	the	impact	of	rpoS	on	specific	folates	or	the	pterin	branch,	as	observed	by	LC-MS/MS	(figure	6.8-6.10)	may	be	accountable	 for	 the	two	observed	phenotypes.	
 
6.4	DISCUSSION	
6.4.1	Inhibiting	bacterial	folate	synthesis	may	remove	a	toxicity	
C.	 elegans	aversion	 behaviour	was	 here	 used	 as	 a	 phenotypic	 readout	 of	 bacterial	toxicity.	On	E.	coli	(K12	and	OP50)	(figure	6.1)	and	the	Enterobacter	cloacae	strain,	B29	(figure	6.4a),	inhibiting	folate	synthesis	was	found	to	markedly	decrease	aversive	behaviour.	The	unique	B29	phenotype	of	reduced	progeny	production	was	also	found	to	 be	 rescued	 following	 the	 inhibition	 of	 folate	 synthesis	 (figure	 6.4b).	 This	 latter	observation	is	in	line	with	the	finding	that	programmed	cell-death	in	the	C.	elegans	
	
a. 
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germline	 resulting	 in	 reduced	 progeny	 production	 occurs	 in	 response	 to	 bacterial	toxicity	 (Aballay	&	Ausubel	et	al.,	2001).	Moreover,	 aversion	was	also	significantly	decreased	on	the	pabA	and	rpoS	mutants,	both	of	which	have	been	shown	here	to	have	low	folate	levels	(figure	6.2).	Together,	the	data	presented	in	this	chapter	supports	the	 hypothesis	 that	 inhibiting	 bacterial	 folate	 synthesis	 removes	 a	 broad-scale	toxicity,	although	further	work	is	required	to	verify	this	hypothesis.		
6.4.2	rpoS	may	regulate	fic-dependent	folate	toxicity		
In	an	attempt	to	understand	how	folate	synthesis	may	be	related	to	toxicity	in	E.	coli	K12,	research	became	focused	on	the	E.	coli	stress	response	sigma	factor,	rpoS.	RpoS	regulates	the	expression	of	genes	involved	in	toxicity	and	virulence,	and	its	deletion	has	 previously	 been	 found	 to	 increase	 C.	 elegans	 lifespan	 (Virk	 et	 al.	 2016).	 As	mentioned,	the	rpoS	mutant	was	found	to	decrease	C.	elegans	aversion	(figure	6.2)	and	its	impact	on	lifespan	was	verified	(figure	6.	5).	The	gcp-2.1	bioassay	(figure	6.13)	and	LC-MS/MS	detection	revealed	that	the	rpoS	mutant	has	low	folate	levels	(figure	6.7-6.9)	 and	 qPCR	 analysis	 of	 rpoS	 gene	 expression	 revealed	 a	 temporal	 pattern	consistent	with	co-expression	with	pabA	(figure	6.11a)	Indeed,	pabA	expression	was	significantly	 lower	 in	 the	rpoS	mutant	 (figure	6.11bi).	Together,	 this	demonstrated	that	the	rpoS	mutant	has	a	role	in	folate	synthesis.		
A	candidate	gene	screen	was	conducted	to	identify	RpoS-downstream	genes	involved	in	toxicity	that	are	also	folate-dependent	(figures	6.5-6.6):	out	of	31	mutants	screened,	only	1	candidate	gene,	fic,	was	identified	which	both	extended	lifespan	and	decreased	
E.	coli	folate	levels,	similarly	to	the	rpoS	mutant	(as	assayed	by	the	gcp-2.1	mutant).	
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LC-MS/MS	detection	of	E.	coli	folates	combined	with	qPCR	analysis	of	gene	expression	confirmed	a	novel	role	of	both	rpoS	and	 fic	as	positive	regulators	of	pabA	and	thus	folate	 synthesis	 (figure	 6.11).	 These	 interactions	 should	 be	 tested	 using	 DNAse	footprinting	or	chromatin	immunoprecipitation	with	microarray	hybridization	(ChIP-chip).	The	fic	gene	is	interesting	for	two	reasons:	its	coding	region	ends	31	nucleotides	upstream	 of	 pabA	 and	 the	 protein	 it	 encodes	 has	 recently	 been	 identified	 in	pathogenic	bacteria	as	a	toxin.	The	potential	role	of	fic	 in	folate-dependent	toxicity	will	be	discussed	in	more	detail	in	Chapter	8.		
6.4.3	rpoS	is	a	novel	regulator	of	folate	synthesis	and	one-carbon	metabolism	
The	regulatory	role	of	rpoS	was	found	to	extend	beyond	folate	synthesis	as	the	folate	profile	in	rpoS	mutant	E.	coli	was	not	restored	to	wild-type	with	the	addition	of	PABA,	as	 was	 observed	 in	 fic	 and	 pabA	mutants	 (figure	 6.8-6.9).	 	 Moreover,	 high	 rpoS	expression	in	the	pabA	mutant	could	not	be	decreased	with	PABA	(figure	6.11)	and	PABA	 could	 not	 reverse	 lifespan	 on	 rpoS	 (figure	 6.12)	 or	 relieve	 gcp-2.1	 folate	deficiency	(figure	6.13).	Together,	this	indicates	that	rpoS	has	a	role	in	E.	coli	folate	which	is	independent	of	its	interaction	with	pabA.		
In	response	to	PABA	in	rpoS	mutants,	5,10-methyelene	THF	and	DHF	remained	low,	whereas	 5/10-formyl	 THF	 and	 5-methylTHF	 were	 higher	 than	 detected	 in	 WT	extracts	 (figure	 6.8-6.9).	 Furthermore,	 rpoS	mutants	 had	 low	 levels	 of	 the	 pterin	pathway	 intermediate,	 7,8-dihydro-D-neopterin,	 and	 abnormal	 accumulation	 of	PABA	in	response	to	PABA	supplementation.	Together,	these	data	suggest	rpoS	has	positive	 regulatory	 control	 over	 the	 pterin	 branch	 of	 folate	 synthesis	 and	 over	
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interconversions	between	THFs	in	the	folate	cycle.		
A	recent	metabolic	modelling	study	has	highlighted	a	link	between	5,10-methylene	THF	 and	 the	 pterin	 branch	 of	 folate	 synthesis,	 based	 on	 the	 initial	 observation	 of	strong	chromosomal	clustering	of	folK	with	panB	in	several	bacterial	genomes		
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Figure	6.14	Pterin	pathway	of	THF	synthesis,	the	5,10-methylene	THF	damage	hypothesis	
and	the	regulatory	roles	of	RpoS.	5,10-methylene	is	damaged	by	a	side-reaction	catalyzed	by	PanB.	The	pterin	moeity	is	recycled	in	a	mechanism	dependent	on	FolK.	RpoS	may	negatively	regulate	PanB,	and	therefore	act	 to	maintain	5,10-methylene	THF	 levels.	This	work	 indicates	that	RpoS	also	regulates	pabA.	It	is	not	clear	if	these	interactions	are	direct	or	indirect.	Adapted	from	Thiaville	et	al.	2016.			
5,10-methylene	THF 
7,8-dihydro-D-neopterin 
RpoS? 
PABA Chorismate	
+glutamine pabA 
RpoS? 
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(Thiaville	 et	 al.,	 2016).	 The	 authors	 revealed	 that	 in	E.	 coli	K12,	 the	 pantothenate	(vitamin	 B5)	 biosynthesis	 enzyme,	 PanB,	 damages	 5,10-methylene	 THF	 in	 a	 side	reaction	and	cells	recycle	the	pterin	moeity	by	an	activity	dependent	on	the	pterin	branch	enzyme,	FolK	(figure	6.14)	(Thiaville	et	al.	2016).	FolK	works	downstream	of	DHNP.	 From	 the	 data	 presented	 here,	 it	 is	 postulated	 that	 RpoS	 may	 negatively	regulate	 panB,	 thus	 offering	 a	 potential	 explanation	 as	 to	 why	 specifically	 5,10-methylene	 THF	 and	 7,8-dihydro-D-neopterin	 (upstream	 of	 FolK)	 are	 low	 in	 rpoS	mutants	in	response	to	PABA.	Indeed,	in	the	same	E.	coli	K12	microarray	dataset	that	indicated	 decreased	 pabA	 expression	 in	 an	 rpoS	mutant,	 panB	 showed	 increased	expression	(Ito	et	al.	2008).	Gene	expression	analysis	in	rpoS	mutants	with	primers	specific	to	genes	involved	in	these	pathways	will	help	to	clarify	these	interactions.		
 
6.4.4	Levels	of	E.	coli	5,10-methylene	THF	correlate	to	C.	elegans	lifespan	
Interestingly,	neither	C.	elegans	lifespan	nor	gcp-2.1	developmental	folate	deficiency	on	 the	 rpoS	mutant	was	 signifiacntly	 altered	 by	 PABA	 supplementation,	 yet	 these	phenotypes	responded	similarly	to	folic	and	folinic	acid	as	in	the	pabA	mutant.	This	acted	 to	 rule	out	 the	possibility	of	 excess	PABA	as	 a	mediator	of	 folate-dependent	toxicity	and	combined	with	the	LC-MS/MS	data,	also	provided	insights	into	possible	mechanisms	of	lifespan	extension.	In	rpoS	mutants,	even	with	1	µM	PABA	(where	C.	
elegans	are	still	 long-lived)	5,10-methylene	THF	remained	below	levels	detected	in	WT	E.	coli	and	similar	to	levels	detected	in	pabA	mutants	with	0.1	µM	PABA	(where	C.	
elegans	are	 long-lived).	 In	pabA	mutants	supplemented	with	1	µM	PABA	(where	C.	
elegans	 are	 short-lived),	 levels	 of	 5,10-methylene	 THF	 were	 in	 line	 with	 WT	
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supplemented	 with	 0.1	 µM	 PABA.	 Thus,	 low	 levels	 of	 5,10-methylene	 may	 be	responsible	for	lifespan	increase	on	these	mutants.	This	counters	the	previous	work	in	 the	 Weinkove	 lab	 which	 had	 suggested	 that	 individual	 folates	 were	 not	determinants	of	longevity	and	therefore	prompts	a	re-evaluation	of	this	hypothesis.		
	
Figure	 6.15	 Diagram	 illustrating	 the	 model	 of	 excessive	 E.	 coli	 folate	 synthesis,	 RpoS-
dependent	bacterial	toxicity	and	C.	elegans	lifespan.	Bacterial	folate	levels	above	the	‘sufficient’	threshold	for	bacterial	growth	are	associated	with	a	toxicity	which	shortens	C.	elegans	lifespan.	Gene	expression	analysis	has	here	shown	 that	pabA	 is	downstream	of	both	rpoS	and	 fic	and	 that	 fic	 is	downstream	of	rpoS.	Possible	mechanisms	via	which	this	pathway	may	lead	to	toxicity	are	outline	in	 Chapter	 8.	 Black	 arrors	 represent	 gene	 regulation	 (dotted=	 indirect);	 green	 arrow	 represents	folate	 synthesis	 pathway;	 Red	 dotted	 arrows	 represent	 possible	 mechanisms	 of	 toxicity;	 THFs	represents	tetrahydrofolates.	
 
? 
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CHAPTER	7.	INVESTIGATING	THE	IMPACT	OF	FOLIC	ACID	ON	E.	COLI	FOLATE	
SYNTHESIS	AND	C.	ELEGANS	LIFESPAN	
 
7.1	INTRODUCTION	Previous	work	in	the	Weinkove	lab	found	that	500	µM	folic	acid	reversed	lifespan	on	the	aroD	mutant,	but	further	work	was	not	carried	out	to	determine	whether	this	 was	 acting	 via	 E.	 coli	 or	 having	 a	 direct	 effect	 on	 C.	 elegans.	This	 chapter	investigates	 whether	 folic	 acid	 impacts	 E.	 coli	 folate	 synthesis	 and	 thus	 if	 it	increases	 bacterial	 folate	 levels	 above	 the	 threshold	 for	 C.	 elegans	 lifespan	modulation.	 As	 folic	 acid	 cannot	 be	 transported	 directly	 by	 E.	 coli,	 a	 route	dependent	on	salvage	of	the	folate	degradation	product,	PABA-glu,	by	the	E.	coli	transporter,	 AbgT,	 will	 be	 investigated.	 Several	 folic	 acid	 sources,	 including	 a	commercial	 over-the-counter	 supplement,	 will	 be	 examined	 for	 their	 quality,	degradation	and	 impact	on	C.	elegans	 lifespan.	This	work	was	prompted	by	 the	growing	 concerns	 over	 the	 safety	 of	 folic	 acid	 as	 a	 supplement	 and	 the	 lack	 of	research	over	its	interaction	with	the	microbiota.		
7.2	CHAPTER	AIMS		
• Aim	1:	 Investigate	whether	 folic	acid	 impacts	E.	coli	 folate	synthesis	and	thus	C.	elegans	lifespan	- create	constructs	to	examine	the	role	of	abgT		- examine	the	degradation	of	folic	acid	in	our	model	system	
• Aim	 2:	 Examine	 whether	 folinic	 acid	 is	 an	 appropriate	 alternative	supplement	
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Figure	7.1	Chemical	structures	of	folic	and	folinic	acid.	Folic	acid	is	oxidized	on	its	pterin	ring.	It	is	a	synthetic	folate	not	found	in	nature.	It	requires	two	reduction	reactions,	catalysed	by	dihydrofolate	reductase,	to	be	converted	first	to	dihydrofolate	and	then	tetrahydrofolate	before	it	can	be	incorporated	into	the	folate	cycle.	The	methylene	bridge	of	folic	acid	is	unstable	and	can	spontaneously	disassociate	to	generate	PABA-glu	and	PABA.	Folinic	acid	is	otherwise	known	as	5-formyl	tetrahydrofolate,	so	called	as	it	carries	a	formyl	group	on	its	pterin	N5	atom.	Folinic	acid	is	the	most	stable	of	naturally	occurring	folates.				
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7.3	RESULTS	
7.3.1	Examining	the	role	of	E.	coli	abgT	on	E.	coli	folate	synthesis	and	C.	elegans	
lifespan	following	folic	acid	supplementation	
As	folic	acid	cannot	be	taken	up	directly	by	E.	coli,	PABA-glu	and	PABA	are	the	only	means	by	which	folic	acid	can	impact	E.	coli	metabolism.	As	discussed	in	Chapter	1,	PABA	can	freely	diffuse	into	cells,	but	PABA-glu	requires	the	transporter,	AbgT	(Carter	et	al.,	2007)	(see	Chapter	1,	figure	1.3).	Constructs	were	created	to	examine	the	effect	of	PABA-glu	on	E.	coli	folate	synthesis.	An	abgT	pabA	double	mutant	was	made	 by	 P1	 transduction	 and	 a	 high	 copy	 number	 plasmid	 (pJ128)	 over-expressing	abgT	was	transformed	into	WT,	pabA	and	abgT	pabA	mutants.	Strains	with	 the	 pJ128	 plasmid	 shall	 be	 denoted	 (abgT	 OE).	 The	 appropriate	 control	strains	were	 transformed	with	an	empty	vector	 (pUC19),	but	 this	has	not	been	denoted	in	the	text.	See	Chapter	2	for	full	outline	of	microbiological	procedures.			
7.3.1i	100	µM	folic	acid	reverses	C.	elegans	lifespan	on	pabA	at	100	µM	Preliminary	work	was	carried	out	to	determine	concentrations	of	folic	acid	that	impact	C.	elegans	lifespan	on	DM.	Lower	concentrations	of	folic	acid	(1	µM,	5	µM)	did	 not	 have	 any	 impact	 on	 lifespan	 on	 the	pabA	mutant	 (data	 not	 shown;	 see	lifespan	supplementary	data),	whereas	10	µM	had	a	partial	effect	and	100	µM	folic	acid	fully	reversed	lifespan	on	pabA	by	16.58%	lifespan	(P<0.0001)	(figure	4.2).	Lifespan	was	not	significantly	affected	by	folic	acid	on	WT	E.	coli.	10	µM	and	100	µM	 folic	 acid	 were	 used	 for	 further	 experiments.	 All	 lifespan	 conditions	 here	(including	 control)	 contain	 0.1	 µM	 PABA	 to	 ensure	 sufficient	 bacterial	 growth,	unless	otherwise	stated.		
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7.3.1i	Folic	acid	shortens	C.	elegans	lifespan	in	an	abgT-dependent	mechanism	In	order	to	examine	the	role	of	the	abgT	gene	in	C.	elegans	lifespan	following	folic	acid	supplementation,	 lifespans	were	carried	out	on	DM	seeded	with	WT,	pabA,	
abgTpabA	and	pabA	(abgT	OE)	(figure	7.3),	supplemented	with	10	and	100µM	folic	acid.	Mean	lifespans	are	displayed	here,	but	P	values	refer	to	Log-rank	statistical	analysis	of	the	Kaplan	Meier	survival	curves.	As	before	(figure	7.1),	folic	acid	was	not	 found	 to	 have	 any	 impact	 on	 C.	 elegans	 longevity	 on	 WT	 E.	 coli	 at	 either	concentration.	In	contrast,	 lifespan	on	the	pabA	mutant	in	response	to	folic	acid	was	dependent	on	abgT	expression:	10	µM	folic	acid	did	not	significantly	impact	lifespan	 on	 pabA	 (Log-rank,	 P=0.7322)	 or	 abgTpabA	 (P=0.4026),	 but	 did	significantly	shorten	lifespan	on	the	pabA	(abgT	OE)	strain	by	14.00%	(P=0.0053);	100	µM	folic	acid	significantly	shortened	lifespan	on	both	pabA	and	pabA	(abgT	OE)	strains	compared	to	their	non-supplemented	controls,	by	13.57%	(P<0.0001),		and	 14.36%,	 respectively	 (P<0.0003),	 but	 did	 not	 affect	 lifespan	 on	 abgTpabA	(P=0.719).	abgT	mutant	had	no	impact	on	longevity	(see	supplementary	table	1).		This	indicates	that	the	over-expression	of	abgT	sensitizes	C.	elegans	lifespan	on	the	
pabA	mutant	to	10	µM	folic	acid,	and	knockout	of	abgT	eliminates	the	effect	of	folic	acid	on	lifespan.	It	is	concluded	that	abgT	expression	mediates	the	negative	impact	of	folic	acid	on	C.	elegans	lifespan.	This	infers	that	PABA-glu	is	available	following	folic	acid	supplementation	and	that	AbgT	uptake	of	PABA-glu	boosts	E.	coli	folate	synthesis	and	thus	shortens	lifespan.	
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Figure	7.2	Lifespan	analysis	 reveals	100	µM	 folic	acid	reverses	C.	 elegans	 longevity	on	
pabA	mutant.	Kaplan-Meier	survival	curves	of	C.	elegans	transferred	onto	WT	or	pabA	mutant	
E.	coli	±	10,	100	µM	folic	acid	at	day	1	of	adulthood.	See	supplementary	table	1	for	full	statistical	analysis,	n	numbers	and	experimental	conditions.				
	
Figure	7.3	Lifespan	analysis	reveals	E.	coli	abgT	determines	lifespan	in	response	to	folic	
acid.	Mean	lifespans	of	C.	elegans	transferred	onto	WT,	pabA,	abgTpabA,	pabA	(abgT	OE)	mutant	
E.	 coli	 ±	 10,	 100	 µM	 folic	 acid	 at	 day	 1	 of	 adulthood.	 Error	 bars	 represent	 standard	 error.	Asterisks	denote	the	result	of	Log-rank	statistical	tests,	where	***P<0.005	
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7.3.1ii	pabA	mutant	growth	is	dependent	on	abgT	following	PABA-glu	supplementation		In	order	to	test	these	hypotheses,	the	following	will	be	carried	out:	1.	LC-MS/MS	detection	of	PABA-glu	in	folic	acid;	2.	Lifespan	analysis	with	PABA-glu;	3.	LC/MS-MS	detection	of	E.	 coli	 folate	 levels	 following	 folic	acid	supplementation.	 It	was	necessary	to	initially	determine	concentrations	of	PABA-glu	equivalent	to	10	µM	and	100	µM	folic	acid.	The	growth	of	the	pabA	strain	in	the	liquid	DM	96-well	plate	assay	was	used	to	test	a	large	range	of	concentrations.	Results	are	plotted	on	a	log-scale	in	figure	7.4a.	PABA-glu	rescued	pabA	growth	with	similar	kinetics	to	folic	acid,	but	at	~10-fold	lower	concentrations,	where	growth	was	similar	at	100	µM	growth	 PABA-glu	 and	 folic	 acid.	 1	 µM	 and	 10	 µM	 PABA-glu	 were	 taken	 as	equivalent	concentrations	as	10	µM	and	100	µM	folic	acid.	These	concentrations	were	tested	for	growth	on	conditions	used	for	C.	elegans	lifespans.	DM	agar	plates	were	seeded	with	WT,	pabA,	abgTpabA	and	pabA	(abgT	OE).	0.1	µM	and	1	µM	PABA	conditions	were	included	as	controls.	OD600	was	measured	96	hours	after	seeding.	P	values	here	indicate	the	result	of	paired,	two-tailed	Student’s	t-tests.		At	 the	 lower	 concentrations	 of	 both	 PABA-glu	 and	 folic	 acid	 (figure	 4.4bi,	 ii),	growth	 was	 dictated	 by	 abgT	 expression:	 the	 pabA	 mutant	 showed	 growth	comparable	to	WT	levels	on	both	conditions;	abgTpabA	growth	was	significantly	lower	than	WT	with	1	µM	PABA-glu	(P=0.016)	and	10	µM	folic	acid	(P=0.005);	and	
pabA	 (abgT	 OE)	 growth	 was	 slightly	 significantly	 higher	 with	 1	 µM	 PABA-glu	(P=0.047)	and	10	µM	folic	acid	(P=0.040)	than	WT.	At	the	higher	concentration,	all	strains	showed	similar	levels	of	growth,	with	the	exception	of	a	slightly	higher	
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Figure	 7.4	 Folic	 acid	 and	 PABA-glu	 rescue	 of	 pabA	 growth	 is	 dependent	 on	 abgT	 a)	determining	equivalent	concentrations	of	PABA-glu	and	folic	acid	required	for	pabA	growth	in	liquid	DM	in	96-well	plate	assay	at	37	 	 ͦC	 for	22	hours.	Growth	of	WT,	pabA,	abgTpabA,	pabA	(abgT	OE)	on	DM	agar	plates		supplemented	with	bi)	10	µM	and	100	µM	folic	acid	ii)	1	µM	and	10	 µM	 PABA-glu	 iii)	 0.1	 µM	 and	 1	 µM	 PABA	 and	 incubated	 at	 25	 	 ͦC	 for	 4	 days.	 Error	 bars	represent	standard	deviation.		
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OD600	of	the	pabA	(abgT	OE)	strain	on	PABA-glu	(P=0.049).	In	contrast,	in	response	to	PABA,	growth	of	all	strains	was	comparable	(figure	7.3c),	consistent	with	the	ability	of	PABA	to	 freely	diffuse	across	biological	membranes,	 independently	of	AbgT.		These	data	are	consistent	with	the	hypothesis	that	PABA-glu	is	transported	by	AbgT.	At	high	concentrations	of	 folic	acid	and	PABA-glu,	 it	 is	 likely	 that	 this	pathway	is	superseded	by	nanomolar	quantities	of	PABA	which	are	able	to	freely	diffuse	into	bacterial	cells,	thus	explaining	why	growth	of	all	strains	is	similar.			
7.3.1	iv	LC-MS/MS	detects	PABA-glu	and	PABA	in	folic	acid	supplements	In	order	to	determine	whether	folic	acid	does	indeed	degrade	to	PABA-glu	in	our	model	system,	standard	solutions	of	folic	acid,	PABA-glu	and	PABA	were	analysed	by	LC-MS/MS	and	standard	curves	created	to	determine	concentration.	The	folic	acid	 used	 in	 this	 study	 is	 a	 high-grade	 compound	 obtained	 from	 a	 specialized	manufacturer	 in	 Switzerland,	 Schricks	 laboratories.	 Here,	 the	 purity	 of	 this	compound	was	 tested	 in	solution	and	 in	extractions	made	 from	DM	agar	plates	after	4	days	incubation	at	25		ͦC		(conditions	used	for	C.	elegans-	E.	coli	assays).	Two	other	 folic	acid	sources	were	also	 tested,	namely,	 from	Sigma	Aldrich	and	a	UK	high-street	 retailer,	 Boots.	 Folic	 acid	 preparations	 were	 solubilised	 in	 weak	sodium	hydroxide,	with	5	technical	replicates	for	each	solution.			PABA-glu	 was	 detected	 in	 all	 three	 folic	 acid	 sources	 (figure	 7.5),	 where	concentration	was	 lowest	 in	 the	 Schircks	 folic	 acid	 solution	 and	 highest	 in	 the	Boots	folic	acid	solution.	Percentage	degradation	of	PABA-glu	was	as	follows:	4%	in	Boots	folic	acid,	1.2%	in	Sigma	folic	acid	and	0.3%	in	Schircks	folic	acid.	PABA	was	detected	at	0.058%,	0.033%	and	0.009%	in	Boots,	Sigma	and	Shircks	folic	acid,		
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Figure	7.5	LC-MS/MS	detects	PABA-glu	and	PABA	in	three	folic	acid	sources.	10	µM	and	100	µM	 solutions	 of	 Schircks,	 Sigma	 and	 Boots	 folic	 acid	 were	 prepared	 in	 weak	 NaOH,	 with	 3	technical	replicates	per	solution.	Solutions	was	analysed	by	LC-MS/MS	and	concentrations	of	PABA-glu,	 PABA	 and	 folic	 acid	were	 calculated	 by	 analysing	 known	 concentrations	 of	 these	compounds.	Schircks	folic	acid	was	also	supplemented	into	DM	plates	and	incubated	for	4	days	at	25	ͦC	before	extraction	and	LC-MS/MS	detection.	Error	bars	represent	standard	deviation.		
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respectively.	Percentages	of	PABA-glu	and	PABA	 in	Schircks	 folic	acid	 from	DM	indicate	that	agar	plates	increased	to	1.2%	and	0.02%,	respectively.	This	is	the	first	study	to	PABA-glu	is	present	in	folic	acid	at	physiological	concentrations	relevant	to	bacterial	growth.	It	is	shows	that	further	breakdown	occurs	during	the	course	of	a	lifespan	experiment.			
7.3.1v	PABA-glu	shortens	C.	elegans	lifespan	in	an	abgT-dependent	mechanism	Lifespan	 analysis	 were	 carried	 out	 on	 pabA,	 abgTpabA,	 pabA	 (abgT	 OE)	 and	
abgTpabA	(abgT	OE)	strains	on	DM	agar	plates	supplemented	with	1	µM	and	10	µM	PABA-glu,	10	µM	and	100	µM	folic	acid	and	1	µM	PABA.	WT	E.	coli	was	included	only	as	a	non-supplemented	control	due	to	confidence	from	previous	experiments	that	 C.	 elegans	 lifespan	 on	 WT	 E.	 coli	 would	 not	 be	 affected	 by	 further	supplementation.	Mean	 lifespans	 are	 displayed	 in	 figure	 7.6	 instead	 of	Kaplan-Meier	 survival	 curves	 due	 to	 the	 large	 number	 of	 lifespans	 conducted	 here.	 P	values	 here	 refer	 to	 Log-rank	 statistical	 analysis	 of	 the	 Kaplan-Meier	 survival	curves	(see	full	lifespan	analysis	in	supplementary	table	1).			Consistent	 with	 previous	 findings,	 C.	 elegans	maintained	 on	 any	 E.	 coli	 pabA	mutant	were	long-lived	compared	to	C.	elegans	fed	wild	type	E.	coli	in	the	absence	of	supplementation	(P<0.001,	in	all	cases).	Similarly	to	the	initial	findings	(figure	4.3),	the	response	to	folic	acid	was	dependent	on	abgT	expression:	10	µM	folic	acid	partially	 reversed	 C.	 elegans	 longevity	 on	 pabA	 by	 9.36	 %	 (P=0.0052);	 no	significant	 reversal	 was	 observed	 on	 abgTpabA	 (P=0.1817);	 and	 a	 complete	reversal	of	lifespan	on	pabA	(abgT	OE)	was	seen	(P<0.0001)	(figure	7.6a).	At	100		
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Figure	7.6	Lifespan	analysis	reveals	E.	coli	abgT	determines	lifespan	in	response	to	both	
folic	acid	and	PABA-glu.	Mean	lifespans	of	C.	elegans	transferred	at	day	1	of	adulthood	onto	WT,	pabA,	abgTpabA,	pabA	(abgT	OE)	mutant	E.	coli	±	a)	10,	100	µM	folic	acid	b)	1,	10	µM	PABA-glu	and	c)	0.1,	1	µM	PABA.	Error	bars	represent	standard	error.	
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µM	folic	acid,	lifespan	was	completely	reversed	on	pabA,	(P<0.0001),	but	still	had	no	significant	impact	on	C.	elegans	lifespan	on	abgT	pabA	(P=0.1901).		These	data	consistent	with	the	previous	lifespan	analysis	(figure	7.3)	and	indicate	that	E.	coli	
abgT	deletion	is	protective	against	folic	acid-induced	lifespan	reduction.			The	response	of	lifespan	to	PABA-glu	mirrored	the	response	to	folic	acid	(figure	7.6b)	 where	 lifespan	 was	 dictated	 by	 abgT	 expression.	 In	 contrast,	 PABA	supplementation	 reversed	 C.	 elegans	 lifespan	 to	 WT	 in	 all	 cases	 and	 was	independent	of	abgT	expression	(figure	7.6c).	Together,	these	results	suggest	that	AbgT-dependent	 uptake	 of	 PABA-glu	 by	 E.	 coli	 following	 folic	 acid	supplementation	is	responsible	for	the	negative	impact	folic	acid	has	on	C.	elegans	lifespan	maintained	on	folate-deficient	E.	coli.			
7.3.1	 iii	 LC-MS/MS	 detects	 that	 folic	 acid	 increases	 E.	 coli	 folate	 levels	 in	 an	 abgT-
dependent	mechanism		In	order	to	test	whether	abgT	expression,	and	thus	C.	elegans	survival,	correlates	to	E.	coli	folate	status	following	folic	acid	supplementation,	folate	extractions	were	carried	out	on	WT,	pabA,	abgTpabA	and	pabA	(abgT	OE)	strains	which	had	been	incubated	on	DM	agar	plates	at	25		ͦC	for	4	days	supplemented	with	10	and	100	µM	folic	acid.	Extraction	volumes	were	normalized	for	growth	and	extracts	subjected	to	LC-MS/MS.	Tri-glutamated	folate	species	were	detected	and	normalized	to	the	signal	of	an	MTX-glu6	internal	standard.	Two-tailed	paired	student’s	t-tests	have	been	carried	out	to	determine	significance	difference	in	counts	of	a	single	folate	species	between	conditions;	asterisks	are	indicated	on	the	graphs,	where	P<0.05	compared	to	counts	detected	in	the	WT	extract	of	the	same	condition	(figure	7.7)	
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Figure	7.7	LC-MS/MS	detects	lower	levels	of	THFs	in	pabA	mutants,	where	abgT	determines	response	to	folic	acid.	Levels	of	THFs	detected	in	extracts	of	E.	coli	WT,	pabA,	
abgTpabA,	pabA	(abgT	OE)	were	analysed	by	LC-MS/MS.	Folate	levels	were	displayed	as	a	ratio	of	an	internal	MTX-glu6	spike	for	normalization	between	samples.	Extracts	were	made	after	4	days	of	bacterial	growth	at	25°C.	Asterisks	denote	the	result	of	Student’s	t-	tests	of	folate	level	in	pabA,	abgTpabA	or	pabA	(abgT	OE)	mutant	extract	on	denoted	condition	compared	to	in	WT	extract	of	the	same	condition,	where,	**P<0.01	*<0.05.	Error	bars	represent	standard	deviation.	
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In	the	absence	of	folic	acid,	levels	of	all	folate	species	were	significantly	lower	in	
pabA	 and	abgTpabA	mutant	 extracts	 compared	 to	WT;	 only	 5-methyl	 THF	was	lower	in	pabA	(abgT	OE)	(figure	4.7).	In	response	to	10	µM	folic	acid,	folate	levels	in	WT	and	pabA	(abgT	OE)	increased	and	were	detected	at	comparable	levels	(with	the	 exception	 of	 5,10-methylene	 THF).	 Folate	 levels	 in	 pabA	 and	 abgTpabA	extracts	were	significantly	lower	compared	to	WT	in	response	to	10	µM	folic	acid,	again	with	the	exception	of	5,10-methylene	THF	and	THF	in	pabA.	In	response	to	100	µM	folic	acid,	 folate	 levels	were	 increased	 in	all	 extracts	compared	 to	non-supplemented	 controls,	 however,	 levels	 detected	 with	 respect	 to	 WT	 were	dependent	on	abgT	expression:	folate	species	in	extracts	of	abgTpabA	remained	significantly	 lower;	 levels	 in	 pabA	 extracts	 were	 comparable;	 and	 levels	 in	
abgTpabA	extracts	were	higher.		The	marked	difference	in	folate	levels	between	these	strains	(despite	comparable	growth)	correlates	to	the	impact	of	these	conditions	on	C.	elegans	lifespan.	Where	folate	levels	are	comparable	to	WT,	such	as	in	the	pabA	mutant	at	100	µM	and	on	the	pabA	(abgT	OE)	mutant	strain	at	10	µM	folic	acid,	lifespan	is	reversed	to	WT.	The	low	levels	of	folates	in	abgTpabA	mutant	extracts	compared	to	all	other	strains	is	consistent	with	its	protective	effect	on	lifespan	in	response	to	folic	acid.		
7.3.2	Examining	abgT	expression	
7.3.2	pabA	is	required	for	wild-type	abgT	expression	The	data	thus	far	have	implicated	abgT	expression	as	a	requirement	for	folic-acid	induced	lifespan	reduction.	Here,	the	expression	pattern	of	abgT	is	examined	using	qPCR	under	the	conditions	used	for	C.	elegans	experiments.	RNA	extractions	were	
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carried	out	on	WT	and	pabA	E.	coli	seeded	onto	DM	plates	supplemented	with	0.1	µM	PABA,	after	96	hours	(day	4)	incubation	at	25		ͦC	.This	was	followed	by	DNase	treatment,	 cDNA	 synthesis	 and	 qPCR.	 RNA	 extractions	 were	 normalized	 for	bacterial	growth	based	on	OD	600	and	cell	number.	These	procedures	had	not	been	carried	 out	 in	 the	Weinkove	 laboratory	 previously	 and	 therefore	 several	 steps	required	optimisation.	See	Chapter	2	 for	 full	outline	of	methods.	Two	reference	genes,	rrsA	and	mdoG	were	initially	analysed	for	their	suitability	for	normalization	in	WT	and	pabA	mutant	cDNA.	These	genes	were	chosen	based	on	peer-reviewed	literature	 (Heng	 et	 al.,	 2011;	 Rocha	 et	 al.,	 2015).	 rrsA	 codes	 for	 the	 16S-RNA	ribosomal	subunit,	and	mdoG	for	an	enzyme	involved	in	glucan	biosynthesis.			Figure	7.8	depicts	abgT	expression	normalized	to	both	rrsA	and	mdoG	reference	genes	 in	WT	and	pabA	E.	coli	at	the	day	4	time	point.	Expression	levels	of	abgT	normalized	to	either	reference	gene	were	consistent	and	indicated	a	significantly	lower	expression	in	pabA	compared	to	WT	E.	coli.	The	rrsA	gene	was	selected	as	a	suitable	 reference	 gene	 for	 further	 qPCR	 analysis	 due	 to	 a	 smaller	 standard	deviation	compared	 to	mdoG	 over	 the	 four	biological	 replicates	 (see	Chapter	2,	figure	2.	4	for	analysis	of	primer	efficiency).	The	low	expression	of	abgT	in	pabA	is	consistent	with	the	lower	response	of	the	pabA	mutant	to	folic	acid	compared	to	the	WT,	as	detected	by	LC-MS/MS.		It	is	concluded	that	abgT	expression	in	wild-type	E.	coli	is	dependent	on	pabA.			
7.3.2i	abgT	is	highly	expressed	in	lag	and	early	exponential	phase	growth	RNA	was	extracted	from	WT	E.	coli	at	different	stages	of	bacterial	growth	on	DM		
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Figure	 7.8	 Quantitative	 PCR	 reveals	 decreased	 abgT	 expression	 in	 pabA	 mutant.	RNA	extractions	were	performed	on	DM	agar	plates	seeded	with	WT	and	pabA	E.	coli.	abgT	mRNA	levels	in	the	pabA	mutant	are	normalized	to	expression	in	the	WT	strain	and	to	two	reference	genes.	See	Chapter	2,	section	2.14	for	full	outline	of	procedure.	Error	bars	represent	standard	deviation.			
	
Figure	7.9	Quantitative	PCR	reveals	expression	of	abgT	in	WT	E.	coli	peaks	during	lag	and	
exponential	growth.	RNA	extractions	were	performed	on	DM	agar	plates	seeded	with	WT	E.	
coli	over	the	course	of	96	hours.	abgT	mRNA	levels	are	normalized	to	expression	in	the	overnight	(O/N)	 cultures	which	were	 pooled	 before	 used	 to	 seed	 the	 plates,	 and	 to	 the	 rrsA	 reference	genes.	Error	bars	represent	standard	deviation.	Bacterial	growth	is	plotted	on	the	secondary	y	axis.		
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agar	plates	(log	phase,	24,	48,	72,	96	hours).	Extractions	of	4	replicate	overnight	cultures	were	made	before	the	cultures	were	pooled	and	used	to	seed	the	plates.	
abgT	expression	was	examined	in	these	extracts	by	qPCR,	where	expression	was	normalized	to	expression	in	O/N	liquid	cultures.	The	primary	y	axis	in	figure	4.9	indicates	normalized	expression	 level	or	 ‘fold-change’	and	 the	secondary	y	axis	plots	 bacterial	 growth.	 abgT	 expression	 increased	 by	 15-fold	 in	 log-phase,	increasing	to	an	18-fold	expression	change	at	24	hours	and	16-fold	at	48	hours.	Normalized	 expression	 lowered	 to	 a	 7-fold	 increase	 at	 72	 hours	 and	 a	 2-fold	increase	 at	 96	 hours.	 This	 indicated	 that	 abgT	 is	 temporally	 expressed	 in	accordance	with	bacterial	growth	phase,	where	expression	is	highest	during	lag	and	early	exponential	growth	and	lower	in	stationary	phase	(O/N	culture	and	96	hour	 time-point).	 Extractions	 were	 not	 carried	 out	 longitudinally	 in	 the	 pabA	mutant,	so	it	is	unclear	how	expression	differs	here.	
7.3.3	Investigating	how	folinic	acid	interacts	with	C.	elegans	and	E.	coli	
The	 previous	 section	 demonstrated	 that	 folic	 acid	 restores	 bacterial	 folate	synthesis	 in	 folate	deficient	bacteria	via	AbgT	uptake	of	PABA-glu	and	 that	 this	pathway	is	responsible	for	shortening	C.	elegans	 lifespan.	This	section	examines	the	impact	of	the	naturally	occurring	reduced	monoglutamated	folate,	folinic	acid,	(5-formyl	THF),	on	C.	elegans	lifespan.	Like	folic	acid,	folinic	acid	cannot	be	taken	up	by	E.	coli	directly.			
7.3.3i	Folinic	acid	does	not	reverse	C.	elegans	lifespan	on	pabA	mutant	E.	coli		Lifespan	 assays	 on	 DM	 supplemented	with	 100	 µM	 folic	 and	 folinic	 acid	 were	carried	out	on	pabA,	abgTpabA	mutant	and	WT	E.	coli,	with	non-supplemented	
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Figure	7.10	Lifespan	analysis	reveals	100	µM	folinic	acid	extends	C.	elegans	lifespan	on	
WT	and	abgTpabA	mutant	E.	coli.	Kaplan-Meier	survival	curves	of	C.	elegans	transferred	onto	WT,	pabA,	abgTpabA	mutant	E.	coli	at	day	1	of	adulthood,	on	DM	plates	supplemented	with	100	µM	folic	and	folinic	acid.			
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plates	included	as	controls.	Consistent	with	previous	findings	(figure	7.3,	7.6),	100	µM	 folic	 acid	 shortened	 lifespan	 significantly	 on	 the	 pabA	mutant	 by	 15.37%	(P<0.001),	but	not	on	abgTpabA	E.	coli	(P=0.0719)	(figure	7.10).	In	contrast,	folinic	acid	did	not	affect	lifespan	of	C.	elegans	on	pabA	E.	coli	(P=0.2046).	Surprisingly,	folinic	acid	was	found	to	increase	lifespan	on	WT	E.	coli	by	18.4%	(P<0.001),	on	
abgTpabA	 E.	 coli	by	 9.61%	 (P=0.0188),	 and	 on	abgT	 single	mutant	 by	 10.31%	(P=0.0040)	 compared	 to	 their	 respective	 non-supplemented	 controls	 (figure	7.10).			
7.3.3	ii	Folinic	acid	is	less	effective	at	rescuing	pabA	mutant	growth	than	folic	acid	The	data	predicts	that	folinic	acid	does	not	interact	with	E.	coli	in	the	same	way	as	folic	 acid.	 In	 order	 to	 understand	 this	 interaction,	 growth	 assays	 of	 pabA	 and	
abgTpabA	mutants	 in	 liquid	DM	 supplemented	with	 folic	 and	 folinic	 acid	were	carried	out	 in	96-well	microtiter	plates,	as	previously	described.	Growth	curves	are	shown	in	figure	4.11	and	are	the	average	of	triplicate	technical	wells.	Mean	end	point	growth	from	these	wells	is	also	(figure	7.11).		At	5	µM	and	10	µM,	folinic	acid	was	found	to	be	less	effective	at	rescuing	both	pabA	and	abgTpabA	growth	than	equivalent	concentrations	of	folic	acid,	where	bacterial	genotype	did	not	significantly	impact	growth	in	response	to	folinic	acid.	Consistent		with	 the	 previous	 findings,	 at	 100	 µM,	 growth	 of	 both	 strains	was	 comparable	regardless	of	supplement	or	bacterial	genotype.	This	assay	was	repeated	several	times	 with	 varying	 concentrations	 of	 supplements	 and	 the	 same	 trends	 were	observed	(data	not	shown).	This	data	suggests	that	folinic	acid	is	less	effective	at			
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Figure	7.11	Folinic	acid	is	less	effective	at	supplementing	pabA	growth	than	folic	acid.	Growth	assays	of	pabA	and	abgTpabA	mutants	were	condiucted	in	liquid	96-well	plates.	Wells	were	supplemented	with	1,	5,	10,	100	µM	folic	or	folinic	acid	and	growth	was	measured	every	5	minutes	for	20	hours	in	a	plate	reader	(see	Chapter	2,	section	2.7.2)	a)	growth	curves	of	i)	pabA	and	ii)	abgTpabA	over	20	hours	b)	end	point	growth	of	i)	pabA	and	ii)	abgTpabA.	Error	bars	represent	standard	deviation.		
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restoring	bacterial	growth	than	folic	acid,	and	unlike	with	folic	acid,	this	is	independent	
of	abgT	expression.		
 
7.3.3iii	Folinic	acid	rescue	of	the	gcp-2.1	mutant	is	not	dependent	on	abgT	expression	In	order	to	understand	how	folinic	acid	interacts	with	E.	coli	folate	levels,	the	gcp-
2.1	mutant	bioassay	was	carried	out.	Synchronous	populations	of	gcp-2.1	mutant	worms	were	raised	from	egg	on	pabA,	abgTpabA	or	pabA	(abgT	OE)	mutant	E.	coli	on	DM	agar	plates	supplemented	with	varying	concentrations	of	folic	and	folinic	acid	(plotted	on	a	log	scale	in	figure	7.12).	Plates	were	incubated	at	25		ͦC	and	body	length	 at	 L4	 stage	 was	 measured	 as	 previously	 described.	 All	 plates	 were	supplemented	with	0.1	µM	PABA.			A	stark	contrast	was	observed	between	the	efficacies	of	 folic	and	 folinic	acid	 to	rescue	gcp-2.1	body	length.	2.5	µM	folinic	acid	completely	rescued	gcp-2.1	body	length	regardless	of	bacterial	genotype,	whereas	200	µM	folic	acid	was	required	for	 equivalent	 rescue	 on	 all	 strains.	 gcp-2.1	 body	 length	was	 dictated	 by	 abgT	expression	 in	 response	 to	 folic	 acid:	 over-expression	 of	 abgT	 increased	 the	responsiveness	to	folic	acid,	whereas	abgT	deletion	rendered	gcp-2.1	mutants	less	responsive.	This	indicates	that,	unlike	folic	acid,	folinic	acid	is	taken	up	directly	by	
C.	elegans	and	is	not	dependent	on	bacterial	abgT	expression.	A	two-way	ANOVA	analysis	finds	significant	interaction	effect	of	strain	type	(F=102.67,	p<0.0001)	and	folic	acid	concentration	(F=123.55,	p<0.0001)	on	C.	elegans	gcp-2.1	body	length.		
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Figure	7.12.	Folic	acid	supplements	C.	elegans	via	an	E.	coli	abgT-dependent	route	during	
development.	Body	length	of	gcp-2.1	mutant	C.	elegans	at	L4	stage	raised	on	DM	agar	plates	seeded	
with	pabA	mutant,	abgTpabA	double	mutant	or	pabA	mutant	over-expressing	abgT	with	increasing	
concentrations	of	a)	folic	acid	and	b)	folinic	acid.	Two-way	ANOVA	analyses	finds	a	significant	
interaction	effect	of	strain	type	(F=102.67,	p<0.0001)	and	folic	acid	concentration	(F=123.55,	
p<0.0001)	on	C.	elegans	gcp-2.1	body	length.	Over-expression	is	conferred	by	transformation	with	a	
high	copy	number	plasmid,	pJ128.	pabA	and	abgTpabA	strain	are	transformed	with	the	empty	vector,	
pUC19.	Error	bars	represent	standard	deviation	of	C.	elegans	body	length;	n	≥40.	
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7.4	DISCUSSION	
7.4.1	Folic	acid	supplements	contain	degradation	products	which	boost	bacterial	
folate	synthesis	and	decrease	C.	elegans	lifespan		
 The	first	section	of	this	chapter	addressed	the	initial	aim	of	determining	how	folic	acid	 impacts	C.	 elegans	 lifespan.	 Folic	 acid	was	here	 found	 to	 impact	C.	 elegans	lifespan	in	a	mechanism	dependent	on	E.	coli	AbgT	uptake	of	PABA-glu.	Indeed,	LC-MS/MS	detected	 PABA-glu	 in	 the	 folic	 acid	 used	 for	 this	 study	 at	 physiological	concentrations.	 Although	 this	 data	 cannot	 determine	 whether	 PABA-glu	 is	 a	contaminant	or	a	degradation	product,	the	further	degradation	of	folic	acid	when	supplemented	 into	 the	media	 suggests	 that	 it	may	be	 the	 latter.	 Folic	 acid	was	found	to	boost	E.	coli	folate	synthesis	in	both	WT	and	pabA	mutant	E.	coli,	where	folate	levels	and	lifespan	in	the	latter	were	dependent	on	abgT	expression.			However,	as	indicated	by	the	gcp-2.1	mutant	bioassay,	the	ability	of	folic	acid	to	boost	 E.	 coli	 folate	 synthesis	 may	 be	 beneficial	 during	 development.	 In	 this	genetically	susceptible	folate-deficient	model,	the	impact	of	folic	acid	on	bacterial	folate	synthesis	was	able	to	rescue	gcp-2.1	developmental	folate	deficiency	on	the	
pabA	mutant	albeit	at	high	concentrations.	Together,	this	points	to	a	novel	role	of	folic	acid	supplements	as	suppliers	of	precursors	(both	PABA-glu	and	PABA)	for	bacterial	folate	synthesis	and	thus	modulators	of	host	health	during	development	and	adulthood.	The	translational	implications	of	these	data	within	the	context	of	the	debate	on	the	safety	of	folic	acid,	and	its	impact	on	the	microbiota	and	ageing	will	be	discussed	in	more	detail	in	Chapter	8.		
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7.4.2	AbgT	as	a	novel	antibacterial	target	
A	 Blastn	 search	 reveals	 that	 abgT	 is	 also	 found	 in	 the	 genomes	 of	 several	pathogenic	 members	 of	 the	 human	 gut	 microbiota,	 including	 Shigella	 boydii,	
Kelbsiella	phenumonia	and	Enterobacter	cloacae,	 in	addition	to	E.	coli.	 Indeed,	E.	
coli	AbgT	has	recently	been	identified	as	a	member	of	a	conserved	superfamily	of	antimetabolite	 transporters	 (Delmar	and	Yu,	2016).	Members	of	 this	 family	are	capable	of	both	import	and	export	of	folate	precursors	and	antimetabolites,	such	as	sulfonamides.	In	light	of	this	recent	literature	and	the	data	presented	here,	AbgT	may	 represent	 a	 novel	 target	 for	 antibiotics.	 The	 finding	 that	 abgT	 is	downregulated	in	the	pabA	strain	is	consistent	with	analysis	of	RNA	sequencing	data	 collected	 in	 the	 Weinkove	 laboratory,	 which	 found	 that	 AbgT	 was	downregulated	in	response	to	SMX	treatment	on	OP50	E.	coli.	It	seems	that	abgT	expression	is	folate-dependent.	Further	work	is	required	in	order	to	characterize	this	association.		
7.4.3	Folinic	acid	increase	C.	elegans	lifespan	and	may	be	a	suitable	alternative	to	
folic	acid	as	a	folate	supplement	
This	 chapter	 also	 aimed	 to	 investigate	 the	 impact	 of	 the	 alternative	 folate	supplement,	folinic	acid,	on	C.	elegans	lifespan.	In	contrast	to	folic	acid,	folinic	acid	was	here	found	to	increase	lifespan.	Folinic	acid	rescued	the	developmental	folate	deficiency	of	the	gcp-2.1	strain	at	almost	200-fold	lower	concentration	(2.5	µM)	than	folic	acid,	in	a	mechanism	independent	of	abgT	expression.	Together,	these	data	indicate	that	folinic	acid	is	taken	up	directly	by	C.	elegans	and	it	does	not	boost	
E.	 coli	 folate	 synthesis	 above	 the	 threshold	 which	 negatively	 effects	 lifespan.	Folinic	 acid	 therefore	 represents	 a	 more	 suitable	 folate	 supplement	 for	
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maintaining	the	 longevity	of	C.	elegans	on	low	folate	E.	coli,	than	folic	acid.	This	may	be	useful	 in	 a	 translational	 capacity,	where	 folate	 supplementation	 should	accompany	 an	 intervention	 that	 targets	 bacterial	 folate	 synthesis	 to	 extend	lifespan,	in	order	to	prevent	folate	deficiency.	Indeed,	folate	deficiency	has	been	reported	 in	 certain	 patients	 receiving	 the	 sulphonamide	 drug,	 sulfasalazine,	 to	treat	Crohn’s	disease (Goldberg, 1983; Nemes et al., 2016; Swinson et al., 1981).	In	these	cases,	folic	acid	is	administered	as	treatment.	It	is	noted	that	the	conclusions	here	are	limited	by	the	lack	of	LC-MS/MS	data	regarding	folinic	acid	degradation	and	of	the	impact	of	folinic	acid	on	E.	coli	folate	levels.	Further	work	should	address	these	limitations.	Possible	mechanisms	underpinning	the	positive	impact	of	folinic	acid	on	C.	elegans	lifespan	will	be	discussed	in	Chapter	8.			The	uptake	of	folinic	acid	by	C.	elegans	is	consistent	with	the	reported	high	affinity	of	 the	C.	elegans	reduced	 folate	carrier	(RFC),	FOLT-1,	 for	 folinic	acid	(5-formyl	THF);	5-formyl	THF	was	 found	 to	 impair	 folic	 acid	uptake	 (Balamurugan	et	 al.,	2007).	However,	owing	to	the	pH-dependence	of	RFCs	(see	Chapter	1),	it	is	unclear	whether	 the	pH	of	 the	DM	 (pH	6.0)	 biases	 this	model	 system	 in	 favour	of	THF	uptake	 over	 oxidized	 folates.	 Studies	 suggest	 that	 C.	 elegans	 do	 however,	differentially	regulate	the	pH	of	their	intestinal	lumen	(Chauhan	et	al.,	2013).	A	C.	
elegans	proton-coupled	folate	transporter	(PCFT)	has	not	been	characterized,	but	a	gene	encoding	for	a	PCFT-like	protein	has	recently	been	identified	(Ortbauer	et	al.,	 2016).	 Further	 study	 would	 use	 RNAi	 to	 knock-down	 folt-1	 and	 pcft	 and	monitor	folic	and	folinic	acid	uptake	by	C.	elegans	under	varying	pHs.	It	is	likely	that	 this	will	 also	have	 an	 effect	 on	 the	 stability	 of	 folic	 and	 folinic	 acid,	which	should	be	monitored	by	LC-MS/MS.	
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Figure	7.13:	Diagrammatic	representation	of	the	routes	of	uptake	of	folic	and	folinic	acid	by	C.	
elegans.	Folic	acid	degrades	to	PABA-glu	and	PABA.	PABA-glu	is	imported	by	E.	coli	AbgT	and	cleaved	intracellularly	by	AbgA/B	to	generate	PABA.	PABA	can	freely	diffuse	into	E.	coli.	This	supply	of	PABA	boosts	 bacterial	 folate	 synthesis	 and	 generates	 THFs.	 Following	 ingestion	 of	 E.	 coli,	 C.	 elegans	 is	supplied	with	THFs	via	this	route.	Folinic	acid	is	absorbed	directly	in	the	intestine	following	ingestion	of	E.	coli.		
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CHAPTER	8.	DISCUSSION	
 
8.1	SUMMARY	OF	MAIN	FINDINGS	The	main	aim	of	this	thesis	was	to	develop	a	defined	system	(where	E.	coli	folate	levels	 could	be	controlled	and	accurately	measured)	 in	order	 to	 investigate	 the	factors	that	influence	bacterial	folate	synthesis	and	thus	C.	elegans	lifespan.	Firstly,	a	folate-free	and	chemically	defined	media	(DM)	was	optimised	to	support	both	E.	
coli	 and	 C.	 elegans	 similarly	 to	 on	 NGM.	 Using	 DM	 and	 sensitive	 LC-MS/MS	detection,	 the	 bacterial	 folate	 threshold	 that	 supports	 bacterial	 growth	 was	distinguished	 from	 the	 higher	 bacterial	 folate	 threshold	 that	 negatively	 affects	lifespan.			This	defined	system	was	then	used	to	investigate	the	impact	of	several	extrinsic	and	intrinsic	genetic	factors	on	these	parameters;	folic	acid	and	glucose	and	the	genes,	rpoS	and	fic,	were	identified	as	novel	mediators	of	bacterial	folate	synthesis	and	modulators	of	C.	 elegans	 lifespan.	 Investigation	 into	 the	 timing	of	 bacterial	folate	 synthesis	 revealed	 a	 novel	 association	 with	 exponential	 growth	 phase.	Based	on	the	characterisation	of	C.	elegans	phenotypes	on	a	pathogenic	bacterial	strain,	it	was	hypothesized	that	bacterial	folate	synthesis	is	linked	to	a	mild	toxicity	which	 is	 responsible	 for	C.	 elegans	ageing.	 The	 implications	 of	 these	 and	 other	emerging	findings	from	this	work	will	be	discussed	below.			
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8.2	IMPLICATIONS	OF	THIS	WORK	
8.2.1	Excessive	bacterial	folate	synthesis	
Using	LC-MS/MS,	 it	has	been	clearly	demonstrated	here	 that	E.	 coli	 synthesizes	folate	above	 the	 threshold	required	 to	support	bacterial	growth.	This	excessive	synthesis	was	found	to	be	temporally	regulated	in	exponential	growth	phase	and	was	 amplified	 by	 glucose.	 Increased	 bacterial	 folate	 production	 in	 glucose	supplemented	media	has	only	been	mentioned	anecdotally	(Sybesma	et	al.,	2003).	In	 mammalian	 cells,	 however,	 a	 pathway	 known	 as	 serine-driven	 one-carbon	metabolism	is	upregulated	in	cancer	cell	 lines	(Labuschagne	et	al.,	2014)	and	in	response	 to	 glucose	 (Tedeschi	 et	 al.,	 2013).	 This	 pathway	 catabolizes	 serine	 to	glycine	 using	 THF	 as	 a	 one-carbon	 acceptor	 to	 form	 5,10-methylene	 THF,	 in	 a	reaction	 catabolized	 by	 serine	 hydroxymethyltransferase	 (SHMT)	 (Lunt	 and	Vander	Heiden,	2011)	(figure	8.2).	Interestingly,	studies	have	suggested	that	the	provision	of	THFs	as	cofactors	to	support	biosynthesis	 in	these	rapidly	dividing	cells	is	secondary	to	the	production	of	ATP	and	NADPH	via	this	pathway	(Fan	et	al.,	2014;	Meiser	et	al.,	2016;	Tedeschi	et	al.,	2013).	Indeed,	Meiser	and	colleagues	demonstrated	that	a	significant	proportion	of	the	one-carbon	units	derived	from	this	pathway	are	excreted	(as	formate).			This	 pathway	 has	 not	 been	 elucidated	 in	 prokaryotic	 cells,	 however,	 it	 may	underpin	why	E.	 coli	here	 synthesizes	 excess	 folate	 during	 exponential	 growth	phase.	Further	work	would	investigate	this	hypothesis	by	monitoring	whether	the	expression	of	genes	involved	in	this	pathway	are	upregulated	in	exponential	phase	and	 in	 response	 to	 glucose.	 Meiser	 and	 colleagues	 observed	 an	 inverse	
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relationship	between	serine	concentration	in	the	media	and	the	amount	of	formate	excreted	by	dividing	cells,	both	 in	vitro	and	 in	vivo	 (Meiser	et	al.,	2016).	 In	our	model	system,	the	serine	concentration	in	DM	can	easily	be	altered	and	the	impact	on	E.	coli	gene	expression,	folate	and	formate	levels	and	C.	elegans	lifespan	could	be	monitored;	serine	concentration	would	be	expected	to	 inversely	correlate	to	longevity	and	positively	correlate	to	bacterial	folate	levels.			Intriguingly,	 the	 mitochondria	 complex-1	 inhibitor,	 metformin,	 was	 found	 to	moderate	serine-driven	one-carbon	metabolism	in	mammalian	cells,	likely	due	to	the	mitochondrial	localization	of	the	enzymes	involved	in	this	pathway	(Meiser	et	al.,	2016).	This	is	of	note	as	metformin	has	also	been	shown	to	increase	C.	elegans	lifespan	in	an	unclarified,	but	E.	coli	folate-dependent	mechanism	(Cabreiro	et	al.,	2013).	 This	 adds	 weight	 to	 the	 hypothesis	 that	 serine-driven	 one-carbon	metabolism	 during	 bacterial	 exponential	 growth	 phase	 may	 be	 modulating	 C.	
elegans	lifespan,	and	therefore	warrants	further	study.			The	obvious	dichotomy	here	is	that	serine-driven	one-carbon	metabolism	does	not	rely	 on	 folate	 synthesis,	 but	 the	 increase	 in	 E.	 coli	 folate	 levels	 in	 response	 to	glucose	was	 found	 here	 to	 be	 dependent	 on	pabA	expression	 (Chapter	 6).	 It	 is	likely,	however,	that	inhibiting	bacterial	folate	synthesis	limits	serine-driven	one-carbon	metabolism,	as	 the	 latter	does	 require	a	 source	of	THF	as	a	one-carbon	acceptor	for	serine	catabolism.	This	pathway	therefore	offers	a	model	which	may	account	for	excessive	folate	production	in	exponential	phase	growth.			
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8.2.2	Folate-dependent	bacterial	toxicity	
The	 data	 presented	 in	 Chapter	 7	 was	 supportive,	 but	 not	 conclusive,	 of	 the	hypothesis	 that	 bacterial	 folate	 synthesis	 is	 associated	with	 a	 toxicity.	 Further	work	would	harness	the	genetic	tractability	of	the	worm	to	test	this	hypothesis.	The	expression	of	C.	elegans	genes	 involved	 in	detoxification	pathways,	 such	as	
skn-1,	 should	 be	 examined	 using	 qPCR	or	 reporter	 constructs	 under	 the	E.	 coli	conditions	found	here	to	decrease	bacterial	folate	levels.	It	is	hypothesized	that	C.	
elegans	mutants	 involved	 in	 detoxification	 pathways	 would	 be	 hyper-sensitive	under	conditions	which	increase	bacterial	folate	levels,	such	as	PABA,	folic	acid	or	glucose	 supplementation.	 Further	work	would	 also	 examine	 the	 source	 of	 this	bacterial	toxicity;	two	avenues	for	further	work	are	outlined	below.			
8.2.2i	fic-folate-dependent	toxicity	Following	the	isolation	of	the	rpoS	gene	as	a	modulator	of	C.	elegans	lifespan	(Virk	et	al.	2016),	it	was	investigated	here	as	a	possible	mediator	of	folate-dependent	toxicity	due	to	its	role	in	virulence	in	pathogenic	bacteria	and	the	identification	of	
pabA	 and	pabB	 as	 downstream	 targets	 (Ito	 et	 al.,	 2008;	Weber	 et	 al.,	 2005).	 A	candidate	mutant	gene	screen	of	 the	RpoS	regulon	revealed	 that	 the	 fic	mutant	both	increased	C.	elegans	lifespan	and	decreased	E.	coli	folate	levels.		
 
fic	was	included	as	a	candidate	gene	in	the	screen	for	two	reasons:	it	lies	directly	upstream	 of	 pabA	 and	 it	 has	 recently	 been	 implicated	 in	 toxicity	 pathogenic	bacteria.	Fic	proteins	are	a	conserved	family	of	eukaryotic	and	prokaryotic	toxins	(Harms	et	al.,	2016),	where	Fic	acts	as	the	toxin	subunit	of	a	toxin-antitoxin	system	(Engel	et	al.,	2012;	Kinch	et	al.,	2009).	Fic	proteins	have	AMP	transferase	activity	
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and	mediate	 AMPylation	 of	 target	 proteins	when	 not	 inhibited	 by	 its	 antitoxin	(Itzen	et	al.,	2011;	Woolery	et	al.,	2010).	Fic	proteins	have	recently	been	identified	in	several	Proteobacteria,	including	species	of	Enterobacter,	Salmonella,	Shigella,	
Klebsiella,	 Yersinia	 and	 Pseuodamonas	 (Stanger	 et	 al.,	 2016).	 In	 vitro	 infection	models	 of	mammalian	 cells	 have	 revealed	 that	 pathogenic	 bacteria	 secrete	 Fic	toxins	which	AMPylate	 target	 proteins	 and	 cause	 cytoskeletal	 collapse	 and	 cell	death	 (Worby	 et	 al.,	 2009).	AMPylation	of	 Fic	 target	 proteins	 in	C.	 elegans	was	recently	found	to	increase	susceptibility	to	killing	by	Pseuodamonas	auerginosa	by	dampening	innate	immunity	and	promoting	pathogen	proliferation	(Truttmann	et	al.,	2016).				The	crystal	structure	of	the	E.	coli	K12	Fic	protein	in	complex	with	its	antitoxin	was	solved	 in	 2016	 and	 the	E.	 coli	 fic	 gene	was	 renamed	 ecficT	 and	 the	 yhfG	 gene	encoding	the	antitoxin,	ecficA	(Stanger	et	al.,	2016).	The	role	of	ecficT	in	toxicity,	however,	is	unclear	due	to	a	lack	of	in	vivo	studies.		However,	the	data	presented	in	Chapter	7	supports	the	hypothesis	that	fic	(ecficT)	may	be	mediating	a	folate-dependent	toxicity	responsible	for	C.	elegans	ageing.	Further	work	is	required	to	investigate	possible	mechanisms	of	this	toxicity	and	whether	it	is	dependent	on,	or	just	coincident	with	folate	synthesis.			In	 order	 to	 design	 experiments	 to	 test	 the	 above	 hypothesis,	 the	 chromosomal	arrangement	of	fic	and	pabA	must	be	understood	(figure	8.1).	The	fic	gene	ends	31	nucleotides	upstream	of	pabA	and	contains	within	its	coding	region	the	pabA	P1	promoter	 (Komano	 et	 al.,	 1991;	 Tran	 et	 al.,	 1990).	 It	 is	 therefore	 possible	 that	decreased	 folate	 levels	 and	 lifespan	 modulation	 in	 the	 fic	 (in-frame)	 mutant	
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observed	 in	 this	 work	 may	 be	 due	 to	 lack	 of	 transcription	 from	 the	 pabA	 P1	promoter.	In	order	to	delineate	the	effect	of	fic	on	E.	coli	folate	levels	and	C.	elegans	lifespan,	we	must	knockout	fic	whilst	preserving	expression	of	pabA.	This	could	be	achieved	 by	 transforming	 the	 fic	 mutant	 with	 a	 plasmid	 containing	 a	 fusion	construct	of	 the	P1	promoter	and	 the	pabA	gene,	 or	 alternatively	by	 creating	a	targeted	knockout	of	the	fic	gene	by	homologous	recombination.		However,	 it	 is	 also	possible	 that	 fic-mediated	 toxicity	 is	 co-dependent	on	 folate	synthesis.	 Indeed,	 a	 secondary	 pabA	 promoter,	 P2,	 is	 located	 upstream	 of	 fic.	Transcription	from	this	site	generates	polycistronic	mRNA	including	both	fic	and	
pabA	and	 only	 occurs	when	 an	mRNA	 stem-loop	 structure,	which	 forms	 in	 the	intergenic	region	between	fic	and	pabA,	is	disrupted	(Tran	et	al.,	1990;	Tran	and	Nichols,	1991).	 It	 is	not	clear	why	 these	 two	genes	are	 transcribed	 together,	or	what	regulatory	elements	stimulate	transcription	from	this	site,	however,	 it	has	been	suggested	that	fic-pabA	co-transcription	facilitates	cell	division	(Komano	et	al.,	 1991),	 owing	 to	 the	 initial	 observation	 that	 fic	 in	 E.	 coli	 mediates	 cell	filimentation	induced	by	cAMP	(Utsumi	et	al.,	1982).	In	light	of	the	more	recently	elucidated	role	of	Fic	proteins	 in	 toxicity,	and	 the	role	of	pabA	and	pabB	 in	 the	virulence	 of	 pathogenic	 bacteria	 (Brown	 and	 Stocker,	 1987;	 Chimalapati	 et	 al.,	2011),	this	co-transcription	may	facilitate	invasion	and	colonization	of	a	host.			
E.	 coli	 K12,	 however,	 is	 a	 lab-adapted	 strain	 and	 not	 classically	 considered	 a	pathogen.	Based	on	the	data	in	this	thesis,	a	model	is	proposed	whereby	the	co-transcription	of	 fic	and	pabA	from	P2	facilitates	cell	division	during	exponential	phase,	where	this	transcription	is	likely	to	be	promoted	by	RpoS.		The	coincident	
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Figure	 8.1.	 Diagrammatic	 representation	 of	 fic-pabA	 chromosomal	 organisation	 and	 a	
mechanism	of	Fic-dependent	lifespan	reduction.	The	fic	coding	region	ends	31	nucleotides	upstream	of	pabA.	pabA	has	two	known	promoters,	P1,	which	is	 located	within	the	fic	coding	region,	and	P2,	located	upstream	of	fic.	Transcription	from	P2	transcribes	polycistronic	mRNA	containing	both	 fic	and	pabA	 (Tran	et	 al.	 1991).	The	 intragenic	 region	between	 fic	and	pabA	forms	 an	mRNA	 stem-loop	 structure,	 which	 is	 disrupted	 following	 transcription	 from	 P2.	 A	mechanism	 is	 proposed	 whereby	 RpoS	 activates	 fic	 and	 pabA	 transcription	 from	 P2	 during	exponential	 growth	phase.	This	 generates	both	 the	Fic	 toxin	 and	 tetrahydrofolates	 following	folate	synthesis	which	together	decrease	C.	elegans	lifespan.			
fic		 									 	 pabA P1 P2 
predicted	mRNA	
stem-loop	structure 
RpoS? 
RpoS? 
Fic	toxins											 THFs 
Decreased	lifespan 
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secretion	 of	 Fic	 toxins	 may	 AMPylate	 C.	 elegans	 target	 proteins	 and	 cause	 an	accumulation	of	damage	which	accelerates	C.	elegans	ageing.	It	would	be	interesting	to	examine	fic-	dependent	toxicity	on	C.	elegans	in	the	O-antigen	restored	K12	strain,	which	is	reported	to	kill	C.	elegans	at	rates	similar	to	those	observed	with	pathogenic	bacterial	species	(Browning	et	al.,	2013)	and	also	in	the	Enterobacter	cloacae	strain,	B29.	Monitoring	changes	in	C.	elegans	protein	AMPylation	under	these	conditions	may	provide	insights	into	the	mechanism	of	fic-folate-dependent	toxicity.	The	interaction	of	 RpoS	 with	 these	 genes	 should	 be	 tested	 by	 DNAse	 footprinting	 or	 chromatin	immunoprecipitation	with	microarray	hybridization	(ChIP-chip).	
	
8.2.2ii	Folate	degradation	and	formaldehyde	toxicity	Previous	work	in	the	Weinkove	laboratory	hypothesized	that	folates	themselves	are	not	toxic	to	C.	elegans,	as	E.	coli	gene	mutants	involved	in	interconversions	of	THFs	in	the	folate	cycle	did	not	have	any	effect	on	lifespan	(Virk	et	al.	2016).	However,	 the	work	 here	 identified	 a	 correlation	 between	 low	 E.	 coli	 5,10-methylene	 THF	 and	increased	C.	elegans	lifespan	(outlined	in	Chapter	7,	section	7.4.4)	which	challenged	this	original	hypothesis.			A	study	published	this	year	has	highlighted	a	direct	link	between	5,10-methylene	THF	and	toxicity	in	mammalian	cells	(Burgos-Barragan	et	al.,	2017).	The	authors	reported	that	oxidative	degradation	of	endogenous	THFs	generates	a	ubiquitous	source	of	the	potent	 genotoxin,	 formaldehyde;	 5,10-methylene	was	 the	most	 prone	 to	 oxidation	and	release	of	 formaldehyde,	 followed	by	THF	and	DHF,	but	 	5-methyl	THF	and	5-formyl	THF	(folinic	acid)	were	resistant	(Burgos-Barragan	et	al.,	2017).	
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	It	is	known	that	both	eukaryotic	and	prokaryotic	cells	have	mechanisms	of	detoxifying	formaldehyde,	by	using	THF	as	a	one-carbon	acceptor	of	formaldehyde	to	generate	5,10-methylene	THF	(Chen	et	al.,	2016).	This	reaction	is	catalysed	by	SHMT	during	the	conversion	of	serine	to	glycine	(as	described	in	section	8.1)	(Burgos-Barragan	et	al.,	 2017).	 Indeed	 5,10-methylene	 has	 been	 coined	 ‘active	 formaldehyde’	 as	 it	 is	known	 to	degrade	spontaneously	 to	generate	 formaldehyde	 in	vitro	 (Osborn	et	al.,	1960).			In	prokaryotic	cells,	folate-dependent	formaldehyde	production	is	not	a	widespread	or	renowned	phenomena	and	the	detoxification	pathway	is	thought	to	compensate	only	for	host-derived	formaldehyde	(Chen	et	al.	2016).	However,	in	light	of	this	recent	discovery	of	mammalian	folate-dependent	formaldehyde	release,	and	given	the	same	biochemistry	of	 eukaryotic	 and	prokaryotic	 folates,	 it	 is	not	unlikely	 that	bacterial	folates	 are	 also	 a	 source	 of	 formaldehyde.	 This	 may	 underpin	 the	 association	 of	excessive	bacterial	 folate	 synthesis,	 and	 indeed	5,10-methylene	THF,	 in	our	model	system	with	C.	elegans	ageing.			Further	work	would	test	this	hypothesis	by	monitoring	formaldehyde	concentrations	in	response	to	the	factors	identified	in	this	work	that	influence	both	E.	coli	folate	levels	and	 C.	 elegans	 lifespan.	 It	 is	 hypothesized	 that	 formaldehyde	 would	 decrease	 in	response	 to	SMX	and	on	pabA,	 rpoS	and	 fic	mutants,	 and	 concentrations	would	be	expected	to	increase	in	response	to	PABA	in	pabA	and	fic	mutants	but	not	in	the	rpoS	
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Figure	8.2	Hypothetical	model	of	folate-dependent	formaldehyde	toxicity	in	E.	coli	The	conversion	of	serine	to	glycine	liberates	a	transient	molecule	of	formaldehyde,	which	reacts	with	THF	to	generate	5,10-methylene	THF.	5,10-methylene	THF	can	spontaneously	degrade	to	release	 formaldehyde.	 Formaldehyde	 can	 diffuse	 across	 biological	 membranes	 and	 is	 a	genotoxic	compound,	where	it	may	disrupt	C.	elegans	DNA	and	decrease	lifespan.	SHMT:	serine	hydroxymethyl	transferase;	THF:	tetrahydrofolate.		Adapted	from	Burgos-	Burgos-Barragan	et	al,	2017.									
													THF	
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mutant.	This	 could	be	sensitively	measured	using	LC-MS/MS	or	an	E.	 coli	reporter	strain.	See	figure	8.2	for	a	model	of	folate-dependent	formaldehyde	toxicity.			A	mechanism	for	RpoS	regulation	of	5,10-methylene	stability	was	proposed	in	light	of	the	co-incidence	of	altered	pterin	levels	in	the	rpoS	mutant	(Chapter	7,	section	7.14).	It	would	be	interesting	to	also	examine	whether	RpoS	regulates	expression	of	glyA,	the	gene	that	encodes	SHMT	and	therefore	regulates	5,10-methylene	levels	(Tibbetts	and	Appling,	2010).	Interestingly,	deletion	of	the	glyA	gene	was	found	to	have	a	small	(~8%	 increase)	 significant	effect	on	 lifespan	 in	 the	 screen	conducted	by	Virk	et	 al	(Virk	et	al.	2016)	but	was	disregarded	for	further	study	as	its	lifespan	effect	was	small.		
8.2.3	Regulation	of	E.	coli	folate	synthesis	
8.2.3i	Temporal	regulation	Given	the	importance	of	bacterial	folate	synthesis	as	an	antibiotic	target,	surprisingly	little	 is	known	about	the	genetic	regulation	of	this	process	and	there	have	been	no	transcription	factors	identified	to	date	which	regulate	genes	involved	in	either	folate	synthesis	or	one-carbon	metabolism.	The	work	presented	in	Chapter	6	suggested	that	folate	synthesis	is	not	constitutive,	but	regulated	temporally,	as	folate	levels	and	pabA	expression	 were	 found	 to	 peak	 during	 early	 exponential	 growth	 phase.	 The	coincidence	of	this	peak	with	rpoS	expression,	and	the	decreased	expression	of	pabA	in	 the	 rpoS	mutant,	 highlighted	 a	 novel	 role	 of	 RpoS,	 as	 a	 regulator	 of	 pabA	 and	therefore	bacterial	 folate	 synthesis.	This	has	 important	 implications	 for	antibiotics	which	target	bacterial	folate	synthesis,	indicating	that	maximum	efficacy	may	only	be	achieved	when	bacterial	cells	are	dividing.		
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8.2.3ii	THF	riboswitch		Further	work	would	also	investigate	the	role	of	the	THF	riboswitch	in	E.	coli.	This	is	an	 mRNA	 motif	 which	 was	 identified	 in	 2010	 and	 found	 upstream	 of	 the	 folate	transporter	folT	and	several	other	genes	involved	in	folate	synthesis	(folC,Q,	P,	B,	K),	but	not	in	the	PABA	branch	(Ames	et	al.,	2010).	The	motif	was	also	found	in	the	human	gut	metagenome.	This	motif	was	found	to	bind	to	the	pterin	moiety	of	THFs,	but	not	PABA,	PABA-glu	or	pterin	alone	(Ames	et	al.,	2010).	The	crystal	structure	of	5-formyl	THF	 revealed	 that	 binding	 to	 the	 ligand-specific	 ‘aptamer’	 domain	 changed	 the	secondary	structure	of	the	‘expression	platform’	domain	(Trausch	et	al.,	2011).	This	conformational	change	supposedly	regulates	gene	expression	by	either	promoting	or	preventing	 access	 of	 the	 RNA	 polymerase	 holoenzyme	 (Wakeman	 et	 al.,	 2007),	however	in	vivo	studies	on	the	regulatory	control	of	the	THF	riboswitch	have	not	been	published.		The	 stem-loop	 secondary	 mRNA	 structure	 which	 forms	 in	 the	 intragenic	 region	between	 fic	and	pabA	as	discussed	(figure	8.2.1),	was	 identified	 in	1991	(Tran	and	Nichols,	1991).	This	structure	is	consistent	with	that	of	a	riboswitch,	although	it	has	not	been	identified	as	one	to	date.	fic	expression	was	upregulated	in	the	pabA	mutant	and	pabA	expression	was	downregulated	 in	 the	 fic	mutant	(Chapter	7,	 figure	7.11)	indicating	possible	negative	feedback	of	a	downstream	pabA	process	on	fic	expression	i.e	 a	 folate	 or	 folate-dependent	 metabolite.	 Further	 work	 would	 carry	 out	 in	 vivo	analyses	of	the	impact	of	this	mRNA	motif	on	transcription/	translation	of	pabA	and	
fic	in	E.	coli	and	examine	the	conditions	that	affect	its	secondary	structure.		
210 
 
8.2.4	Folinic	acid-dependent	lifespan	extension	
In	Chapter	7,	a	marked	difference	between	the	impact	of	folic	and	folinic	acid	on	C.	
elegans	 lifespan	was	observed:	whilst	 folic	acid	decreased	 lifespan	on	pabA	E.	 coli,	folinic	acid	markedly	increased	lifespan	on	WT	and	the	abgTpabA	mutant,	but	did	not	further	increase	the	lifespan	of	the	pabA	mutant.	Further	work	would	investigate	this	interaction,	 especially	 given	 the	 detrimental	 impact	 of	 folic	 acid	 on	 C.	 elegans	longevity.			Folinic	 acid	 is	 the	monoglutamated	derivative	of	5-formyl	THF	and	 the	only	 folate	species	which	does	not	serve	as	a	co-factor	for	one-carbon	metabolism.	5-formyl	THF	is	 formed	 solely	 from	 a	 side-reaction	 mediated	 by	 SMHT,	 where	 5,10-methenyltetrahydrofolate	 is	 converted	 to	 5-formyl	 THF	 in	 the	 presence	 of	 glycine	(Stover	 and	 Schirch,	 1991).	 The	 only	 known	metabolic	 roles	 of	 5-formyl	 THF	 are	inhibition	of	various	enzymes	 involved	 in	one-carbon	metabolism,	 including	SHMT	(Stover	and	Schirch,	1991,	1993).	As	discussed,	folinic	acid	has	been	shown	to	bind	the	THF	riboswitches	 (Trausch	et	al.,	2011),	 and	although	 this	mechanism	of	gene	expression	has	not	been	demonstrated	in	vivo,	it	is	likely	that	this	is	how	folinic	acid	inhibits	gene	expression.			This	 suggests	a	possible	mechanism	whereby	 folinic	acid	 supplementation	may	be	increasing	C.	elegans	lifespan	by	lowering	E.	coli	folate	levels.	LC-MS/MS	analysis	of	bacterial	folate	levels	following	folinic	acid	supplementation	would	be	useful	to	clarify	this	 hypothesis.	 Specifically,	 we	 may	 expect	 to	 see	 decreased	 levels	 of	 5,10-
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methyelene	THF,	due	 to	 the	 inhibitory	action	of	 folinic	acid	on	SHMT.	 Intriguingly,	whilst	5,10-methylene	THF	was	identified	as	the	most	potent	source	of	formaldehyde	in	 the	Burgos-Barragan	 study,	5-formyl	THF	was	not	 found	 to	generate	detectable	levels	 of	 formaldehyde	 (Burgos-Barragan	 et	 al.,	 2017).	 This	 is	 consistent	with	 the	hypothesis	that	bacterial	levels	of	5,10-methylene	THF	correlate	to	C.	elegans	lifespan.		Alternatively,	 lifespan	 extension	 in	 response	 to	 folinic	 acid	may	 be	mediated	 by	 a	direct	effect	on	C.	elegans.	Indeed,	folinic	acid	was	shown	to	supplement	the	gcp-2.1	strain	 at	 low	 concentrations	 and	 independently	 of	 bacterial	 genotype	 (Chapter	 7).	Furthermore,	 gcp-2.1	 folate	 levels	 as	 detected	 by	 LC-MS/MS	 were	 increased	 with	folinic	 acid	 (Chapter	5).	 Further	work	would	 examine	 the	 expression	of	C.	 elegans	genes	 involved	 in	 longevity	pathways	 in	 response	 to	 folinic	 acid	 supplementation;	combined	with	lifespan	analysis	of	known	long-lived	C.	elegans	mutants	on	folinic	acid	supplemented	DM.	In	light	of	the	negative	health	associations	of	folic	acid,	this	work	may	provide	 the	basis	 for	 the	development	of	 folinic	 acid	as	a	widespread	dietary	supplement.	
8.2.5	Does	folic	acid	supplementation	boost	folate	synthesis	in	the	gut	microbiota?	
The	 work	 presented	 in	 Chapter	 7	 demonstrated	 that	 folic	 acid	 supplementation	boosts	both	wild-type	and	pabA	mutant	E.	coli	folate	synthesis.	This	was	found	to	be	dependent	on	the	degradation	of	folic	acid	into	PABA-glu,	which	was	detected	in	three	independent	folic	acid	sources,	solubilized	in	weak	sodium	hydroxide,	by	LC-MS/MS.	The	commercially	available	folic	acid	supplement	contained	the	highest	proportion	of	PABA-glu	 and	 PABA.	 The	 uptake	 of	 PABA-glu	 by	 E.	 coli	 AbgT	 was	 found	 to	 be	
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responsible	 for	 shortening	 C.	 elegans	 lifespan	 on	 pabA	 E.	 coli	 following	 folic	 acid	supplementation.	These	data	therefore	highlight	an	indirect	pathway	whereby	folic	acid	interacts	with	bacterial	folate	synthesis	and	negatively	impacts	animal	long-term	health.			As	discussed,	several	pathogenic	species	of	the	gut	microbiota	possess	AbgT	(Blastn	search)	and	are	therefore	able	to	transport	PABA-glu,	and	many	others	are	able	to	use	PABA	for	folate	synthesis.	It	is	likely	that	PABA-glu	and	PABA	will	be	available	to	the	gut	microbiota	following	folic	acid	supplementation,	given	the	instability	of	folic	acid	at	low	pH	(such	as	in	the	stomach	and	the	upper	small	intestine).	Furthermore,	a	US	study	 investigating	 the	quality	of	 commercial	 folic	 acid	 supplements	 reported	 that	only	three	out	of	nine	multivitamin	products	tested	met	US	Pharmacopeia	standards	for	folic	acid	dissolution	(Hoag	et	al.,	1997).	A	study	in	the	UK	reported	that	only	seven	out	of	11	commercial	folic	acid	supplements	met	the	British	Pharmacopeia	dissolution	specifications	(Sculthorpe	et	al.,	2001).	It	has	recently	been	revealed	that	due	to	issues	with	 folic	acid	 instability,	manufactures	have	adopted	a	policy	of	 ‘overages’,	where	folic	 acid	 supplements	may	 contain	up	 to	150%	of	 the	 stated	dose;	 indeed,	 in	 this	study,	Boots	 folic	acid	was	 found	 to	 contain	107%	of	 the	 stated	dose	 (Flynn	et	al.,	2016;	Mudryj	et	al.,	2016).			Together,	this	indicates	that	folic	acid	supplements	may	supply	the	microbiota	with	precursors	 for	 folate	 synthesis.	 In	 light	 of	 the	 associations	 of	 folic	 acid	supplementation	with	negative	health	consequences	(as	discussed	in	Chapter	1),	the	work	here	suggests	that	the	quality	of	folic	acid	supplements	should	be	reviewed	and	
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the	role	of	the	microbiota	following	folic	acid	supplementation	should	be	investigated	(Andrews	et	al.,	2017).	Indeed,	work	presented	in	Chapter	5	demonstrated	a	complex	interplay	 between	 bacterial	 folate	 status,	 folic	 acid	 supplementation,	 and	 animal	folate,	 where	 C.	 elegans	 folate	 levels	 decreased	 in	 response	 to	 folic	 acid	supplementation	on	pabA	E.	coli.	It	is	hypothesized	that	the	patient	specific	microbiota	may	be	a	confounding	variable	underlying	the	inability	of	meta-analyses	to	agree	on	the	outcome	of	folic	acid	supplementation	on	human	health.	It	would	be	interesting	to	conduct	clinical	 trials	examining	gut	microbiota	composition	following	folic	acid	supplementation	 and	monitor	 long-term	 health.	 Preliminary	 studies	 could	 also	 be	carried	out	using	Drosophila	or	mice.		
8.2.6	Sulfonamides	and	ageing	in	higher	model	organisms 
The	C.	elegans-	E.	coli	simplified	system	was	used	here	to	investigate	the	parameters	that	 influence	bacterial	 folate	 synthesis	 in	order	 to	better	define	how	 this	process	affects	animal	ageing.	The	logical	progression	of	this	work	is	to	test	whether	inhibiting	bacterial	 folate	 synthesis	 is	 a	 viable	 means	 to	 extend	 lifespan,	 and	 importantly	healthspan,	 in	 higher	 model	 organisms	 with	 established	 microbiotas.	 Preliminary	work	in	collaboration	with	the	Clark	laboratory	at	Durham	University	indicates	that	SMX	may	also	increase	the	lifespan	of	Drosophila.	It	is	hoped	that	perseverance	with	this	genetically	tractable	model	organism	with	its	relatively	simplified	microbiota	will	further	our	understanding	of	how	this	intervention	extends	lifespan.			
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An	interesting	insight	from	a	rodent	study	conducted	in	the	1950s	showed	that	the	sulfonamide	drug,	sulfadiazine,	significantly	increased	the	health	and	lifespan	of	both	rats	 and	 mice.	 Longevity	 was	 not	 achieved	 in	 a	 cohort	 supplemented	 with	 both	sulfadiazine	and	PABA	(Hackmann,	1958).	As	 the	 researchers	here	were	primarily	concerned	 with	 the	 animal	 side-effects	 of	 sulfonamides,	 there	 was	 no	acknowledgement	of	the	impact	on	the	gut	microbiota.	Conducting	rodent	studies	and	analysing	longitudinal	changes	in	microbiota	composition	over	time,	in	response	to	an	intervention	that	targets	bacterial	folate	synthesis,	would	provide	useful	insights	into	how	this	intervention	promotes	longevity.			
8.3	BACTERIAL	FOLATE	SYNTHESIS	IN	THE	MICROBIOTA:	A	CAUSE	OF	AGEING?	Dysbiosis,	in	both	ageing	and	disease,	is	often	associated	with	an	increased	abundance	of	Proteobacteria	(Hughes	et	al.,	2017;	Shin	et	al.,	2015).	Magnusodottir	et	al.	reported	that	71%	of	Proteobacteria	in	the	human	gut	microbiota	are	able	to	synthesize	folate	
de	novo	(Magnusdottir	et	al.,	2015).	It	is	hypothesized	here	that	folate-synthesizing	Proteobacteria	 in	 the	 intestine	 may	 generate	 a	 folate-dependent	 toxicity	 that	promotes	the	host	inflammatory	response	and	thus	drives	dysbiosis.	Thus,	the	factors	identified	here	to	promote	bacterial	folate	synthesis,	such	as	folic	acid	and	glucose,	may	promote	dysbiosis	and	thus	alter	host	health	via	the	gut	microbiota.			Evidence	for	this	model	comes	from	the	use	of	the	sulfonamide	drug,	sulfasalazine	for	patient’s	with	inflammatory	disorders,	such	as	Crohn’s	disease,	ulcerative	colitis	and	rheumatoid	arthritis.	Sulfasalazine	is	a	two-part	molecule	whose	action	is	dependent	
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on	cleavage	by	intestinal	bacteria	into	5-aminosalicylate	and	sulfapyridine	(Sack	and	Peppercorn,	1983).	The	efficacy	of	sulfasalazine	is	widely	attributed	to	the	unclarified	function	of	5-aminosalicylate	on	host	cells	and	the	action	of	sulfapyridine	on	bacterial	folate	 synthesis	 is	 overlooked.	 It	 is	 not	 unlikely	 that	 sulfasalazine	 tempers	inflammation	by	inhibiting	bacterial	folate	synthesis.	Further	clinical	evidence	comes	from	the	association	of	small	intestinal	bacterial	overgrowth	with	both	inflammation	and	increased	serum	folate	 levels	(Camilo	et	al.,	1996).	Mechanistic	work	in	model	organisms	is	required	in	order	to	determine	whether	bacterial	 folate	synthesis	is	a	causative	agent	of	inflammation.		In	 a	 normal	 ‘healthy’	 microbiota,	 a	 model	 is	 proposed	 whereby	 bacterial	 folate	synthesis	throughout	one’s	lifetime	contributes	to	a	chronic	toxicity	that	accelerates	ageing.	 This	 is	 perhaps	 best	 considered	within	 the	 framework	 of	 the	 antagonistic	pleiotropy	theory	of	ageing,	proposed	in	1957	by	George	Williams	(Williams,	1957).	Williams	 reasoned	 that	 a	 gene	 with	 a	 detrimental	 impact	 on	 host	 fitness	 post	reproductive	age	will	be	selected	for	by	natural	selection	if	it	has	a	fitness	advantage	during	development.	Applied	to	the	microbiota	and	ageing,	this	theory	may	underpin	why	 the	bacterial	 synthesis	of	 folate,	which	 is	beneficial	as	a	micronutrient	during	development,	is	sustained	as	an	activity	in	the	adult	microbiota,	despite	its	negative	impact	 on	 long-term	 host	 health.	 This	 continued	 synthesis	 of	 folate,	 above	 the	biosynthetic	demands	of	the	host,	is	consistent	with	the	studies	which	have	identified	a	 large	 depository	 of	 folate	 in	 the	 human	 colon	 (Kim	 et	 al.,	 2004).	 It	 is	 therefore	hypothesized	that	bacterial	folate	synthesis	in	the	microbiota	may	be	a	double-edged	sword	for	human	health	and	longevity.	
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Supplementary	Table	1.	Details	of	all	lifespan	experiments	conducted		All	lifespans	were	carried	out	at	25	°C	using	the	SS104	(glp4(bn2))	temperature-sensitive	strain	according	to	the	protocol	outlined	in	Chapter	2,	section	2.12	*	Data	not	shown	in	text	
 
Chapter		 Fig.	 Group	name	 n	 Censor	 Mean	
lifespan	
Std.	
error	
%	change	 p	value	
(Log	rank)	
p	value	
(Wilcoxon)	
Supplement		 Bacterial	
genotype/	strain	
Plasmid	 Antibiotics	
3	 3.3	 NGM,	NGM	 153	 7	 14.523	 0.35956	 Control	 n/a	 n/a	 n/a	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  NGM,	DM	 150	 0	 15.800	 0.38472	 8.80%	 0.0254*	 0.0352*	 n/a	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  NGM,	DM	+	
B12	
133	 13	 16.894	 0.46279	 16.33%	 <.0001	 0.0003	 10	nM	B12	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  DM,	NGM	 129	 0	 14.388	 0.39549	 Control	 n/a	 n/a	 n/a	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  DM,	DM	 113	 27	 15.621	 0.41116	 8.57%	 0.0351	 0.0177	 n/a	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  DM,	DM	+	
B12	
113	 8	 16.181	 0.44747	 12.46%	 0.0067	 0.0051	 10	nM	B12	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  DM	+	B12,	
NGM	
91	 3	 14.422	 0.43774	 Control	 n/a	 n/a	 n/a	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  DM	+	B12,	
DM	
147	 6	 16.901	 0.3662	 17.19%	 <.0001	 <.0001	 n/a	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  DM	+	B12,	
DM	+	B12	
165	 10	 18.575	 0.49146	 28.79%	 <.0001	 <.0001	 10	nM	B12	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
              
3	 3.6	 WT	+	0.1	µM	
PABA	
143	 0	 10.636	 0.25487	 Control	 n/a	 n/a	 0.1	μM	
PABA	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	0.2	µM	
PABA	
106	 0	 10.689	 0.27938	 0.49%	 0.99	 0.7301	 0.2	μM	
PABA	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	0.5	µM	
PABA	
150	 0	 10.500	 0.2387	 -1.28%	 0.6339	 0.7709	 0.5	μM	
PABA	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	1	µM	
PABA	
108	 0	 10.694	 0.27167	 0.55%	 0.9792	 0.6495	 1	μM	PABA	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	5	µM	
PABA	
168	 0	 10.833	 0.23469	 1.85%	 0.5777	 0.4938	 5	μM	PABA	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
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	  pabA	+	0.1	
µM	PABA	
131	 0	 14.214	 0.39403	 33.63%	 <0.0001*	 <0.0001*	 0.1	μM	
PABA	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	0.2	
µM	PABA	
125	 0	 13.152	 0.39383	 23.65%	 <0.0001*	 <0.0001*	 0.2	μM	
PABA	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	0.5	
µM	PABA	
100	 0	 12.320	 0.3339	 15.83%	 <0.0002*	 <0.0001*	 0.5	μM	
PABA	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	1	µM	
PABA	
155	 0	 10.568	 0.25052	 -0.65%	 0.8769	 0.7959	 1	μM	PABA	 ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	5	µM	
PABA	
139	 0	 11.022	 0.264	 3.62%	 0.489	 0.3319	 5	μM	PABA	 ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	              
4	 *	 WT	 118	 2	 12.529	 0.38704	 Control	 n/a	 n/a	 Alkaline	
control	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	10µM	
folic	acid	
125	 6	 12.588	 0.45631	 0.47%	 0.8981	 0.9513	 10	µM	folic	
acid	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  pabA	 130	 1	 15.425	 0.45812	 Control	 n/a	 n/a	 Alkaline	
control	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	1µM	
folic	acid	
117	 1	 15.928	 0.47219	 3.26%	 0.4924	 0.2536	 1	µM	folic	
acid	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	5µM	
folic	acid	
103	 0	 15.340	 0.51321	 -0.55%	 0.8751	 0.9723	 5	µM	folic	
acid	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	10µM	
folic	acid	
132	 1	 14.181	 0.33544	 -8.06%	 0.0121*	 0.1849	 10	µM	folic	
acid	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	              
4	 4.2	 WT	 108	 0	 14.583	 0.40466	 Control	 n/a	 n/a	 Alkaline	
control	
WT/	BW25113	 pGreen	
0029	
25	µg/	ml	
kan	
	  WT	+	10	µm	
folic	acid	
115	 0	 15.000	 0.3937	 2.86%	 0.4448	 0.4588	 10	µM	folic	
acid	
WT/	BW25113	 pGreen	
0029	
25	µg/	ml	
kan	
	  WT	+	100	µm	
folic	acid	
106	 1	 14.569	 0.48154	 -0.10%	 0.566	 0.844	 100	µM	
folic	acid	
WT/	BW25113	 pGreen	
0029	
25	µg/	ml	
kan	
	  pabA	 102	 2	 18.914	 0.4233	 Control	 n/a	 n/a	 Alkaline	
control	
ΔpabA/	JW3323-1	 n/a	 25	µg/	ml	
kan	
	  pabA	+	10	µm	
folic	acid	
84	 2	 18.195	 0.56211	 -3.80%	 0.7322	 0.43	 10	µM	folic	
acid	
ΔpabA/	JW3323-1	 n/a	 25	µg/	ml	
kan	
	  pabA	+	100	
µm	folic	acid	
122	 0	 15.967	 0.43551	 -15.58%	 <.0001*	 <.0001*	 100	µM	
folic	acid	
ΔpabA/	JW3323-1	 n/a	 25	µg/	ml	
kan	
	              
4	 *	 WT	 91	 9	 13.849	 0.44	 Control	 n/a	 n/a	 n/a	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
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	  abgT	 114	 3	 12.675	 0.35	 -8.48%	 0.4312	 0.0963	 n/a	 ΔabgT/	JW5822-1	 n/a	 25	µg/ml	
kan	
	              
4	 4.3	 WT	 102	 9	 15.956	 0.47723	 Control	 n/a	 n/a	 Alkaline	
control	
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  WT	+	10	µM	
folic	
98	 12	 15.961	 0.58353	 0.03%	 0.8268	 0.4283	 10	µM	folic	
acid	
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  WT	100	µM	
folic	
102	 18	 16.014	 0.48219	 0.36%	 0.866	 0.7792	 100	µM	
folic	acid	
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	 113	 10	 18.351	 0.55995	 Control	 n/a	 n/a	 Alkaline	
control	
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	10	µM	
folic	
90	 11	 17.442	 0.63673	 -4.95%	 0.2527	 0.2605	 10	µM	folic	
acid	
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	100	µM	
folic	
122	 3	 15.860	 0.4041	 -13.57%	 <.0001*	 0.0019*	 100	µM	
folic	acid	
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  abgTpabA	 136	 14	 18.932	 0.49624	 Control	 n/a	 n/a	 Alkaline	
control	
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  abgTpabA	+	
10	µM	folic	
115	 26	 19.217	 0.5155	 1.51%	 0.6416	 0.5684	 10	µM	folic	
acid	
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  abgTpabA	+	
100	µM	folic	
93	 11	 19.255	 0.59683	 1.71%	 0.5868	 0.4482	 100	µM	
folic	acid	
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	(abgT	
OE)		
101	 23	 18.416	 0.55641	 Control	 n/a	 n/a	 Alkaline	
control	
CM2/pJ128*	 pJ128	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	(abgT	
OE)	+	10	µM	
folic	
124	 0	 15.839	 0.46927	 -14.00%	 0.0005*	 0.0035*	 10	µM	folic	
acid	
CM2/pJ128*	 pJ128	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	(abgT	
OE)	100	µM	
folic	
105	 0	 15.771	 0.49895	 -14.36%	 0.0003*	 0.0041*	 100	µM	
folic	acid	
CM2/pJ128*	 pJ128	 50	µg/ml	
carb,	25	
µg/	ml	kan	
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	  WT	(abgT	OE)		 110	 9	 16.109	 0.49644	 Control	 n/a	 n/a	 Alkaline	
control	
CM1/pJ128*	 pJ128	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  WT	(abgT	OE)	
+	10	µM	folic	
99	 4	 16.050	 0.57274	 -0.37%	 0.9479	 0.8905	 10	µM	folic	
acid	
CM1/pJ128*	 pJ128	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  WT	(abgT	OE)	
+	100	µM	
folic	
127	 4	 15.783	 0.38634	 -2.02%	 0.3698	 0.8168	 100	µM	
folic	acid	
CM1/pJ128*	 pJ128	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	              
4	 4.6	 WT		 108	 0	 15.790	 0.53	 n/a	 n/a	 n/a	 Alkaline	
control	
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA		 94	 3	 20.076	 0.52	 Control	 n/a	 n/a	 Alkaline	
control	
CM2/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	+	0.1	
µM	PABA	
107	 0	 19.299	 0.46	 -3.89%	 0.0973	 0.3296	 0.1	µM	
pABA	
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	+	1	µM	
PABA	
118	 0	 15.907	 0.45	 -20.78%	 <.0001*	 <.0001*	 1	µM	pABA	 CM2/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	+	1	µM	
pAB-glu	
110	 2	 18.575	 0.40	 -7.49%	 0.0030*	 0.0277*	 1	µM	pAB-
glu	
CM2/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	+	10	µM	
pAB-glu	
125	 10	 16.433	 0.46	 -18.16%	 <.0001*	 <.0001*	 10	µM	pAB-
glu	
CM2/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	+	10	µM	
folic	acid	
93	 5	 18.201	 0.55	 -9.36%	 0.0052*	 0.0061*	 10	µM	
Schircks	
folic	acid		
CM2/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	+	100	
µM	folic	acid	
112	 1	 15.275	 0.45	 -23.93%	 <.0001*	 <.0001*	 100	µM	
Schircks	
folic	acid		
CM2/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  *pabA	+	10	
uM	Boots	
126	 1	 15.939	 0.48256	 -20.61%	 <.0001*	 <.0001*	 10	µM	
Boots	folic	
acid		
CM2/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
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	  *pabA	+	10	
uM	Sigma	
110	 0	 17.727	 0.50764	 -8.14%	 0.0005*	 0.0053*	 10	µM	
Sigma	folic	
acid		
CM2/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  abgTpabA		 91	 3	 20.103	 0.44	 Control	 n/a	 n/a	 Alkaline	
control	
CM3/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  abgTpabA	+	
0.1	µM	PABA	
91	 6	 18.716	 0.49	 -6.88%	 0.0631	 0.0477*	 0.1	µM	
pABA	
CM3/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  abgTpabA	+	1	
µM	PABA	
102	 1	 16.711	 0.45	 -16.86%	 <.0001*	 <.0001*	 1	µM	pABA	 CM3/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  abgTpabA	+	1	
pAB-glu	
101	 11	 18.105	 0.52421	 -9.94%	 0.0698	 0.0333*	 1	µM	pAB-
glu	
CM3/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  abgTpabA	+	
10	µM	pAB-
glu	
106	 4	 18.996	 0.46	 -5.49%	 0.1817	 0.0512	 10	µM	pAB-
glu	
CM3/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  abgTpabA	+	
10	µM	folic	
acid	
110	 1	 19.198	 0.43	 -4.49%	 0.1901	 0.114	 10	µM	
Schircks	
folic	acid		
CM3/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  abgTpabA	+	
100	µM	folic	
acid	
100	 3	 19.160	 0.40	 -4.67%	 0.0476*	 0.0743	 100	µM	
Schircks	
folic	acid		
CM1/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  *abgTpabA	+	
10	uM	Boots	
92	 3	 19.634	 0.44283	 -2.33%	 0.3997	 0.5249	 10	µM	
Boots	folic	
acid		
CM3/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  *abgTpabA	+	
10	uM	Sigma	
92	 0	 20.457	 0.47624	 9.30%	 0.2876	 0.4599	 10	µM	
Sigma	folic	
acid		
CM3/puc19	 pUC19	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	(abgT	
OE)		
62	 10	 19.895	 0.52	 Contol	 n/a	 n/a	 Alkaline	
control	
CM2/pJ128	 pJ128		 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	(abgT	
OE)	+	0.1	µM	
PABA	
121	 1	 18.552	 0.45	 -6.72%	 0.0049*	 0.0184*	 0.1	µM	
pABA	
CM2/pJ128	 pJ128		 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	(abgT	
OE)	+	1	µM	
PABA	
104	 2	 16.072	 0.50	 -19.19%	 <.0001*	 <.0001*	 1	µM	pABA	 CM2/pJ128	 pJ128		 50	µg/ml	
carb,	25	
µg/	ml	kan	
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	  pabA	(abgT	
OE)	+	1	µM	
pAB-glu	
104	 1	 17.012	 0.43	 -14.47%	 <.0001*	 <.0001*	 1	µM	pAB-
glu	
CM2/pJ128	 pJ128		 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	(abgT	
OE)	+	10	µM	
pAB-glu	
117	 0	 15.051	 0.41	 -24.33%	 <.0001*	 <.0001*	 10	µM	pAB-
glu	
CM2/pJ128	 pJ128		 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	(abgT	
OE)	+	10	µM	
folic	acid	
119	 0	 16.647	 0.42	 -16.30%	 <.0001*	 <.0001*	 10	µM	
Schircks	
folic	acid		
CM2/pJ128	 pJ128		 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  pabA	(abgT	
OE)	+	100	µM	
folic	acid	
117	 0	 16.188	 0.42	 -18.61%	 <.0001*	 <.0001*	 100	µM	
Schircks	
folic	acid		
CM2/pJ128	 pJ128		 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  *pabA	(abgT	
OE)	+	10	uM	
Boots	
105	 0	 17.648	 0.50799	 -11.29%	 0.0032*	 0.0067*	 10	µM	
Boots	folic	
acid		
CM2/pJ128	 pJ128	 50	µg/ml	
carb,	25	
µg/	ml	kan	
	  *pabA	(abgT	
OE)	+	10	uM	
Sigma	
108	 0	 16.167	 0.47479	 -18.74%	 <.0001*	 <.0001*	 10	µM	
Sigma	folic	
acid		
CM2/pJ128	 pJ128	 50	µg/ml	
carb,	25	
µg/	ml	kan	
              
4	 4.1	 WT	 99	 26	 14.947	 0.33973	 Control	 n/a	 n/a	 Alkaline	
control	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	100	µM	
folic	acid	
132	 3	 15.439	 0.35922	 3.30%	 0.1964	 0.6903	 100	µM	
folic	acid	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	100	µM	
folinic	acid	
120	 9	 17.697	 0.47526	 18.40%	 <.0001*	 0.0003*	 100	µM	
folinic	acid	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  pabA	 113	 1	 18.540	 0.43348	 Control	 n/a	 n/a	 Alkaline	
control	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	100	
µM	folic	acid	
107	 9	 15.505	 0.39687	 -16.37%	 <.0001*	 <.0001*	 100	µM	
folic	acid	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	100	
µM	folinic	
acid	
131	 3	 17.768	 0.4008	 -4.17%	 0.2046	 0.2109	 100	µM	
folinic	acid	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  abgT	 130	 2	 15.309	 0.36093	 Control	 n/a	 n/a	 Alkaline	
control	
ΔabgT/	JW5822-1	 n/a	 25	µg/ml	
kan	
	  abgT	+	100	
µM	folic	acid	
137	 5	 15.018	 0.40015	 -1.90%	 0.9233	 0.6568	 100	µM	
folic	acid	
ΔabgT/	JW5822-1	 n/a	 25	µg/ml	
kan	
	  abgT	+	100	
µM	folinic	
acid	
120	 1	 16.886	 0.47067	 10.31%	 0.0040*	 0.0176*	 100	µM	
folinic	acid	
ΔabgT/	JW5822-1	 n/a	 25	µg/ml	
kan	
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	  abgTpabA	 148	 1	 18.352	 0.4141	 Control	 n/a	 n/a	 Alkaline	
control	
CMabgTpabA	 n/a	 25	µg/ml	
kan	
	  abgTpabA	+	
100µM	folic	
acid	
111	 17	 17.608	 0.38666	 -4.05%	 0.0719	 0.4487	 100	µM	
folic	acid	
CMabgTpabA	 n/a	 25	µg/ml	
kan	
	  abgTpabA	+	
100µM	folinic	
acid	
101	 29	 20.115	 0.46278	 9.61%	 0.0188*	 0.0021*	 100	µM	
folinic	acid	
CMabgTpabA	 n/a	 25	µg/ml	
kan	
	              
6	 6.4	 WT	 80	 9	 14.929	 0.67224	 Control	 n/a	 n/a	 Volume	
control	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	SMX	 92	 6	 21.603	 0.85748	 44.71%	 <.0001*	 <.0001*	 Volume	
control	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  pabA	 96	 5	 21.983	 0.74544	 47.25%	 <.0001*	 <.0001*	 Volume	
control	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  WT	+	0.1	%	
glucose	
74	 10	 11.300	 0.38043	 Control	 n/a	 n/a	 0.1	%	
glucose	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	SMX	+	
0.1%	glucose	
104	 6	 12.735	 0.509	 12.70%	 0.003*	 0.137	 0.1	%	
glucose	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  pabA	+	0.1%	
glucose	
76	 3	 15.861	 0.68494	 40.37%	 <.0001*	 <.0001*	 0.1	%	
glucose	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	              
6	 6.6	 Control	
transfer	
124	 2	 12.373	 0.37099	 Control	 n/a	 n/a	 Alkaline	
control	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  SMX	transfer	 131	 9	 19	 0.4289	 53.56%	 <.0001*	 <.0001*	 128	µg/ml	
SMX	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  Day	2	SMX	
transfer	
123	 1	 14.2581	 0.37805	 15.24%	 0.0012*	 <.0001*	 128	µg/ml	
SMX	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  Day	4	SMX	
transfer	
129	 0	 11.9302	 0.2685	 -3.58%	 0.2748	 0.8838	 128	µg/ml	
SMX	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  Control	non-
transfer	
96	 0	 12.7292	 0.38459	 Control	 n/a	 n/a	 Alkaline	
control	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  SMX	non-
transfer	
123	 1	 18.1532	 0.45491	 42.61%	 <.0001*	 <.0001*	 128	µg/ml	
SMX	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  Day	2	SMX	
non-transfer	
126	 2	 16.875	 0.42703	 32.57%	 <.0001*	 <.0001*	 128	µg/ml	
SMX	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  Day	4	SMX	
non-transfer	
119	 0	 14.1849	 0.37284	 11.44%	 0.0117*	 0.0086*	 128	µg/ml	
SMX	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
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7	 7.1	 OP50	 154	 6	 15.442	 0.40087	 Control	 n/a	 n/a	 Alkaline	
control	
WT/	OP50	 n/a	 No	kan	
	  OP50	+	SMX	 123	 26	 21.9287	 0.51584	 (from	
OP50)	
42.01%	
<0.0001*	 <0.0001*	 128µg/ml	
SMX	
WT/	OP50	 n/a	 No	kan	
	  WT	 114	 3	 12.6754	 0.35294	 (from	
OP50)		-
17.92%		
<0.0001*	 <0.0001*	 Alkaline	
control	
WT/	BW25113	 pGreen	
0029	
No	kan	
	  WT	+	SMX	 138	 4	 19.307	 0.44371	 (from	
WT)	
52.32%	
<0.0001*	 <0.0001*	 128µg/ml	
SMX	
WT/	BW25113	 pGreen	
0029	
No	kan	
	              
7	 *	 WT	 150	 3	 12.8878	 0.29364	 Control	 n/a	 n/a	 Alkaline	
control	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	SMX	 139	 4	 16.8407	 0.41393	 30.67%	 <0.0001*	 <0.0001*	 128	µg/ml	
SMX	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  pabA	 127	 2	 15.1621	 0.38482	 17.65%	 <0.0001*	 <0.0001*	 Alkaline	
control	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	SMX	 124	 3	 16.01	 0.43418	 (from	WT	
+	SMX)	-
4.93%	
0.2121	 0.1918	 128	µg/ml	
SMX	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  rpoS	 65	 0	 14.9538	 0.58975	 16.03%	 0.0003*	 0.0025*	 Alkaline	
control	
ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
	  rpoS	+	SMX	 150	 2	 17.6372	 0.38484	 (from	WT	
+	SMX)	
4.73%	
0.2189	 0.1214	 128	µg/ml	
SMX	
ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
	              
7	 7.5a	 WT	 112	 0	 13.7768	 0.36513	 Control	 n/a	 n/a	 n/a	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  trpB	 82	 6	 12.9083	 0.3865	 -6.30%	 0.1002	 0.195	 n/a	 ΔtrpB/	JW1253-1	 n/a	 25	µg/ml	
kan	
	  tnaA	 99	 4	 13.3178	 0.33556	 -3.33%	 0.356	 0.5006	 n/a	 ΔtnaA/	JW3686-7	 n/a	 25	µg/ml	
kan	
	  ompF	 79	 7	 13.3357	 0.36955	 -3.20%	 0.3095	 0.6389	 n/a	 ΔompF/	JW0912-1	 n/a	 25	µg/ml	
kan	
	  yhfG	 84	 8	 13.4665	 0.42254	 -2.25%	 0.6263	 0.575	 n/a	 ΔyhfG/	JW3325-1	 n/a	 25	µg/ml	
kan	
	  ompT	 104	 0	 13.625	 0.41359	 -1.10%	 0.9282	 0.5002	 n/a	 ΔompT/	JW0554-1	 n/a	 25	µg/ml	
kan	
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	  csgD	 106	 0	 13.6698	 0.37167	 -0.78%	 0.6796	 0.7029	 n/a	 ΔcsgD/	JW1023-1	 n/a	 25	µg/ml	
kan	
	  crl	 93	 6	 13.8953	 0.46595	 0.86%	 0.5229	 0.8497	 n/a	 Δcrl/	JW0230-1	 n/a	 25	µg/ml	
kan	
	  ompA	 98	 0	 14.1429	 0.35618	 2.66%	 0.0905	 0.4742	 n/a	 ΔompA/	JW0940-
6	
n/a	 25	µg/ml	
kan	
	  hlyE	 100	 4	 14.2409	 0.34054	 3.37%	 0.6171	 0.3494	 n/a	 ΔhlyE/	JW5181-1	 n/a	 25	µg/ml	
kan	
	  ompC	 78	 5	 14.651	 0.37566	 6.35%	 0.1647	 0.0504	 n/a	 ΔompC/	JW2203-1	 n/a	 25	µg/ml	
kan	
	  astA	 111	 1	 15.4485	 0.39575	 12.13%	 0.0019*	 0.0038*	 n/a	 ΔastA/	JW1736-1	 n/a	 25	µg/ml	
kan	
	  bipA	 98	 3	 15.4648	 0.4014	 12.25%	 0.0026*	 0.0018*	 n/a	 ΔbipA/	JW5571-1	 n/a	 25	µg/ml	
kan	
	  lrhA	 83	 4	 15.6581	 0.57238	 13.66%	 0.0007*	 0.0108*	 n/a	 ΔlrhA/	JW2284-6	 n/a	 25	µg/ml	
kan	
	  crp	 95	 0	 15.7684	 0.48342	 14.46%	 0.0003*	 0.0017*	 n/a	 Δcrp/	JW5702-4	 n/a	 25	µg/ml	
kan	
	  cfa	 97	 0	 16.2577	 0.46466	 18.01%	 <.0001*	 <.0001*	 n/a	 Δcfa/	JW1653-1	 n/a	 25	µg/ml	
kan	
	              
7	 7.5b	 WT	 95	 11	 12.8174	 0.50518	 Control	 n/a	 n/a	 n/a	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  gadX	 104	 1	 12.7146	 0.45509	 -0.80%	 0.7316	 0.9559	 n/a	 ΔgadX/	JW3484-1	 n/a	 25	µg/ml	
kan	
	  bipA	 109	 4	 12.9689	 0.47313	 1.18%	 0.6526	 0.717	 n/a	 ΔbipA/	JW5571-1	 n/a	 25	µg/ml	
kan	
	  tktB	 119	 1	 13.6318	 0.41869	 6.35%	 0.3347	 0.1482	 n/a	 ΔtktB/	JW2449-4	 n/a	 25	µg/ml	
kan	
	  osmY	 110	 5	 13.9034	 0.43454	 8.47%	 0.2018	 0.0828	 n/a	 ΔosmY/	JW4338-1	 n/a	 25	µg/ml	
kan	
	  gabB	 123	 0	 13.9756	 0.44868	 9.04%	 0.0813	 0.0818	 n/a	 ΔgadB/	JW1488-7	 n/a	 25	µg/ml	
kan	
	  slp	 109	 12	 14.0418	 0.471	 9.55%	 0.0574	 0.0628	 n/a	 Δslp/	JW3474-5	 n/a	 25	µg/ml	
kan	
	  mysB	 96	 3	 14.2527	 0.4484	 11.20%	 0.1451	 0.0278*	 n/a	 ΔmysB/	JW1912-1	 n/a	 25	µg/ml	
kan	
	  gadE	 121	 3	 14.4077	 0.44506	 12.41%	 0.0217*	 0.0175*	 n/a	 ΔgadE/	JW3480-2	 n/a	 25	µg/ml	
kan	
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	  cfa	 121	 6	 14.5964	 0.38252	 13.88%	 0.0281*	 0.0025*	 n/a	 Δcfa/	JW1653-1	 n/a	 25	µg/ml	
kan	
	  osmC	 94	 2	 14.6298	 0.50133	 14.14%	 0.0154*	 0.0105*	 n/a	 ΔosmC/	JW1477-1	 n/a	 25	µg/ml	
kan	
	  csrA	 128	 0	 14.6563	 0.35502	 14.35%	 0.0312*	 0.0017*	 n/a	 ΔcsrA/	JW3221-5	 n/a	 25	µg/ml	
kan	
	  gadA	 114	 6	 14.8649	 0.40842	 15.97%	 0.0079*	 0.0011*	 n/a	 ΔgadA/	JW3485-1	 n/a	 25	µg/ml	
kan	
	  talA	 119	 0	 15.084	 0.3859	 17.68%	 0.0037*	 0.0003*	 n/a	 ΔtalA/	JW2448-4	 n/a	 25	µg/ml	
kan	
	  relA	 123	 2	 15.6017	 0.40588	 21.72%	 <.0001*	 <.0001*	 n/a	 ΔrelA/	JW2755-3	 n/a	 25	µg/ml	
kan	
	  sodA	 120	 1	 15.7144	 0.44081	 22.60%	 <.0001*	 <.0001*	 n/a	 ΔsodA/	JW3879-1	 n/a	 25	µg/ml	
kan	
	  otsB	 112	 9	 15.7178	 0.42563	 22.63%	 <.0001*	 <.0001*	 n/a	 ΔotsB/	JW1886-1	 n/a	 25	µg/ml	
kan	
	  fic	 122	 6	 16.1549	 0.41128	 26.04%	 <.0001*	 <.0001*	 n/a	 Δfic/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  astA	 107	 7	 16.317	 0.4366	 27.30%	 <.0001*	 <.0001*	 n/a	 ΔastA/	JW1736-1	 n/a	 25	µg/ml	
kan	
	  crp	 120	 1	 16.5538	 0.42341	 29.15%	 <.0001*	 <.0001*	 n/a	 Δcrp/	JW5702-4	 n/a	 25	µg/ml	
kan	
	  rpoS	 83	 9	 17.2864	 0.54141	 34.87%	 <.0001*	 <.0001*	 n/a	 ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
	  lrhA	 121	 2	 18.1628	 0.39001	 41.70%	 <.0001*	 <.0001*	 n/a	 ΔlrhA/	JW2284-6	 n/a	 25	µg/ml	
kan	
	              
7	 7.12a	 rpoS	+	0.1	µM	
PABA	
98	 3	 13.5063	 0.48124	 Control	 n/a	 n/a	 0.1	μM	
PABA	
ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
	  rpoS	+	0.2		
µM	PABA	
115	 5	 14.9349	 0.43591	 10.58%	 0.0004*	 0.0031*	 0.2	μM	
PABA	
ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
	  rpoS	+	0.5	µM	
PABA	
108	 2	 13.3179	 0.44282	 -1.39%	 0.3738	 0.9232	 0.5	μM	
PABA	
ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
	  rpoS	+	1	µM	
PABA	
133	 0	 13.0226	 0.34146	 -3.58%	 0.1482	 0.5852	 1	μM	PABA	 ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
	  rpoS	+	5	µM	
PABA	
134	 0	 12.8806	 0.3531	 -4.63%	 0.8655	 0.8009	 5	μM	PABA	 ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
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7	 7.12b	 WT	 102	 5	 15.1059	 0.43811	 Control	 n/a	 n/a	 Alkaline	
control	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	1	µM	
PABA	
121	 0	 15.1653	 0.31739	 0.39%	 0.3299	 0.9042	 1	μM	PABA	 WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	100	µM	
folic	
97	 6	 14.5767	 0.3859	 -3.88%	 0.1289	 0.3348	 100	μM	
folic	acid	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  WT	+	100	µM	
folinic	
79	 24	 15.9143	 0.50855	 9.18%	 0.0639	 0.2332	 100	μM	
folinic	acid	
WT/	BW25113	 pGreen	
0029	
25	µg/ml	
kan	
	  rpoS	 66	 0	 16.6515	 0.53914	 Control	 n/a	 n/a	 Alkaline	
control	
ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
	  rpoS+	1	µM	
PABA	
106	 17	 16.5113	 0.38532	 -0.84%	 0.1647	 0.432	 1	μM	PABA	 ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
	  rpoS	+	100	
µM	folic	
100	 12	 14.6164	 0.43298	 -12.22%	 0.0041*	 0.0091*	 100	μM	
folic	acid	
ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
	  rpoS	+	100	
µM	folinic	
93	 17	 17.3562	 0.38808	 4.23%	 0.5785	 0.3742	 100	μM	
folinic	acid	
ΔrpoS/	JW5437-1	 n/a	 25	µg/ml	
kan	
	  	 	 	 	 	 	 	 	 	 	 	 	
7	 *	 pabA	 73	 10	 16.5554	 0.4857	 Control	 n/a	 n/a	 Alkaline	
control	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	1	µM	
PABA	
125	 10	 14.6716	 0.34406	 -11.38%	 0.0003*	 0.0021*	 1	μM	PABA	 ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	100	
µM	folic	
85	 24	 14.1619	 0.42421	 -14.46%	 <.0001*	 0.0006*	 100	μM	
folic	acid	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
	  pabA	+	100	
µM	folinic	
103	 13	 16.0138	 0.42221	 -3.27%	 0.5331	 0.42	 100	μM	
folinic	acid	
ΔpabA/	JW3323-1	 n/a	 25	µg/ml	
kan	
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